<SEC-DOCUMENT>0001193125-19-113381.txt : 20190422
<SEC-HEADER>0001193125-19-113381.hdr.sgml : 20190422
<ACCEPTANCE-DATETIME>20190422161104
ACCESSION NUMBER:		0001193125-19-113381
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190530
FILED AS OF DATE:		20190422
DATE AS OF CHANGE:		20190422
EFFECTIVENESS DATE:		20190422

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYNAVAX TECHNOLOGIES CORP
		CENTRAL INDEX KEY:			0001029142
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330728374
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34207
		FILM NUMBER:		19759549

	BUSINESS ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
		BUSINESS PHONE:		5108485100

	MAIL ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d707175ddef14a.htm
<DESCRIPTION>DEFINITIVE PROXY STATEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Definitive Proxy Statement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filed by a Party other than
the Registrant&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Preliminary Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Confidential, for Use of the Commission Only (as permitted by Rule <FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Definitive Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Definitive Additional Materials</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Soliciting Material under <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>DYNAVAX TECHNOLOGIES CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate
box):</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">No fee required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee computed on table below per Exchange Act Rules <FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of each class of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate number of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule <FONT STYLE="white-space:nowrap">0-11</FONT>
(set forth the amount on which the filing fee is calculated and state how it was determined):</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposed maximum aggregate value of transaction:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">5.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Total fee paid:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Check box if any part of the fee is offset as provided by Exchange Act Rule <FONT STYLE="white-space:nowrap">0-11(a)(2)</FONT> and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its filing.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">6.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amount Previously Paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">7.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form, Schedule or Registration Statement No.:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">8.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing Party:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">9.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date Filed:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DYNAVAX TECHNOLOGIES CORPORATION </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2929 Seventh Street, Suite 100 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Berkeley, California 94710 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTICE OF 2019 ANNUAL MEETING OF STOCKHOLDERS
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>May&nbsp;30, 2019 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dear Stockholder: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You are cordially invited to attend the 2019 Annual Meeting of
Stockholders of Dynavax Technologies Corporation, a Delaware corporation, or the Company. The meeting will be held on May&nbsp;30, 2019, at 9:00 a.m. Pacific Time, at the Company&#146;s executive offices at 2929 Seventh Street, Suite 100, Berkeley,
California 94710 for the following purposes: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To elect our nominees for Class&nbsp;I directors to hold office until the 2022 Annual Meeting of Stockholders or until their respective
successors are duly elected and qualified. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To approve an amendment and restatement of the Dynavax Technologies Corporation 2018 Equity Incentive Plan to, among other things, increase
the aggregate number of shares of common stock authorized for issuance under the plan by 2,300,000. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To approve, on an advisory basis, the compensation of the Company&#146;s named executive officers, as disclosed in the Proxy Statement
accompanying this Notice. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To ratify the selection of Ernst&nbsp;&amp; Young LLP as the independent registered public accounting firm of the Company for its fiscal year
ending December&nbsp;31, 2019. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To conduct any other business properly brought before the meeting or any adjournment(s) thereof. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These items of business are more fully described in the Proxy Statement accompanying this Notice. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The record date for the 2019 Annual Meeting is April&nbsp;9, 2019. Only stockholders of record at the close of business on that date may
vote at the meeting or any adjournment thereof. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1pt;background-color:;;padding-top:2px;padding-bottom:3px">
<P STYLE="margin-top:0px;margin-bottom:0px;padding-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Important Notice Regarding the Availability of Proxy Materials for the Stockholders&#146; Meeting to Be Held at 9:00
a.m., Pacific Time, on May&nbsp;30, 2019 at 2929 Seventh Street, Suite 100, Berkeley, California 94710. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The proxy
statement and annual report to stockholders </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>are available at <U>http://investors.dynavax.com/annuals-proxies.cfm</U>.
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The Board of Directors recommends that you vote FOR the proposals identified above.
</B></FONT></P></div> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By Order of the Board of Directors</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Steven N. Gersten</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven N. Gersten</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Secretary</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Berkeley, California </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;22, 2019 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1pt;background-color:;;padding-top:2px;padding-bottom:3px">
<P STYLE="margin-top:0px;margin-bottom:0px;padding-top:0px; margin-left:2%;margin-right:2%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Your vote is very important, regardless of the number of shares you own. Whether or not
you expect to attend the meeting, please complete, date, sign and return the enclosed proxy as promptly as possible in order to ensure your representation at the meeting. A return envelope (which is postage prepaid if mailed in the United States) is
enclosed for your convenience. Even if you have voted by proxy, you may still vote in person if you attend the meeting. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the
meeting, you must obtain a proxy issued in your name from that record holder. </B></FONT></P></div>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DYNAVAX TECHNOLOGIES CORPORATION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2929 Seventh Street, Suite 100 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Berkeley, California 94710 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROXY STATEMENT </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR THE 2019 ANNUAL MEETING OF STOCKHOLDERS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">May&nbsp;30, 2019 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Why am I receiving these materials? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have sent you this proxy statement and the enclosed proxy card because the Board of Directors, or Board, of Dynavax Technologies Corporation, or the Company or Dynavax, or we or us, is soliciting your
proxy to vote at the 2019 Annual Meeting of Stockholders, or Annual Meeting. You are invited to attend the Annual Meeting to vote on the proposals described in this proxy statement. However, you do not need to attend the Annual Meeting to vote your
shares. Instead, you may simply complete, sign and return the enclosed proxy card. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to mail this proxy statement and
accompanying proxy card on or about April&nbsp;25, 2019, to all stockholders of record entitled to vote at the Annual Meeting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How do I
attend the Annual Meeting? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Annual Meeting will be held on May&nbsp;30, 2019 at 9:00 a.m. Pacific Time, at our
executive offices at 2929 Seventh Street, Suite 100, Berkeley, California 94710. Directions to the Annual Meeting may be found at <U>http://www.dynavax.com/contact</U>. Information on how to vote in person at the Annual Meeting is discussed below.
For admission to the Annual Meeting, stockholders may be asked to present proof of identification and a statement from their bank, broker or other nominee reflecting their beneficial ownership of our common stock as of April&nbsp;9, 2019, as well as
a proxy from the record holder to the stockholder. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Who can vote at the Annual Meeting? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Only stockholders of record at the close of business on April&nbsp;9, 2019, will be entitled to vote at the Annual Meeting. On this record
date, there were 65,063,889 shares of common stock outstanding and entitled to vote. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stockholder of Record: Shares
Registered in Your Name </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If on April&nbsp;9, 2019, your shares were registered directly in your name with our transfer
agent, then you are a stockholder of record. As a stockholder of record, you may vote in person at the Annual Meeting or vote by proxy. Whether or not you plan to attend the Annual Meeting, we urge you to fill out and return the enclosed proxy card
to ensure your vote is counted. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Beneficial Owner: Shares Registered in the Name of a Broker or Bank </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If on April&nbsp;9, 2019, your shares were held, not in your name, but rather in an account at a brokerage firm, bank, dealer or other
similar organization, then you are the beneficial owner of shares held in &#147;street name&#148; and these proxy materials are being forwarded to you by that organization. The organization holding your account is considered to be the stockholder of
record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker or other agent regarding how to vote the shares in your account. You are also invited to attend the Annual Meeting. However, since
you are not the stockholder of record, you may not vote your shares in person at the Annual Meeting unless you request and obtain a valid proxy from your broker or other agent. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What am I voting on? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are asking you to vote on four&nbsp;proposals: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To elect our nominees for Class&nbsp;I directors to hold office until the 2022 Annual Meeting of Stockholders or until their respective
successors are duly elected and qualified. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To approve an amendment and restatement of the Dynavax Technologies Corporation 2018 Equity Incentive Plan (the &#147;2018 EIP&#148;) to,
among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 2,300,000. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To approve, on an advisory basis, the compensation of the Company&#146;s named executive officers, as disclosed in this proxy statement.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To ratify the selection of Ernst&nbsp;&amp; Young LLP as the independent registered public accounting firm of the Company for its fiscal year
ending December&nbsp;31, 2019. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What is the Board&#146;s recommendation? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board recommends that you vote &#147;For&#148; each of the four proposals. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>What if another matter is properly brought before the Annual Meeting? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the Annual Meeting, it is the intention of the persons named in the accompanying proxy to vote on those
matters in accordance with her or his best judgment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How do I vote? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may either vote &#147;For&#148; all the nominees to the Board or you may &#147;Withhold&#148; your vote for any nominee you specify.
For each of the other matters to be voted on, you may vote &#147;For&#148; or &#147;Against&#148; or abstain from voting. The procedures for voting are fairly simple: </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stockholder of Record: Shares Registered in Your Name </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you are a
stockholder of record, you may vote in person at the Annual Meeting or vote by proxy using the enclosed proxy card. Whether or not you plan to attend the Annual Meeting, we urge you to vote by proxy to ensure your vote is counted. You may still
attend the Annual Meeting and vote in person even if you have already voted by proxy. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To vote in person, come to the Annual Meeting and we will give you a ballot when you arrive. Directions to the Annual Meeting may be found at
<U>http://www.dynavax.com/contact</U>. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To vote using the proxy card, simply complete, sign and date the enclosed proxy card and return it promptly in the envelope provided. If you return
your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To vote using the telephone, simply follow the instructions on the enclosed proxy card. Voting by telephone has the same effect as voting by mail. You
may vote by telephone until 11:59 p.m., Eastern Time, May&nbsp;29, 2019. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To vote using the internet, simply follow the instructions on the enclosed proxy card. You may vote by using the internet until 11:59 p.m., Eastern
Time, May&nbsp;29, 2019. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Beneficial Owner: Shares Registered in the Name of Broker or Bank
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have
received a proxy card and voting instructions with these proxy materials from that organization rather than </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
from Dynavax. Simply complete and mail the proxy card to ensure that your vote is counted. To vote in person at the Annual Meeting, you must obtain a valid proxy from your broker, bank or other
agent. Follow the instructions from your broker, bank or other agent included with these proxy materials, or contact your broker, bank or other agent to request a proxy form. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1pt;background-color:;;padding-top:2px;padding-bottom:3px">
<P STYLE="margin-top:0px;margin-bottom:0px;padding-top:0px; margin-left:2%;margin-right:2%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We provide internet proxy voting to allow you to vote your shares online, with
procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and
telephone companies. </B></FONT></P></div> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How many votes do I have? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On each matter to be voted upon, you have one vote for each share of common stock you own as of April&nbsp;9, 2019. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>What happens if I do not vote? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stockholder of Record: Shares
Registered in Your Name </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you are a stockholder of record and do not vote by completing your proxy card, by
telephone, through the internet or in person at the Annual Meeting, your shares will not be voted. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Beneficial Owner:
Shares Registered in the Name of Broker or Bank </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you are a beneficial owner and do not instruct your broker, bank,
or other agent how to vote your shares, the question of whether your broker or nominee will still be able to vote your shares depends on whether the applicable stock exchange deems the particular proposal to be a &#147;routine&#148; matter. Brokers
and nominees can use their discretion to vote &#147;uninstructed&#148; shares with respect to matters that are considered to be &#147;routine,&#148; but not with respect to <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters.
Under the rules and interpretations of the NYSE, <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters are matters that may substantially affect the rights or privileges of stockholders, such as mergers, stockholder proposals,
elections of directors (even if not contested), executive compensation (including any advisory stockholder votes on executive compensation and on the frequency of stockholder votes on executive compensation), and certain corporate governance
proposals, even if management-supported. Accordingly, your broker or nominee may not vote your shares on Proposals 1, 2, or 3 without your instructions, but may vote your shares on Proposal 4. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What if I return a proxy card but do not make specific choices? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If you return a signed and dated proxy card without marking any voting selections, your shares will be voted: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 1: &#147;For&#148; election of our nominees for Class&nbsp;I directors. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 2: &#147;For&#148; approval of the amendment and restatement of the 2018 EIP to, among other things, increase the aggregate number of
shares of common stock authorized for issuance under the plan by 2,300,000; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 3: &#147;For&#148; advisory approval of executive compensation; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 4: &#147;For&#148; ratification of the selection of Ernst&nbsp;&amp; Young LLP as the independent registered public accounting firm
of the Company for its fiscal year ending December&nbsp;31, 2019. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any other matter is properly presented
at the Annual Meeting, your proxyholder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Who is paying for this proxy solicitation? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will pay for the entire cost of soliciting proxies. In addition to mailing these proxy materials, our directors and employees may also
solicit proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other agents for the cost of
forwarding proxy materials to beneficial owners. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What does it mean if I receive more than one proxy card? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you receive more than one proxy card, your shares are registered in more than one name or are registered in different accounts. Please
complete, sign and return each proxy card to ensure that all of your shares are voted. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Can I change my vote after submitting my proxy?
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yes. You can revoke your proxy at any time before the final vote at the Annual Meeting. If you are the record holder of
your shares, you may revoke your proxy in any one of three ways: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may submit another properly completed proxy card with a later date. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may send a timely written notice that you are revoking your proxy to Dynavax Technologies Corporation, Attention: Corporate Secretary, 2929 Seventh
Street, Suite 100, Berkeley, California 94710. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may attend the Annual Meeting and vote in person. Simply attending the Annual Meeting will not, by itself, revoke your proxy.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your proxy card with the most recent date is the one that will be counted. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If your shares are held by your broker or bank as a nominee or agent, you should follow the instructions provided by your broker or bank.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>When are stockholder proposals due for next year&#146;s Annual Meeting? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">To be considered for inclusion in next year&#146;s proxy materials, your proposal must be submitted in writing by
December&nbsp;24, 2019 to Dynavax Technologies Corporation, Attention: Corporate Secretary, 2929 Seventh Street, Suite 100, Berkeley, California 94710, if mailed prior to June&nbsp;1, 2019, or to 5959 Horton Street, Suite 700, Emeryville, California
94608, if mailed on or after June&nbsp;1, 2019. However, if our 2020 Annual Meeting of Stockholders is not held between April&nbsp;30, 2020, and June&nbsp;29, 2020, then the deadline will be a reasonable time before we begin to print and send our
proxy materials. If you wish to submit a proposal (including a director nomination) that is not to be included in next year&#146;s proxy materials or nominate a director, you must do so no later than the close of business on March&nbsp;1, 2020, and
no earlier than the close of business on January&nbsp;31, 2020. However, if our 2020 Annual Meeting of Stockholders is not held between April&nbsp;30, 2020, and June&nbsp;29, 2020, then you must submit your proposal (or director nomination) not
earlier than the close of business on the 120</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> day prior
to such annual meeting and not later than the close of business on the 90</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> day prior to such annual meeting or the 10</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> day following the day on which public announcement of the date of such meeting is first made. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How many votes are needed to approve each proposal? </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 1, to elect our nominees for Class&nbsp;I directors, the three nominees receiving the most &#147;For&#148; votes from the holders of shares
present (either in person or represented by proxy) and cast for the election of directors will be elected. Only votes &#147;For&#148; will affect the outcome of the vote; &#147;Withhold&#148; votes will have no effect on the outcome of the vote.
However, if a nominee receives a greater number of &#147;Withhold&#148; votes than &#147;For&#148; votes, such nominee will submit his or her offer of resignation for consideration by our Nominating and Corporate Governance Committee in accordance
with our Majority Vote Policy discussed in more detail on page 58 of this proxy statement. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 2, to approve the amendment and restatement of the 2018 EIP to, among other things, increase the aggregate number of shares of common stock
authorized for issuance under the 2018 EIP by 2,300,000, must receive &#147;For&#148; votes from the holders of a majority of shares present (either in person or by proxy) and entitled to vote on the matter at the meeting. If you return your proxy
and select &#147;Abstain,&#148; it will have the same effect as an &#147;Against&#148; vote. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 3, advisory approval of the compensation of the Company&#146;s named executive officers, will be considered to be approved if it receives
&#147;For&#148; votes from the holders of a majority of shares present (either in person or by proxy) and entitled to vote on the matter at the meeting. If you return your proxy and select &#147;Abstain&#148; from voting, it will have the same
effect as an &#147;Against&#148; vote. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 4, to ratify the selection of Ernst&nbsp;&amp; Young LLP as the Company&#146;s independent registered public accounting firm for our fiscal
year ending December&nbsp;31, 2019, must receive &#147;For&#148; votes from the holders of a majority of shares present (either in person or by proxy) and entitled to vote on the matter at the meeting. If you return your proxy and select
&#147;Abstain&#148; from voting, it will have the same effect as an &#147;Against&#148; vote. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect, however, as Proposal 4 is considered a &#147;routine&#148; matter, we do not
expect to receive any broker <FONT STYLE="white-space:nowrap">non-votes.</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What is the quorum requirement?
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A quorum of stockholders is necessary to hold a valid Annual Meeting. A quorum will be present if stockholders holding at
least a majority of the outstanding shares entitled to vote are present at the Annual Meeting in person or represented by proxy. On the record date, there were 65,063,889 shares outstanding and entitled to vote. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank
or other nominee) or if you vote in person at the Annual Meeting. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will be counted towards the quorum requirement. If there is no quorum, the holders of a majority of shares
present at the Annual Meeting in person or represented by proxy may adjourn the Annual Meeting to another date. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How can I find out the
results of the voting at the Annual Meeting? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preliminary voting results will be announced at the Annual Meeting. Final
voting results will be published in a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> within four business days following the voting. If we are unable to obtain final results in that time, we will announce the preliminary results
and subsequently file a second current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> with the final results. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What proxy
materials are available on the internet? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 2019 proxy statement and 2018 Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> are available at <U>http://investors.dynavax.com/annuals-proxies.cfm</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Householding of Proxy
Materials </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Securities and Exchange Commission, or SEC, has adopted rules that permit companies and intermediaries
(e.g., brokers) to satisfy the delivery requirements for Annual Meeting materials with respect to two or more stockholders sharing the same address by delivering a single set of Annual Meeting materials addressed to those stockholders. This process,
which is commonly referred to as &#147;householding,&#148; potentially means extra convenience for stockholders and cost savings for companies. A number of brokers with account holders who are Dynavax stockholders will be &#147;householding&#148;
our proxy materials. A single set of Annual Meeting materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your
broker that they will be &#147;householding&#148; communications to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
your address, &#147;householding&#148; will continue until you are notified otherwise or until you revoke your consent. If you no longer wish to participate in &#147;householding&#148; and would
prefer to receive a separate set of Annual Meeting materials, please notify your broker and we will promptly deliver to you a separate set of our Annual Meeting materials. direct your written request to Dynavax Technologies Corporation, Attention:
Corporate Secretary, 2929 Seventh Street, Suite 100, Berkeley, California 94710, if mailed prior to June&nbsp;1, 2019, or to 5959 Horton Street, Suite 700, Emeryville, California 94608, if mailed on or after June&nbsp;1, 2019, or contact
Dynavax&#146;s Corporate Secretary at <FONT STYLE="white-space:nowrap">(510)&nbsp;848-5100.</FONT> Stockholders who currently receive multiple copies of the Annual Meeting materials at their addresses and would like to request
&#147;householding&#148; of their communications should contact their brokers. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROPOSAL 1 </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ELECTION OF DIRECTORS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our Board is divided into three classes, and each class has a three-year term. Vacancies on the Board may be filled only by persons elected by a majority of the remaining directors. A director elected by
the Board to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director&#146;s successor is elected and qualified. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board presently has eight members. There are three directors in the class whose term of office expires in 2019: Dennis A. Carson,
M.D., Eddie Gray, and Laura Brege, each of whom is a nominee for director and currently a director of the Company. Dr.&nbsp;Carson, Mr.&nbsp;Gray and Ms.&nbsp;Brege were previously elected by the stockholders in 2016. If each nominee is elected at
the Annual Meeting, each of these nominees will serve until the 2022 Annual Meeting and until his or her successor is elected and has qualified, or, if sooner, until the director&#146;s death, resignation or removal. We have a policy encouraging our
directors&#146; attendance at our annual meetings. There were six directors in attendance at our 2018 Annual Meeting. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Directors are elected by a plurality of the votes of the holders of shares present in person or represented by proxy and entitled to vote
on the election of directors. The three nominees receiving the highest number of affirmative votes will be elected. Shares represented by executed proxies will be voted, if authority to do so is not withheld, for the election of the nominees named
below. Although the election of directors at the Annual Meeting is uncontested and directors are elected by a plurality of votes cast, and we therefore anticipate that each of the named nominees for director will be elected at the Annual Meeting,
under our Corporate Governance Guidelines, any nominee for director is required to submit an offer of resignation for consideration by the Nominating and Corporate Governance Committee if such nominee for director (in an uncontested election)
receives a greater number of &#147;Withhold&#148; votes than &#147;For&#148; votes. In such case, the Nominating and Corporate Governance Committee will then consider all of the relevant facts and circumstances and recommend to the Board the action
to be taken with respect to such offer of resignation. For more information on this policy see the section entitled &#147;Corporate Governance.&#148; If any nominee becomes unavailable for election as a result of an unexpected occurrence, your
shares will be voted for the election of a substitute nominee proposed by our Board. Each person nominated for election has agreed to serve if elected. Our Board has no reason to believe that any nominee will be unable to serve. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A V<SMALL>OTE</SMALL> I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL> E<SMALL>ACH</SMALL> N<SMALL>AMED</SMALL>
N<SMALL>OMINEE</SMALL>. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Set forth below is certain biographical information as of April&nbsp;9, 2019, for the nominees
and each person whose term as a director will continue after the Annual Meeting. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Position</B></FONT></P></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnold L. Oronsky, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">78</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairperson of the Board</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Francis R. Cano, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dennis A. Carson, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laura Brege</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer (&#147;CEO&#148;) and Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Daniel L. Kisner, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peggy V. Phillips</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Natale Ricciardi</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>LASS</SMALL> I D<SMALL>IRECTORS</SMALL> N<SMALL>OMINEES</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dennis A. Carson, M.D. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Carson has been a member of our Board since December 1997. Dr.&nbsp;Carson is a noted researcher in the fields of autoimmune and
immunodeficiency diseases and is <FONT STYLE="white-space:nowrap">co-discoverer</FONT> with Dr.&nbsp;Eyal Raz of the immunostimulatory sequences (ISS) that form the basis of our technology. He has played key roles in the founding of Vical, Inc., a
gene therapy company, IDEC Pharmaceuticals, a biopharmaceutical company, and Triangle Pharmaceuticals, a pharmaceutical company. Dr.&nbsp;Carson is former director of the Rebecca and John Moores Cancer Center at the University of California, San
Diego and has been a professor in the Department of Medicine at the University of California, San Diego since 1990. The Board believes that Dr.&nbsp;Carson&#146;s significant experience in research and development provides important insights for the
strategy of the Company, particularly with regard to scientific opportunities for development by the Company, and qualifies Dr.&nbsp;Carson to be nominated as a director. He is a member of the National Academy of Sciences, the American Academy of
Arts and Sciences, and the Institute of Medicine, as well as the American Association for Cancer Research, the American Society for Clinical Investigation, the American Society of Hematology and the Association of American Physicians. He received
his M.D. from Columbia University and his B.A. from Haverford College. Dr.&nbsp;Carson completed his residency in internal medicine and a postdoctoral fellowship at the University of California, San Diego. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eddie Gray &#150; CEO and Director </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Gray joined Dynavax as Chief Executive Officer and was appointed to our Board in May 2013. Most recently, Mr.&nbsp;Gray served as the President of Pharmaceuticals Europe and a member of the
corporate executive team at GlaxoSmithKline plc (GSK) from 2008 until 2013 and as Senior Vice President and General Manager of Pharmaceuticals UK from 2001 through 2007. Prior to the formation of GSK, Mr.&nbsp;Gray was with SmithKline Beecham from
1988 through 2000 serving in various positions of increasing responsibility, including Vice President and Director of Anti-Infectives Marketing in the U.S., Vice President and Director of the Vaccines Business Unit in the U.S., and Vice President
and General Manager of Pharmaceuticals in Canada. Our Board believes that Mr.&nbsp;Gray&#146;s more than 30 years of pharmaceutical industry experience, including, most recently, as the President of Pharmaceuticals Europe at GSK, a leading
pharmaceutical company, and other senior management roles at GSK and its predecessor, where he was responsible for the launch, commercialization and strategic development of vaccines and other products, enables him to provide commercial and
strategic leadership to the Company and qualifies Mr.&nbsp;Gray to be nominated as a director. Mr.&nbsp;Gray received a Bachelor of Science degree in Chemistry and Management Studies from the University of London and an MBA from the Cranfield School
of Management in the UK. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Laura Brege </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Brege has been a member of our Board since February 2015. Since September 2015, she has served as managing director of Cervantes Life Science Partners, LLC, a consulting firm providing integrated
business solutions to life sciences companies. She has over 20 years of executive management experience in the pharmaceutical, biotechnology and venture capital industries. From September 2012 to July 2015, Ms.&nbsp;Brege was President and Chief
Executive Officer of Nodality Inc., a life sciences company focused on innovative personalized medicine. Prior to joining Nodality in 2012, Ms.&nbsp;Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., a biopharmaceutical and
biotherapeutics company, from 2006 until 2012, including positions as Executive Vice President and Chief Operating Officer. While at Onyx she led multiple functions, including commercialization, strategic planning, corporate development, and
medical, scientific and government affairs. Prior to Onyx, Ms.&nbsp;Brege was a General Partner at Red Rock Capital Management, a venture capital firm specializing in early stage financing for technology companies. Previously Ms.&nbsp;Brege was
Senior Vice President and Chief Financial Officer at COR Therapeutics, where she helped build the company from an early stage R&amp;D company through commercial launch of a successful cardiovascular product. Earlier in her career, she served as
Chief Financial Officer at Flextronics, Inc. and Treasurer of The Cooper Companies. She serves on the board of directors of the following public pharmaceutical companies: Acadia Pharmaceuticals, Inc., Pacira Pharmaceuticals, Inc., Portola
Pharmaceuticals, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Inc. and HLS Therapeutics, Inc., a pharmaceutical company. During the past five years, Ms.&nbsp;Brege also served on the boards of directors of Angiotech Pharmaceuticals, Inc., a biotechnology
company, Delcath Systems, Inc., a pharmaceutical company, and Aratana Therapeutics Inc., a pharmaceutical company. Our Board believes that Ms.&nbsp;Brege&#146;s background in finance and management of biotechnology companies and her participation as
a member of the audit committees of other public companies provides important strategic insights for the Board in setting strategy and reviewing the operations of the Company, as well as qualifies Ms.&nbsp;Brege to be nominated as a director.
Ms.&nbsp;Brege attended all Board and Audit Committee meetings of the Company and all meetings of the boards and committees on which she sits at other companies during the past year. Ms.&nbsp;Brege earned her undergraduate degrees from Ohio
University (Honors Tutorial College) and her MBA degree from the University of Chicago. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>LASS</SMALL> II D<SMALL>IRECTORS</SMALL>
C<SMALL>ONTINUING</SMALL> <SMALL>IN</SMALL> O<SMALL>FFICE</SMALL> U<SMALL>NTIL</SMALL> <SMALL>THE</SMALL> 2020 A<SMALL>NNUAL</SMALL> M<SMALL>EETING</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Daniel L. Kisner, M.D. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Kisner has been a member of our Board
since July 2010. From 2003 to 2010, Dr.&nbsp;Kisner served as a partner at Aberdare Ventures and prior to that as President and CEO of Caliper Technologies, leading its evolution from a <FONT STYLE="white-space:nowrap">start-up</FONT> focused on
microfluidic <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">lab-on-chip</FONT></FONT> technology to a publicly traded, commercial organization. Prior to Caliper, he was the President and Chief Operating Officer of Isis
Pharmaceuticals, Inc., a biomedical pharmaceutical company. Previously, Dr.&nbsp;Kisner was Division Vice President of Pharmaceutical Development for Abbott Laboratories and Vice President of Clinical Research and Development at SmithKline Beckman
Pharmaceuticals. In addition, he held a tenured position in the Division of Oncology at the University of Texas, San Antonio School of Medicine and is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology.
Additionally, he is currently serving on the boards of Conatus Pharmaceuticals, Inc., a biotechnology company and Zynerba Pharmaceuticals, a biotechnology company. Dr.&nbsp;Kisner previously served as Chairman of the board for Tekmira
Pharmaceuticals, a biopharmaceutical company, until March 2015, and as a director of Lpath, Inc., a medical device company. Our Board believes that Dr.&nbsp;Kisner&#146;s background with larger, complex technology-based organizations as well as his
significant experience with corporate transactions, including investing in venture-backed life science companies provides the Board with insights for setting strategy of the Company and qualifies him to serve as a director. He holds a B.A. from
Rutgers University and an M.D. from Georgetown University. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Natale (&#147;Nat&#148;) Ricciardi </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Ricciardi has been a member of our Board since June 2013. Mr.&nbsp;Ricciardi spent his entire
<FONT STYLE="white-space:nowrap">39-year</FONT> career at Pfizer Inc., a biopharmaceutical company, retiring in 2011 as a member of the Pfizer Executive Leadership Team. While holding the positions of President, Pfizer Global Manufacturing, and
Senior Vice President of Pfizer Inc. from 2004 until 2011, Mr.&nbsp;Ricciardi was directly responsible for all of Pfizer&#146;s internal and external supply organization, a global enterprise that grew to more than 100 manufacturing facilities
supplying small and large molecule pharmaceuticals, vaccines, consumer, nutrition and animal health products. Mr.&nbsp;Ricciardi maintained responsibility for global manufacturing activities from 2004 through 2011. Previously, from 1999 to 2004, he
had oversight for Pfizer&#146;s U.S. manufacturing operations and from 1995 to 1999 was Vice President of Manufacturing for Pfizer&#146;s Animal Health Group. Mr.&nbsp;Ricciardi is currently a member of the board of directors of Rapid Micro
Biosystems, Inc., a technology company focused on microbiology automation, and Prestige Consumer Healthcare, Inc., a healthcare company. Mr.&nbsp;Ricciardi also serves as a member of the board of directors of the 21st Century Foundation of The City
College of New York and as a member of the Advisory Board of HealthCare Royalty Partners. Our Board believes Mr.&nbsp;Ricciardi&#146;s <FONT STYLE="white-space:nowrap">39-year</FONT> career at Pfizer Inc., a leading pharmaceutical company, including
as a member of the Pfizer Executive Leadership Team and direct responsibility for all of Pfizer&#146;s internal supply organization, including global manufacturing, provides the Board with insights for reviewing the operations of the Company and
qualifies him to serve as a director. Mr.&nbsp;Ricciardi earned a degree in Chemical Engineering from The City College of New York and an MBA in Finance and International Business from Fordham University. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>LASS</SMALL> III D<SMALL>IRECTORS</SMALL> C<SMALL>ONTINUING</SMALL> <SMALL>IN</SMALL>
O<SMALL>FFICE</SMALL> U<SMALL>NTIL</SMALL> <SMALL>THE</SMALL> 2021 A<SMALL>NNUAL</SMALL> M<SMALL>EETING</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Arnold L. Oronsky,
Ph.D. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Oronsky has been a member of our Board since November 1996 and became Chairperson of
the Board in February 2006. Dr.&nbsp;Oronsky has been a managing director with InterWest Partners, a venture capital firm, since 2009. Prior to joining InterWest Partners in 1994, Dr.&nbsp;Oronsky was Vice President of Discovery Research for the
Lederle Laboratories division of American Cyanamid, a pharmaceutical company. From 1973 until 1976, Dr.&nbsp;Oronsky was head of the inflammation, allergy and immunology research program at Ciba-Geigy Pharmaceutical Company. Dr.&nbsp;Oronsky also
serves as a senior lecturer in the Department of Medicine at The Johns Hopkins Medical School. Dr.&nbsp;Oronsky has won numerous grants and awards and has published over 125 scientific articles. Dr.&nbsp;Oronsky currently serves on the board of
directors of KalVista Pharmaceuticals, Inc., a biotechnology company.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"> </SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Oronsky also served on the board of directors of MacroGenics, Inc., a biopharmaceutical company, from 2000 to 2014, Applied Genetic Technologies Corporation, a biotechnology company, from
November 2003 until August 2017, and Tesaro, Inc., an oncology-focused biopharmaceutical company from June 2011 until May 2018. The Board believes that Dr.&nbsp;Oronsky&#146;s significant experience in growing and developing life sciences companies,
particularly in the immunology area, provides significant leadership and insights for the Board in defining the strategy of the Company and qualifies him to serve as a director. He received his Ph.D. from Columbia University, College of Physicians
and Surgeons and his A.B. from New York University. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Francis R. Cano, Ph.D. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Cano was appointed to our Board in November 2009. Dr.&nbsp;Cano has been President and Founder of Cano Biotech Corp., a
consulting firm focusing on the vaccine business, since 1996 and also serves on the board of Biomerica, Inc., a developer and manufacturer of diagnostic products. Previously, Dr.&nbsp;Cano served on the board of Arbor Vita Corporation, a
biopharmaceutical company. From 1993 to 1996, Dr.&nbsp;Cano was President and Chief Operating Officer for Aviron, a biopharmaceutical company, which was later acquired by MedImmune in 2001. As a <FONT STYLE="white-space:nowrap">Co-Founder</FONT> of
Aviron, he completed two rounds of venture financing, a licensing agreement with SmithKline Biologicals and <FONT STYLE="white-space:nowrap">in-licensed</FONT> <FONT STYLE="white-space:nowrap">Flu-Mist</FONT> influenza vaccine from the National
Institutes of Health. For 21 years, Dr.&nbsp;Cano worked with the Lederle Laboratories Division of American Cyanamid, including as its Vice President and General Manager of the Biologicals unit. The Board believes that Dr.&nbsp;Cano&#146;s
experience as a founder of and advisor to established vaccine businesses provides significant insights for the strategy of the Company with respect to key technical and operational issues in vaccine development and qualifies him to serve as a
director. He earned a Ph.D. in Microbiology from Pennsylvania State University, served as a Research Associate at Rutgers Institute of Microbiology, and holds a M.S. in Microbiology and a B.S. in Biology from St. John&#146;s University. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Peggy V. Phillips </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Phillips has been a member of our Board since August 2006. Ms.&nbsp;Phillips served on the board of directors of several biopharmaceutical companies: PhaseRx, Inc. from 2016 to 2018, Tekmira
Pharmaceuticals from 2014 to 2015, Portola Pharmaceuticals from 2006 to 2013, as well as the Naval Academy Foundation from 2003 to 2011. From 1996 until 2002, she served on the board of directors of Immunex Corporation, a biotechnology company, and,
from 1999, she served as its Chief Operating Officer until the company was acquired by Amgen in 2002. During her career at Immunex, she held positions of increasing responsibility in research, development, manufacturing, sales and marketing. As
Senior Vice President for Pharmaceutical Development and General Manager for Enbrel<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> from 1994 until 1998, she
was responsible for clinical development and regulatory affairs as well as the launch, sales and marketing of the product. Prior to joining Immunex, Ms.&nbsp;Phillips worked at Miles Laboratories. The Board believes that Ms.&nbsp;Phillips provides
significant experience in development and commercialization of biotechnology products. Her background and experience with larger, complex organizations provides significant operational and strategic insights in assessing the strategy of the Company
and qualifies her to serve as a director. Ms.&nbsp;Phillips holds a B.S. and a M.S. in microbiology from the University of Idaho. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROPOSAL 2 </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>APPROVAL OF AN AMENDMENT AND RESTATEMENT OF THE 2018 EQUITY INCENTIVE PLAN </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board is requesting stockholder approval of an amendment and restatement of the Dynavax Technologies Corporation 2018 Equity
Incentive Plan (the &#147;2018 EIP&#148;). We refer to such amendment and restatement of the 2018 EIP in this proxy statement as the &#147;Amended 2018 EIP&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Amended 2018 EIP contains the following material changes from the 2018 EIP: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to adjustment for certain changes in our capitalization, the aggregate number of shares of our common stock that may be issued under the
Amended 2018 EIP will not exceed 7,440,250 shares (plus the Prior Plans&#146; Returning Shares (as defined below), as such shares become available from time to time), which is an increase of 2,300,000 shares over the aggregate number of shares of
our common stock that may be issued under the 2018 EIP. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 2018 EIP contains a &#147;fungible share counting&#148; structure, whereby the number of shares of our common stock available for issuance under
the 2018 EIP will be reduced by: (i)&nbsp;one share for each share issued pursuant to a stock option or stock appreciation right with an exercise price that is at least 100% of the fair market value of our common stock on the date of grant (an
&#147;Appreciation Award&#148;) granted under the 2018 EIP; and (ii) 1.28 shares for each share issued pursuant to a stock award that is not an Appreciation Award (a &#147;Full Value Award&#148;) granted under the 2018 EIP. The Amended 2018 EIP
retains such fungible share counting structure, except that the number of shares of our common stock available for issuance under the Amended 2018 EIP will be reduced by 1.40 shares for each share issued pursuant to a stock award that is a Full
Value Award granted under the Amended 2018 EIP on or after May&nbsp;30, 2019. As part of such fungible share counting structure, the number of shares of our common stock available for issuance under the Amended 2018 EIP will be increased by:
(i)&nbsp;one share for each share that becomes available again for issuance under the terms of the Amended 2018 EIP subject to an Appreciation Award and (ii) 1.40 shares for each share that becomes available again for issuance under the terms of the
Amended 2018 EIP subject to a Full Value Award on or after May&nbsp;30, 2019. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 2018 EIP provides that if a corporate transaction or change in control (each, a &#147;Transaction&#148;) occurs and the surviving or acquiring
corporation (or its parent company) does not assume or continue outstanding awards under the 2018 EIP and/or any Prior Plan (i.e., the Dynavax Technologies Corporation 2011 Equity Incentive Plan (the &#147;2011 EIP&#148;) or the Dynavax Technologies
Corporation 2017 Inducement Award Plan), or substitute similar stock awards for such outstanding awards, then with respect to any such awards that have not been assumed, continued or substituted and that are held by participants whose continuous
service has not terminated prior to the Transaction, the vesting of such awards will be accelerated in full to a date prior to the Transaction (contingent upon the closing or completion of the Transaction). The Amended 2018 EIP retains such
provision, but specifies that for purposes of such acceleration, with respect to performance stock awards, vesting will be deemed to be satisfied at the target level of performance. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Why We Are Asking Our Stockholders to Approve the Amended 2018 EIP </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are seeking stockholder approval of the Amended 2018 EIP to increase the number of shares available for the grant of stock options, restricted stock unit awards and other awards by 2,300,000 shares,
which will enable us to have a competitive equity incentive program to compete with our peer group for key talent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
stockholders&#146; approval of the Amended 2018 EIP will allow us to continue to grant stock options, restricted stock unit awards and other awards at levels determined appropriate by the Board or Compensation Committee. The Amended 2018 EIP will
also allow us to further utilize a broad array of equity incentives in order to secure and retain the services of our employees and directors, and to continue to provide long-term incentives that align the interests of our employees and directors
with the interests of our stockholders. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stockholder Approval </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If this Proposal 2 is approved by our stockholders, the Amended 2018 EIP will become effective as of the date of the Annual Meeting. In the event that our stockholders do not approve this Proposal 2, the
Amended 2018 EIP will not become effective and the 2018 EIP will continue in its current form. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Why You Should Vote for the
Amended 2018 EIP </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The Amended 2018 EIP Combines Compensation and Governance Best Practices </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Amended 2018 EIP includes provisions that are designed to protect our stockholders&#146; interests and to reflect corporate governance
best practices including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stockholder approval is required for additional shares</I>.&nbsp;&nbsp;&nbsp;&nbsp;The Amended 2018 EIP does not contain an annual
&#147;evergreen&#148; provision. The Amended 2018 EIP authorizes a fixed number of shares, so that stockholder approval is required to issue any additional shares. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Repricing is not allowed</I>.&nbsp;&nbsp;&nbsp;&nbsp;The Amended 2018 EIP prohibits the repricing of stock options and stock appreciation rights
without prior stockholder approval. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>No discounted stock options or stock appreciation rights.</I>&nbsp;&nbsp;&nbsp;&nbsp;All stock options and stock appreciation rights granted under
the Amended 2018 EIP must have an exercise price equal to or greater than the fair market value of our common stock on the date the stock option or stock appreciation right is granted. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Reasonable share counting provisions.</I>&nbsp;&nbsp;&nbsp;&nbsp;In general, when awards granted under the Amended 2018 EIP lapse or are canceled,
the shares reserved for those awards will be returned to the share reserve and be available for future awards. However, any shares received from the exercise of stock options or withheld for taxes will not be returned to our share reserve.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Minimum vesting requirements.</I>&nbsp;&nbsp;&nbsp;&nbsp;The Amended 2018 EIP provides that no award may vest until at least 12 months following the
date of grant of such award, except that shares up to 5% of the share reserve of the Amended 2018 EIP may be issued pursuant to awards that do not meet such vesting requirements. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Limit on <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation.</I>&nbsp;&nbsp;&nbsp;&nbsp;The aggregate value of all cash and
equity-based compensation granted or paid by us to any individual for service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director of the Board with respect to any fiscal year of the Company will not exceed (i)&nbsp;a total of $200,000
with respect to any such cash compensation and (ii)&nbsp;$800,000 in total value with respect to any such equity-based compensation (including awards granted under the Amended 2018 EIP and any other equity-based awards), calculating the value of any
such awards based on the grant date fair value of such awards for financial reporting purposes. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Restrictions on dividends.</I>&nbsp;&nbsp;&nbsp;&nbsp;The Amended 2018 EIP provides that (i)&nbsp;no dividends or dividend equivalents may be paid
with respect to any shares of our common stock subject to an award before the date such shares have vested, (ii)&nbsp;any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and
conditions applicable to such shares under the terms of the applicable award agreement (including any vesting conditions), and (iii)&nbsp;any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to us
on the date such shares are forfeited to or repurchased by us due to a failure to vest. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overhang </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table provides certain information regarding our equity incentive program. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;of&nbsp;April&nbsp;9,&nbsp;2019</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total number of shares of common stock
subject to outstanding stock options</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,293,909</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted-average exercise price of
outstanding stock options</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.22</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted-average remaining term of
outstanding stock options</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.60 years</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total number of shares of common stock
subject to outstanding full value awards</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,189,334</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total number of shares of common stock
available for grant under the 2018 EIP</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,554,878</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total number of shares of common stock
outstanding</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65,063,889</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Per-share</FONT> closing price of common stock as reported on NASDAQ Capital Market</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.99</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">As of April&nbsp;9, 2019, there were no shares of common stock available for grant under any of our other equity incentive plans.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We Manage Our Equity Incentive Award Use Carefully and Dilution Is Reasonable </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We continue to believe that equity incentive awards such as stock options and restricted stock unit awards are a vital part of our overall
compensation program. Our compensation philosophy reflects broad-based eligibility for equity incentive awards, and we grant awards to substantially all of our employees. However, we recognize that equity incentive awards dilute existing
stockholders, and, therefore, we must responsibly manage the growth of our equity compensation program. We are committed to effectively monitoring our equity compensation share reserve, including our &#147;burn rate,&#148; to ensure that we maximize
stockholders&#146; value by granting the appropriate number of equity incentive awards necessary to attract, reward, and retain employees. In addition, the vesting of some of our equity awards granted to our named executive officers are contingent
on meeting <FONT STYLE="white-space:nowrap">pre-defined</FONT> performance criteria, thereby ensuring alignment with value creation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table shows our responsible historical dilution and burn rate percentages. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of December&nbsp;31</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Full Dilution</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross Burn Rate (as discussed in greater detail below)</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Full Dilution is calculated as (shares available for grant + shares subject to outstanding equity incentive awards)/(weighted average common stock
outstanding + shares available for grant + shares subject to outstanding equity incentive awards). </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Gross Burn Rate is calculated as (shares subject to options granted + shares subject to other equity incentive awards granted)/weighted average common
stock outstanding. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The Size of Our Share Reserve Increase Request Is Reasonable </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If this Proposal 2 is approved by our stockholders, we will have 2,300,000 new shares available for grant after our Annual Meeting for a
total of approximately 3,854,878 shares available for grant after our Annual Meeting (plus the Prior Plans&#146; Returning Shares (as defined below), as such shares become available from time to time), and absent any unforeseen circumstances, we
anticipate returning to stockholders for additional shares in 2020. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Burn Rate </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table provides detailed information regarding the activity related to our equity incentive plans for fiscal years 2018, 2017 and 2016. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8px">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fiscal&nbsp;Year&nbsp;2018</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fiscal&nbsp;Year&nbsp;2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fiscal&nbsp;Year&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total
number of shares of common stock subject to stock options granted</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,502,817</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">535,497</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,414,262</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total number of shares of common stock subject to full value awards
granted</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">457,542</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,217,303</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">856,258</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted-average number of shares of common stock outstanding</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,361,828</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,613,215</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,505,856</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Burn Rate</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.75</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.23</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.90</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Description of the Amended 2018 EIP </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A summary of the principal features of the Amended 2018 EIP follows below. The summary is qualified by the full text of the Amended 2018
EIP that is attached as Appendix A to this proxy statement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Purpose </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Amended 2018 EIP is designed to secure and retain the services of our employees and directors, provide incentives for our employees
and directors to exert maximum efforts for the success of the Company and its affiliates, and provide a means by which our employees and directors may be given an opportunity to benefit from increases in the value of our common stock. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Types of Awards </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Amended 2018 EIP provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock
awards, and other stock awards. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Shares Available for Awards </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to adjustment for certain changes in our capitalization, the aggregate number of shares of our common stock that may be issued
under the Amended 2018 EIP will not exceed 7,440,250 shares (which is the sum of (i) 140,250 shares (the number of unallocated shares that were available for grant under the 2011 EIP as of the effective date of the 2018 EIP), (ii) 5,000,000
additional shares that were reserved as of the effective date of the 2018 EIP, and (iii) 2,300,000 newly requested shares), plus the Prior Plans&#146; Returning Shares (as defined below), as such shares become available from time to time.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term &#147;Prior Plans&#146; Returning Shares&#148; refers to the following shares of our common stock subject to any
outstanding stock award granted under either of the Prior Plans: (i)&nbsp;any shares subject to such stock award that are not issued because such stock award expires or otherwise terminates without all of the shares covered by such stock award
having been issued; (ii)&nbsp;any shares subject to such stock award that are not issued because such stock award is settled in cash; and (iii)&nbsp;any shares issued pursuant to such stock award that are forfeited back to or repurchased by us
because of a failure to vest. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following shares of our common stock (collectively, the &#147;Amended 2018 EIP Returning
Shares&#148;) will also become available again for issuance under the Amended 2018 EIP: (i)&nbsp;any shares subject to a stock award granted under the Amended 2018 EIP that are not issued because such stock award expires or otherwise terminates
without all of the shares covered by such stock award having been issued; (ii)&nbsp;any shares subject to a stock award granted </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
under the Amended 2018 EIP that are not issued because such stock award is settled in cash; and (iii)&nbsp;any shares issued pursuant to a stock award granted under the Amended 2018 EIP that are
forfeited back to or repurchased by us because of a failure to vest. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following shares of our common stock will not become
available again for issuance under the Amended 2018 EIP: (i)&nbsp;any shares that are reacquired or withheld (or not issued) by us to satisfy the exercise, strike or purchase price of a stock award granted under the Amended 2018 EIP or any Prior
Plan (including any shares subject to such award that are not delivered because such award is exercised through a reduction of shares subject to such award); (ii)&nbsp;any shares that are reacquired or withheld (or not issued) by us to satisfy a tax
withholding obligation in connection with a stock award granted under the Amended 2018 EIP or any Prior Plan; (iii)&nbsp;any shares repurchased by us on the open market with the proceeds of the exercise, strike or purchase price of a stock award
granted under the Amended 2018 EIP or any Prior Plan; and (iv)&nbsp;in the event that a stock appreciation right granted under the Amended 2018 EIP or any Prior Plan is settled in shares, the gross number of shares subject to such award. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of shares of our common stock available for issuance under the Amended 2018 EIP will be reduced by: (i)&nbsp;one share for
each share issued pursuant to an Appreciation Award granted under the Amended 2018 EIP; (ii) 1.28 shares for each share issued pursuant to a Full Value Award granted under the Amended 2018 EIP prior to May&nbsp;30, 2019; and (iii) 1.40 shares for
each share issued pursuant to a Full Value Award granted under the Amended 2018 EIP on or after May&nbsp;30, 2019. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number
of shares of our common stock available for issuance under the Amended 2018 EIP will be increased by: (i)&nbsp;one share for each Prior Plans&#146; Returning Share or Amended 2018 EIP Returning Share subject to an Appreciation Award; (ii) 1.28
shares for each Prior Plans&#146; Returning Share or Amended 2018 EIP Returning Share subject to a Full Value Award that returns to the Amended 2018 EIP prior to May&nbsp;30, 2019; and (iii) 1.40 shares for each Prior Plans&#146; Returning Share or
Amended 2018 EIP Returning Share subject to a Full Value Award that returns to the Amended 2018 EIP on or after May&nbsp;30, 2019. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Eligibility </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All of our (including our affiliates&#146;) employees
and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors are eligible to participate in the Amended 2018 EIP and may receive all types of awards other than incentive stock options. Incentive stock options may be granted under the Amended
2018 EIP only to our (including our affiliates&#146;) employees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of April&nbsp;9, 2019, we (including our affiliates) had
approximately 298 employees and seven <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The aggregate value of all cash and
equity-based compensation granted or paid by us to any individual for service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director of the Board with respect to any fiscal year of the Company will not exceed (i)&nbsp;a total of $200,000
with respect to any such cash compensation and (ii)&nbsp;$800,000 in total value with respect to any such equity-based compensation (including awards granted under the Amended 2018 EIP and any other equity-based awards), calculating the value of any
such awards based on the grant date fair value of such awards for financial reporting purposes. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Administration
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Amended 2018 EIP will be administered by our Board, which may in turn delegate authority to administer the Amended
2018 EIP to a committee. Our Board has delegated concurrent authority to administer the Amended 2018 EIP to our Compensation Committee, but may, at any time, <FONT STYLE="white-space:nowrap">re-vest</FONT> in itself some or all of the power
delegated to our Compensation Committee. Our Board and Compensation Committee are each considered to be a Plan Administrator for purposes of this Proposal 2. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the terms of the Amended 2018 EIP, the Plan Administrator may determine the
recipients, the types of awards to be granted, the number of shares of our common subject to or the cash value of awards, and the terms and conditions of awards granted under the Amended 2018 EIP, including the period of their exercisability and
vesting. The Plan Administrator also has the authority to provide for accelerated exercisability and vesting of awards. Subject to the limitations set forth below, the Plan Administrator also determines the fair market value applicable to a stock
award and the exercise or strike price of stock options and stock appreciation rights granted under the Amended 2018 EIP. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Plan Administrator may also delegate to one or more officers the authority to designate employees who are not officers to be recipients of certain stock awards and the number of shares of our common stock subject to such stock awards. Under any such
delegation, the Plan Administrator will specify the total number of shares of our common stock that may be subject to the stock awards granted by such officer. The officer may not grant a stock award to himself or herself. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Repricing; Cancellation and <FONT STYLE="white-space:nowrap">Re-Grant</FONT> of Stock Awards </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Amended 2018 EIP, the Plan Administrator does not have the authority to reprice any outstanding stock option or stock
appreciation right by reducing the exercise or strike price of the stock option or stock appreciation right or to cancel any outstanding stock option or stock appreciation right that has an exercise or strike price greater than the then-current fair
market value of our common stock in exchange for cash or other stock awards without obtaining the approval of our stockholders. Such approval must be obtained within 12 months prior to such an event. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Minimum Vesting Requirements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the Amended 2018 EIP, no award may vest until at least 12 months following the date of grant of such award, except that shares up to 5% of the share reserve of the Amended 2018 EIP may be issued
pursuant to awards that do not meet such vesting requirements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Dividends and Dividend Equivalents </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Amended 2018 EIP provides that dividends or dividend equivalents may be paid or credited with respect to any shares of our common
stock subject to an award, as determined by the Plan Administrator and contained in the applicable award agreement;<I>&nbsp;provided, however</I>, that (i)&nbsp;no dividends or dividend equivalents may be paid with respect to any such shares before
the date such shares have vested, (ii)&nbsp;any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and conditions applicable to such shares under the terms of the applicable award
agreement (including any vesting conditions), and (iii)&nbsp;any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to us on the date such shares are forfeited to or repurchased by us due to a
failure to vest. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock Options </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Stock options may be granted under the Amended 2018 EIP pursuant to stock option agreements. The Amended 2018 EIP permits the grant of stock options that are intended to qualify as incentive stock
options, or ISOs, and nonstatutory stock options, or NSOs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The exercise price of a stock option granted under the Amended
2018 EIP may not be less than 100% of the fair market value of our common stock on the date of grant and, in some cases (see &#147;Limitations on Incentive Stock Options&#148; below), may not be less than 110% of such fair market value. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term of stock options granted under the Amended 2018 EIP may not exceed seven years from the date of grant and, in some cases (see
&#147;Limitations on Incentive Stock Options&#148; below), may not exceed five years from the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
date of grant. Except as otherwise provided in a participant&#146;s stock option agreement or other written agreement with us or one of our affiliates, if a participant&#146;s service
relationship with us or any of our affiliates (referred to in this Proposal 2 as &#147;continuous service&#148;) terminates (other than for cause and other than upon the participant&#146;s death or disability), the participant may exercise any
vested stock options for up to three months following the participant&#146;s termination of continuous service. Except as otherwise provided in a participant&#146;s stock option agreement or other written agreement with us or one of our affiliates,
if a participant&#146;s continuous service terminates due to the participant&#146;s disability or death (or the participant dies within a specified period, if any, following termination of continuous service), the participant, or his or her
beneficiary, as applicable, may exercise any vested stock options for up to 12 months following the participant&#146;s termination due to the participant&#146;s disability or for up to 18 months following the participant&#146;s death. Except as
explicitly provided otherwise in a participant&#146;s stock option agreement or other written agreement with us or one of our affiliates, if a participant&#146;s continuous service is terminated for cause (as defined in the Amended 2018 EIP), all
stock options held by the participant will terminate upon the participant&#146;s termination of continuous service and the participant will be prohibited from exercising any stock option from and after such termination date. Except as otherwise
provided in a participant&#146;s stock option agreement or other written agreement with us or one of our affiliates, the term of a stock option may be extended if the exercise of the stock option following the participant&#146;s termination of
continuous service (other than for cause and other than upon the participant&#146;s death or disability) would be prohibited by applicable securities laws or if the sale of any common stock received upon exercise of the stock option following the
participant&#146;s termination of continuous service (other than for cause) would violate our insider trading policy. In no event, however, may a stock option be exercised after its original expiration date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acceptable forms of consideration for the purchase of our common stock pursuant to the exercise of a stock option under the Amended 2018
EIP will be determined by the Plan Administrator and may include payment: (i)&nbsp;by cash, check, bank draft or money order payable to us; (ii)&nbsp;pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board;
(iii)&nbsp;by delivery to us of shares of our common stock (either by actual delivery or attestation); (iv)&nbsp;by a net exercise arrangement (for NSOs only); or (v)&nbsp;in other legal consideration approved by the Plan Administrator. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock options granted under the Amended 2018 EIP may vest and become exercisable in cumulative increments, as determined by the Plan
Administrator at the rate specified in the stock option agreement (subject to the limitations described in &#147;Minimum Vesting Requirements&#148; above). Shares covered by different stock options granted under the Amended 2018 EIP may be subject
to different vesting schedules as the Plan Administrator may determine. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Plan Administrator may impose limitations on the
transferability of stock options granted under the Amended 2018 EIP in its discretion. Generally, a participant may not transfer a stock option granted under the Amended 2018 EIP other than by will or the laws of descent and distribution or, subject
to approval by the Plan Administrator, pursuant to a domestic relations order or an official marital settlement agreement. However, the Plan Administrator may permit transfer of a stock option in a manner that is not prohibited by applicable tax and
securities laws. In addition, subject to approval by the Plan Administrator, a participant may designate a beneficiary who may exercise the stock option following the participant&#146;s death. Notwithstanding the foregoing, no option may be
transferred to any financial institution without prior stockholder approval. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Limitations on Incentive Stock Options
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The aggregate fair market value, determined at the time of grant, of shares of our common stock with respect to ISOs
that are exercisable for the first time by a participant during any calendar year under all of our stock plans may not exceed $100,000. The stock options or portions of stock options that exceed this limit or otherwise fail to qualify as ISOs are
treated as NSOs. No ISO may be granted to any person who, at the time of grant, owns or is deemed to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
own stock possessing more than 10% of our total combined voting power or that of any affiliate unless the following conditions are satisfied: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the exercise price of the ISO must be at least 110% of the fair market value of our common stock on the date of grant; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the term of the ISO must not exceed five years from the date of grant. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to adjustment for certain changes in our capitalization, the aggregate maximum number of shares of our common stock that may be
issued pursuant to the exercise of ISOs under the Amended 2018 EIP is 10,000,000 shares. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock Appreciation Rights
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock appreciation rights may be granted under the Amended 2018 EIP pursuant to stock appreciation right agreements.
Each stock appreciation right is denominated in common stock share equivalents. The strike price of each stock appreciation right will be determined by the Plan Administrator, but will in no event be less than 100% of the fair market value of our
common stock on the date of grant. The term of stock appreciation rights granted under the Amended 2018 EIP may not exceed seven years from the date of grant. The Plan Administrator may also impose restrictions or conditions upon the vesting of
stock appreciation rights that it deems appropriate (subject to the limitations described in &#147;Minimum Vesting Requirements&#148; above). The appreciation distribution payable upon exercise of a stock appreciation right may be paid in shares of
our common stock, in cash, in a combination of cash and stock, or in any other form of consideration determined by the Plan Administrator and set forth in the stock appreciation right agreement. Stock appreciation rights will be subject to the same
conditions upon termination of continuous service and restrictions on transfer as stock options under the Amended 2018 EIP. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Restricted Stock Awards </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Restricted stock awards may be granted under the Amended 2018 EIP pursuant to restricted stock award agreements. A restricted stock award may be granted in consideration for cash, check, bank draft or
money order payable to us, the participant&#146;s services performed for us or any of our affiliates, or any other form of legal consideration acceptable to the Plan Administrator. Shares of our common stock acquired under a restricted stock award
may be subject to forfeiture to or repurchase by us in accordance with a vesting schedule to be determined by the Plan Administrator (subject to the limitations described in &#147;Minimum Vesting Requirements&#148; above). Rights to acquire shares
of our common stock under a restricted stock award may be transferred only upon such terms and conditions as are set forth in the restricted stock award agreement;<I>&nbsp;provided, however</I>, that no restricted stock award may be transferred to
any financial institution without prior stockholder approval. Upon a participant&#146;s termination of continuous service for any reason, any shares subject to restricted stock awards held by the participant that have not vested as of such
termination date may be forfeited to or repurchased by us. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Restricted Stock Unit Awards </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock unit awards may be granted under the Amended 2018 EIP pursuant to restricted stock unit award agreements. Payment of any
purchase price may be made in any form of legal consideration acceptable to the Plan Administrator. A restricted stock unit award may be settled by the delivery of shares of our common stock, in cash, in a combination of cash and stock, or in any
other form of consideration determined by the Plan Administrator and set forth in the restricted stock unit award agreement. Restricted stock unit awards may be subject to vesting in accordance with a vesting schedule to be determined by the Plan
Administrator (subject to the limitations described in &#147;Minimum Vesting Requirements&#148; above). Except as otherwise provided in a participant&#146;s restricted stock unit award agreement or other written agreement with us or one of our
affiliates, restricted stock units that have not vested will be forfeited upon the participant&#146;s termination of continuous service for any reason. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Performance Stock Awards </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A performance stock award is a stock award that is payable (including that may be granted, may vest, or may be exercised) contingent upon
the attainment of <FONT STYLE="white-space:nowrap">pre-determined</FONT> performance goals during a performance period. A performance stock award may require the completion of a specified period of continuous service. The length of any performance
period, the performance goals to be achieved during the performance period, and the measure of whether and to what degree such performance goals have been attained will be determined by the Plan Administrator (subject to the limitations described in
&#147;Minimum Vesting Requirements&#148; above). In addition, to the extent permitted by applicable law and the performance stock award agreement, the Plan Administrator may determine that cash may be used in payment of performance stock awards.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Performance goals under the Amended 2018 EIP will be based on any one or more of the following performance criteria:
(i)&nbsp;earnings (including earnings per share and net earnings); (ii) earnings before interest, taxes and depreciation; (iii)&nbsp;earnings before interest, taxes, depreciation and amortization (EBITDA); (iv) total stockholder return;
(v)&nbsp;return on equity or average stockholder&#146;s equity; (vi)&nbsp;return on assets, investment, or capital employed; (vii)&nbsp;stock price or stock price performance; (viii)&nbsp;margin (including gross margin); (ix) net income (before or
after taxes); (x) operating income; (xi)&nbsp;operating income after taxes; <FONT STYLE="white-space:nowrap">(xii)&nbsp;pre-tax</FONT> profit; (xiii)&nbsp;operating cash flow; (xiv)&nbsp;sales or revenue targets; (xv)&nbsp;increases in revenue or
product revenue; (xvi)&nbsp;expenses and cost reduction goals; (xvii)&nbsp;improvement in or attainment of working capital levels; (xviii)&nbsp;economic value added (or an equivalent metric); (xix) market share; (xx)&nbsp;cash flow; (xxi)&nbsp;cash
flow per share; (xxii)&nbsp;share price performance; (xxiii)&nbsp;debt reduction; (xxiv)&nbsp;implementation or completion of projects or processes; (xxv)&nbsp;customer satisfaction; (xxvi)&nbsp;stockholders&#146; equity; (xxvii)&nbsp;capital
expenditures; (xxviii)&nbsp;debt levels; (xxix)&nbsp;operating profit or net operating profit; (xxx)&nbsp;workforce diversity; (xxxi)&nbsp;growth of net income or operating income; (xxxii)&nbsp;billings; (xxxiii) submission to, or approval by, a
regulatory body (including but not limited to the U.S. Food and Drug Administration) of an applicable filing for a product candidate or other product development milestones; (xxxiv)&nbsp;acquisitions, divestitures, joint ventures, strategic
alliances, licenses or collaborations; (xxxv)&nbsp;spin-offs, <FONT STYLE="white-space:nowrap">split-ups,</FONT> reorganizations, recapitalizations, restructurings, financings (debt or equity) or refinancings; (xxxvi)&nbsp;manufacturing or process
development, clinical trial, regulatory, intellectual property, compliance or research objectives; and (xxxvii)&nbsp;any other measures of performance selected by the Plan Administrator. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Performance goals may be based on a company-wide basis, with respect to one or more business units, divisions, affiliates or business
segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. The Plan Administrator is authorized to make appropriate adjustments in the method of
calculating the attainment of performance goals for a performance period as follows: (i)&nbsp;to exclude restructuring and/or other nonrecurring charges; (ii)&nbsp;to exclude exchange rate effects, as applicable, for
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> dollar denominated performance goals; (iii)&nbsp;to exclude the effects of changes to generally accepted accounting principles; (iv)&nbsp;to exclude the effects of any statutory adjustments to
corporate tax rates; (v)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under generally accepted accounting principles; (vi)&nbsp;to exclude the dilutive effects of
acquisitions or joint ventures; (vii)&nbsp;to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (viii)&nbsp;to exclude the
effect of any change in the outstanding shares of our common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or
exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (ix)&nbsp;to exclude the effects of stock based compensation and/or the award of an annual cash incentive under our
Annual Incentive Program; (x)&nbsp;to exclude the effect of any other unusual, <FONT STYLE="white-space:nowrap">non-recurring</FONT> gain or loss or other extraordinary item; and (xi)&nbsp;to make other appropriate adjustments selected by the Plan
Administrator. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the Plan Administrator retains the discretion to reduce or eliminate the compensation or economic
benefit due upon the attainment of any performance goals and to define the manner of calculating the performance criteria it selects to use for a performance period. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Stock Awards </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other forms of stock awards valued in whole or in part by reference to, or otherwise based on, our common stock may be granted either
alone or in addition to other stock awards under the Amended 2018 EIP. Subject to the terms of the Amended 2018 EIP (including the limitations described in &#147;Minimum Vesting Requirements&#148; above), the Plan Administrator will have sole and
complete authority to determine the persons to whom and the time or times at which such other stock awards will be granted, the number of shares of our common stock to be granted and all other terms and conditions of such other stock awards.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clawback/Recoupment </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Awards granted under the Amended 2018 EIP will be subject to recoupment in accordance with any clawback policy that we are required to adopt pursuant to the listing standards of any national securities
exchange or association on which our securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Plan Administrator may impose other clawback, recovery
or recoupment provisions in an award agreement, including a reacquisition right in respect of previously acquired shares or other cash or property upon the occurrence of cause. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Changes to Capital Structure </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the event of certain capitalization adjustments, the Plan Administrator will appropriately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the Amended 2018 EIP; (ii)&nbsp;the
class(es) and maximum number of securities that may be issued pursuant to the exercise of ISOs; and (iii)&nbsp;the class(es) and number of securities and price per share of stock subject to outstanding stock awards. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Corporate Transaction and Change in Control </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following provisions will apply to outstanding awards under the Amended 2018 EIP and any Prior Plan in the event of a corporate transaction (as defined in the Amended 2018 EIP and described below) or
a change in control (as defined in the Amended 2018 EIP and described below) unless otherwise provided in the instrument evidencing the award, in any other written agreement between us or one of our affiliates and the participant, or in our director
compensation policy. For purposes of this Proposal 2, the term &#147;Transaction&#148; will mean such corporate transaction or change in control. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the event of a Transaction, any surviving or acquiring corporation (or its parent company) may assume or continue any or all outstanding awards under the Amended 2018 EIP and/or any Prior Plan, or may
substitute similar stock awards for such outstanding awards (including, but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Transaction), and any reacquisition or repurchase rights
held by the Company in respect of shares issued pursuant to any outstanding awards under the Amended 2018 EIP and/or any Prior Plan may be assigned by the Company to the surviving or acquiring corporation (or its parent company). The terms of any
such assumption, continuation or substitution will be set by the Plan Administrator. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event of a Transaction in which
the surviving or acquiring corporation (or its parent company) does not assume or continue outstanding awards under the Amended 2018 EIP and/or any Prior Plan, or substitute similar stock awards for such outstanding awards, then with respect to any
such awards that have not been assumed, continued or substituted and that are held by participants whose continuous service has not terminated prior to the effective time of the Transaction (the &#147;Current Participants&#148;), the vesting (and
exercisability, if applicable) of such awards will be accelerated in full (and with respect to performance stock awards, vesting will be deemed to be satisfied at the target level of performance) to a date prior to the effective time of the
Transaction (contingent upon the closing or completion of the Transaction) as the Plan Administrator will determine (or, if the Plan Administrator does not determine such a date, to the date that is five days prior to the effective time of the
Transaction), and such awards will terminate if not exercised (if applicable) prior to the effective time of the Transaction in accordance </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
with the exercise procedures determined by the Plan Administrator, and any reacquisition or repurchase rights held by the Company with respect to such awards will lapse (contingent upon the
closing or completion of the Transaction). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event of a Transaction in which the surviving or acquiring corporation (or
its parent company) does not assume or continue outstanding awards under the Amended 2018 EIP and/or any Prior Plan, or substitute similar stock awards for such outstanding awards, then with respect to any such awards that have not been assumed,
continued or substituted and that are held by participants other than the Current Participants, such awards will terminate if not exercised (if applicable) prior to the effective time of the Transaction in accordance with the exercise procedures
determined by the Plan Administrator; <I>provided, however</I>, that any reacquisition or repurchase rights held by the Company with respect to such awards will not terminate and may continue to be exercised notwithstanding the Transaction.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the foregoing, in the event any outstanding award under the Amended 2018 EIP and/or any Prior Plan held by a
participant will terminate if not exercised prior to the effective time of a Transaction, the Plan Administrator may provide that the participant may not exercise such award but instead will receive a payment, in such form as may be determined by
the Plan Administrator, equal in value to the excess, if any, of (i)&nbsp;the value of the property the participant would have received upon the exercise of such award immediately prior to the effective time of the Transaction, over (ii)&nbsp;any
exercise price payable by the participant in connection with such exercise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless provided otherwise in the
participant&#146;s award agreement, in any other written agreement or plan with us or one of our affiliates, or in our director compensation policy, outstanding awards under the Amended 2018 EIP and any Prior Plan will not be subject to additional
acceleration of vesting and exercisability upon or after a change in control. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of the Amended 2018 EIP, a
corporate transaction generally will be deemed to occur in the event of the consummation of: (i)&nbsp;a sale or other disposition of all or substantially all of our consolidated assets; (ii)&nbsp;a sale or other disposition of at least 90% of our
outstanding securities; (iii)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&nbsp;a merger, consolidation or similar transaction following which we are the surviving corporation but
the shares of our common stock outstanding immediately prior to the transaction are converted or exchanged into other property by virtue of the transaction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For purposes of the Amended 2018 EIP, a change in control generally will be deemed to occur in the event: (i)&nbsp;a person, entity or group acquires, directly or indirectly, our securities representing
more than 50% of the combined voting power of our then outstanding securities, other than by virtue of a merger, consolidation, or similar transaction; (ii)&nbsp;there is consummated a merger, consolidation, or similar transaction and, immediately
after the consummation of such transaction, our stockholders immediately prior thereto do not own, directly or indirectly, more than 50% of the combined outstanding voting power of the surviving entity or the parent of the surviving entity in
substantially the same proportions as their ownership of our outstanding voting securities immediately prior to such transaction; (iii)&nbsp;there is consummated a sale or other disposition of all or substantially all of our consolidated assets,
other than a sale or other disposition to an entity in which more than 50% of the entity&#146;s combined voting power is owned by our stockholders in substantially the same proportions as their ownership of our outstanding voting securities
immediately prior to such sale or other disposition; or (iv)&nbsp;over a period of 12 months or less, a majority of our Board becomes comprised of individuals whose nomination, appointment, or election was not approved by a majority of the Board
members or their approved successors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Plan Amendments and Termination </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Plan Administrator has the authority to amend or terminate the Amended 2018 EIP at any time. However, except as otherwise provided in
the Amended 2018 EIP or an award agreement, no amendment or termination of the Amended 2018 EIP may materially impair a participant&#146;s rights under his or her outstanding awards without the participant&#146;s consent. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will obtain stockholder approval of any amendment to the Amended 2018 EIP as
required by applicable law and listing requirements. No incentive stock options may be granted under the Amended 2018 EIP after April&nbsp;8, 2028, which is the tenth anniversary of the date the 2018 EIP was originally adopted by the Board.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>U.S. Federal Income Tax Consequences </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following is a summary of the principal United States federal income tax consequences to participants and us with respect to participation in the Amended 2018 EIP. This summary is not intended to be
exhaustive and does not discuss the income tax laws of any local, state or foreign jurisdiction in which a participant may reside. The information is based upon current federal income tax rules and therefore is subject to change when those rules
change. Because the tax consequences to any participant may depend on his or her particular situation, each participant should consult the participant&#146;s tax adviser regarding the federal, state, local and other tax consequences of the grant or
exercise of an award or the disposition of stock acquired the Amended 2018 EIP. The Amended 2018 EIP is not qualified under the provisions of Section&nbsp;401(a) of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), and is not
subject to any of the provisions of the Employee Retirement Income Security Act of 1974. Our ability to realize the benefit of any tax deductions described below depends on our generation of taxable income as well as the requirement of
reasonableness, the provisions of Section&nbsp;162(m) of the Code and the satisfaction of our tax reporting obligations. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Nonstatutory Stock Options </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Generally, there is no taxation upon the grant of an NSO if the stock option is granted with an exercise price equal to the fair market value of the underlying stock on the grant date. Upon exercise, a
participant will recognize ordinary income equal to the excess, if any, of the fair market value of the underlying stock on the date of exercise of the stock option over the exercise price. If the participant is employed by us or one of our
affiliates, that income will be subject to withholding taxes. The participant&#146;s tax basis in those shares will be equal to their fair market value on the date of exercise of the stock option, and the participant&#146;s capital gain holding
period for those shares will begin on that date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will generally be entitled to a tax deduction equal to the taxable
ordinary income realized by the participant. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Incentive Stock Options </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Amended 2018 EIP provides for the grant of stock options that are intended to qualify as &#147;incentive stock options,&#148; as
defined in Section&nbsp;422 of the Code. Under the Code, a participant generally is not subject to ordinary income tax upon the grant or exercise of an ISO. If the participant holds a share received upon exercise of an ISO for more than two years
from the date the stock option was granted and more than one year from the date the stock option was exercised, which is referred to as the required holding period, the difference, if any, between the amount realized on a sale or other taxable
disposition of that share and the participant&#146;s tax basis in that share will be long-term capital gain or loss. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If,
however, a participant disposes of a share acquired upon exercise of an ISO before the end of the required holding period, which is referred to as a disqualifying disposition, the participant generally will recognize ordinary income in the year of
the disqualifying disposition equal to the excess, if any, of the fair market value of the share on the date of exercise of the stock option over the exercise price. However, if the sales proceeds are less than the fair market value of the share on
the date of exercise of the stock option, the amount of ordinary income recognized by the participant will not exceed the gain, if any, realized on the sale. If the amount realized on a disqualifying disposition exceeds the fair market value of the
share on the date of exercise of the stock option, that excess will be short-term or long-term capital gain, depending on whether the holding period for the share exceeds one year. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of the alternative minimum tax, the amount by which the fair market value of a share of stock acquired upon exercise of an
ISO exceeds the exercise price of the stock option generally will be an adjustment </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
included in the participant&#146;s alternative minimum taxable income for the year in which the stock option is exercised. If, however, there is a disqualifying disposition of the share in the
year in which the stock option is exercised, there will be no adjustment for alternative minimum tax purposes with respect to that share. In computing alternative minimum taxable income, the tax basis of a share acquired upon exercise of an ISO is
increased by the amount of the adjustment taken into account with respect to that share for alternative minimum tax purposes in the year the stock option is exercised. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are not allowed a tax deduction with respect to the grant or exercise of an ISO or the disposition of a share acquired upon exercise of an ISO after the required holding period. If there is a
disqualifying disposition of a share, however, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the participant, provided that either the employee includes that amount in income or we timely satisfy
our reporting requirements with respect to that amount. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Restricted Stock Awards </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, the recipient of a restricted stock award will recognize ordinary income at the time the stock is received equal to the excess,
if any, of the fair market value of the stock received over any amount paid by the recipient in exchange for the stock. If, however, the stock is not vested when it is received (for example, if the employee is required to work for a period of time
in order to have the right to sell the stock), the recipient generally will not recognize income until the stock becomes vested, at which time the recipient will recognize ordinary income equal to the excess, if any, of the fair market value of the
stock on the date it becomes vested over any amount paid by the recipient in exchange for the stock. A recipient may, however, file an election with the Internal Revenue Service, within 30 days following his or her receipt of the stock award, to
recognize ordinary income, as of the date the recipient receives the award, equal to the excess, if any, of the fair market value of the stock on the date the award is granted over any amount paid by the recipient for the stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The recipient&#146;s basis for the determination of gain or loss upon the subsequent disposition of shares acquired from a restricted
stock award will be the amount paid for such shares plus any ordinary income recognized either when the stock is received or when the stock becomes vested. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the restricted stock award. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Restricted Stock Unit Awards </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Generally, the recipient of a restricted stock unit award structured to comply with the requirements of Section&nbsp;409A of the Code or an exemption to Section&nbsp;409A of the Code will recognize
ordinary income at the time the stock is delivered equal to the excess, if any, of the fair market value of the stock received over any amount paid by the recipient in exchange for the stock. To comply with the requirements of Section&nbsp;409A of
the Code, the stock subject to a restricted stock unit award may generally only be delivered upon one of the following events: a fixed calendar date (or dates), separation from service, death, disability or a change in control. If delivery occurs on
another date, unless the restricted stock unit award otherwise complies with or qualifies for an exemption to the requirements of Section&nbsp;409A of the Code, in addition to the tax treatment described above, the recipient will owe an additional
20% federal tax and interest on any taxes owed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The recipient&#146;s basis for the determination of gain or loss upon the
subsequent disposition of shares acquired from a restricted stock unit award will be the amount paid for such shares plus any ordinary income recognized when the stock is delivered. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the restricted stock
unit award. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock Appreciation Rights </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, if a stock appreciation right is granted with an exercise price equal to the fair market value of the underlying stock on the
grant date, the recipient will recognize ordinary income equal to the fair market value of the stock or cash received upon such exercise. We will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient
of the stock appreciation right. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Section&nbsp;162(m) Limitations </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Section&nbsp;162(m) of the Code (&#147;Section&nbsp;162(m)&#148;), compensation paid to any publicly held corporation&#146;s
&#147;covered employees&#148; that exceeds $1&nbsp;million per taxable year for any covered employee is generally <FONT STYLE="white-space:nowrap">non-deductible.</FONT> Awards granted under the Amended 2018 EIP will be subject to the deduction
limit under Section&nbsp;162(m) and will not be eligible to qualify for the performance-based compensation exception under Section&nbsp;162(m) pursuant to the transition relief provided by the Tax Cuts and Jobs Act. For further information regarding
the deduction limit under Section&nbsp;162(m) and such transition relief, see the section entitled &#147;Compensation Discussion and Analysis &#150; Other Executive Compensation Matters &#150; Tax Effects of Executive Compensation.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>New Plan Benefits under Amended 2018 EIP </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CEO and
Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Chief
Financial Officer and Chief Business Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President and
Chief Scientific Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Medical Officer and
Senior Vice President, Clinical Development, Medical and Regulatory Affairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President,
Operations and Quality</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All current executive officers as a group</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All current directors who are not executive officers as a group</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">105,000&nbsp;per&nbsp;calendar&nbsp;year</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All employees, including all current officers who are not executive officers, as a group</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Awards granted under the Amended 2018 EIP to our executive officers and other employees are discretionary and are not subject to set benefits or
amounts under the terms of the Amended 2018 EIP, and our Board and our Compensation Committee have not granted any awards under the Amended 2018 EIP subject to stockholder approval of this Proposal 2. Accordingly, the benefits or amounts that will
be received by or allocated to our executive officers and other employees under the Amended 2018 EIP are not determinable. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Awards granted under the Amended 2018 EIP to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors are discretionary and are not subject
to set benefits or amounts under the terms of the Amended 2018 EIP. However, pursuant to our current compensation program for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, each of our current
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors is eligible to receive an annual grant of a stock option to purchase 15,000 shares of our common stock. On and after the date of the Annual Meeting, any such stock options will be
granted under the Amended 2018 EIP if this Proposal 2 is approved by our stockholders. For additional information regarding our current compensation program for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, please see
&#147;Director Compensation&#148; below. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Awards Granted under the 2018 EIP </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth, for each of the individuals and various groups indicated, the total number of shares of our common stock
subject to awards that have been granted under the 2018 EIP as of April&nbsp;9, 2019. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2018 Equity Incentive Plan </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of<BR>April&nbsp;9, 2019<BR>Number&nbsp;of&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CEO and Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">350,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Chief Financial Officer and Chief Business Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">110,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President and Chief Scientific Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">110,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory
Affairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">130,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Operations and Quality</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">130,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All current executive officers as a group</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">830,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All current directors who are not executive officers as a group</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">105,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each <FONT STYLE="white-space:nowrap">non-employee</FONT> nominee for election as a director:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laura Brege</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dennis A. Carson, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each associate of any executive officers, current directors or director nominees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each other person who received or is to receive 5% of awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All employees, including all current officers who are not executive officers, as a group</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,609,608</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Vote Required </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The affirmative vote of the holders of a majority of shares present (either in person or by proxy) and entitled to vote on the matter at the Annual Meeting will be required to approve this Proposal 2.
Abstentions will be counted toward the tabulation of votes cast on proposals presented to the stockholders and will have the same effect as negative votes. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are counted towards a quorum but are
not counted for any purpose in determining whether this Proposal 2 has been approved. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>HE</SMALL>
B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A V<SMALL>OTE</SMALL>
I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL> P<SMALL>ROPOSAL</SMALL> 2. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROPOSAL 3 </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ADVISORY VOTE ON EXECUTIVE COMPENSATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the Dodd-Frank Wall Street Reform and Consumer Protection Act and Section&nbsp;14A of the Exchange Act, Dynavax stockholders are being asked to approve, on an advisory basis, the compensation of our
named executive officers as disclosed in this proxy statement, which is commonly referred to as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay</FONT></FONT> vote.&#148; This vote is not intended to address any
specific item of compensation, but rather the overall compensation of our named executive officers, which results from our compensation philosophy, policies and practices as discussed in this proxy statement. The compensation of our named executive
officers subject to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> vote is described in the Compensation Discussion and Analysis, the accompanying tables, and the related narrative disclosure contained
in this proxy statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Compensation Committee is responsible for designing and administering our executive compensation
programs. Our Compensation Committee firmly believes that Dynavax&#146;s executive compensation programs should reward our named executive officers for performance, and that when key performance objectives are not achieved, the compensation of our
named executive officers should reflect as much. We believe that the compensation of our named executive officers, as disclosed in this proxy, reflects this philosophy. In addition, our Compensation Committee believes that the compensation programs
for our named executive officers have been instrumental in helping Dynavax be able to attract, retain and motivate our executive team, thereby enabling our company to be in a position to move forward with our business strategy. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board of Directors is now asking our stockholders to indicate their support for the compensation of our named executive officers as
described in this proxy statement by casting a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote &#147;For&#148; the following resolution: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;RESOLVED, that the compensation paid to Dynavax&#146;s named executive officers, as disclosed pursuant to Item&nbsp;402 of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> including the
Compensation Discussion and Analysis, compensation tables and narrative discussion, is hereby APPROVED.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although this
vote is advisory and the outcome is not binding on our Board of Directors, the views expressed by our stockholders, whether through this vote or otherwise, are important to us. As a result, the Board of Directors and the Compensation Committee will
carefully review the results of this vote, and they will consider these results in making future decisions about our executive compensation programs and arrangements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Unless our Board of Directors modifies its policy on the frequency of future advisory votes on the compensation of our named executive officers, the next advisory vote on the compensation of our named
executive officers will be held at the 2020 annual meeting of stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approval of this advisory proposal requires the
affirmative vote of the holders of a majority of shares present (either in person or by proxy) and entitled to vote on the matter at the Annual Meeting. Abstentions will be counted toward the tabulation of votes cast on proposals presented to the
stockholders and will have the same effect as negative votes. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are counted towards a quorum but are not counted for any purpose in determining whether this Proposal 3 has been approved.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL>
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A V<SMALL>OTE</SMALL> I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL> P<SMALL>ROPOSAL</SMALL> 3.
</B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROPOSAL 4 </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RATIFICATION OF SELECTION OF </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee has
selected Ernst&nbsp;&amp; Young LLP, or Ernst&nbsp;&amp; Young, as our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2019. Ernst&nbsp;&amp; Young has audited our financial statements since 2002.
Representatives of Ernst&nbsp;&amp; Young are expected to be present at the Annual Meeting. Ernst&nbsp;&amp; Young will have an opportunity to make a statement if it so desires and will be available to respond to appropriate questions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the stockholders fail to ratify the selection of Ernst&nbsp;&amp; Young, the Audit Committee will reconsider whether or not to retain
that firm. Even if the selection is ratified, the Audit Committee in its discretion may direct the appointment of a different independent registered public accounting firm at any time during the year if it determines that such a change would be in
the best interests of the Company and its stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The affirmative vote of the holders of a majority of the shares
present (either in person or by proxy) and entitled to vote on the matter at the Annual Meeting will be required to ratify the selection of Ernst&nbsp;&amp; Young. Abstentions will be counted toward the tabulation of votes cast on proposals
presented to the stockholders and will have the same effect as negative votes. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are counted towards a quorum but are not counted for any purpose in determining whether this matter has been
approved; however, Proposal 4 is considered a &#147;routine&#148; matter, and therefore no broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are expected to exist in connection with this Proposal 4. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A V<SMALL>OTE</SMALL> I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL> P<SMALL>ROPOSAL</SMALL> 4. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>UDIT</SMALL> F<SMALL>EES</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with the audit of our 2018 financial statements, we entered into an engagement agreement with Ernst&nbsp;&amp; Young which sets forth the terms by which Ernst&nbsp;&amp; Young will perform
audit services for us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table represents aggregate fees billed to the Company for the fiscal years ended
December&nbsp;31, 2018 and 2017 by Ernst&nbsp;&amp; Young, our principal auditors. The Audit Committee <FONT STYLE="white-space:nowrap">pre-approved</FONT> all service fees described below. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fiscal Year Ended</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit Fees</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,442,681</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,203,801</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax Fees</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">79,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All Other Fees</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,995</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,995</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,523,876</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,246,296</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Audit fees include fees for the audit of our consolidated financial statements and interim reviews of our quarterly financial statements, including
compliance with the provisions of Section&nbsp;404 of the Sarbanes-Oxley Act as well as fees related to registration statements, consents and other services related to SEC matters. In each of 2017 and 2018, audit fees included fees related to a
comfort letter in connection with an equity offering. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Tax fees include Section&nbsp;382 study and other tax advisory services. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">All other fees represent subscription fees for an online accounting research tool and related database. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>RE</SMALL>-<SMALL>APPROVAL</SMALL> P<SMALL>OLICIES</SMALL> A<SMALL>ND</SMALL> P<SMALL>ROCEDURES</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Audit Committee has adopted a policy and procedures for the <FONT STYLE="white-space:nowrap">pre-approval</FONT> of audit and <FONT
STYLE="white-space:nowrap">non-audit</FONT> services rendered by our independent registered public accounting firm, Ernst&nbsp;&amp; Young. Under the policy, the Audit </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Committee <FONT STYLE="white-space:nowrap">pre-approves</FONT> specified services in the defined categories of audit services, audit-related services, tax services and all other services up to
specified amounts. <FONT STYLE="white-space:nowrap">Pre-approval</FONT> may be given as part of the Audit Committee&#146;s approval of the scope of the engagement of the independent registered public accounting firm or on an interim basis by the
Audit Committee Chair, as needed and on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis before the independent registered public accounting firm is engaged to provide each service. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee has determined that services rendered by Ernst&nbsp;&amp; Young are compatible with maintaining the principal
auditors&#146; independence. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXECUTIVE OFFICERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth certain information with respect to our executive officers as of April&nbsp;9, 2019: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="54%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Position</B></FONT></P></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer and Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Chief Financial Officer and Chief Business Officer</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President and Chief Scientific Officer</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Operations and Quality</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Please see &#147;Proposal 1 &#150; Election of Directors&#148; in this proxy statement for more information about Mr.&nbsp;Gray.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Michael S. Ostrach &#150; Senior Vice President, Chief Financial Officer and Chief Business Officer </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Ostrach is our Senior Vice President, Chief Financial Officer and Chief Business Officer. Mr.&nbsp;Ostrach joined Dynavax in
October 2006 as Vice President, Chief Business Officer and General Counsel, and became Principal Financial Officer in September 2013, Chief Financial Officer in March 2015 and Senior Vice President in February 2016. Mr.&nbsp;Ostrach held the
position of Dynavax&#146;s General Counsel from October 2006 to September 2015. From 2005 to 2006, he was Chief Operating Officer, Chief Financial Officer and General Counsel at Threshold Pharmaceuticals. From 1997 to 2004, Mr.&nbsp;Ostrach was at
Kosan Biosciences, most recently as President and Chief Operating Officer. Mr.&nbsp;Ostrach began his corporate career at Cetus Corporation, where he served in several capacities between 1981 and 1991, initially as General Counsel and finally as
Senior Vice President of Corporate Affairs and General Counsel. Following the acquisition of Cetus by Chiron Corporation in 1991, Mr.&nbsp;Ostrach became President of Chiron Technologies. He holds a B.A. from Brown University and a J.D. from
Stanford Law School. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Robert L. Coffman, Ph.D. &#150; Senior Vice President and Chief Scientific Officer </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Coffman was appointed Senior Vice President and Chief Scientific Officer of Dynavax in February 2014, and prior to that he was
Vice President and Chief Scientific Officer of Dynavax since December 2000. Prior to joining Dynavax in 2000, Dr.&nbsp;Coffman was a founding member of the DNAX Research Institute in Palo Alto, California. Dr.&nbsp;Coffman has authored over 200
scientific publications, is a member of the National Academy of Sciences and the American Academy of Microbiology, and has received a number of prestigious awards for his work. With colleague Dr.&nbsp;Tim Mosmann, he defined the two principal
subtypes of helper T cells, termed Th1 and Th2 cells, and demonstrated the central relationship between their differences in cytokine expression and function. Dr.&nbsp;Coffman defined basic mechanisms of
<FONT STYLE="white-space:nowrap">T-cell</FONT> regulation in asthma and infectious and parasitic diseases, and demonstrated the central role of regulatory CD4+ T cells in preventing inflammatory bowel disease. At Dynavax, Dr.&nbsp;Coffman has
pioneered the development of agonists and antagonists for Toll-Like Receptors (&#147;TLRs&#148;), key recognition receptors in innate immunity. Dr.&nbsp;Coffman received an A.B. in Microbiology from Indiana University and a Ph.D. in Immunology from
the University of California, San Diego. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Robert Janssen, M.D. &#150; Chief Medical Officer and Senior Vice President, Clinical
Development, Medical and Regulatory Affairs </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Janssen was appointed Chief Medical Officer and Senior Vice
President, Clinical Development, Medical and Regulatory Affairs in January 2018. Dr.&nbsp;Janssen was appointed Chief Medical Officer and Vice President, Clinical Development and Regulatory Affairs in July 2013. He served as Dynavax&#146;s Vice
President, Medical Affairs since November 2012 and was previously Senior Director, Clinical Development at Dynavax from 2010 through 2012, during which time he was extensively involved with Phase 3 clinical development of <FONT
STYLE="white-space:nowrap">HEPLISAV-B</FONT> and its </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
U.S. and European licensing applications. Prior to joining Dynavax, Dr.&nbsp;Janssen was Vice President, Medical Affairs at Gilead from 2008 to 2010 where he was responsible for oversight of
physician and health care provider education focused on HIV and hepatitis B therapies. Until 2008, Dr.&nbsp;Janssen spent 23 years at the U.S. Centers for Disease Control and Prevention (&#147;CDC&#148;), most recently as the Director of the
Division of HIV/AIDS Prevention from 2000 to 2008. Under his leadership, the CDC first explored HIV treatment as a mode of HIV prevention and launched several of the earliest Phase 3 trials of <FONT STYLE="white-space:nowrap">pre-exposure</FONT>
prophylaxis for HIV. Dr.&nbsp;Janssen received a Bachelor of Arts degree with Honors in Humanities from Stanford University and his M.D. degree from the University of Southern California. He is a neurologist with training in virology received at the
University of Pennsylvania. Dr.&nbsp;Janssen has been the beneficiary of numerous honors and awards during his career. He has published over 130 scientific articles in a variety of journals and has served as a reviewer for leading scientific
journals. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>David F. Novack &#150; Senior Vice President, Operations and Quality </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Novack joined Dynavax in March 2013 as Senior Vice President, Operations and Quality. Mr.&nbsp;Novack was formerly with Novartis
Vaccines&nbsp;&amp; Diagnostics where he served since 2009 as the Global Head of Technical Operations and Supply Chain for Diagnostics and previously from 2007 to 2009 as the Global Head of Vaccine Manufacturing Strategy. Prior to Novartis,
Mr.&nbsp;Novack was the Vice President, Business Development for Vaxin, Inc., a vaccine company, from 2004 to 2006. From 1993 until 2004, Mr.&nbsp;Novack worked at MedImmune, formerly Aviron, serving in several capacities including business
development, manufacturing, contract operations and most recently as Senior Director, Supply Chain Operations. Previously, from 1989 to 1993, Mr.&nbsp;Novack was with American Cyanamid Company in various roles. Mr.&nbsp;Novack received a B.S. in
Biology from State University of New York and an M.B.A. from Columbia University. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>OMPENSATION</SMALL>
D<SMALL>ISCUSSION</SMALL> A<SMALL>ND</SMALL> A<SMALL>NALYSIS</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Compensation Discussion and Analysis discusses our executive compensation philosophy and practices and provides an overview of the
Compensation Committee&#146;s 2018 decisions for the following named executive officers (&#147;NEOs&#148;) whose compensation is set forth in the Summary Compensation Table and other related tables contained in this proxy statement: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray, Chief Executive Officer and Director; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach, Senior Vice President, Chief Financial Officer and Chief Business Officer; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D., Senior Vice President and Chief Scientific Officer; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D., Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack, Senior Vice President, Operations and Quality. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We present this Compensation Discussion and Analysis in the following sections: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B>&#8195;&#8194;&#8201;<I>Executive Summary</I>.&nbsp;&nbsp;&nbsp;&nbsp;Provides an overview of our 2018 and early 2019
corporate performance and certain governance aspects of our executive compensation program.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">p. 31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B>&#8195;&#8194;&#8201;<I>Executive Compensation Program</I>.&nbsp;&nbsp;&nbsp;&nbsp;Describes the Company&#146;s
executive compensation philosophy and process and the material elements of our executive compensation program.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">p.&nbsp;34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B>&#8195;&#8194;&#8201;<I>2018 Executive Compensation Decisions</I>.&nbsp;&nbsp;&nbsp;&nbsp;Provides a synopsis of the
Compensation Committee&#146;s executive compensation decisions for 2018 and certain actions taken before or after 2018 when doing so enhances the understanding of our executive compensation program.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">p. 38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.</B>&#8195;&#8194;&#8201;<I>Other Executive Compensation Matters</I>.&nbsp;&nbsp;&nbsp;&nbsp;Reviews the accounting and tax
treatment of compensation and the relationship between our compensation program and risk.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">p. 45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Executive Summary </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Business Overview, Corporate Developments in 2018 and Early 2019 and Relationship to Executive Compensation </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a fully-integrated biopharmaceutical company focused on leveraging the power of the body&#146;s innate and
adaptive immune responses through toll-like receptor (&#147;TLR&#148;) stimulation. Our first commercial product,
<FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT><B><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></B> (Hepatitis B Vaccine (Recombinant), Adjuvanted), was approved by the United States Food and Drug Administration
(&#147;FDA&#148;) in November 2017 for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.&nbsp;We commenced commercial shipments of <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> in
January 2018 and deployed our field sales force in February 2018. In March 2018, we received regulatory approval of the <FONT STYLE="white-space:nowrap">pre-filled</FONT> syringe (&#147;PFS&#148;) presentation of
<FONT STYLE="white-space:nowrap">HEPLISAV-B.</FONT> Our development efforts are primarily focused on stimulating the innate immune response to treat cancer in combination with other immunomodulatory agents. Our&nbsp;lead investigational
immuno-oncology product candidates are <FONT STYLE="white-space:nowrap">SD-101,</FONT> currently being evaluated in Phase 2 clinical studies, and DV281, in a Phase 1 safety study. Given the long product development cycles in our business, we believe
delivery of long term value to our stockholders is the best measure of our performance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Heading into 2018, we had worked to
diversify our portfolio such that our focus for the year was balanced between ongoing manufacturing, quality, commercialization and market adoption efforts for <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> and advancing our oncology program. As
a result of this diversification, we viewed our success in 2018 and beyond as being based on our commercialization progress for <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> and achievements in our oncology program. Thus, we designed our 2018
executive compensation program to reward achievement of the specific related objectives we believed would advance our business strategy and create long-term value for our stockholders. In particular, our 2018 annual incentive program was aligned
with our corporate objectives by selecting and weighting corporate goals as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commercialization, dosage volume sold and manufacturing goals for <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> were weighted at 42.5%;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Objectives specific to advancing our oncology pipeline were weighted at 42.5%; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Business plan goals that supported advancing our business and portfolio strategies were weighted at 15%. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Committed to achieving these corporate goals in 2018, our NEOs were focused on executing our <FONT
STYLE="white-space:nowrap">HEPLISAV-B</FONT> business strategy by working to successfully commercialize it, deploy a field sales force, develop a distribution network, obtain reimbursement coverage, develop and implement a healthcare compliance
program to support compliant product-related business practices, and ensure that we achieved sufficient manufacturing capability to successfully meet demand and that such manufacturing was done in accordance with applicable quality requirements. Our
NEOs were also focused on advancing a robust pipeline of immuno-oncology clinical stage development programs and discovering other cutting-edge <FONT STYLE="white-space:nowrap">TLR-based</FONT> vaccines and immunotherapies. We believe that we have
balanced the diverse needs of being a fully-operational commercial company with continuing to advance our scientific progress in research and development in our immuno-oncology program, including reporting significant results relating to <FONT
STYLE="white-space:nowrap">SD-101</FONT> in combination with Keytruda<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (pembrolizumab), an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy, and initiating a Phase 1 safety study of DV281 in combination with another
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Propelled by our
diversification strategy and the performance of our NEOs, we believe 2018 was a year of many positive developments for our company. For <FONT STYLE="white-space:nowrap">HEPLISAV-B,</FONT> we not only commercialized the product and made significant
strides advancing it through the multiple-step decision-making process employed by institutional hepatitis B vaccine purchasers, but we also gained regulatory approval of the PFS presentation of the vaccine&#151;we believe this was an important
accomplishment, as it increased our ability to achieve faster adoption of our product by physicians and other key decision-makers. <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> also received a recommendation from the Centers for Disease Control
Advisory Committee on Immunization Practices (&#147;ACIP&#148;) and additional payer and policy review and approval. Each of these developments served to lay a foundation for future sales growth for <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT>
through advocacy and adoption efforts. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also successfully delivered certain key corporate goals related to advancing our
immuno-oncology programs. In particular, we announced results associated with <FONT STYLE="white-space:nowrap">SD-101</FONT> and advanced DV281 into the clinical stage. We also achieved certain business plan goals that supported advancing our
business and portfolio strategies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain key events that took place for our company involving <FONT
STYLE="white-space:nowrap">HEPLISAV-B</FONT> and our immuno-oncology pipeline in 2018 are summarized below: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January, we announced that <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> was available to adults in the United States, becoming the first new
hepatitis B vaccine in the United States in more than 25 years and the only <FONT STYLE="white-space:nowrap">two-dose</FONT> hepatitis B vaccine for adults. Commercial sales followed immediately after availability. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February, we deployed our field sales force for <FONT STYLE="white-space:nowrap">HEPLISAV-B,</FONT> and the sales force members immediately began
meeting with institutional decision-makers about <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> and commencing other selling efforts. In addition, we announced that ACIP voted unanimously in favor of including
<FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> on its list of ACIP-recommended products for use to vaccinate adults against hepatitis B. The ACIP recommendation is required by many insurance plans and institutions in order to cover or make
available <FONT STYLE="white-space:nowrap">HEPLISAV-B,</FONT> and was an essential step in providing patients with broad access to <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> going forward. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In March, we received FDA approval of the PFS presentation of <FONT STYLE="white-space:nowrap">HEPLISAV-B,</FONT> enabling us to meet the preferred
means of physicians, institutions and payers in delivering the only <FONT STYLE="white-space:nowrap">two-dose</FONT> adult hepatitis B vaccine in the United States. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April, we presented durability of response data in advanced melanoma patients from the ongoing Phase 1b/2 study investigating <FONT
STYLE="white-space:nowrap">SD-101</FONT> in combination with pembrolizumab. This data showed that 86% of initial responses were ongoing after a median of 18 months of <FONT STYLE="white-space:nowrap">follow-up</FONT> in patients that were na&iuml;ve
to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/L1</FONT></FONT> monotherapy. We also, presented interim data for <FONT STYLE="white-space:nowrap">SD-101</FONT> in combination with pembrolizumab for patients with
advanced squamous cell carcinoma of the head and neck, indicating, among other things, an overall response rate (&#147;ORR&#148;) of 33%, and that <FONT STYLE="white-space:nowrap">SD-101</FONT> was well-tolerated with no dose-limiting toxicities.
The data was presented at the 2018 American Association for Cancer Research Annual Meeting. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April, we also announced the CDC&#146;s publication of ACIP&#146;s recommendation for the use of <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT>
for adults in the United States in the Morbidity and Mortality Weekly Report (&#147;MMWR&#148;). Publication in the MMWR is the final endorsement of <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> that was required by many institutional policies
for reimbursement. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June, we announced the presentation of updated findings in patients with advanced melanoma in the ongoing Phase 1b/2 study <FONT
STYLE="white-space:nowrap">investigating&nbsp;SD-101</FONT> in combination with pembrolizumab. The data showed a 70% ORR in patients who received the <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT> 2 mg dose of
<FONT STYLE="white-space:nowrap">SD-101</FONT> and a <FONT STYLE="white-space:nowrap">6-month</FONT> progression free survival rate of 76% in patients na&iuml;ve to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> treatment in patients who received the <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT> 2 mg dose of <FONT STYLE="white-space:nowrap">SD-101.</FONT> The data was
presented at the 2018 American Society of Clinical Oncology Annual Meeting. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June, we also announced results of a post hoc analysis of data from HBV 23, the pivotal Phase 3 trial of HEPLISAV B evaluating data for participants
with type 2 diabetes aged 60 to 70. The per protocol analysis showed that the seroprotection rate at week 28 for <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> was 85.8% compared to 58.5% for <FONT STYLE="white-space:nowrap">Engerix-B</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, that <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> induced higher geometric mean concentration at week 24 than
<FONT STYLE="white-space:nowrap">Engerix-B</FONT> at week 28, and that <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> had a similar safety profile compared to <FONT STYLE="white-space:nowrap">Engerix-B,</FONT> regardless of study subgroup. The
data were presented at the 2018&nbsp;American Diabetes Association Annual Meeting. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In August, we announced that 100% of Medicare-insured lives, 94% of commercially-insured lives, and 74% of lives under state Medicaid plans were now
covered for <FONT STYLE="white-space:nowrap">HEPLISAV-B,</FONT> ensuring a strong reimbursement environment as we continue to seek market share. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In August, we also announced that two peer-reviewed papers reporting clinical studies of <FONT STYLE="white-space:nowrap">SD-101</FONT> were published
by<I>&nbsp;Cancer Discovery</I>, a journal publication from the&nbsp;American Association of Cancer </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
Research&nbsp;(&#147;AACR&#148;). The investigators reported clinical activity and broad immune activation in the tumor microenvironment when <FONT STYLE="white-space:nowrap">SD-101</FONT> is
administered in combination with either low dose radiation in patients with indolent lymphoma or in combination with <FONT STYLE="white-space:nowrap">PD-1</FONT> blockade in patients with unresectable or metastatic melanoma.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September, we announced publication of a preclinical study demonstrating that inhalation of a TLR9 agonist, such as DV281, can stimulate effective
immunity against lung tumors and complement the actions of <FONT STYLE="white-space:nowrap">PD-1</FONT> blockade to generate durable, systemic anti-tumor immunity. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October, we announced that the combination of <FONT STYLE="white-space:nowrap">SD-101</FONT> and pembrolizumab would be evaluated in a new
randomized, investigational treatment arm for the ongoing <FONT STYLE="white-space:nowrap">I-SPY</FONT> 2 Trial&#153; for neoadjuvant treatment of locally advanced breast cancer, expanding <FONT STYLE="white-space:nowrap">SD-101&#146;s</FONT>
potential use in the field of neoadjuvant immunotherapy. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October, we also presented interim data from our ongoing Phase 1b/2 <FONT STYLE="white-space:nowrap">SYNERGY-001</FONT> study investigating <FONT
STYLE="white-space:nowrap">SD-101</FONT> in combination with pembrolizumab in patients with advanced melanoma na&iuml;ve to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/L1</FONT></FONT> therapy. The interim data showed
a 70% ORR in advanced melanoma patients na&iuml;ve to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/L1</FONT></FONT> therapy who received the <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT> 2 mg dose of <FONT
STYLE="white-space:nowrap">SD-101</FONT> and a 48% ORR in the group receiving the 8 mg dose of <FONT STYLE="white-space:nowrap">SD-101.&nbsp;The</FONT> data was presented at the European Society for Medical Oncology 2018 Congress.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In November, we announced significant progress on <FONT STYLE="white-space:nowrap">HEPLISAV-B&#146;s</FONT> commercialization, including obtaining
Pharmacy and Therapeutics (&#147;P&amp;T&#148;) committee approval from six of the top 10 integrated delivery networks, and that 402 of our largest targeted customers have received P&amp;T committee approval, of whom 200 have progressed to purchase <FONT
STYLE="white-space:nowrap">HEPLISAV-B</FONT> and 68 have implemented <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> throughout their system, indicating continuing adoption of <FONT STYLE="white-space:nowrap">HELPISAV-B</FONT> as the standard of
care for hepatitis B vaccination in adults in the U.S. This progress is critical to our achievement of <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> in 2019 and beyond. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Governance Highlights </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>What we do</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>What we do not do</B></FONT></P></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Design executive compensation program to align pay with performance</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No excessive change in control or severance payments (no cash severance multiplier greater than 2x base + target bonus)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Majority of pay is variable and not guaranteed (over 86% for our CEO in 2018)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No repricing of underwater stock options without stockholder approval</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prohibit hedging and discourage pledging by executive officers and directors (no pledging occurred in 2018)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No tax <FONT STYLE="white-space:nowrap">gross-ups</FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grant equity awards with performance-based vesting</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No perquisites</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conduct an annual <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> vote</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No guaranteed bonuses</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Seek input from, listen to and respond to stockholders</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consideration of Our Prior <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Say-on-Pay</FONT></FONT>
Votes and Related Stockholder Engagement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2016, our Board of Directors adopted, and our stockholders approved, a policy
that we would hold a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> vote on a yearly basis. Since adjusting to an annual
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> practice, we have experienced continued favorable voting results with our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> practices. The results of the past three years&#146; voting have been over </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
70%, 85%, and 95% in fiscal years 2016, 2017, and 2018, respectively, of stockholders voting in favor of our pay practices. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because of its importance, we continue to solicit feedback from our stockholders regarding our executive compensation program as part of
our stockholder outreach. We view the stockholder feedback process as a year-round activity, and we have incorporated stockholder feedback into our pay practices, such as implementing performance-based equity measures for our NEOs. As a result, we
obtained feedback from our stockholders in the spring and fall of 2018, and plan to do so again in 2019. As part of our annual stockholder feedback program, we contacted 12 of our largest 20 institutional stockholders in early fall 2018, and we
spoke with 100% of the stockholders that wanted to provide us with feedback at that time about our corporate governance and executive compensation practices. During these discussions, which included an opportunity for detailed questions, none of our
stockholders expressed any concerns about our corporate governance or executive compensation practices. The bulk of the stockholders, while appreciating the outreach, did not feel a need to talk at the time. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Executive Compensation Program </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Philosophy and Objectives </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe our NEOs&#146; compensation should align our executives&#146; success with that of our stockholders over the long-term through
achievement of strategic corporate objectives that are fundamental to our business model and that will create long-term stockholder value. Our executive compensation programs are designed to be competitive with our peer group to enable us to
attract, motivate, reward, and retain outstanding talent. Our compensation programs are based on the following key principles: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A significant component of pay is linked with performance and the achievement of our strategic goals; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alignment of our executives&#146; interests with those of our stockholders through equity compensation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Overall compensation that is competitive in the industry in which we compete for executive talent; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recognition of individual contributions, teamwork and corporate performance. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation-Setting Process </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:6%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Role of the Compensation Committee and Management </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation
Committee oversees and administers our executive compensation programs. The Compensation Committee acts pursuant to a charter adopted by our Board, which can be found at our website, www.dynavax.com. The Compensation Committee generally determines
the compensation to be paid to the executive officers, including our NEOs. Either the Compensation Committee or the independent members of our Board, upon recommendation from the Compensation Committee, approve certain compensation of our CEO, and
references in this Compensation Discussion and Analysis to our Board approving our CEO&#146;s compensation refer to the independent members of our Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee (and the board of directors, with respect to our CEO)&nbsp;approves our corporate goals and the individual goals of our NEOs after considering the Company&#146;s recommendations
on these matters. The Compensation Committee annually reviews the base salaries, cash incentives and equity compensation of our NEOs and periodically reviews other elements of our compensation. Compensation decisions are based primarily on the
following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Peer and Industry Data</I> &#150; The Compensation Committee uses peer and industry data provided by its consultant, Arnosti Consulting Inc.
(&#147;Arnosti&#148;), as a reference in setting base salaries and target cash compensation, determining appropriate levels and mix of equity compensation and determining the type and portion of compensation tied to performance goals.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Annual Performance Reviews</I> &#150; The Chair of the Compensation Committee conducts annual performance reviews of our CEO taking into
consideration feedback obtained during the course of the year from the </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
independent members of our Board and the CEO&#146;s direct reports. Our CEO conducts and presents the performance reviews of the other NEOs to the Compensation Committee after the end of each
fiscal year. In reviewing and determining the compensation of each NEO, the Compensation Committee also considers individual factors, such as potential for future contributions to Company growth, industry experience and retention concerns.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>CEO Recommendations</I> &#150; The Compensation Committee seeks input from our CEO for setting the salary and target cash compensation levels for
the other NEOs, and also for purposes of setting annual performance metrics and target amounts under our annual incentive program. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:6%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Role of Compensation Consultant </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnosti has been the Compensation
Committee&#146;s independent compensation consultant since 2010, and the Compensation Committee meets regularly with Arnosti, both with and without management present, depending upon the topic being discussed. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2018 and again in February 2019, the Compensation Committee reviewed whether the work of Arnosti as a compensation consultant
raised any conflict of interest, taking into consideration the following factors: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The provision of other services to the Company; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amount of fees paid to Arnosti by the Company; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnosti&#146;s policies and procedures that are designed to prevent conflicts of interest; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any business or personal relationship of Arnosti or the individual compensation advisors employed by Arnosti with an executive officer of the Company;
and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any Company stock owned by Arnosti or the individual compensation advisors employed by Arnosti. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on the Compensation Committee&#146;s review of this information, it determined the work of Arnosti and the individual compensation
advisors employed by Arnosti as compensation consultant to the Compensation Committee, did not create any conflict of interest. The Compensation Committee has the sole authority to direct, terminate or continue Arnosti&#146;s services, although the
Company pays the cost for Arnosti&#146;s services. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2018, Arnosti provided advice to the Compensation Committee on several
different aspects of its responsibilities related to our compensation programs and practices. Specifically, during 2018, Arnosti assisted the Compensation Committee as follows: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reviewed and analyzed compensation levels of our NEOs in comparison to those of our peer companies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provided general information concerning executive compensation trends and developments; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provided recommendations to the Compensation Committee on refining our peer group; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provided an assessment of the annual meeting voting results; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provided the Board with a review of competitive data from the peer group on Board compensation; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reviewed the Compensation Discussion and Analysis for inclusion in our proxy statement. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2018 Peer Group </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
Compensation Committee uses a peer group for a general understanding of market compensation practices and our positioning within the peer group. Our Compensation Committee believes that over-reliance on benchmarking could result in compensation that
is unrelated to the value delivered by the NEOs because compensation benchmarking does not take the specific performance of the NEOs, or the performance of the Company, into account. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Compensation Committee does not have a specific target compensation level for the
NEOs or otherwise use a formulaic approach to setting pay at a particular positioning within the market data; rather, the Compensation Committee reviews a range of market data reference points of the Company&#146;s peer group with respect to total
target cash compensation (including both base salary and the annual target performance bonus) and equity compensation (valued based on an approximation of grant date fair value and also considered as shares as a percentage of total common shares
outstanding) to support its compensation decisions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For 2018 compensation decisions, our Compensation Committee approved a
peer group of biotechnology companies at a similar stage of product development with which we compete for executive talent that were of similar size to the Company in terms of market capitalization, product portfolio, pipeline and number of
employees. To align with our strategic plan, which included commercialization of <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> and expansion of our pipeline with early clinical development in cancer immunotherapy, our peer group included
companies that were: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commercial-stage (italicized in the list below and representing approximately 32% of the companies in our peer group); </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Both oncology and <FONT STYLE="white-space:nowrap">non-oncology</FONT> focused; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Companies that had their own manufacturing operations. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The change in our peer group from 2017 to 2018 included removing five companies for various reasons including market caps that were out of range or because the company had been acquired. The companies
that were removed were Ariad Biotech Inc., Celldex Therapeutics, Inc., Exelixis, Inc., Kite Pharma, Inc. and NewLink Genetics Corporation. As of September 2017, which was shortly before the 2018 peer group was approved, the companies in the 2018
peer group had market capitalizations between ranging from $296&nbsp;million to $3.9&nbsp;billion and the median market capitalization of our peer group was $870&nbsp;million. At that time, our market capitalization was $1.258&nbsp;billion. The
following table lists our 2018 peer group. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aduro Biotech, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Amicus Therapeutics, Inc.</I> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Array Biopharma, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">BioCryst Pharmaceuticals, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ChemoCentryx, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cytokinetics, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clovis Oncology, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Depomed, Inc.</I> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Demira, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Eagle Pharmaceuticals, Inc.</I> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Emergent BioSolutions, Inc.</I> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Epizyme, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Heron Therapeutics, Inc.</I>
</FONT></P></TD></TR></TABLE></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>ImmunoGen, Inc.</I> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nektar Therapeutics, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Novavax, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Puma Biotechnology, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repligen Corp. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rigel Pharmaceuticals, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Sarepta Therapeutics, Inc.</I> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Supernus Pharmaceuticals, Inc.</I> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">TG Therapeutics, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Xenocor, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ziopharm Oncology, Inc.
</FONT></P></TD></TR></TABLE></div><div style="clear:both; height:0px; font-size:0px">&nbsp;</div>
 <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Elements of Executive Compensation
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our executive team continues to manage a changing and increasingly complex business. We strive to recognize these efforts
by compensating our NEOs for the demands and risks associated with our business through three primary elements that are designed to reward performance in a simple and straightforward manner&#151;base salaries, annual performance-based cash
incentives and long-term equity awards. During our annual stockholder outreach, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
our key stockholders expressed support for the elements of our executive compensation program, including our continued use of stock options as one portion of long-term equity awards and
continuing to grant a portion of long-term equity awards with performance-based vesting. As reflected in the chart below, we utilized performance-based vesting for a portion of our 2018 long-term equity awards. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below summarizes the purpose and key characteristics of each of our compensation elements. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="41%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Element</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Purpose</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Key Characteristics</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Base Salary</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provides a fixed level of compensation for performing the essential
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> elements of the job; gives executives a degree of certainty in light of having a majority of their compensation at risk.</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fixed compensation that is reviewed annually and adjusted if and when appropriate;
reflects each NEO&#146;s performance, experience, skills, level of responsibility and the breadth, scope and complexity of the position as well as the competitive marketplace for executive talent specific to our industry.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Annual Incentive Program</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Motivates executive officers to achieve corporate and individual business goals, which we believe increase stockholder value, while providing
flexibility to respond to opportunities and changing market conditions.</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annual cash incentive based on corporate and
individual performance compared to <FONT STYLE="white-space:nowrap">pre-established</FONT> goals. Our CEO&#146;s annual incentive is based entirely on corporate goals.</FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate goals focus on overarching objectives for the Company
which will support long-term value, while individual objectives represent key performance expectations at the departmental or individual level.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate goals are aligned with our business strategy and weighted by relative importance so that achievement can be objectively
measured.</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Long-Term Equity Incentives (Stock
Options)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Motivates executive officers to achieve our business objectives by tying incentives to the appreciation of our common stock over the long
term.</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock options with an exercise price equal to
the fair market value on the date of grant vesting over three years; the ultimate value realized, if any, depends on the appreciation of our common stock price and if our stock price does not appreciate, there is no value realized. In determining
the aggregate size of equity grants in any given year, the Compensation Committee generally considers the same factors described above under &#147;Base Salaries&#148; as well as the criticality of the executive to the long-term achievement of
corporate goals.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In March 2018, 20% of our
NEO&#146;s annual grants were performance-based stock option awards vesting upon the Compensation Committee&#146;s certification of achievement of <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals discussed below.</FONT></P>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Element</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Purpose</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Key Characteristics</B></FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time, we may also use special grants of stock options for purposes of
retention or to reward continuous service within the company, as was done in 2018 in the case of two of our NEOs.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Long-Term Equity Incentives (RSUs)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Motivates executive officers to achieve our corporate objectives by tying compensation to the performance of our common stock over the long
term and/or the achievement of business and clinical development goals over the long term; motivates our executive officers to remain with the Company by mitigating swings in incentive values during periods when market volatility weighs on our stock
price.</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock unit awards may vest based
on continued service over a specified period of time and/or achievement of performance goals; the ultimate value realized varies with our common stock price.</FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time, we may also use special RSU awards for
purposes of retention or to reward continuous service within the company. No such RSUs were granted to NEOs in 2018.</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Compensation</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our executive officers participate in the same benefits offered to all other employees, which promote employee health and welfare and assist
in attracting and retaining our executive officers.</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indirect compensation element consisting of programs such as medical, vision, dental, life
and accidental death, long-term care and disability insurance as well as a 401(k) plan with a Company matching contribution, and other plans and programs made available to all eligible employees.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Severance and Change in Control Benefits</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Serves our retention objectives by helping our named executive officers maintain continued focus and dedication to their responsibilities to
maximize stockholder value, including in the event of a transaction that could result in a change in control of our Company.</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provides protection in the event of a termination of employment under specified
circumstances, including following a change in control of our Company as described below under &#147;Potential Payments Upon Change in Control or Involuntary Termination.&#148;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2018 Executive Compensation Decisions </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Total Target Cash Compensation &#150; Base Salaries and Target Bonus Percentages </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">When determining 2018 base salary and target bonus percentage adjustments, the Compensation Committee considered each individual&#146;s performance and Company performance, each individual&#146;s industry
experience and tenure, internal pay equity, and retention concerns. The Compensation Committee also reviewed a range of market data reference points (the 10th, 25th, 50th, 60th, 75th and 90th percentiles of peer group data) with respect to total
target cash compensation (including both base salary and the annual target performance bonus). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee (and the board of directors, with respect to our CEO)
decided that for 2018 each NEO&#146;s target bonus percentage would remain the same as in 2017 (which has not increased for any of our NEOs since 2013) and base salaries would be increased as shown in the table below. In determining NEO
compensation, the Compensation Committee takes into account peer group data; each NEO&#146;s industry experience, expertise, and tenure with the Company; internal pay equity and the Company&#146;s annual salary budget. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2018 Base<BR>Salary</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>%&nbsp;Increase<BR>from
Prior<BR>Year<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2018<BR>Target<BR>Bonus</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">621,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">439,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">483,134</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">438,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">401,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Dr.&nbsp;Janssen was promoted to his current position of Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory
Affairs in 2018. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Long-Term Equity Incentive Awards </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In making annual long-term equity incentive awards to NEOs in early 2018, the Compensation Committee considered each NEO&#146;s total
options outstanding as of December&nbsp;31, 2017, his performance during 2017, the potential amount that could be realized at different hypothetical stock prices upon exercise of those awards and each NEO&#146;s percentage of ownership of the
Company. The Compensation Committee also reviewed peer group data reference points (the 10th, 25th, 50th, 60th, 75th and 90th percentiles of the market data) with respect to an approximation of grant date fair value and shares as a percentage of
total common shares outstanding. Additionally, the Compensation Committee considered the mix of stock options and RSUs granted in 2017. The Compensation Committee made final determinations based on its judgment in accordance with our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pay-for-performance</FONT></FONT> philosophy and the need to retain and motivate these highly experienced and essential members of our management team. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee (and the board of directors, with respect to our CEO) determined to grant each NEO&#146;s annual long-term
incentive compensation with a blend of both time-based options and performance-based options in 2018. The Compensation Committee&#146;s determination to only grant stock options to each NEO in 2018 was partially based upon the Compensation
Committee&#146;s grant of both <FONT STYLE="white-space:nowrap">time-and</FONT> performance-based RSUs in 2017 as part of each NEO&#146;s annual long-term incentive compensation, as well <FONT STYLE="white-space:nowrap">one-time</FONT> retention
grants of RSUs to our NEOs that were made in 2017. As a result, the Compensation Committee determined that a blend of time-based and performance-based stock options was most appropriate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2018, the Compensation Committee approved annual grants in the form of stock options. Eighty percent of each NEO&#146;s 2018 annual
grant was in the form of a time-based option, subject to each individual&#146;s continuous service, <FONT STYLE="white-space:nowrap">one-third</FONT> of the shares subject to each grant vested on February&nbsp;1, 2019 and the remainder vests in
equal monthly installments thereafter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The remaining 20% of the NEO&#146;s 2018 annual grant were performance-based stock
options that vest solely upon the Compensation Committee&#146;s certification of achievement of the following equally weighted performance goals: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Achieve approval by the FDA of <FONT STYLE="white-space:nowrap">Pre-filled</FONT> Syringe (&#147;PFS&#148;) and &#147;potency assay&#148; applications;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales of at least 200,000 doses of <FONT STYLE="white-space:nowrap">HEPLISAV-B;</FONT> </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Release 720,000 doses of <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> PFS; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Complete <FONT STYLE="white-space:nowrap">SD-101</FONT> and DV281 development plans; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initiate expanded <FONT STYLE="white-space:nowrap">SD-101</FONT> clinical trial program; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Achieve financing to ensure certain <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cash-on-hand</FONT></FONT> goals.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2019, the Compensation Committee (and the Board, with respect to our CEO) affirmed the
achievement of the performance goals at the 90% level and the vesting of these stock options at such level. The table below describes the aggregate grant date fair value of these stock options granted in fiscal year 2018. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant&nbsp;Date&nbsp;Fair&nbsp;Value<BR>of February 2018</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Time-Based Stock<BR>Option Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant&nbsp;Date&nbsp;Fair&nbsp;Value<BR>of March 2018<BR>Performance-Based<BR>Stock Option
Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,032,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">758,100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">866,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">216,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">866,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">216,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">866,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">216,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">866,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">216,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, in March 2018, the Compensation Committee made a special time-based stock option grant to
Mr.&nbsp;Ostrach and Dr.&nbsp;Coffman of 150,000 shares each, of which 50% will vest in March 2020, and the remainder will vest in March 2021. Our Compensation Committee determined that it was necessary to grant these retention equity awards to
Mr.&nbsp;Ostrach and Dr.&nbsp;Coffman during this critical time so as to secure their continued leadership, including, for Mr.&nbsp;Ostrach, oversight of accounting, finance, business development and intellectual property, in connection with
integration of the <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> field sales team as Dynavax employees and our continued commercialization efforts, and as we make decisions to advance our immuno-oncology program, and for Dr.&nbsp;Coffman, with
respect to our immuno-oncology program, including his key scientific role in advancing <FONT STYLE="white-space:nowrap">SD-101</FONT> and DV281. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In February 2019, our Board (with respect to our CEO and upon the recommendation of the Compensation Committee) and the Compensation Committee (with respect to our other NEOs) approved annual long-term
equity incentive awards to our NEOs. These awards consisted of 80% time-based stock option awards, and 20% performance-based RSU awards. The stock option grants vest over three years, with <FONT STYLE="white-space:nowrap">one-third</FONT> of the
shares subject to each portion vesting 12 months after the grant date, and the remainder vesting in equal monthly installments thereafter. The performance-based RSUs will vest, if at all, upon the Compensation Committee&#146;s determination that
certain performance goals are met. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2018 Annual Incentive Program &#150; Structure, Goals and Payout Decision </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Structure</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our CEO does not have individual goals separate from the Company&#146;s corporate objectives. For
our other NEOs, their total cash incentive payout is typically based on a weighting of 50% corporate and 50% individual goals. Our CEO recommends individual goals for each NEO, which are aligned with our business strategy and linked with corporate
goals, and our Compensation Committee approves these goals. The individual goals for the NEOs are in addition to the general responsibilities each officer has for managing his respective functional or operational area. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>2018 Corporate Goals</I>.&nbsp;&nbsp;&nbsp;&nbsp;In early 2018, the Compensation Committee established the corporate and individual
goals described below. While we now are a fully-integrated biopharmaceutical company with a marketed product and robust development programs, at the time our marketed product was very newly introduced to the market, and so our corporate goals were
directly aligned with the specific strategic objectives, including completing important foundational elements for <FONT STYLE="white-space:nowrap">HEPLISAV-B,</FONT> such as restarting the Dusseldorf manufacturing facility, obtaining FDA approval of
the PFS application and deploying the field sales team, and advancing the development programs that we continue to believe will create long-term value for stockholders. In February 2019, the Compensation Committee evaluated the accomplishments and
performance of the Company against such corporate goals. With respect to each of the categories of Corporate Goals (that is, <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> Advancement; Oncology: Advance the Pipeline; and Sustain the Dynavax
Business Plan), the Committee took into consideration each of the goals identified and the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
level of completion in making an overall determination of goal completion for each category. We have omitted details about the 2018 goals or achievement of goals in the table below only where we
believe disclosing such details would result in competitive harm. After its consideration of the Company&#146;s performance, as more specifically described in the following chart, the Compensation Committee rated our 2018 corporate achievement at
90% of our 2018 corporate goals. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate Goal</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighting</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate Achievement</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate<BR>Achievement<BR>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT
STYLE="white-space:nowrap">HEPLISAV-B</FONT> Advancement</B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Obtain ACIP recommendation.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Post-marketing study and &#147;first patient in.&#148;</FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;FDA approval of PFS and
&#147;potency assay&#148; applications.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Engage, train and deploy field sales organization.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Minimum 90% reimbursement coverage of commercial lives 90 days post-ACIP
recommendation.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Minimum of 200,000 doses sold.</FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;720,000 doses of PFS
doses released.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Execute <FONT STYLE="white-space:nowrap">re-start</FONT> plan for Dusseldorf manufacturing
facility and release 2 hepatitis B surface antigen batches.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Develop and implement healthcare compliance program to ensure compliant <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> operations.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42.5%</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee determined that we achieved the goals
in this category at an overall percentage of 85%. In determining this percentage, the Compensation Committee considered several factors, including:</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Obtaining the ACIP recommendation.</FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Achieving the first
patient enrolled in post-marketing study.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Obtaining FDA approval of PFS and &#147;potency assay&#148;.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Successful deployment of field sales organization.</FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Achievement of
reimbursement coverage of commercial lives goal.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Positioning us for increasing <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> sales in 2019 and beyond by advancing through the lengthy institutional decision-making process in
2018.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;100,000
doses of <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> sold.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Introduction of PFS to market and rapid customer uptake of this presentation.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Successfully restarting the Dusseldorf manufacturing facility.</FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Successful
implementation of a healthcare compliance program associated with status as a commercial company.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">85%</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Oncology:
Advance the Pipeline</B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Advance oncology programs that are in clinical studies, including initiating enrollment in
various studies for <FONT STYLE="white-space:nowrap">SD-101</FONT> and advance intra-tumoral vaccination studies for 2019 initiation.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Complete <FONT STYLE="white-space:nowrap">SD-101</FONT> and DV281 development
plans.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42.5%</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee determined that we achieved the goals
in this category at an overall percentage of 95%. In determining this percentage, the Compensation Committee considered several factors, including:</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Advancement of <FONT STYLE="white-space:nowrap">SD-101</FONT> in melanoma and squamous cell
head and neck cancer and data presentation of results at key oncology meetings.</FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">95%</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate Goal</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighting</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate Achievement</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate<BR>Achievement<BR>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Select lead compound TLR 7/8 agonists and develop and explore production and collaboration
strategies.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Identify and execute oncology-specific meeting presentation/publication
timetable.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;The selection of <FONT STYLE="white-space:nowrap">SD-101</FONT> and pembrolizumab in combination for advanced breast cancer in the <FONT STYLE="white-space:nowrap">on-going</FONT> <FONT
STYLE="white-space:nowrap">I-SPY</FONT> 2 trial.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Initiation of DV281 Phase 1 study.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Completion of <FONT STYLE="white-space:nowrap">SD-101</FONT> and DV281 Development
Plans.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Sustain the
DVAX Business Plan</B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;At least one year of cash at year end 2018.</FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Control net cash usage
within budget.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Establish and implement necessary financial reports and controls to deliver compliant
commercial organization.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Implement quality systems automation.</FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Complete preparations
for pharmacovigilance inspection.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Develop and implement investor relations and corporate communications program, including
regular investor engagement.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Recruit key leadership positions.</FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Develop strategic plan
document and update Board of Directors on a <FONT STYLE="white-space:nowrap">bi-annual</FONT> basis.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15%</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee determined that we achieved the goals
in this category at an overall percentage of 90%. In determining this percentage, the Compensation Committee considered several factors, including:</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Maintaining one year of cash at year end.</FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Controlling net cash
usage.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Establishing and implementing financial reports and controls.</FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Successful
pharmacovigilance inspection.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Hiring VPs of Quality and Investor Relations&nbsp;&amp; Corporate
Communications.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90%</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>100%</B></FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>90%</B></FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The terms used, but not defined above, have the following definitions: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>ACIP</I></B>&#148; is the Centers for Disease Control and Prevention&#146;s Advisory Committee on Immunization Practices.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#147;</B><B><I><FONT STYLE="white-space:nowrap">I-SPY</FONT> 2</I></B><B>&#148;</B> is the &#147;Investigation of Serial Studies to Predict Your
Therapeutic Response With Imaging And moLecular Analysis 2&#148; study. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>2018 Individual
Goals</I>.&nbsp;&nbsp;&nbsp;&nbsp;As described above, our CEO does not have individual goals separate from the Company&#146;s corporate objectives. For our other NEOs, the total cash incentive payout for 2018 was based on a weighting of 50%
corporate and 50% individual goals. Our CEO recommends individual goals for each NEO, which are aligned with our business strategy and linked with corporate goals, and our Compensation Committee approves these goals. The individual goals for our
NEOs relate to critical responsibilities of each NEO that go beyond the corporate goals and are significant to our success. The 2018 individual goals for the NEOs include those listed below. These specific goals were in addition to the general
responsibilities each officer had for managing his respective functional operational area. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Compensation Committee, in
recognition of the fact that 50% of the incentive payout for each NEO is based on corporate goal achievement, believes it is of equal importance to assess the individual achievement portion </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of the goal grading in a manner that is reflective of performance against the individual goals. Thus, as is the case with respect to the 2018 individual goals, there may be circumstances where
the individual goal grading exceeds the corporate goal grading, and there may be instances where the corporate goal grading will surpass the individual goal grading. In early 2019, based on the recommendation of our CEO, as well as the observations
by Compensation Committee members of these officers and its own assessment of each NEO&#146;s effectiveness, the Compensation Committee determined the level of achievement of each NEO&#146;s individual performance goals as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Individual Goals</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Individual Achievement</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Individual<BR>Achievement<BR>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael
S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.&#8195;&#8194;&#8202;Meet key financial objectives, including securing adequate financing to support business
operations, establish and implement accounting policies and controls related to <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> commercialization, complete implementation of major IT requirements, optimize processes for managing financial
reporting.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.&#8195;&#8194;&#8202;Develop business and communications strategies that are implementable and target the right
opportunities.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.&#8195;&#8194;&#8202;Optimize internal IP function and file strategic patents related to oncology
assets.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Ostrach exceeded his individual goals by, among other
things:</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Managing our financial strategy, implementing new processes and securing debt financing which
was critical to funding the launch of <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> and our clinical trials;</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Implementing accounting policies and controls to support commercialization of <FONT
STYLE="white-space:nowrap">HEPLISAV-B;</FONT></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Hiring and integrating a VP of Investor Relations and Corporate Communications to enable expanding and deepening both investor relations and corporate communications; and</FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Securing patents,
including pertaining to <FONT STYLE="white-space:nowrap">Heplisav-B</FONT> (method of use) and DV281 (composition of matter) and development function and IP needs.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">107%</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert
L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.&#8195;&#8194;&#8202;Evaluate combinations for possible 2019 DV281 studies.</FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.&#8195;&#8194;&#8202;Advance preclinical
and clinical vaccine and oncology programs.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.&#8195;&#8194;&#8202;Develop and implement strategies that will continue to broaden our scientific platform.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.&#8195;&#8194;&#8202;Advance business development initiatives.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Coffman exceeded his individual goals by, among other
things:</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Making significant progress with evaluations of combinations for possible DV281
studies;</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Overseeing the <FONT STYLE="white-space:nowrap">on-going</FONT> Phase 1 study of DV281 for
lung cancer; and</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Contributing significant time and effort on a wide range of business development initiatives,
including finalizing a finalizing a full license agreement to access of TLR7/8.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108%</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Individual Goals</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Individual Achievement</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Individual<BR>Achievement<BR>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert
Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.&#8195;&#8194;&#8202;Lead efforts to obtain ACIP recommendation and initiation and continuation of various
studies to enhance <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> adoption across indications.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.&#8195;&#8194;&#8202;Develop and implement clinical, regulatory and medical affairs strategies to advance
immuno-oncology and vaccine programs in the clinic, including initiation of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">I-SPY-2</FONT></FONT> neoadjuvant study and developing DV281 combinations clinical plan for
initiation.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.&#8195;&#8194;&#8202;Develop and advance Company&#146;s immuno-oncology presence and profile, including
supporting business development goals and recruitment of key medical leadership positions.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Janssen exceeded his individual goals by, among other
things:</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Obtaining ACIP recommendation for <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> and
initiation of post-marketing studies;</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Advancing development activities for further vaccines;</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Contributing to the selection of <FONT STYLE="white-space:nowrap">SD-101</FONT> to inclusion
in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">I-SPY-2</FONT></FONT> neoadjuvant clinical study for breast cancer; and</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Recruiting a VP of Clinical Operations with extensive oncology development
experience.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108%</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David
Novack</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.&#8195;&#8194;&#8202;Ensure and execute against goals relating to commercial supply and distribution of <FONT
STYLE="white-space:nowrap">HEPLISAV-B</FONT> and process development and continuous improvement of <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> manufacturing.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.&#8195;&#8194;&#8202;Develop and implement manufacturing and quality strategies for advancing our
immuno-oncology programs in the clinic.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.&#8195;&#8194;&#8202;Continue to implement quality assurance strategies required for a commercial organization.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.&#8195;&#8194;&#8202;Enhance efforts to grow the Company&#146;s overall vaccine business and vaccine
collaborative efforts.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Novack exceeded his individual goals by, among other
things:</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Successfully transitioning manufacturing at our Dusseldorf site to full commercial operations
after being put on hold prior to FDA approval of <FONT STYLE="white-space:nowrap">HEPLISAV-B;</FONT></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Leading the company&#146;s successful effort to obtain FDA approval of the PFS presentation
of <FONT STYLE="white-space:nowrap">HEPLISAV-B,</FONT> resulting in increased customer and practitioner uptake;</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Successfully completing process development and manufacturing of clinical and registration
batches to advance various oncology programs; and</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8194;Completing implementation of quality system automation and other improvements to support commercial product and advancing/expanding development portfolio.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">120%</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After making these determinations regarding levels of corporate and individual performance achieved
against the <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals, the Compensation Committee (and the Board with respect to the CEO) </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
reviewed and approved the cash incentive payouts noted below. As noted above, for the NEOs other than the CEO, the cash incentive payouts are based 50% on achievement of corporate goals and 50%
on achievement of individual goals. There were no changes to the NEOs&#146; target annual cash incentive percentages between 2017 and 2018. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2018 Target Annual<BR>Cash Incentive</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2018 Actual Annual Cash Incentive Paid</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Achievement of<BR>Corporate Goals</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Achievement of<BR>Individual Goals</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>% of<BR>Base<BR>Salary</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>% of<BR>Target<BR>Annual<BR>Cash<BR>Incentive</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>$*</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>% of<BR>Target<BR>Annual<BR>Cash<BR>Incentive</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>$*</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total*</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">372,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">335,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">335,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">219,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98,972</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">117,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">216,639</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">241,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108,705</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">130,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">239,151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">219,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98,550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">118,260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">216,810</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90,383</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">120,510</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">210,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Amounts are rounded to the nearest dollar </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Other Executive Compensation Matters </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Equity Compensation Policies
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Compensation Committee approves equity awards for NEOs and authorizes the CEO to approve equity awards for all
other employees based on approved pools for annual and new hire grants. NEO awards are approved either at a regularly-scheduled meeting of the Compensation Committee or by unanimous written consent. The effective date of the grant is generally the
date of the meeting, or the date the last person executes the unanimous written consent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The exercise price of stock options
is not less than the closing price of our common stock on the Nasdaq Capital Market on the grant date of the stock option. We have no practice of timing grants of stock options or restricted stock awards to coordinate with the release of material <FONT
STYLE="white-space:nowrap">non-public</FONT> information, and we have not timed the release of material <FONT STYLE="white-space:nowrap">non-public</FONT> information for purposes of affecting the value of the compensation awarded to our NEOs or any
other employee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We encourage our NEOs to hold a significant equity interest in our Company, but we have not set specific
stock ownership guidelines. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have a policy that prohibits our executive officers, directors and other members of management
from engaging in short sales, transactions in put or call options, hedging transactions or other inherently speculative transactions with respect to our stock. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Tax Effects of Executive Compensation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Section&nbsp;162(m) of
the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), compensation paid to any publicly held corporation&#146;s &#147;covered employees&#148; that exceeds $1&nbsp;million per taxable year for any covered employee is generally <FONT
STYLE="white-space:nowrap">non-deductible.</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to the enactment of the Tax Cuts and Jobs Act, Section&nbsp;162(m) of
the Code (&#147;Section&nbsp;162(m)&#148;) provided a performance-based compensation exception, pursuant to which the deduction limit under Section&nbsp;162(m) did not apply to any compensation that qualified as &#147;performance-based
compensation&#148; under Section&nbsp;162(m). Pursuant to the Tax Cuts and Jobs Act, the performance-based compensation exception under Section&nbsp;162(m) was repealed with respect to taxable years beginning after December&nbsp;31, 2017, except
that certain transition relief is provided for compensation paid pursuant to a written binding contract which was in effect on November&nbsp;2, 2017 and which is not modified in any material respect on or after such date. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Compensation paid to each of the Company&#146;s &#147;covered employees&#148; in excess
of $1&nbsp;million per taxable year generally will not be deductible unless it qualifies for the performance-based compensation exception under Section&nbsp;162(m) pursuant to the transition relief described above. Because of certain ambiguities and
uncertainties as to the application and interpretation of Section&nbsp;162(m), as well as other factors beyond the control of the Compensation Committee, no assurance can be given that any compensation paid by the Company will be eligible for such
transition relief and be deductible by the Company in the future. Although the Compensation Committee will continue to consider tax implications as one factor in determining executive compensation, the Compensation Committee also looks at other
factors in making its decisions and retains the flexibility to provide compensation for the Company&#146;s named executive officers in a manner consistent with the goals of the Company&#146;s executive compensation program and the best interests of
the Company and its stockholders, which may include providing for compensation that is not deductible by the Company due to the deduction limit under Section&nbsp;162(m). The Compensation Committee also retains the flexibility to modify compensation
that was initially intended to be exempt from the deduction limit under Section&nbsp;162(m) if it determines that such modifications are consistent with the Company&#146;s business needs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee also considers the impact of Section&nbsp;409A of the Code, and in general, our executive plans and programs
are designed to comply with the requirements of that section so as to avoid possible adverse tax consequences that may result from <FONT STYLE="white-space:nowrap">non-compliance.</FONT> </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Accounting Considerations </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accounting impact of our compensation
programs is one of many factors that the Compensation Committee considers in determining the structure and size of our executive compensation programs. In general, the Company accounts for equity compensation paid to our employees under the
Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation&#151;Stock Compensation, or ASC 718, which requires us to estimate and record an expense over the service period of the equity award, and our cash
compensation is recorded as an expense at the time the obligation is accrued. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Compensation Recovery Policy </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts paid and awards granted under our 2011 and 2018 Plans will be subject to recoupment in accordance with the Dodd-Frank Wall Street
Reform and Consumer Protection Act and any applicable regulations under the Act, any clawback policy the Company adopts or as is required by applicable law. In addition, as a public company subject to the provisions of Section&nbsp;304 of the
Sarbanes-Oxley Act of 2002, if we are required as a result of misconduct to restate our financial results due to our material noncompliance with any financial reporting requirements under the federal securities laws, our chief executive officer and
chief financial officer may be legally required to reimburse us for any bonus or other incentive-based or equity-based compensation they receive. In addition, we will comply with the requirements of the Dodd-Frank Wall Street Reform and Consumer
Protection Act once the SEC final regulations on the subject become effective. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Risk Analysis </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During fiscal 2018, our Compensation Committee reviewed our compensation policies as generally applicable to our employees in order to
determine whether any such programs were likely to present a material risk to the Company. As part of its assessment, the Compensation Committee considered, among other things, the allocation of compensation among base salary and short- and
long-term compensation, our approach to establishing Company-wide and individual financial, operational and other performance targets, and the nature of our key performance metrics. As a result of this review and analysis, the Compensation
Committee&#146;s determined that our policies and programs do not encourage excessive or inappropriate risk taking, and that the level of risk that they do encourage is not reasonably likely to have a material adverse effect on the Company.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Report of the Compensation Committee of the Board of Directors on Executive Compensation
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In early 2019, the Compensation Committee discussed with management the Compensation Discussion and Analysis, contained in
this proxy statement. Based on this review and discussion, the Compensation Committee has recommended to the Board that the Compensation Discussion and Analysis be included in this proxy statement and incorporated into our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2018. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The material in this report is
not &#147;soliciting material,&#148; is furnished to, but not deemed &#147;filed&#148; with, the SEC and is not deemed to be incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, other than the
Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> where it shall be deemed to be &#147;furnished,&#148; whether made before or after the date hereof and irrespective of any general incorporation language in any such
filing. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Peggy&nbsp;V. Phillips, Chairperson </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Francis&nbsp;R. Cano, Ph.D. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Daniel Kisner, M.D. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>UMMARY</SMALL> C<SMALL>OMPENSATION</SMALL>
T<SMALL>ABLE</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows for the fiscal years ended December&nbsp;31, 2018, 2017 and 2016,
compensation awarded to or paid to, or earned by, NEOs. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Principal Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Salary</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock<BR>Awards<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT>
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Awards<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></B></FONT>
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive<BR>Compensation<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All
Other<BR>Compensation<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">621,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,790,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">335,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4,748,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">CEO and Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">600,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,094,113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">450,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,146,113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">600,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,345,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,947,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">439,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,904,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">216,639</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,562,514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Senior Vice President, Chief Financial Officer, Chief Business Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">425,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,126,060</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">265,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,818,685</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">425,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">703,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,130,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">483,134</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,904,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">239,151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,628,285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Senior Vice President and Chief Scientific Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">466,796</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,223,041</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">297,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,989,419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">466,796</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">703,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,172,548</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">438,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,083,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">216,810</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,739,810</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs</FONT></P></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">400,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,068,056</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">260,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,730,056</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2016</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">400,000</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">670,240</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,072,240</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT><BR></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">401,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,083,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">210,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,697,593</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Senior Vice President, Operations and Quality</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">386,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,036,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">241,406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,665,804</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">386,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">536,192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">924,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the aggregate grant date fair value of RSUs granted in the fiscal year in accordance with ASC 718. See note 15 of our &#147;Notes to
Consolidated Financial Statements&#148; in our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on February&nbsp;27, 2019 for a discussion of assumptions we made in determining the compensation costs included in
this column. With regard to RSUs with performance-based vesting, the grant date fair value included in the table above assumes the highest level of achievement had been met. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Except as otherwise set forth in this footnote, represents the aggregate grant date fair value of option awards granted in the fiscal year in
accordance with ASC 718. A portion of the options granted in fiscal year 2018 are subject to performance-based vesting, as described in the &#147;Compensation Discussion and Analysis.&#148; The grant date fair value for such options with
performance-based vesting is based on the probable outcome of the performance conditions as of the grant date. The maximum potential value of such options with performance-based vesting, assuming the highest level of performance achievement is as
follows: </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Options with<BR>Performance-<BR>Based&nbsp;Vesting</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">758,100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">216,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">216,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">216,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">216,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">For a further discussion of assumptions we made in determining the compensation costs included in this column, see note 15 of our &#147;Notes to
Consolidated Financial Statements&#148; in our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on February&nbsp;27, 2019.<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">.</SUP>
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the annual incentive bonuses earned pursuant to our annual incentive bonus plan for services rendered in the fiscal year. For further
discussion see the section entitled &#147;Compensation Discussion and Analysis &#150; 2018 Executive Compensation Decisions &#150; 2018 Annual Incentive Program &#150; Structure, Goals and Payout Decision.&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents $2,000 401(k) matching contribution for each NEO made by the Company in the fiscal year. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>G<SMALL>RANTS</SMALL> O<SMALL>F</SMALL> P<SMALL>LAN</SMALL> B<SMALL>ASED</SMALL> A<SMALL>WARDS</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows certain information regarding grants of plan-based awards to NEOs during the fiscal year ended December&nbsp;31,
2018. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant&nbsp;Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Estimated<BR>Future<BR>Payouts<BR>Under<BR><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive<BR>Plan
<BR>Awards<BR>Target<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP><BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Estimated<BR>Future<BR>Payouts<BR>Under<BR>Equity<BR>Incentive<BR>Plan<BR>Awards<BR>Target<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)<BR></SUP>(#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All Other<BR>Option<BR>Awards:<BR>Number of<BR>Securities<BR>Underlying<BR>Options<BR>(#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise<BR>or Base<BR>Price of<BR>Option<BR>Awards<BR>($/Share)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant Date<BR>Fair Value<BR>of RSU and<BR>Option<BR>Awards<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">372,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/1/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">280,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,032,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/1/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">758,100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">219,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/1/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">866,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/1/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">216,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/21/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,821,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">241,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/1/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">866,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/1/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">216,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/21/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,821,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">219,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/1/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">866,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/1/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">216,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/1/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">866,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/1/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">216,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the target cash incentive award in fiscal year 2018 as further described under &#147;Compensation Discussion and Analysis &#150; Elements of
Executive Compensation&#148;; our annual incentive program does not specify minimum or maximum levels. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the number of options granted in the fiscal year that are subject to performance-based vesting, as described in the &#147;Compensation
Discussion and Analysis,&#148; and do not include minimum or maximum levels. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the aggregate grant date fair value of options granted in fiscal year 2018 in accordance with ASC 718. See Note&nbsp;15 of our &#147;Notes
to Consolidated Financial Statements&#148; in our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on February&nbsp;27, 2019 for a discussion of the assumptions we made in determining the compensation costs
included in this column. With regard to options with performance-based vesting, the grant date fair value assumes the probable outcome of the conditions, as reported in the &#147;Summary Compensation Table.&#148; For further discussion of these
performance-based options, see the section entitled &#147;Compensation Discussion and Analysis &#150; 2018 Executive Compensation Decisions &#150; Long-Term Equity Incentive Awards.&#148; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N<SMALL>ARRATIVE</SMALL> D<SMALL>ISCLOSURE</SMALL> <SMALL>TO</SMALL> S<SMALL>UMMARY</SMALL>
C<SMALL>OMPENSATION</SMALL> T<SMALL>ABLE</SMALL> <SMALL>AND</SMALL> G<SMALL>RANTS</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL> B<SMALL>ASED</SMALL> A<SMALL>WARDS</SMALL> T<SMALL>ABLE</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The material terms of NEOs&#146; annual compensation and the explanations of the amounts of base salary, annual cash-based incentives, and
equity-based awards in proportion to total compensation are described under &#147;Compensation Discussion and Analysis&#148; in this proxy statement. Our severance and change in control benefits are described under &#147;Summary of Change in Control
and Involuntary Termination Arrangements&#148; in this proxy statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As discussed in the &#147;Compensation Discussion and
Analysis,&#148; the fiscal year 2018 cash incentive amounts were paid pursuant to the annual cash incentive compensation program, based on the achievement of certain corporate and individual performance goals. Equity-based awards were granted in
2018 under our 2018 Plan and represent a mix of time based and performance based options, as described in the &#147;Compensation Discussion and Analysis.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>O<SMALL>UTSTANDING</SMALL> E<SMALL>QUITY</SMALL> A<SMALL>WARDS</SMALL> A<SMALL>T</SMALL> F<SMALL>ISCAL</SMALL> Y<SMALL>EAR</SMALL> E<SMALL>ND</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows certain information regarding outstanding equity awards for NEOs as of December&nbsp;31, 2018. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Unearned<BR>Options (#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Exercise<BR>Price<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Vesting<BR>Commencement<BR>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Expiration<BR>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number<BR>of<BR>Shares<BR>or Units<BR>that<BR>Have<BR>Not<BR>Vested<BR>(#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Market<BR>Value<BR>of Stock<BR>that<BR>Have<BR>Not<BR>Vested<BR>($)<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number<BR>of<BR>Unearned<BR>Shares or<BR>Other<BR>Rights<BR>that
Have<BR>Not<BR>Vested&nbsp;(#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Market<BR>or Payout<BR>Value of<BR>Unearned<BR>Shares<BR>or
Other<BR>Rights<BR>that Have<BR>Not<BR>Vested&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">22.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5/1/2013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4/30/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">75,001</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/31/2014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/30/2024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">215,624</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">9,376</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/9/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/8/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">264,444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">15,556</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">21.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">75,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">686,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">74,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">677,100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">75,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">686,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">280,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/1/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/31/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">70,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/31/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3/10/2009</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3/9/2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,673</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">15.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/19/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/18/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">31.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/6/2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/5/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">18,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">34.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/31/2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/30/2022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">30.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/5/2013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">27,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">64,208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,792</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/9/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/8/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">24,166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4,834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">28.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">8/27/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">8/26/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">79,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">21.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">49,804</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">455,707</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">155,550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">49,804</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">455,707</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">80,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/1/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/31/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/31/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(8)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">18.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3/21/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3/20/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Unearned<BR>Options (#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Exercise<BR>Price<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Vesting<BR>Commencement<BR>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Expiration<BR>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number<BR>of<BR>Shares<BR>or Units<BR>that<BR>Have<BR>Not<BR>Vested<BR>(#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Market<BR>Value<BR>of Stock<BR>that<BR>Have<BR>Not<BR>Vested<BR>($)<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number<BR>of<BR>Unearned<BR>Shares or<BR>Other<BR>Rights<BR>that
Have<BR>Not<BR>Vested&nbsp;(#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Market<BR>or Payout<BR>Value of<BR>Unearned<BR>Shares<BR>or
Other<BR>Rights<BR>that Have<BR>Not<BR>Vested&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">10,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">15.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/19/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/18/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">30,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">31.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/6/2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/5/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">18,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">34.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/31/2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/30/2022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">18,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">30.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/5/2013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">71,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/9/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/8/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">13,751</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">28.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">8/27/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">8/26/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">79,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">21.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">54,702</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">500,523</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">155,550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">54,702</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">500,523</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">80,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/1/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/31/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/31/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(8)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">18.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3/21/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3/20/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">13.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4/7/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4/6/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">31.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/6/2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/5/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">36.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/1/2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/31/2022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">15,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">41.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">10/31/2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">10/30/2022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">18,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">53,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,334</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/9/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/8/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">75,555</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">21.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">46,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">428,906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">155,550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">46,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">428,906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">80,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/1/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/31/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/31/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">30,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">21.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3/25/2013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3/24/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">22,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">71,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/9/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/8/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">60,444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,556</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">21.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">45,263</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">414,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">155,550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">45,263</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">414,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">80,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/1/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/31/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7)</SUP>&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/31/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the aggregate fair value of RSUs in accordance with ASC 718, based on the last closing price per share as of December&nbsp;31, 2018 of
$9.15. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Options vest at the rate of 1/4th of the shares on the first anniversary of the vesting commencement date, with 1/48th of the total number of shares
vesting each month thereafter. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Options vests at the rate of 1/3rd of the shares on the first anniversary of the vesting commencement date, with 1/36th of the total number of shares
vesting each month thereafter. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">RSU vested 50% on February&nbsp;22, 2018 and 50% on February&nbsp;22, 2019. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">RSU vested <FONT STYLE="white-space:nowrap">one-third</FONT> on February&nbsp;22, 2018, <FONT STYLE="white-space:nowrap">one-third</FONT> vested on
February&nbsp;22, 2019 and the remainder will vest on February&nbsp;22, 2020. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">RSU vested 50% on June&nbsp;2, 2018 and the remainder will vest on June&nbsp;2, 2019. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the number of options granted in the fiscal year that are subject to performance-based vesting, as described in the &#147;Compensation
Discussion and Analysis.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(8)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Options vest 50% on March&nbsp;21, 2020 and the remainder will vest on March&nbsp;21, 2021. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>O<SMALL>PTION</SMALL> E<SMALL>XERCISES</SMALL> A<SMALL>ND</SMALL> S<SMALL>TOCK</SMALL>
V<SMALL>ESTED</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table provides information on stock awards that vested, including the number of shares
acquired upon vesting and the value realized, determined as described below, for the named executive officers in the fiscal year ended December&nbsp;31, 2018. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD style="width:31pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:31pt"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD style="width:25pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:25pt"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD style="width:31pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:31pt"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD style="width:25pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:25pt"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock Awards</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Shares<BR>Acquired on<BR>Exercise (#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Value&nbsp;Realized<BR>on Exercise<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Shares<BR>Acquired on<BR>Vesting (#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Value&nbsp;Realized<BR>on
Vesting<BR>($)<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">214,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,626,363</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">114,485</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,914,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">124,281</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,077,196</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,817,306</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">105,403</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,763,821</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">The value realized on vesting is determined by multiplying the number of shares of stock by the market value of the underlying shares as reported by
the Nasdaq Capital Market on the vesting date. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>ENSION</SMALL> B<SMALL>ENEFITS</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">None of the NEOs participates in or has an account balance under any pension or qualified or
<FONT STYLE="white-space:nowrap">non-qualified</FONT> defined benefit retirement plans sponsored by the Company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N<SMALL>ON</SMALL> <FONT
STYLE="white-space:nowrap">-Q</FONT><SMALL>UALIFIED</SMALL> D<SMALL>EFERRED</SMALL> C<SMALL>OMPENSATION</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">None of
the NEOs participates in or has an account balance under any <FONT STYLE="white-space:nowrap">non-qualified</FONT> defined contribution plans or other <FONT STYLE="white-space:nowrap">non-qualified</FONT> deferred compensation plans maintained by
the Company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>OTENTIAL</SMALL> P<SMALL>AYMENTS</SMALL> U<SMALL>PON</SMALL> C<SMALL>HANGE</SMALL> <SMALL>IN</SMALL>
C<SMALL>ONTROL</SMALL> <SMALL>OR</SMALL> I<SMALL>NVOLUNTARY</SMALL> T<SMALL>ERMINATION</SMALL> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Summary of Change in Control and
Involuntary Termination Arrangements. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To promote retention of certain key executives, our Board has authorized the Company
to enter into Management Continuity and Severance Agreements with each NEO. We refer to the agreements in effect as of December&nbsp;31, 2018 as the &#147;Management Agreements.&#148; In order to be eligible to receive benefits under the Management
Agreements, our NEOs and other officers must execute a general waiver and release of claims, and such release must become effective in accordance with its terms. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Change in Control. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Management Agreement with Mr.&nbsp;Gray
provides that, as of immediately prior to the effective date of a Change in Control (as described below), all of Mr.&nbsp;Gray&#146;s then-outstanding equity awards (including stock options and RSUs) under the 2011 Plan or the 2018 Plan shall
automatically accelerate and fully vest, subject to Mr.&nbsp;Gray&#146;s execution and delivery of a release. Upon a Change in Control, Mr.&nbsp;Gray would have 598,932 aggregate equity awards subject to accelerated vesting, with a value of
$2,049,600, assuming the event occurred on December&nbsp;31, 2018. This amount represents the value of stock and accelerated stock option and award vesting if the event took place on December&nbsp;31, 2018. The value for RSUs is calculated in
accordance with ASC 718, based on the closing price per share on December&nbsp;31, 2018. The value for stock option awards is calculated based on the &#147;spread&#148; between the closing price per share on December&nbsp;31, 2018 of $9.15 and the
exercise price of the vested awards, to the extent such vested awards were &#147;in the money.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The other NEOs do not
receive an equity acceleration benefit in the event of a Change in Control (without termination of employment) of the Company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Qualifying Termination in Connection with a Change in Control. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Management Agreements, if, on or during the <FONT STYLE="white-space:nowrap">two-year</FONT> period following a Change in
Control (as described below), the NEO&#146;s employment is involuntarily terminated, the NEO will, subject to the execution of a release of claims, be entitled to receive: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a <FONT STYLE="white-space:nowrap">lump-sum</FONT> cash payment equal to a specified number of months (24 months for Mr.&nbsp;Gray and 12 months for
our other NEOs) of the executive&#146;s then-effective annual base salary; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a <FONT STYLE="white-space:nowrap">lump-sum</FONT> cash payment equal to the NEO&#146;s target annual variable cash compensation (200% of such target
for Mr.&nbsp;Gray and 100% of such target for our other NEOs) for the year of termination; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">cash payments equal to the applicable COBRA premiums for up to the same number of months as the NEO receives in base salary, as set forth in the first
bullet (the &#147;COBRA Payment&#148;); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">acceleration of vesting of all outstanding equity awards at the time of such termination (provided, however, that Mr.&nbsp;Gray will receive
accelerated vesting for only those grants that (i)&nbsp;were issued under the 2011 Plan (or any equity plan of a successor company) and (ii)&nbsp;are subject to time-based vesting criteria if issued after the Change of Control); and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the extension of exercisability of all stock options to purchase the Company&#146;s common stock for a period of 3 years following termination of
employment (but in any event not beyond each option&#146;s expiration date). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, if any payments
or benefits would constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Code and such payments would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, then such payments will either be
(1)&nbsp;provided to the NEO in full or (2)&nbsp;reduced to such lesser amount that would result in no portion of such payments being subject to the excise tax, whichever amount after taking into account all applicable taxes, including the excise
tax, would result in the NEO&#146;s receipt, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, of the greatest amount of such payments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Management Agreements generally define a Change in Control to mean the occurrence of a change in the majority ownership of the voting securities of the Company; a merger that results in change in the
majority ownership of the voting securities of the Company; the sale of all or substantially all of the assets; or (for all of our NEOs except Mr.&nbsp;Gray) over a period of 12 months or less, when a majority of our Board becomes comprised of
individuals who were not serving on our Board as of a specified date, or whose nomination, appointment, or election was not approved by a majority of the directors who were serving on our Board as such specified date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below outlines the potential payments and benefits payable to each NEO in the event such executive&#146;s termination in
connection with a Change in Control of the Company, assuming such event had occurred on December&nbsp;31, 2018. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Severance<BR>Payment</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Continuation<BR>of Benefits</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Value
of<BR>Accelerated<BR>Stock<BR>Awards<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,987,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59,253</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,049,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,096,053</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">659,813</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,047</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,066,963</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,761,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">724,701</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,726</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,156,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,911,024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">657,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,726</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,013,363</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,700,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">602,550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,047</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">983,863</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,621,460</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the value of accelerated vesting of equity awards if the event took place on December&nbsp;31, 2018. The value for RSUs is calculated in
accordance with ASC 718, based on the closing price per share on December&nbsp;31, 2018. The value for stock option awards is calculated based on the &#147;spread&#148; between the closing price per share on December&nbsp;31, 2018 of $9.15 and the
exercise price of the vested awards, to the extent such vested awards were &#147;in the money.&#148; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Involuntary Termination. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the terms of the Management Agreements, upon an &#147;involuntary&#148; termination without &#147;cause&#148; or, if applicable,
upon a resignation for &#147;good reason&#148; (as defined below), the NEO will, subject to the execution of a release of claims, be entitled to receive: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a <FONT STYLE="white-space:nowrap">lump-sum</FONT> cash payment equal to the specified number of months (ranging from 6 to 24) of the executive&#146;s
then-effective annual base salary; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the COBRA Payment; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">accelerated vesting of all equity awards that are held by Mr.&nbsp;Gray on the effective date of termination and subject to time-based vesting
criteria; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">for Mr.&nbsp;Gray, the extension of exercisability of all vested stock options to purchase the Company&#146;s common stock for a period of 3 years
following termination of employment (but in any event not beyond each option&#146;s expiration date). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under
the terms of the Management Agreements: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Gray will receive 24 months of base salary, 200% of his target annual cash incentive, the COBRA Payment, accelerated vesting of his
then-outstanding employee stock options and restricted stock awards, and up to 3 years to exercise the vested options; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our other NEOs will receive 6 months of base salary and the COBRA Payment. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below outlines the potential payments and benefits payable to each NEO in the event of such NEO&#146;s involuntary termination
had occurred on December&nbsp;31, 2018.</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Severance<BR>Payment</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Continuation<BR>of Benefits</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Value of<BR>Accelerated<BR>Stock&nbsp;Awards<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,987.200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59,253</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,049,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,096,053</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">219,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,524</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">237,461</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">241,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,863</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">256,430</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">219,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,863</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">233,863</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,524</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">218,374</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the value of accelerated vesting of equity awards that are subject to time-based vesting criteria if the event took place on
December&nbsp;31, 2018. The value for RSUs is calculated in accordance with ASC 718, based on the closing price per share on December&nbsp;31, 2018. The value for stock option awards is calculated based on the &#147;spread&#148; between the closing
price per share on December&nbsp;31, 2018 of $9.15 and the exercise price of the vested awards, to the extent such vested awards were &#147;in the money.&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of the Management Agreements, &#147;cause&#148; generally means (1)&nbsp;gross negligence or willful misconduct in the
performance of duties to the Company, where such gross negligence or willful misconduct has resulted or is likely to result in substantial and material damage to the Company or its subsidiaries; (2)&nbsp;repeated unexplained or unjustified absence
from the Company; (3)&nbsp;a material and willful violation of any federal or state law; (4)&nbsp;commission of any act of fraud with respect to the Company; or (5)&nbsp;conviction of a felony or a crime involving moral turpitude causing material
harm to the standing and reputation of the Company, in each case as determined in good faith by the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of
the Management Agreements, &#147;good reason&#148; generally means the NEO&#146;s voluntary termination following (1)&nbsp;a material reduction or change in job duties, responsibilities, and requirements inconsistent with the NEO&#146;s position
with the Company and his or her prior duties, responsibilities, and requirements, or a material change in the level of management to which the NEO reports; (2)&nbsp;any material reduction of base compensation (other than in connection with a general
decrease in base salaries for most officers of the successor corporation); or (3)&nbsp;the refusal to relocate to a facility or location more than 35 miles from the Company&#146;s current location. The NEO must provide 90 days&#146; notice of the
event giving rise to good reason, give the Company </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
30 days to cure (if curable), and any resignation for good reason must occur within 180 days after the occurrence of the event giving rise to such resignation right. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>AY</SMALL> R<SMALL>ATIO</SMALL> D<SMALL>ISCLOSURE</SMALL> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under SEC rules, we are required to calculate and disclose the annual total compensation of our median employee, as well as the ratio of
the annual total compensation of our median employee as compared to the annual total compensation of our CEO (&#147;CEO Pay Ratio&#148;). To identify our median employee, we used the following methodology: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To determine our total population of employees, we included all full-time, part-time, and temporary employees as of December&nbsp;31, 2018.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To identify our median employee from our employee population, we calculated the aggregate amount of each employee&#146;s 2018 base salary (using a
reasonable estimate of the hours worked and overtime actually paid during 2018 for hourly employees and actual salary paid for our remaining employees), the target value of annual cash incentive awards, and the value of equity awards granted in 2018
using the same methodology we use for estimating the value of the equity awards granted to our named executive officers and reported in our Summary Compensation Table. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In making this determination, we annualized the compensation elements listed above of employees who were employed by us for less than the entire
calendar year. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Compensation paid in foreign currencies was converted to U.S. dollars based on exchange rates in effect on December&nbsp;31, 2018.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Using this approach, we determined our median employee. Once the median employee was identified, we then
calculated the annual total compensation of this employee for 2018 in accordance with the requirements of the Summary Compensation Table. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For 2018, the median of the annual total compensation of our employees (other than our CEO) was $162,137 and the annual total compensation of our CEO, as reported in the Summary Compensation Table
included in this Proxy Statement, was $4,748,840. Based on this information, the ratio of the annual total compensation of our CEO to the median of the annual total compensation of all employees was 29 to 1. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The CEO Pay Ratio above represents our reasonable estimate calculated in a manner consistent with SEC rules and applicable guidance. SEC
rules and guidance provide significant flexibility in how companies identify the median employee, and each company may use a different methodology and make different assumptions particular to that company. As a result, and as explained by the SEC
when it adopted these rules, in considering the pay ratio disclosure, stockholders should keep in mind that the rule was not designed to facilitate comparisons of pay ratios among different companies, even companies within the same industry, but
rather to allow stockholders to better understand and assess each particular company&#146;s compensation practices and pay ratio disclosures. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Neither the Compensation Committee nor our management used our CEO Pay Ratio measure in making compensation decisions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DIRECTOR COMPENSATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>N<SMALL>ON</SMALL>-E<SMALL>MPLOYEE</SMALL> D<SMALL>IRECTOR</SMALL> C<SMALL>OMPENSATION</SMALL> P<SMALL>HILOSOPHY</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation philosophy is based on the following guiding principles: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aligning the long-term interests of stockholders and directors; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Compensating directors appropriately and adequately for their time, effort and experience </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The elements of director compensation consist of annual cash retainers and equity awards, as well as customary and usual expense
reimbursement in attending Board and committee meetings. In an effort to align the long-term interests of our stockholders and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, the mix of cash and equity compensation has historically
been, and is currently, weighted more heavily to equity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee determines
<FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation, which the full Board reviews and approves upon recommendation from the Compensation Committee. When considering <FONT STYLE="white-space:nowrap">non-employee</FONT> director
compensation decisions, the Compensation Committee believes it is important to be informed as to current compensation practices of comparable publicly-held companies in the life sciences industry, especially to understand the demand and
competitiveness for attracting and retaining an individual with each <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s specific expertise and experience. Thus, the Compensation Committee considers recommendations from Arnosti
based on an analysis of peer group Board compensation. Our compensation arrangements for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors are set forth in our <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director
Compensation Policy (the &#147;Director Compensation Policy&#148;). The Director Compensation Policy outlines cash and equity compensation automatically payable to <FONT STYLE="white-space:nowrap">non-employee</FONT> members of the Board, unless
such <FONT STYLE="white-space:nowrap">non-employee</FONT> director declines receipt of such cash or equity compensation by written notice to us. The Compensation Committee reviews our <FONT STYLE="white-space:nowrap">non-employee</FONT> director
compensation relative to industry practices at least every other year, and the last review was done in February 2019. No changes to Director compensation were made in 2019. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In 2018, our stockholders approved a limit on the amount of <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation under our 2018 Equity Incentive Plan. The aggregate value of all cash
and equity-based compensation granted or paid by us to any individual for service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director of the Board with respect to any fiscal year of the Company may not exceed (i)&nbsp;a total of
$200,000 with respect to any such cash compensation and (ii) $800,000 in total value with respect to any such equity-based compensation (including awards granted under our 2018 Equity Incentive Plan and any other equity-based awards), calculating
the value of any such awards based on the grant date fair value of such awards for financial reporting purposes. This limit was not intended to serve as an increase in the annual amount of <FONT STYLE="white-space:nowrap">non-employee</FONT>
director compensation; rather, this action was approved for the purpose of limiting the amount of compensation the Board can approve for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors each year. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>ASH</SMALL> C<SMALL>OMPENSATION</SMALL> A<SMALL>RRANGEMENTS</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2018, each member of our Board who was not an employee or officer of the Company received the following cash compensation for Board
services: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A $65,000 annual retainer for service as chairman of the Board and a $40,000 annual retainer for service as a member of the Board.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A $20,000 annual retainer for the Chair of the Audit Committee and a $10,000 annual retainer for each additional member of the Audit Committee.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A $15,000 annual retainer for the Chair of the Compensation Committee and a $7,000 annual retainer for each additional member of the Compensation
Committee. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A $10,000 annual retainer for the Chair of the Nominating and Governance Committee and $5,000 annual retainer for each additional member of the
Nominating and Governance Committee. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also reimburse our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their reasonable expenses incurred in attending meetings of our Board and committees of our Board. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>QUITY</SMALL> A<SMALL>WARDS</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our compensation program for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, was modified in February 2018 to increase of
the size of the Subsequent Grant described below from 7,500 shares to 15,000 shares. The compensation program currently provides that: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each director and the chairman of the Board automatically receives an initial equity award, or Initial Grant, consisting of a <FONT
STYLE="white-space:nowrap">non-qualified</FONT> stock option to purchase 15,000 shares and 25,000 shares, respectively, of Dynavax common stock upon the date each such person is elected or appointed to the Board. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On the date of each annual meeting of the Company&#146;s stockholders, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director also
automatically receives a subsequent equity award, or Subsequent Grant, consisting of a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option to purchase 15,000 shares of Dynavax common stock. However, the
<FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s first Subsequent Grant shall be reduced to 75% of the Subsequent Grant, or 11,250 shares, if the service period from the <FONT STYLE="white-space:nowrap">non-employee</FONT>
director&#146;s initial election date to the annual meeting is between 7 and 10 months, 50% of the Subsequent Grant, or 7,500 shares, if the service period from the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s initial
election date to the annual meeting is between 4 and 7 months, and 25% of the Subsequent Grant, or 3,750 shares, if the service period from the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s initial election date to the annual
meeting is between 1 and 4 months. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective as of the 2016 Annual Meeting, each Initial Grant vests in
equal annual installments over three years on the anniversary of the grant date. Each Subsequent Grant vests in full on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the grant date. The exercise price per share of each Initial
Grant and Subsequent Grant shall be one hundred percent of the fair market value per share on the date of grant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board
may approve additional cash and equity awards for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>IRECTOR</SMALL> C<SMALL>OMPENSATION</SMALL> T<SMALL>ABLE</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table shows for the fiscal year ended December&nbsp;31, 2018, certain information with respect to the compensation of all <FONT STYLE="white-space:nowrap">non-employee</FONT> directors of
the Company: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fees&nbsp;Earned<BR>or Paid
in<BR>Cash<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Awards<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)(3)</SUP></B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnold L. Oronsky, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">156,767</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">231,767</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laura Brege</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">156,767</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">216,767</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Francis R. Cano, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">156,767</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">208,767</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dennis A. Carson, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">156,767</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">196,767</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Daniel L. Kisner, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">156,767</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">213,767</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peggy V. Phillips</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">156,767</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">221,767</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stanley A. Plotkin, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Natale Ricciardi</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">156,767</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">201,767</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of fees earned or paid in 2018 for Board and committee meeting membership as described above. Dr.&nbsp;Plotkin voluntarily resigned from the
Board effective as of May&nbsp;31, 2018, and was only eligible for cash fees in fiscal year 2018. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the aggregate grant date fair value of stock options granted in the fiscal year in accordance with ASC 718. See note 15 of our &#147;Notes
to Consolidated Financial Statements&#148; in our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on February&nbsp;27, 2019, for a discussion of assumptions we made in determining the compensation costs included
in this column. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">As of December&nbsp;31, 2018, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director held stock options to purchase the following numbers
of shares of our common stock: Dr.&nbsp;Oronsky held options to purchase 58,950 shares of our common stock; Ms.&nbsp;Brege held options to purchase 42,675 shares of our common stock; Dr.&nbsp;Cano held options to purchase 55,050 shares of our common
stock; Dr.&nbsp;Carson held options to purchase 48,750 shares of our common stock; Dr.&nbsp;Kisner held options to purchase 58,450 shares of our common stock; Ms.&nbsp;Phillips held options to purchase 58,950 shares of our common stock; and
Mr.&nbsp;Ricciardi held options to purchase 42,750 shares of our common stock. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>QUITY</SMALL> C<SMALL>OMPENSATION</SMALL> P<SMALL>LANS</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows activity under our equity compensation plans as of the fiscal year ended December&nbsp;31, 2018. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Plan Category</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>securities&nbsp;to<BR>be&nbsp;issued&nbsp;upon&nbsp;exercise<BR>of outstanding
options,<BR>warrants and rights</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>exercise price of<BR>outstanding<BR>options,
warrants<BR>and rights</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number<BR>of&nbsp;securities&nbsp;remaining<BR>available for future<BR>issuance
under<BR>equity&nbsp;compensation<BR>plans (excluding<BR>securities reflected in<BR>the first column)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity compensation plans approved by security holders:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2004 Stock Incentive Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,223</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011 Equity Incentive Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,740,931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2014 Employee Stock Purchase Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">573,034</FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2018 Equity Incentive Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">474,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.78</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,810,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity compensation plans not approved by security holders:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2010 Employment Inducement Award Plan</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,450</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2017 Inducement Award Plan</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">484,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,750,404</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,383,146</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">As of December&nbsp;31, 2018, an aggregate of 573,034 shares remained available for future issuance under the 2014 Employee Stock Purchase Plan, and as
of April&nbsp;9, 2019, up to a maximum of 498,472 shares may be purchased in the current purchase period. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">In order to induce qualified individuals to join our Company, our Board adopted the 2010 Employment Inducement Award Plan, or the 2010 Inducement Plan,
effective January&nbsp;8, 2010, which provided for the issuance of up to 150,000 shares of Company common stock to new employees of the Company. Stockholder approval of the 2010 Inducement Plan was not required under Nasdaq Marketplace Rule
5635(c)(4). Upon the effectiveness of the Amended 2011 Plan, no additional awards were granted under either the 2004 Stock Incentive Plan or the 2010 Inducement Plan. All shares currently subject to awards outstanding under the 2004 Stock Incentive
Plan or 2010 Inducement Plan, which awards expire or are forfeited, will be included in the reserve for the Amended 2011 Plan to the extent such shares would otherwise return to such plans. Awards granted under the 2010 Inducement Plan have a term
of 10 years. Exercisability, option price and other terms are determined by the plan administrator, but the option price cannot be less than 100% of fair market value of those shares on the date of grant. Stock options granted under the 2010
Inducement Plan generally vest over a period of four years, with the exception of performance based awards which will vest upon achievement of certain performance conditions. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">In order to induce qualified individuals to join our Company, on November&nbsp;28, 2017, our Board adopted the 2017 Inducement Award Plan, or the 2017
Inducement Plan, which provided for the issuance of up to 1,200,000 shares of Company common stock to new employees of the Company. Stockholder approval of the 2017 Inducement Plan was not required under Nasdaq Marketplace Rule 5635(c)(4). Upon the
effectiveness of the 2018 Equity Incentive Plan, no additional awards were granted under the 2017 Inducement Plan. All shares currently subject to awards outstanding under the 2017 Inducement Plan, which awards expire or are forfeited, are included
in the reserve for the 2018 Equity Incentive Plan to the extent such shares would otherwise return to such plan. Awards granted under the 2017 Inducement Plan have a term of 10 years. Exercisability, option price and other terms are determined by
the plan administrator, but the option price cannot be less than 100% of fair market value of those shares on the date of grant. Stock options granted under the 2017 Inducement Plan generally vest over a period of four years, with the exception of
performance based awards which will vest upon achievement of certain performance conditions. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CORPORATE GOVERNANCE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>ORPORATE</SMALL> G<SMALL>OVERNANCE</SMALL> G<SMALL>UIDELINES</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2016, our Board adopted Corporate Governance Guidelines that set forth key principles to guide the Board in its exercise of
responsibilities and serve the interests of the Company and our stockholders. The Corporate Governance Guidelines were reviewed and updated by the Board in February 2018. Our Corporate Governance Guidelines can be found on the Corporate Governance
page under the Investors and Media&nbsp;&#150; Corporate Governance section of our website at www.dynavax.com. In addition, these guidelines are available in print to any stockholder who requests a copy. Please direct all requests to our Corporate
Secretary, Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100, Berkeley, California 94710, if mailed prior to June&nbsp;1, 2019, or to 5959 Horton Street, Suite 700, Emeryville, California 94608, if mailed on or after June&nbsp;1,
2019. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>TOCKHOLDER</SMALL> O<SMALL>UTREACH</SMALL> <SMALL>AND</SMALL> E<SMALL>NGAGEMENT</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board of Directors and management team value the views of our stockholders and we proactively engage with our major stockholders on a
regular basis. We believe our outreach efforts help ensure that our stockholders are aware of our governance initiatives and provide us with valuable feedback in order to enhance our governance practices and disclosure to stockholders. In early
spring 2018, and again in fall 2018, we contacted 12 of our 20 largest stockholders and we spoke with 100% of the stockholders that wanted to provide us with feedback at that time. The bulk of the stockholders, while appreciating the outreach, did
not feel a need to talk at the time. During these discussions we solicited feedback from our stockholders on our corporate governance and executive compensation practices, and provided an opportunity for each stockholder with whom we spoke to ask
questions concerning our corporate governance and executive compensation practices. During these conversations, none of our stockholders expressed any concerns about our about our corporate governance or executive compensation practices. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>M<SMALL>AJORITY</SMALL> V<SMALL>OTE</SMALL> P<SMALL>OLICY</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our Corporate Governance Guidelines include a provision whereby any nominee for director in an uncontested election would submit an offer of resignation for consideration by the Nominating and Corporate
Governance Committee of the Board, if such nominee receives a greater number of &#147;Withhold&#148; votes than &#147;For&#148; votes. The Nominating and Corporate Governance Committee would then consider all of the relevant facts and circumstances
and recommend to the Board the action to be taken with respect to such offer of resignation. Promptly following the Board&#146;s decision, we would disclose that decision and an explanation of such decision in a filing with the SEC or a press
release. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>I<SMALL>NDEPENDENCE</SMALL> O<SMALL>F</SMALL> T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL>
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As required under the Nasdaq Stock Market, or Nasdaq listing standards, and our Corporate Governance Guidelines, a
majority of the members of a listed company&#146;s board of directors must qualify as &#147;independent,&#148; as affirmatively determined by the board of directors. In addition, applicable Nasdaq rules require that, subject to specified exceptions,
each member of a listed company&#146;s audit, compensation and nominating committees be independent within the meaning of applicable Nasdaq rules. Audit committee members must also satisfy the independence criteria set forth in Rule <FONT
STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consistent with these considerations, our Board undertook a
review of the independence of each director and considered whether any director has a material relationship that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. After review of all
relevant transactions or relationships between each director, or any of his or her family members, and the Company, its senior management and its independent registered public accounting firm, the Board has affirmatively determined that the
following directors are independent directors within the meaning of the applicable Nasdaq listing standards: Ms.&nbsp;Phillips, Ms.&nbsp;Brege and Mr.&nbsp;Ricciardi as well as Drs. Carson, Cano, Kisner and Oronsky. In making these determinations,
the Board found that none of these directors has a material or other disqualifying relationship with the Company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In determining the independence of Dr.&nbsp;Carson, the Board took into account his
role as the university-nominated representative on the evaluation committee to oversee aspects of the agreement between the Regents of the University of California and Dynavax and determined that this relationship would not interfere with
Dr.&nbsp;Carson&#146;s exercise of independent judgment in carrying out his responsibilities as a director. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">By virtue of his
employment with the Company, Eddie Gray, our Chief Executive Officer is not an independent director. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>B<SMALL>OARD</SMALL>
L<SMALL>EADERSHIP</SMALL> S<SMALL>TRUCTURE</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board is currently chaired by Dr.&nbsp;Oronsky. The duties of the
chairman include presiding over all meetings of the Board; preparing the agenda for Board meetings in consultation with the CEO and other members of our Board; calling and presiding over meetings of
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors; and managing the Board&#146;s process for annual evaluation of the CEO. Accordingly, the chairman has substantial ability to shape the work of our Board. Our Board currently believes
that separation of the positions of chairman and CEO reinforces the independence of our Board in its oversight of our business and affairs. In addition, such separation helps create an environment that is more conducive to objective evaluation and
oversight of management&#146;s performance, increasing management accountability and improving the ability of our Board to monitor whether management&#146;s actions are in the best interests of our Company and its stockholders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board also believes there may be advantages to having an independent chairman for matters such as communications and relations
between our Board, the CEO and other senior management and in assisting our Board in reaching consensus on particular strategies and policies. Having a chairman separate from the CEO also allows the chairman to focus on assisting the CEO and other
senior management in seeking and adopting successful business strategies and risk management policies and in making successful choices in management succession. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>B<SMALL>OARD</SMALL>&#146;<SMALL>S</SMALL> R<SMALL>OLE</SMALL> I<SMALL>N</SMALL> R<SMALL>ISK</SMALL> O<SMALL>VERSIGHT</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk assessment and oversight are an integral part of our governance and management processes. Our Board encourages management to promote
a culture that incorporates risk management into our corporate strategy and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business operations. Management discusses strategic and operational risks at
regular management meetings, and conducts specific strategic planning and review sessions during the year that include a focused discussion and analysis of the risks facing the Company. Throughout the year, senior management reviews these risks with
the Board at regular Board meetings as part of management presentations that focus on particular business functions, operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board does not have a standing risk management committee but rather administers this oversight function directly through our Board as
a whole as well as through various standing committees of our Board that address risks inherent in their respective areas of oversight. In particular, our Board is responsible for monitoring and assessing strategic risk exposure, including
overseeing our healthcare compliance program pertaining to healthcare laws, regulations and industry standards applicable to pharmaceutical companies. Our Audit Committee has the responsibility to oversee our major financial risk exposures and the
steps our management has taken to monitor and control these exposures as well as oversight of our enterprise risk management program. The Audit Committee also monitors compliance with legal and regulatory requirements, oversees the performance of
our internal audit function and approves or disapproves any related-persons transactions. Our Nominating and Governance Committee monitors the effectiveness of our corporate governance guidelines and manages the process for annual director
self-assessment and evaluation of the Board. Our Compensation Committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>M<SMALL>EETINGS</SMALL> O<SMALL>F</SMALL> T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board met five times during fiscal year 2018. All Board members attended at least 75% or more of the aggregate of the meetings of the
Board and of the committees on which the member served held during the period of service as a director or committee member. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>OMMITTEES</SMALL> O<SMALL>F</SMALL> T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL>
O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board has three standing committees: an Audit Committee, a Compensation
Committee and a Nominating and Governance Committee. The following table provides membership and meeting information for fiscal year 2018 for each of the Board committees: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Audit</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Compensation</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nominating</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnold L. Oronsky, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Francis R. Cano, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laura Brege</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Daniel L. Kisner, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peggy V. Phillips</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Natale Ricciardi</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Members</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Meetings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Committee Chairperson </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Below is a description of each committee of our Board. Each of the committees has authority to engage legal counsel or other experts or consultants as it deems appropriate to carry out its
responsibilities. Our Board has determined that each member of each committee meets the applicable Nasdaq listing standards and related rules and regulations regarding &#147;independence&#148; and that each member is free of any relationship that
would impair his or her individual exercise of independent judgment with regard to the Company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Audit Committee </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee for 2018 was comprised of three directors: Ms.&nbsp;Brege (Chairperson), Dr.&nbsp;Oronsky and Ms.&nbsp;Phillips. In
addition to determining that all members of the Audit Committee are independent (as independence is currently defined in Rule 5605(c)(2)(A)(i) and (ii)&nbsp;of the Nasdaq listing standards), the Board determined that Ms.&nbsp;Brege qualified as an
&#147;audit committee financial expert,&#148; as defined in applicable SEC rules. The Board made a qualitative assessment of Ms.&nbsp;Brege&#146;s level of knowledge and experience based on a number of factors, including Ms.&nbsp;Brege&#146;s formal
education and experience as a chief financial officer. The Audit Committee was established by the Board in accordance with Section&nbsp;3(a)(58)(A) of the Exchange Act to oversee the Company&#146;s corporate accounting and financial reporting
processes and audits of its financial statements. The Audit Committee operates under a written charter that is available on the Company&#146;s website at <U>http://investors.dynavax.com/corporate-governance</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Among other things, the charter specifically requires our Audit Committee to: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review and monitor the policies and procedures adopted by the Company to fulfill its responsibilities regarding the fair and accurate presentation of
the Company&#146;s financial statements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">appoint, compensate, and oversee the work of the Company&#146;s independent registered public accounting firm; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">approve and monitor all audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services performed by the Company&#146;s independent registered
public accounting firm; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">investigate, review and report the propriety and ethical implications of any transactions between the Company and any related persons;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">consult and discuss with management and the independent registered public accounting firm regarding the effectiveness of the Company&#146;s internal
controls over financial reporting; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establish procedures, as required under applicable law, for the receipt, retention and treatment of complaints received by the Company regarding
accounting, internal controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review and evaluate the Company&#146;s accounting principles and systems of internal controls; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review and discuss the disclosure of the Company&#146;s annual audited financial statements and quarterly financial statements, including reviewing the
Company&#146;s disclosures under &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Management is responsible for the financial reporting process, including the system of internal controls and for the preparation of consolidated financial statements in accordance with accounting
principles generally accepted in the United States. Ernst&nbsp;&amp; Young, the Company&#146;s independent registered public accounting firm, is responsible for auditing or reviewing those financial statements. The Audit Committee monitors and
reviews these processes. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Report of the Audit Committee of the Board of Directors </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2018, the Audit Committee met on four occasions. During these meetings the Committee met with Ernst&nbsp;&amp; Young, without the
presence of the Company&#146;s management. During the course of these meetings, we: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">discussed with management and Ernst&nbsp;&amp; Young management&#146;s continued testing and evaluation of its system of internal control over
financial reporting. We also reviewed Ernst&nbsp;&amp; Young&#146;s Report of Independent Registered Public Accounting Firm included in the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> or Annual Report, related to its audit of
the effectiveness of the Company&#146;s internal control over financial reporting; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewed and discussed with management and Ernst&nbsp;&amp; Young the annual audited financial statements before filing the Annual Report with the SEC,
addressing the acceptability of the Company&#146;s accounting principles and such other matters as applicable auditing standards require us to discuss; the Audit Committee has discussed with the independent registered public accounting firm the
matters required to be discussed by Auditing Standard No.&nbsp;1301, Communications with Audit Committees (&#147;AS 1301&#148;), as adopted by the Public Company Accounting Oversight Board (&#147;PCAOB&#148;) and recommended to the Board that the
financial statements should be included in the Annual Report; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewed and discussed with management and Ernst&nbsp;&amp; Young the Company&#146;s quarterly unaudited financial statements before the issuance of
its quarterly financial results press releases and the filing of its Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> with the SEC; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">discussed with management and Ernst&nbsp;&amp; Young significant financial reporting matters, including liquidity and capital requirements, and the
accounting for significant transactions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">appointed and oversaw the work and compensation of Ernst&nbsp;&amp; Young, including the review of engagement agreement terms;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewed and provided guidance with respect to the external audit and the Company&#146;s relationship with Ernst&nbsp;&amp; Young by (1)&nbsp;reviewing
Ernst&nbsp;&amp; Young&#146;s proposed audit scope, approach, compensation and independence; (2)&nbsp;obtaining written statements and disclosures from Ernst&nbsp;&amp; Young regarding relationships and services with the Company which may impact
independence as required by Ethics and Independence Rule 3526, &#147;Communications with Audit Committees Concerning Independence&#148;; (3)&nbsp;discussing with Ernst&nbsp;&amp; Young the financial statements and audit findings, including any
significant adjustments, management judgments and accounting estimates, significant new accounting policies and whether there were disagreements with management; and (4)&nbsp;obtaining assurance from Ernst&nbsp;&amp; Young that the requirements of
Section&nbsp;10A of the Exchange Act have been met; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewed, in conjunction with the Company&#146;s legal counsel, all legal matters that could have a significant impact on the Company&#146;s financial
statements or compliance policies. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on our reviews and discussions as described above, and based on
the report of Ernst&nbsp;&amp; Young, we recommended to the Board, and the Board approved, that the audited financial statements be included in the Company&#146;s Annual Report for the year ended December&nbsp;31, 2018, filed with the SEC. We also
approved, subject to stockholder ratification, the selection of Ernst&nbsp;&amp; Young as the Company&#146;s independent registered public accounting </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
firm for 2019. In making this recommendation, we considered whether Ernst&nbsp;&amp; Young&#146;s provision of services other than audit services is compatible with maintaining independence of
our independent registered public accounting firm. Although we have the sole authority to appoint the independent registered public accounting firm, we continued the long-standing practice of recommending that the Board ask the stockholders at their
Annual Meeting to ratify the appointment of Ernst&nbsp;&amp; Young as the Company&#146;s independent registered public accounting firm. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>The material in this report is not &#147;soliciting material,&#148; is not deemed &#147;filed&#148; with the SEC and is not to be incorporated by reference in any filing of the Company under the
Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Laura Brege, Chairperson </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Arnold&nbsp;L. Oronsky, Ph.D. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Peggy&nbsp;V. Phillips </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Committee </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Compensation Committee is composed of three directors: Ms.&nbsp;Phillips (Chairperson) and Drs. Kisner and Cano. All members of the
Compensation Committee are independent as required by Nasdaq Rule 5605(d) (as independence is currently defined in Rule 5605(a)(2) of the Nasdaq listing standards), are &#147;outside directors&#148; for purposes of Section&nbsp;162(m) of the Code
and are <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> directors&#148; for purposes of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> under the Exchange Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee acts on behalf of the Board to review, recommend for adoption, and oversee the Company&#146;s compensation strategy, policies, plans and programs. The Compensation Committee
operates under a written charter that is available on the Company&#146;s website at <U>http://investors.dynavax.com/corporate-governance</U>. Among other things, the charter specifically requires our Compensation Committee to: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annually review and approve the Company&#146;s corporate goals and objectives relevant to CEO compensation, evaluate the CEO&#146;s performance in
light of such goals and objectives, and recommend to the Board the CEO&#146;s compensation level based on this evaluation. In determining the long-term incentive component of the CEO&#146;s compensation, the Compensation Committee will consider the
Company&#146;s performance and relative stockholder return, the value of similar incentive awards to CEOs at comparable companies, and the awards given to the Company&#146;s CEO in past years; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">annually review and make recommendations to the Board with respect to incentive compensation plans and equity-based plans;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">annually review Director compensation and make recommendation to the Board; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">administer the Company&#146;s incentive-compensation plans and equity-based plans as in effect and as adopted from time to time by the Board provided
that the Board shall retain the authority to interpret such plans; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">annually review and approve for the Company&#146;s executive officers as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(f)</FONT> of the
Exchange Act: i) annual base salary levels; ii) annual incentive compensation levels; iii) long-term incentive compensation levels; and iv) employment agreements, severance agreements, change of control agreements/provisions and any other
compensatory arrangements, in each case as, when and if appropriate; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">make regular reports to the Board; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">perform such other functions and have such other powers consistent with the Compensation Committee Charter, the Company&#146;s Bylaws and governing
laws as the Compensation Committee or the Board may deem appropriate. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under its charter, our Compensation Committee may form, and delegate authority to,
subcommittees, as appropriate. Our Compensation Committee has authorized and delegated authority to our CEO to grant stock options to employees and consultants who are not officers of the Company from
<FONT STYLE="white-space:nowrap">pre-approved</FONT> pools and in accordance with guidelines designated for new hire and annual grants. The purpose of this delegation is to enhance the flexibility of option administration within the Company and to
facilitate the timely grant of options to <FONT STYLE="white-space:nowrap">non-executive</FONT> employees, particularly new employees, within specified limits and values approved by our Compensation Committee. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Committee Interlocks and Insider Participation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During the fiscal year ended December&nbsp;31, 2018, Ms.&nbsp;Phillips and Drs. Cano and Kisner, each served as a member of the Compensation Committee. None of the members of our Compensation Committee at
any time has been one of our officers or employees or an officer or employee of one of our subsidiaries at any time during the fiscal year ended December&nbsp;31, 2018. None of our executive officers currently serve, or in the past year has served,
as a member of the board of directors or compensation committee of any entity that has one or more executive officers on our Board or Compensation Committee. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Nominating and Governance Committee </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Nominating and Governance
Committee is composed of three directors: Drs. Kisner (Chairperson) and Cano, and Mr.&nbsp;Ricciardi. All members of the Nominating and Governance Committee are independent (as independence is currently defined in Rule 5605(a)(2) of the Nasdaq
listing standards). The Nominating and Governance Committee is responsible for identifying, reviewing and evaluating candidates to serve as directors of the Company (consistent with criteria approved by the Board), reviewing and evaluating incumbent
directors and identifying with the CEO candidates for appointment or election to the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In identifying potential director
candidates, the Nominating and Governance Committee considers Board candidates through a variety of methods and sources. These include suggestions from current Board members, senior management, stockholders, professional search firms and other
sources. At this time, the Nominating and Governance Committee does not have a policy with regard to the consideration of director candidates recommended by stockholders. While the Nominating and Governance Committee does not have such a formal
policy, it will consider such a recommendation, as reflected by its decision to recommend Mr.&nbsp;Ricciardi to the Board following a stockholder recommendation. Our Board believes that it is appropriate that the Nominating and Corporate Governance
Committee does not have such a policy because the Nominating and Corporate Governance Committee reviews all candidates in the same manner regardless of the source of the recommendation. In the case of a new director candidate, the Nominating and
Governance Committee also determines whether the nominee is independent based upon applicable Nasdaq listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary. Among the qualifications to be considered in the
selection of candidates are broad experience in business, finance or administration, familiarity with the Company&#146;s industry, and prominence and reputation. Since prominence and reputation in a particular profession or field of endeavor are
what bring most persons to the Board&#146;s attention, there is further consideration of whether the individual has the time available to devote to the work of the Board and one or more of its committees. In addition, our Nominating and Governance
Committee will consider whether the candidate assists in achieving a mix of members that represents a diversity of backgrounds and experience, including with respect to age, gender, international background, race and specialized experience. Each
year, our Nominating and Governance Committee reviews its Board membership criteria and assesses the composition of the Board against the criteria. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Nominating and Governance Committee discussed committee business a number of times during the year and held three formal meetings. The Nominating and Governance Committee has adopted a written charter
that is available to stockholders on the Company&#146;s website at <U>http://investors.dynavax.com/corporate-governance</U>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>TOCKHOLDER</SMALL> C<SMALL>OMMUNICATIONS</SMALL> W<SMALL>ITH</SMALL> T<SMALL>HE</SMALL>
B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders may communicate with our Board by directing
comments, concerns, and questions to the Corporate Secretary at Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100, Berkeley, California 94710, if mailed prior to June&nbsp;1, 2019, or to 5959 Horton Street, Suite 700, Emeryville,
California 94608, if mailed on or after June&nbsp;1, 2019. Communications will be distributed to the Board, or to any individual directors as appropriate, depending on the facts and circumstances outlined in the communication. In that regard, our
Board has requested that certain items that are unrelated to the duties and responsibilities of the Board be filtered, including product complaints or inquiries, new product suggestions, r&eacute;sum&eacute;s and other forms of job inquiries,
surveys, or business solicitations or advertisements. In addition, material that is unduly hostile, threatening, illegal or similarly unsuitable will be excluded, with the provision that any communication that is filtered out must be made available
to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director upon request. Stockholders may also communicate with our Board as a group through our website at <U>http://investors.dynavax.com/confirmation/contact-board</U>. All communications
directed to the Audit Committee in accordance with our whistleblower policy that relate to questionable accounting or auditing matters involving the Company will be promptly and directly forwarded to the chairperson of the Audit Committee. Every
effort has been made to ensure that the views of stockholders are heard by the Board or individual directors, as applicable, and that appropriate responses are provided to stockholders in a timely manner. We believe our responsiveness to stockholder
communications to the Board has been excellent. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CERTAIN TRANSACTIONS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There has not been, nor is there currently proposed, any transaction or series of similar transactions to which the Company was or is to
be a party in which the amount involved exceeds $120,000 and in which any current director, executive officer, holder of more than 5% of our common stock or any immediate family member of any of the foregoing persons had or will have a direct or
indirect material interest other than compensation arrangements, described under the sections entitled &#147;Executive Compensation&#148; and &#147; Director Compensation,&#148; other than with respect to the indemnification agreements described
below. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Related Persons Transactions and Indemnification </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Policies and Procedures for Related Person Transactions </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Audit
Committee is responsible for reviewing and approving all related party transactions, which would include a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we and any
&#147;related person&#148; are participants involving an amount that exceeds $120,000, not including transactions involving compensation for services provided to Dynavax as an employee, director, consultant or similar capacity by a related person.
Related parties include any of our directors or executive officers, certain of our stockholders and their immediate family members. This obligation is set forth in writing in the Audit Committee charter. A copy of the Audit Committee charter is
available on the Company&#146;s website at <U>http://investors.dynavax.com/corporate-governance</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Where a transaction has
been identified as a related-person transaction, management would present information regarding the proposed related-person transaction to the Audit Committee (or, where Audit Committee approval would be inappropriate, to another independent body of
the Board) for consideration and approval or ratification. The presentation would include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to Dynavax of the
transaction and whether any alternative transactions were available. To identify related-person transactions in advance, the Audit Committee relies on information supplied by our executive officers and directors. In considering related-person
transactions, the Audit Committee takes into account the relevant available facts and circumstances including, but not limited to (a)&nbsp;the risks, costs and benefits to Dynavax, (b)&nbsp;the impact on a director&#146;s independence in the event
the related person is a director, immediate family member of a director or an entity with which a director is affiliated, (c)&nbsp;the terms of the transaction, (d)&nbsp;the availability of other sources for comparable services or products and
(e)&nbsp;the terms available to or from, as the case may be, unrelated third parties or to or from employees generally. In the event a director has an interest in the proposed transaction, the director must recuse himself or herself from the
deliberations and approval. In determining whether to approve, ratify or reject a related-person transaction, the Audit Committee considers, in light of known circumstances, whether the transaction is in, or is not inconsistent with, the best
interests of Dynavax and our stockholders, as the Audit Committee determines in the good faith exercise of its discretion. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Transactions
With Related Persons </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have no related person transactions to report. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Indemnity Agreements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have entered into indemnity agreements with some of our officers and directors so that they will be free from undue concern about personal liability in connection with their service to the Company. The
indemnity agreements provide, among other things, that the Company will indemnify such officer or director, under the circumstances and to the extent provided for therein, for expenses, damages, judgments, fines and settlements he or she may be
required to pay in actions or proceedings which he or she is or may be made a party by reason of his or her position as a director, officer or other agent of the Company, and otherwise to the fullest extent permitted under Delaware law. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>ECTION</SMALL> 16(<SMALL>A</SMALL>) B<SMALL>ENEFICIAL</SMALL> O<SMALL>WNERSHIP</SMALL>
R<SMALL>EPORTING</SMALL> C<SMALL>OMPLIANCE</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;16(a) of the Exchange Act requires the Company&#146;s
directors and executive officers, and persons who own more than ten percent of a registered class of the Company&#146;s equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and
other equity securities of the Company. Officers, directors and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">greater-than-ten-percent</FONT></FONT> stockholders are required by SEC regulation to furnish the Company with copies
of all Section&nbsp;16(a) forms they file. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the Company&#146;s knowledge, based solely on a review of the copies of such
reports furnished to the Company and written representations that no other reports were required, during the fiscal year ended December&nbsp;31, 2018, all Section&nbsp;16(a) filing requirements applicable to its officers, directors and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">greater-than-ten-percent</FONT></FONT> beneficial owners were in compliance. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>ODE</SMALL> O<SMALL>F</SMALL> B<SMALL>USINESS</SMALL> C<SMALL>ONDUCT</SMALL> A<SMALL>ND</SMALL> E<SMALL>THICS</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have adopted the Dynavax Code of Business Conduct and Ethics that applies to all officers, directors and employees. Our Code of
Business Conduct and Ethics is available on our website at <U>http://investors.dynavax.com/corporate-governance</U> and upon written request. We will provide a written copy of the Dynavax Code of Business Conduct and Ethics to anyone without charge,
upon request written to Dynavax Technologies Corporation, Attention: Chief Compliance Officer, 2929 Seventh Street, Suite 100, Berkeley, California 94710, if mailed prior to June&nbsp;1, 2019, or to 5959 Horton Street, Suite 700, Emeryville,
California 94608, if mailed on or after June&nbsp;1, 2019, or contact Dynavax&#146;s Chief Compliance Officer at <FONT STYLE="white-space:nowrap">(510)&nbsp;848-5100.</FONT> If we make any substantive amendments to or grant any waiver from a
provision of the Code of Business Conduct and Ethics to any executive officer or director, we will promptly disclose the nature of the amendment or waiver on our website. There have been no waivers under the Code of Business Conduct and Ethics as of
April&nbsp;9, 2019. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECURITY OWNERSHIP OF </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CERTAIN BENEFICIAL OWNERS AND MANAGEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth certain information regarding the ownership of the Company&#146;s common stock as of January&nbsp;31, 2019 by: (i)&nbsp;each director and nominee for director; (ii)&nbsp;the
NEOs; (iii)&nbsp;all executive officers and directors of the Company as a group; and (iv)&nbsp;all those known by the Company to be beneficial owners of more than five percent of its common stock. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Address of Beneficial Holder</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number
of<BR>Shares<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percent&nbsp;of&nbsp;Shares<BR>Beneficially<BR>Owned<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5% Stockholders:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">BlackRock, Inc.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,128,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 East 52nd Street</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">New York, New York 10055</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">HealthCor Management, L.P.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,613,280</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 Hudson Yards, 28</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">New York, New York 10001</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Franklin Resources, Inc.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,199,278</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">One Franklin Parkway</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">San Mateo, California 94403-1906</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senvest Management, L.L.C.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,173,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">540 Madison Avenue, 32</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">New York, New York 10022</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Federated Investors, Inc.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(8)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,661,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.78</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Federated Investors Tower</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pittsburgh, Pennsylvania 15222-3779</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>NEOs and Directors (1)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(9)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,329,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(10)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">451,527</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(11)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">437,769</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(12)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">379,614</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(13)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">318,366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnold L. Oronsky, Ph.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(14)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81,456</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laura Brege</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(15)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Francis R. Cano, Ph.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(16)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,050</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dennis A. Carson, M.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(17)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,562</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Daniel L. Kisner, M.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(18)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peggy V. Phillips</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(19)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Natale Ricciardi</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(20)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All executive officers and directors as a group (12 persons)</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(21)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,237,294</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Less than one percent. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">The address of each of the NEOs and directors is, prior to June&nbsp;1, 2019, c/o Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100,
Berkeley, California 94710, or on or after June&nbsp;1, 2019, c/o Dynavax Technologies Corporation, 5959 Horton Street, Suite 700, Emeryville, California 94608. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">To our knowledge, except as set forth in the footnotes to this table, and subject to applicable community property laws, each person named in this
table has sole voting and investment power with respect to the shares set forth opposite such person&#146;s name. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to the
securities. Shares of our common stock subject to options currently exercisable or that will become exercisable within 60 days after January&nbsp;31, 2019, are deemed outstanding for computing the percentage of the person holding such options but
are not deemed outstanding for computing the percentage of any other person. Applicable percentages are based on 63,378,738 shares of our common stock outstanding as of January&nbsp;31, 2019, adjusted as required by the rules of the SEC.
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">This information is based solely on a Schedule 13G/A filed by BlackRock, Inc., on February&nbsp;4, 2019, with the SEC. BlackRock beneficially owns and
has sole dispositive power over 4,128,600 shares of common stock, of which 3,996,747 are held with sole voting power. The address of the principal business and office of BlackRock, Inc. and its affiliates is BlackRock Inc., 55 East 52nd Street, New
York, NY 10055. The Schedule 13G/A provides information only as of December&nbsp;31, 2018, and, consequently, the beneficial ownership of the above-mentioned reporting person may have changed between December&nbsp;31, 2018 and January&nbsp;31, 2019.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">This information is based solely on Schedule 13G/A filed by HealthCor Management, L.P. on February&nbsp;14, 2019, with the SEC. HealthCor Management,
L.P. beneficially owns 4,613,280 shares and has no sole dispositive or sole voting power. The address of the principal business and office of HealthCor Management, L.P. is, 55 Hudson Yards, 28<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP> Floor, New York, NY 10001. The Schedule 13G/A provides information only as of December&nbsp;31, 2018 and consequently, the beneficial ownership of the above-mentioned reporting
person may have changed between December&nbsp;31, 2018 and January&nbsp;31, 2019. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">This information is based solely on Schedule 13G/A filed by Franklin Resources, Inc. on January&nbsp;25, 2019, with the SEC. Franklin Resources, Inc.
beneficially owns and has sole dispositive and voting power over 3,199,278 shares. The address of the principal business and office of Franklin Resources, Inc. is, One Franklin Parkway, San Mateo, CA 94403-1906. The Schedule 13G/A provides
information only as of December&nbsp;31, 2018 and consequently, the beneficial ownership of the above-mentioned reporting person may have changed between December&nbsp;31, 2018 and January&nbsp;31, 2019. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">This information is based solely on Schedule 13G filed by Sunvest Management, LLC on January&nbsp;8, 2019, with the SEC. Sunvest Management, LLC
beneficially owns 3,173,112 shares and has no sole dispositive or sole voting power. The address of the principal business and office of Sunvest Management, LLC is, 540 Madison Avenue, 32<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP> Floor, New York, NY 10022. The Schedule 13G provides information only as of January&nbsp;7, 2019 and consequently, the beneficial ownership of the above-mentioned reporting
person may have changed between January&nbsp;7, 2019 and January&nbsp;31, 2019. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(8)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">This information is based solely on Schedule 13G/A filed by Federated Investors, Inc. on February&nbsp;13, 2019, with the SEC. Federated Investors,
Inc. beneficially owns 3,661,600 shares and has sole dispositive and sole voting power over such shares. The address of the principal business and office of Federated Investors, Inc. is, Federated Investors Tower, Pittsburgh, PA 15222-3779. The
Schedule 13G/A provides information only as of December&nbsp;31, 2018 and consequently, the beneficial ownership of the above-mentioned reporting person may have changed between December&nbsp;31, 2018 and January&nbsp;31, 2019.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(9)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of 158,934 shares of common stock owned directly by Mr.&nbsp;Gray, restricted stock awards to be converted into 112,000 shares of common stock
within 60 days of January&nbsp;31, 2019 and options to purchase 1,058,889 shares of common stock exercisable within 60 days of January&nbsp;31, 2019. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(10)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of 76,554 shares of common stock owned directly by Mr.&nbsp;Ostrach, restricted stock awards to be converted into 58,304 shares of common
stock within 60 days of January&nbsp;31, 2019 and options to purchase 316,669 shares of common stock exercisable within 60 days of January&nbsp;31, 2019. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(11)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of 77,768 shares of common stock owned directly by Dr.&nbsp;Coffman, restricted stock awards to be converted into 63,202 shares of common
stock within 60 days of January 31, 2019 and options to purchase 296,799 shares of common stock exercisable within 60 days of January&nbsp;31, 2019. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(12)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of 93,378 shares of common stock owned directly by Dr.&nbsp;Janssen, 948 of which were purchased through the employee stock purchase plan;
restricted stock awards to be converted into 55,375 shares of common stock within 60 days of January&nbsp;31, 2019 and options to purchase 230,861 shares of common stock exercisable within 60 days of January&nbsp;31, 2019.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(13)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of 22,492 shares of common stock owned directly by Mr.&nbsp;Novack, restricted stock awards to be converted into 53,763 shares of common stock
within 60 days of January&nbsp;31, 2019 and options to purchase 242,111 shares of common stock exercisable within 60 days of January&nbsp;31, 2019. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(14)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of 37,506 shares of common stock owned directly by Dr.&nbsp;Oronsky and options to purchase 43,950 shares of common stock exercisable within
60 days of January&nbsp;31, 2019. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(15)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of options to purchase 27,675 shares of common stock exercisable within 60 days of January&nbsp;31, 2019. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(16)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of options to purchase 40,050 shares of common stock exercisable within 60 days of January&nbsp;31, 2019. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(17)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of 6,812 shares of common stock owned directly by Dr.&nbsp;Carson and options to purchase 33,750 shares of common stock exercisable within 60
days of January&nbsp;31, 2019. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(18)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of 1,500 shares of common stock owned directly by Dr.&nbsp;Kisner and options to purchase 43,450 shares of common stock exercisable within 60
days of January&nbsp;31, 2019. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(19)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of 13,802 shares of common stock owned directly by Ms.&nbsp;Phillips and options to purchase 43,950 shares of common stock exercisable within
60 days of January&nbsp;31, 2019. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(20)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consists of options to purchase 27,750 shares of common stock exercisable within 60 days of January&nbsp;31, 2019. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(21)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Total number of shares includes 488,746 shares of common stock in aggregate held as of January&nbsp;31, 2019, by our executive officers and directors
and entities affiliated with such executive officers and directors. Also includes restricted stock awards to be converted into 342,644 </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">
shares of common stock within 60 days of January&nbsp;31, 2019 and options to purchase 2,405,904 shares of common stock exercisable within 60 days of January&nbsp;31, 2019.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>ERFORMANCE</SMALL> G<SMALL>RAPH</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The chart below compares total stockholder return on an investment of $100 in cash on December&nbsp;31, 2013, for: our common stock, The Nasdaq Stock Market (U.S. companies), and the Nasdaq Pharmaceutical
Preparation Index. All values assume reinvestment of the full amount of all dividends. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Note: Dynavax management cautions that
the stock price performance shown in the graph below should not be considered indicative of potential future stock price performance. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g707175g74w49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Section is not &#147;soliciting material,&#148; is not deemed &#147;filed&#148; with the SEC and
is not to be incorporated by reference in any filing of Dynavax Technologies Corporation under the Securities Act, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such
filing. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">69 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OTHER MATTERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly
brought before the Annual Meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By Order of the Board of Directors</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Steven N. Gersten</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven N. Gersten</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Secretary</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;22, 2019 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>A copy of the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2018, is available without charge upon written request to:
Dynavax Technologies Corporation, Attention: Corporate Secretary, 2929 Seventh Street, Suite 100, Berkeley, California 94710. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">70 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Appendix A </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>YNAVAX</SMALL> T<SMALL>ECHNOLOGIES</SMALL> C<SMALL>ORPORATION</SMALL> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>2018 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>:
A<SMALL>PRIL</SMALL>&nbsp;8, 2018 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL>
S<SMALL>TOCKHOLDERS</SMALL>: M<SMALL>AY</SMALL>&nbsp;31, 2018 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL>
R<SMALL>ESTATED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>: A<SMALL>PRIL</SMALL>&nbsp;9, 2019 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>: [M<SMALL>AY</SMALL>&nbsp;30, 2019] </B></FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>G<SMALL>ENERAL</SMALL>.</B> </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> <B>Successor to and Continuation of 2011 Plan.</B> The Plan is intended as the successor to and continuation of the Dynavax Technologies Corporation 2011 Equity Incentive Plan (the
&#147;<B><I>2011 Plan</I></B>&#148;). Following the Effective Date, no additional awards may be granted under the 2011 Plan or the Dynavax Technologies Corporation 2017 Inducement Award Plan (the &#147;<B><I>2017 Inducement Plan</I></B>&#148;) (each
of the 2011 Plan and 2017 Inducement Plan, a &#147;<B><I>Prior Plan</I></B>&#148;). Any unallocated shares remaining available for grant under the 2011 Plan as of 12:01 a.m. Pacific Time on the Effective Date (the &#147;<B><I>2011
Plan</I></B><B><I>&#146;</I></B><B><I>s Available Reserve</I></B>&#148;) will cease to be available under the 2011 Plan at such time and will be added to the Share Reserve (as defined in Section&nbsp;3(a)(i)) and be then immediately available for
grant and issuance pursuant to Awards granted under this Plan. From and after 12:01 a.m. Pacific Time on the Effective Date, except as provided in Sections 9(c), 9(d) and 9(e), all outstanding stock awards granted under either of the Prior Plans
(each, a &#147;<B><I>Prior Plan Award</I></B>&#148;) will remain subject to the terms of the applicable Prior Plan; <I>provided, however</I>, that the following shares of Common Stock subject to any outstanding Prior Plan Award (collectively, the
&#147;<B><I>Prior Plans</I></B><B><I>&#146;</I></B><B><I> Returning Shares</I></B>&#148;) will immediately be added to the Share Reserve (as defined in Section&nbsp;3(a)(i)) as and when such shares become Prior Plans&#146; Returning Shares and will
become available for grant and issuance pursuant to Awards granted under this Plan: (i)&nbsp;any shares subject to such stock award that are not issued because such stock award or any portion thereof expires or otherwise terminates without all of
the shares covered by such stock award having been issued; (ii)&nbsp;any shares subject to such stock award that are not issued because such stock award or any portion thereof is settled in cash; and (iii)&nbsp;any shares issued pursuant to such
stock award that are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares. All Awards granted on or after 12:01 a.m. Pacific Time on the Effective Date will
be subject to the terms of this Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> <B>Eligible Award Recipients.</B> Subject to Section&nbsp;4, Employees and
Directors are eligible to receive Awards. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> <B>Available Awards.</B> The Plan provides for the grant of the
following types of Awards: (i)&nbsp;Incentive Stock Options; (ii)&nbsp;Nonstatutory Stock Options; (iii)&nbsp;Stock Appreciation Rights; (iv)&nbsp;Restricted Stock Awards; (v)&nbsp;Restricted Stock Unit Awards; (vi)&nbsp;Performance Stock Awards;
and (vii)&nbsp;Other Stock Awards. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B> <B>Purpose.</B> The Plan, through the granting of Awards, is intended to help
the Company and any Affiliate secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which such persons may
benefit from increases in value of the Common Stock. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>DMINISTRATION</SMALL>. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> <B>Administration by Board.</B> The Board will administer the Plan. The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section&nbsp;2(c). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> <B>Powers of Board.</B> The Board will have the power, subject to, and within the limitations of, the express provisions of
the Plan: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> To determine (A)&nbsp;who will be granted Awards, (B)&nbsp;when and how each Award will be granted,
(C)&nbsp;what type of Award will be granted, (D)&nbsp;the provisions of each Award (which need not be identical), including </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-1
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
when a Participant will be permitted to exercise or otherwise receive cash or Common Stock under the Award, (E)&nbsp;the number of shares of Common Stock subject to, or the cash value of, an
Award, and (F)&nbsp;the Fair Market Value applicable to an Award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> To construe and interpret the Plan and Awards
granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Award
Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Award fully effective. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> To settle all controversies regarding the Plan and Awards granted under it. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv)</B> To accelerate, in whole or in part, the time at which an Award may be exercised or vest (or at which cash or shares of Common
Stock may be issued in settlement thereof). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(v)</B> To suspend or terminate the Plan at any time. Except as otherwise
provided in the Plan (including Section&nbsp;2(b)(viii)) or an Award Agreement, suspension or termination of the Plan will not materially impair a Participant&#146;s rights under an outstanding Award without his or her written consent. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(vi)</B> To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting
amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section&nbsp;409A of the Code and/or to make the Plan or Awards granted under the Plan compliant with the requirements for Incentive Stock Options or
exempt from or compliant with the requirements for nonqualified deferred compensation under Section&nbsp;409A of the Code, subject to the limitations, if any, of applicable law. However, if required by applicable law or listing requirements, and
except as provided in Section&nbsp;9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that (A)&nbsp;materially increases the number of shares of Common Stock available for issuance
under the Plan, (B)&nbsp;materially expands the class of individuals eligible to receive Awards under the Plan, (C)&nbsp;materially increases the benefits accruing to Participants under the Plan, (D)&nbsp;materially reduces the price at which shares
of Common Stock may be issued or purchased under the Plan, or (E)&nbsp;materially expands the types of Awards available for issuance under the Plan. Except as otherwise provided in the Plan (including Section&nbsp;2(b)(viii)) or an Award Agreement,
no amendment of the Plan will materially impair a Participant&#146;s rights under an outstanding Award without his or her written consent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(vii)</B> To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of (A)&nbsp;Section&nbsp;422 of the
Code regarding incentive stock options or (B)&nbsp;Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(viii)</B> To
approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more outstanding Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award
Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; <I>provided, however,</I> that except as otherwise provided in the Plan (including this Section&nbsp;2(b)(viii)) or an Award Agreement, no amendment of
an outstanding Award will materially impair a Participant&#146;s rights under such Award without his or her written consent. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the foregoing or anything in the Plan to the contrary, unless prohibited by applicable law, the Board may amend the terms
of any outstanding Award or the Plan, or may suspend or terminate the Plan, without the affected Participant&#146;s consent, (A)&nbsp;to maintain the qualified status of the Award as an Incentive Stock Option under Section&nbsp;422 of the Code,
(B)&nbsp;to change the terms of an Incentive Stock Option, if such change results in impairment of the Award solely because it impairs the qualified status of the Award as an Incentive Stock Option under Section&nbsp;422 of the Code, (C)&nbsp;to
clarify the manner of exemption from, or to bring the Award or the Plan into compliance with, Section&nbsp;409A of the Code or (D)&nbsp;to comply with other applicable laws or listing requirements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-2
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ix)</B> Generally, to exercise such powers and to perform such acts as the Board
deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(x)</B> To adopt such procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit participation in the Plan by Employees or Directors who are foreign
nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) Delegation to Committee. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> <B>General.</B> The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will
have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the
Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable). Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the
provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee. The Board may retain the
authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> <B>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> Compliance.</B> The Committee may consist solely of two or more <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors in
accordance with Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B> <B>Delegation to an Officer.</B> The Board may
delegate to one or more Officers the authority to do one or both of the following: (i)&nbsp;designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by applicable law, other Awards) and, to the
extent permitted by applicable law, the terms of such Awards; and (ii)&nbsp;determine the number of shares of Common Stock to be subject to such Awards granted to such Employees; <I>provided, however</I>, that the Board resolutions regarding such
delegation will specify the total number of shares of Common Stock that may be subject to the Awards granted by such Officer and that such Officer may not grant an Award to himself or herself. Any such Awards will be granted on the form of Award
Agreement most recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving the delegation of authority. The Board may not delegate authority to an Officer who is acting solely in the capacity of an
Officer (and not also as a Director) to determine the Fair Market Value of the Common Stock pursuant to Section&nbsp;13(w)(iii). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(e)</B> <B>Effect of Board&#146;s Decision.</B> All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final,
binding and conclusive on all persons. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(f)</B> <B>Cancellation and <FONT STYLE="white-space:nowrap">Re-Grant</FONT> of
Awards.</B> Neither the Board nor any Committee will have the authority to (i)&nbsp;reduce the exercise or strike price of any outstanding Option or SAR or (ii)&nbsp;cancel any outstanding Option or SAR that has an exercise or strike price (per
share) greater than the then-current Fair Market Value of the Common Stock in exchange for cash or other Awards under the Plan, unless the stockholders of the Company have approved such an action within 12 months prior to such an event. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(g)</B> <B>Minimum Vesting Requirements.</B> No Award may vest (or, if applicable, be exercisable) until at least 12 months following
the date of grant of the Award; <I>provided, however</I>, that shares of Common Stock up to 5% of the Share Reserve (as defined in Section&nbsp;3(a)(i)) may be issued pursuant to Awards that do not meet such vesting (and, if applicable,
exercisability) requirements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(h)</B> <B>Dividends and Dividend Equivalents.</B> Dividends or dividend equivalents may be
paid or credited, as applicable, with respect to any shares of Common Stock subject to an Award, as determined by the Board and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-3
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
contained in the applicable Award Agreement; <I>provided, however</I>, that (i)&nbsp;no dividends or dividend equivalents may be paid with respect to any such shares before the date such shares
have vested under the terms of such Award Agreement, (ii)&nbsp;any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and conditions applicable to such shares under the terms of
such Award Agreement (including, but not limited to, any vesting conditions), and (iii)&nbsp;any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to the Company on the date, if any, such shares
are forfeited to or repurchased by the Company due to a failure to meet any vesting conditions under the terms of such Award Agreement. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>HARES</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Share Reserve. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> Subject to Section&nbsp;3(a)(iii) and Section&nbsp;9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards from and
after the Effective Date will not exceed (A) 7,440,250 shares (which number is the sum of (i)&nbsp;the number of shares (140,250) subject to the 2011 Plan&#146;s Available Reserve, (ii)&nbsp;an additional 5,000,000 shares that were approved at the
Company&#146;s 2018 Annual Meeting of Stockholders, and (iii)&nbsp;an additional 2,300,000 shares that were approved at the Company&#146;s 2019 Annual Meeting of Stockholders), <I>plus</I> (B)&nbsp;the Prior Plans&#146; Returning Shares, if any,
which become available for issuance under this Plan from time to time (such aggregate number of shares described in (A)&nbsp;and (B), the &#147;<B><I>Share Reserve</I></B>&#148;). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> Subject to Section&nbsp;3(b), the number of shares of Common Stock available for issuance under the Plan will be reduced by:
(A)&nbsp;one share for each share of Common Stock issued pursuant to an Appreciation Award granted under the Plan; (B) 1.28 shares for each share of Common Stock issued pursuant to a Full Value Award granted under the Plan prior to May&nbsp;30,
2019; and (C) 1.40 shares for each share of Common Stock issued pursuant to a Full Value Award granted under the Plan on or after May&nbsp;30, 2019. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> Subject to Section&nbsp;3(b), the number of shares of Common Stock available for issuance under the Plan will be increased by: (A)&nbsp;one share for each Prior Plans&#146; Returning Share or
2018 Plan Returning Share (as defined in Section&nbsp;3(b)(i)) subject to an Appreciation Award; (B) 1.28 shares for each Prior Plans&#146; Returning Share or 2018 Plan Returning Share subject to a Full Value Award that returns to the Plan prior to
May&nbsp;30, 2019; and (C) 1.40 shares for each Prior Plans&#146; Returning Share or 2018 Plan Returning Share subject to a Full Value Award that returns to the Plan on or after May&nbsp;30, 2019. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv)</B> For clarity, the Share Reserve in this Section&nbsp;3(a) is a limitation on the number of shares of Common Stock that may be
issued pursuant to the Plan. Accordingly, this Section&nbsp;3(a) does not limit the granting of Awards except as provided in Section&nbsp;7(a). Shares may be issued in connection with a merger or acquisition as permitted by NASDAQ Listing Rule
5635(c) or, if applicable, NYSE Listed Company Manual Section&nbsp;303A.08, AMEX Company Guide Section&nbsp;711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) Reversion of Shares to the Share Reserve. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> <B>Shares Available for Subsequent Issuance. </B>The following shares of Common Stock (collectively, the &#147;<B><I>2018 Plan</I></B> <B><I>Returning Shares</I></B>&#148;) will become
available again for issuance under the Plan: (A)&nbsp;any shares subject to an Award that are not issued because such Award or any portion thereof expires or otherwise terminates without all of the shares covered by such Award having been issued;
(B)&nbsp;any shares subject to an Award that are not issued because such Award or any portion thereof is settled in cash; and (C)&nbsp;any shares issued pursuant to an Award that are forfeited back to or repurchased by the Company because of the
failure to meet a contingency or condition required for the vesting of such shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> <B>Shares Not Available for
Subsequent Issuance. </B>The following shares of Common Stock will not become available again for issuance under the Plan: (A)&nbsp;any shares that are reacquired or withheld (or not issued) by
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-4
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the Company to satisfy the exercise, strike or purchase price of an Award or a Prior Plan Award (including any shares subject to such award that are not delivered because such award is exercised
through a reduction of shares subject to such award (<I>i.e</I>., &#147;net exercised&#148;)); (B) any shares that are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with an Award or a
Prior Plan Award; (C)&nbsp;any shares repurchased by the Company on the open market with the proceeds of the exercise, strike or purchase price of an Award or a Prior Plan Award; and (D)&nbsp;in the event that a Stock Appreciation Right granted
under the Plan or a stock appreciation right granted under either of the Prior Plans is settled in shares of Common Stock, the gross number of shares of Common Stock subject to such award. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> <B>Incentive Stock Option Limit. </B>Subject to the Share Reserve and Section&nbsp;9(a) relating to Capitalization
Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be 10,000,000 shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B> <B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit.</B> The aggregate value of all cash and equity-based compensation granted or paid, as applicable, by the
Company to any individual for service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director with respect to any fiscal year of the Company will not exceed (i)&nbsp;a total of $200,000 with respect to any such cash compensation and (ii)
$800,000 in total value with respect to any such equity-based compensation (including Awards and any other equity-based awards), calculating the value of any such awards based on the grant date fair value of such awards for financial reporting
purposes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e)</B> <B>Source of Shares.</B> The stock issuable under the Plan will be shares of authorized but unissued or
reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>LIGIBILITY</SMALL>. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> <B>Eligibility for Specific Awards.</B> Incentive Stock Options may be granted only to employees of the Company or a &#147;parent corporation&#148; or &#147;subsidiary corporation&#148; thereof
(as such terms are defined in Sections 424(e) and 424(f) of the Code). Awards other than Incentive Stock Options may be granted to Employees and Directors; <I>provided, however</I>, that Awards may not be granted to Employees and Directors who are
providing Continuous Service only to any &#147;parent&#148; of the Company, as such term is defined in Rule 405, unless (i)&nbsp;the stock underlying such Awards is treated as &#147;service recipient stock&#148; under Section&nbsp;409A of the Code
(for example, because the Awards are granted pursuant to a corporate transaction such as a spin off transaction) or (ii)&nbsp;the Company, in consultation with its legal counsel, has determined that such Awards are otherwise exempt from or
alternatively comply with Section&nbsp;409A of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> <B>Ten Percent Stockholders.</B> A Ten Percent
Stockholder will not be granted an Incentive Stock Option unless the exercise price (per share) of such Option is at least 110% of the Fair Market Value of the Common Stock on the date of grant of such Option and the Option is not exercisable after
the expiration of five years from the date of grant. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>ROVISIONS</SMALL> R<SMALL>ELATING</SMALL> <SMALL>TO</SMALL> O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL> S<SMALL>TOCK</SMALL>
A<SMALL>PPRECIATION</SMALL> R<SMALL>IGHTS</SMALL>. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each Option or SAR Agreement will be in such form and
will contain such terms and conditions as the Board deems appropriate. All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or
certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some
portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option. The terms and conditions of separate Option or SAR Agreements need not
be identical; <I>provided, however</I>, that each Award Agreement will conform to (through incorporation of the provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions:
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-5
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> <B>Term.</B> Subject to the provisions of Section&nbsp;4(b) regarding Ten
Percent Stockholders, no Option or SAR will be exercisable after the expiration of seven years from the date of its grant or such shorter period specified in the Award Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B><B> Exercise or Strike Price.</B> Subject to the provisions of Section&nbsp;4(b) regarding Ten Percent Stockholders, the
exercise or strike price (per share) of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock on the date the Award is granted. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or
strike price (per share) less than 100% of the Fair Market Value of the Common Stock on the date the Award is granted if such Award is granted pursuant to an assumption of, or substitution for, another option or stock appreciation right pursuant to
a Transaction and in a manner consistent with the provisions of Section&nbsp;409A of the Code and, if applicable, Section&nbsp;424(a) of the Code. Each SAR will be denominated in shares of Common Stock equivalents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B><B> Payment of Exercise Price for Options.</B> The exercise price of an Option may be paid, to the extent permitted by
applicable law and as determined by the Board in its sole discretion, by one or more of the methods of payment set forth below that are specified in the Option Agreement. The Board has the authority to grant Options that do not permit all of the
following methods of payment (or that otherwise restrict the ability to utilize certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> By cash (including electronic funds transfers), check, bank draft or money order payable to the Company; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> Pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of
the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> By delivery to the Company (either by actual delivery or attestation) of shares of Common Stock; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv)</B> If an Option is a Nonstatutory Stock Option, by a &#147;net exercise&#148; arrangement pursuant to which the Company will
reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; <I>provided, however</I>, that the Company will accept a cash or
other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued. Shares of Common Stock will no longer be subject to an Option and
will not be exercisable thereafter to the extent that (A)&nbsp;shares issuable upon exercise are used to pay the exercise price pursuant to the &#147;net exercise,&#148; (B) shares are delivered to the Participant as a result of such exercise, and
(C)&nbsp;shares are withheld to satisfy tax withholding obligations; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(v)</B> In any other form of legal consideration
that may be acceptable to the Board and specified in the applicable Award Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B> <B>Exercise and Payment of a
SAR.</B> To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Award Agreement evidencing such SAR. The appreciation distribution payable on the exercise of a
SAR will be not greater than an amount equal to the excess of (A)&nbsp;the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the
Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B)&nbsp;the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is
exercising the SAR on such date. The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing such
SAR. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-6
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e)</B> <B>Transferability of Options and SARs.</B> The Board may, in its sole
discretion, impose such limitations on the transferability of Options and SARs as the Board will determine. In the absence of such a determination by the Board to the contrary, the restrictions set forth in this Section&nbsp;5(e) on the
transferability of Options and SARs will apply. Notwithstanding the foregoing or anything in the Plan or an Award Agreement to the contrary, no Option or SAR may be transferred to any financial institution without prior stockholder approval.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> <B>Restrictions on Transfer.</B> An Option or SAR will not be transferable, except by will or by the laws of
descent and distribution (and pursuant to Sections 5(e)(ii) and 5(e)(iii) below), and will be exercisable during the lifetime of the Participant only by the Participant. Subject to the foregoing paragraph, the Board may, in its sole discretion,
permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws. Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> <B>Domestic Relations Orders.</B> Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be
transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.421-1(b)(2).</FONT>
If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> <B>Beneficiary Designation.</B> Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the
Company (or the designated broker), designate a third party who, upon the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. In the
absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant&#146;s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such
exercise. However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(f)</B> <B>Vesting.</B> The total number of shares of Common Stock subject to an Option or SAR may vest and become exercisable in
periodic installments that may or may not be equal. The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of Performance Goals or other
criteria) as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary. The provisions of this Section&nbsp;5(f) are subject to Section&nbsp;2(g) and any Option or SAR provisions governing the minimum number of
shares of Common Stock as to which an Option or SAR may be exercised. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(g)</B> <B>Termination of Continuous Service.</B>
Except as otherwise provided in the applicable Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#146;s Continuous Service terminates (other than for Cause and other than upon the
Participant&#146;s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such
period of time ending on the earlier of (i)&nbsp;the date that is three months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii)&nbsp;the expiration of the term of the
Option or SAR as set forth in the Award Agreement. If, after such termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time period, the Option or SAR (as applicable) will
terminate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(h)</B> <B>Extension of Termination Date.</B> Except as otherwise provided in the applicable Award Agreement or
other written agreement between a Participant and the Company or an Affiliate,<B> </B>if the exercise of an Option or SAR following the termination of a Participant&#146;s Continuous Service (other than for Cause and other than upon the
Participant&#146;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier
of (i)&nbsp;the expiration of a total period of time (that need not be consecutive) equal to the applicable post-</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-7
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
termination exercise period after the termination of the Participant&#146;s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration
requirements or (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement. In addition, except as otherwise provided in the applicable Award Agreement or other written agreement between a Participant
and the Company or an Affiliate, if the sale of any Common Stock received upon exercise of an Option or SAR following the termination of a Participant&#146;s Continuous Service (other than for Cause) would violate the Company&#146;s insider trading
policy, then the Option or SAR will terminate on the earlier of (i)&nbsp;the expiration of a total period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#146;s
Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company&#146;s insider trading policy or (ii)&nbsp;the expiration of the term of the Option or SAR as set forth
in the applicable Award Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> <B>Disability of Participant.</B> Except as otherwise provided in the
applicable Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#146;s Continuous Service terminates as a result of the Participant&#146;s Disability, the Participant may exercise his or
her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i)&nbsp;the date that is 12 months
following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after such termination of
Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time period, the Option or SAR (as applicable) will terminate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(j)</B> <B>Death of Participant.</B> Except as otherwise provided in the applicable Award Agreement or other written agreement between
a Participant and the Company or an Affiliate, if (i)&nbsp;a Participant&#146;s Continuous Service terminates as a result of the Participant&#146;s death, or (ii)&nbsp;a Participant dies within the period (if any) specified in the Award Agreement
for exercisability after the termination of the Participant&#146;s Continuous Service (for a reason other than death), then the Participant&#146;s Option or SAR may be exercised (to the extent that the Participant was entitled to exercise such
Option or SAR as of the date of death) by the Participant&#146;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance, or by a person designated to exercise the Option or SAR upon the Participant&#146;s
death, but only within such period of time ending on the earlier of (i)&nbsp;the date that is 18 months following the date of death (or such longer or shorter period specified in the Award Agreement), and (ii)&nbsp;the expiration of the term of the
Option or SAR as set forth in the Award Agreement. If, after the Participant&#146;s death, the Option or SAR (as applicable) is not exercised within the applicable time period, the Option or SAR (as applicable) will terminate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(k)</B> <B>Termination for Cause.</B> Except as explicitly provided otherwise in the applicable Award Agreement or other individual
written agreement between a Participant and the Company or an Affiliate, if a Participant&#146;s Continuous Service is terminated for Cause, the Participant&#146;s Option or SAR will terminate immediately upon such termination of Continuous Service,
and the Participant will be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(l)</B> <B><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employees.</B> If an Option or SAR is granted to an Employee who is a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee for
purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six months following the date of grant of the Option or SAR (although the Award may vest
prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i)&nbsp;if such <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee dies or suffers a Disability, (ii)&nbsp;upon a Transaction in which such Option
or SAR is not assumed, continued or substituted, (iii)&nbsp;upon a Change in Control, or (iv)&nbsp;upon the Participant&#146;s retirement (as such term may be defined in the Participant&#146;s Award Agreement, in another written agreement between
the Participant and the Company or an Affiliate, or, if no such definition, in accordance with the Company&#146;s or Affiliate&#146;s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised
earlier than six months following the date of grant. The foregoing provision is intended to operate so that any income derived by a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee in connection with the exercise or vesting of an
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-8
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Option or SAR will be exempt from his or her regular rate of pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived
by a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee in connection with the exercise, vesting or issuance of any shares under any other Award will be exempt from the employee&#146;s regular rate of pay, the provisions of this
Section&nbsp;5(l) will apply to all Awards and are hereby incorporated by reference into such Award Agreements. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>ROVISIONS</SMALL> <SMALL>OF</SMALL> A<SMALL>WARDS</SMALL> O<SMALL>THER</SMALL> <SMALL>THAN</SMALL> O<SMALL>PTIONS</SMALL>
<SMALL>AND</SMALL> SAR<SMALL>S</SMALL>. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> <B>Restricted Stock Awards.</B> Each Restricted Stock
Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate. To the extent consistent with the Company&#146;s bylaws, at the Board&#146;s election, shares of Common Stock underlying a Restricted
Stock Award may be (i)&nbsp;held in book entry form subject to the Company&#146;s instructions until any restrictions relating to the Restricted Stock Award lapse, or (ii)&nbsp;evidenced by a certificate, which certificate will be held in such form
and manner as determined by the Board. The terms and conditions of separate Restricted Stock Award Agreements need not be identical; <I>provided, however</I>, that each Restricted Stock Award Agreement will conform to (through incorporation of the
provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> <B>Consideration.</B> A Restricted Stock Award may be awarded in consideration for (A)&nbsp;cash (including electronic funds transfers), check, bank draft or money order payable to the Company,
(B)&nbsp;past services to the Company or an Affiliate or (C)&nbsp;any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> <B>Vesting. </B>Subject to Section&nbsp;2(g), shares of Common Stock awarded under a Restricted Stock Award Agreement may be
subject to forfeiture to or repurchase by the Company in accordance with a vesting schedule to be determined by the Board. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> <B>Termination of Continuous Service.</B> If a Participant&#146;s Continuous Service terminates, the Company may receive
through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant that have not vested as of the date of such termination under the terms of the Participant&#146;s Restricted Stock Award Agreement.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv)</B> <B>Transferability.</B> Rights to acquire shares of Common Stock under a Restricted Stock Award Agreement will be
transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award
Agreement remains subject to the terms of the Restricted Stock Award Agreement. Notwithstanding the foregoing or anything in the Plan or a Restricted Stock Award Agreement to the contrary, no Restricted Stock Award may be transferred to any
financial institution without prior stockholder approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> <B>Restricted Stock Unit Awards. </B>Each Restricted
Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate. The terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical; <I>provided, however</I>,
that each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> <B>Consideration.</B> At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if
any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit
Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> <B>Vesting. </B>Subject to Section&nbsp;2(g), at the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the
Restricted Stock Unit Award as it, in its sole discretion, deems appropriate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-9
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> <B>Payment</B><B>.</B> A Restricted Stock Unit Award may be settled by the
delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv)</B> <B>Additional Restrictions. </B>At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems
appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to the Restricted Stock Unit Award to a time after the vesting of the Restricted Stock Unit Award.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(v)</B> <B>Termination of Continuous Service. </B>Except as otherwise provided in the applicable Restricted Stock Unit
Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#146;s Continuous Service terminates, any portion of the Participant&#146;s Restricted Stock Unit Award that has not vested as of the
date of such termination will be forfeited upon such termination. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) Performance Stock Awards.</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> <B>General.</B> A Performance Stock Award is an Award that is payable (including that may be granted, vest or be exercised)
contingent upon the attainment during a Performance Period of specified Performance Goals. A Performance Stock Award may, but need not, require the Participant&#146;s completion of a specified period of Continuous Service. Subject to
Section&nbsp;2(g), the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by
the Board, in its sole discretion. In addition, to the extent permitted by applicable law and the applicable Award Agreement, the Board may determine that cash may be used in payment of Performance Stock Awards. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> <B>Board Discretion.</B> With respect to any Performance Stock Award, the Board retains the discretion to (A)&nbsp;reduce or
eliminate the compensation or economic benefit due upon the attainment of any Performance Goals on the basis of any considerations as the Board, in its sole discretion, may determine and (B)&nbsp;define the manner of calculating the Performance
Criteria it selects to use for a Performance Period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B> <B>Other Stock Awards. </B>Other forms of Awards valued in
whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (<I>e.g</I>., options or stock appreciation rights with an exercise or strike price (per share) less than 100% of the Fair Market
Value of the Common Stock on the date of grant) may be granted either alone or in addition to Awards granted under Section&nbsp;5 and this Section&nbsp;6. Subject to the provisions of the Plan (including, but not limited to, Sections 2(g) and 2(h)),
the Board will have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to
such Other Stock Awards and all other terms and conditions of such Other Stock Awards. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL>.</B> </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> <B>Availability of Shares.</B> The Company will keep available at all times the number of shares of Common Stock reasonably
required to satisfy then-outstanding Awards. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> <B>Securities Law Compliance.</B> The Company will seek to obtain
from each regulatory commission or agency having jurisdiction over the Plan the authority required to grant Awards and to issue and sell shares of Common Stock upon exercise of the Awards; <I>provided, however</I>, that this undertaking will not
require the Company to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such
regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock
upon exercise of such Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of an Award or the subsequent issuance of cash or Common Stock pursuant to the Award if such grant or issuance would be in
violation of any applicable securities law. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-10
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> <B>No Obligation to Notify or Minimize Taxes. </B>The Company will have no
duty or obligation to any Participant to advise such holder as to the time or manner of exercising an Award. Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of
an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>M<SMALL>ISCELLANEOUS</SMALL>.</B> </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> <B>Use of Proceeds from Sales of Common Stock. </B>Proceeds from the sale of shares of Common Stock issued pursuant to Awards will constitute general funds of the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> <B>Corporate Action Constituting Grant of Awards.</B> Corporate action constituting a grant by the Company of an Award to any
Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate or letter evidencing the Award is communicated to, or actually received or
accepted by, the Participant. In the event that the corporate records (<I>e.g</I>., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (<I>e.g</I>., exercise price, vesting schedule or
number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the corporate records will control and the
Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> <B>Stockholder Rights.</B> No Participant will be deemed to be the holder of, or to have any of the rights of a holder with
respect to, any shares of Common Stock subject to an Award unless and until (i)&nbsp;such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Award pursuant to its terms, and (ii)&nbsp;the
issuance of the Common Stock subject to such Award has been entered into the books and records of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B>
<B>No Employment or Other Service Rights.</B> Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to
serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or will affect the right of the Company or an Affiliate to terminate (i)&nbsp;the employment of an Employee with or without notice and with or without
cause, or (ii)&nbsp;the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e)</B> <B>Change in Time Commitment.</B> In the event a Participant&#146;s regular level of time commitment in the
performance of his or her services for the Company or any Affiliate is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time
Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board has the right in its sole discretion to (i)&nbsp;make a corresponding reduction in the number of shares or cash amount subject to any
portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (ii)&nbsp;in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In
the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(f)</B> <B>Incentive Stock Option Limitation.</B> To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are
exercisable for the first time by any Participant during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing
Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any
contrary provision of the applicable Option Agreement(s). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-11
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(g)</B> <B>Investment Assurances.</B> The Company may require a Participant, as a
condition of exercising or acquiring Common Stock under any Award, (i)&nbsp;to give written assurances satisfactory to the Company as to the Participant&#146;s knowledge and experience in financial and business matters and/or to employ a purchaser
representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of
exercising the Award and (ii)&nbsp;to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Award for the Participant&#146;s own account and not with any present intention of
selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A)&nbsp;the issuance of the shares upon the exercise or acquisition of Common Stock under
the Award has been registered under a then currently effective registration statement under the Securities Act or (B)&nbsp;as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in
the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with
applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(h)</B>
<B>Withholding Obligations.</B> Unless prohibited by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any federal, state, local or foreign tax withholding obligation relating to an Award by any of the following means
or by a combination of such means: (i)&nbsp;causing the Participant to tender a cash payment; (ii)&nbsp;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award;
(iii)&nbsp;withholding cash from an Award settled in cash; (iv)&nbsp;withholding payment from any amounts otherwise payable to the Participant; or (v)&nbsp;by such other method as may be set forth in the Award Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> <B>Electronic Delivery.</B> Any reference herein to a &#147;written&#148; agreement or document will include any agreement or
document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#146;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(j)</B> <B>Deferrals.</B> To the extent permitted by applicable law, the Board, in its sole discretion, may determine that
the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants. Deferrals by
Participants will be made in accordance with Section&nbsp;409A of the Code. Consistent with Section&nbsp;409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the
Company or an Affiliate. The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#146;s termination of
Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(k)</B> <B>Section 409A. </B>Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the
Plan and the Awards granted hereunder exempt from Section&nbsp;409A of the Code, and, to the extent not so exempt, in compliance with Section&nbsp;409A of the Code. If the Board determines that any Award granted hereunder is not exempt from and is
therefore subject to Section&nbsp;409A of the Code, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section&nbsp;409A(a)(1) of the Code, and to the extent an Award
Agreement is silent on terms necessary for compliance with Section&nbsp;409A of the Code, such terms are hereby incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement
specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes &#147;deferred compensation&#148; under Section&nbsp;409A of the Code is a &#147;specified employee&#148; for
purposes of Section&nbsp;409A of the Code, no distribution or payment of any amount under such Award that is due because of a &#147;separation from service&#148; (as defined in Section&nbsp;409A of the Code without regard to alternative definitions
thereunder) will be issued or paid before the date that is six months and one </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-12
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
day following the date of such Participant&#146;s &#147;separation from service&#148; or, if earlier, the date of the Participant&#146;s death, unless such distribution or payment may be made in
a manner that complies with Section&nbsp;409A of the Code, and any amounts so deferred will be paid in a lump sum on the day after such <FONT STYLE="white-space:nowrap">six-month</FONT> period elapses, with the balance paid thereafter on the
original schedule. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(l)</B> <B>Clawback/Recovery.</B> All Awards granted under the Plan will be subject to recoupment in
accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#146;s securities are listed or as is otherwise required by the
Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate,
including, but not limited to, a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving
rise to a right to resign for &#147;good reason&#148; or &#147;constructive termination&#148; (or similar term) under any agreement with the Company or an Affiliate. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>;
O<SMALL>THER</SMALL> C<SMALL>ORPORATE</SMALL> E<SMALL>VENTS</SMALL>.</B> </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> <B>Capitalization
Adjustments.</B> In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the Plan pursuant to Section&nbsp;3(a); (ii) the class(es) and
maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section&nbsp;3(c); and (iii)&nbsp;the class(es) and number of securities and price per share of stock subject to outstanding Awards. The
Board will make such adjustments and its determination will be final, binding and conclusive. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> <B>Dissolution or
Liquidation.</B> Except as otherwise provided in the applicable Award Agreement or other written agreement between a Participant and the Company or an Affiliate, in the event of a dissolution or liquidation of the Company, all outstanding Awards
(other than Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#146;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation,
and the shares of Common Stock subject to a forfeiture condition or the Company&#146;s right of repurchase may be reacquired or repurchased by the Company notwithstanding the fact that the holder of such Award is providing Continuous Service.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> <B>Transactions.</B> In the event of a Transaction, the provisions of this Section&nbsp;9(c) will apply to each
outstanding Award and Prior Plan Award, in each case unless otherwise provided in the instrument evidencing the Award or Prior Plan Award (as applicable), in any other written agreement between the Company or any Affiliate and the Participant, or in
any director compensation policy of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> <B>Awards May Be Assumed.</B> In the event of a Transaction, any
surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#146;s parent company) may assume or continue any or all outstanding Awards and/or Prior Plan Awards or may substitute similar stock awards for any or all
outstanding Awards and/or Prior Plan Awards (including, but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Transaction), and any reacquisition or repurchase rights held by the Company
in respect of Common Stock issued pursuant to any outstanding Awards and/or Prior Plan Awards may be assigned by the Company to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#146;s parent company). For
clarity, in the event of a Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#146;s parent company) may choose to assume or continue only a portion of an outstanding Award or Prior Plan Award,
to substitute a similar stock award for only a portion of an outstanding Award or Prior Plan Award, or to assume or continue, or substitute similar stock awards for, the outstanding Awards and/or Prior Plan Awards held by some, but not all,
Participants. The terms of any such assumption, continuation or substitution will be set by the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> <B>Awards
Held by Current Participants.</B> In the event of a Transaction in which the surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#146;s parent company) does not assume
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-13
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
or continue outstanding Awards and/or Prior Plan Awards, or substitute similar stock awards for outstanding Awards and/or Prior Plan Awards, then with respect to any such Awards and/or Prior Plan
Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Transaction (referred to as the &#147;<B><I>Current
Participants</I></B>&#148;), the vesting (and exercisability, if applicable) of such Awards and Prior Plan Awards will be accelerated in full (and with respect to Performance Stock Awards, vesting will be deemed to be satisfied at the target level
of performance) to a date prior to the effective time of the Transaction (contingent upon the closing or completion of the Transaction) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior
to the effective time of the Transaction), and such Awards and Prior Plan Awards will terminate if not exercised (if applicable) prior to the effective time of the Transaction in accordance with the exercise procedures determined by the Board, and
any reacquisition or repurchase rights held by the Company with respect to such Awards and Prior Plan Awards will lapse (contingent upon the closing or completion of the Transaction). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> <B>Awards Held by Participants other than Current Participants.</B> In the event of a Transaction in which the surviving
corporation or acquiring corporation (or the surviving or acquiring corporation&#146;s parent company) does not assume or continue outstanding Awards and/or Prior Plan Awards, or substitute similar stock awards for outstanding Awards and/or Prior
Plan Awards, then with respect to any such Awards and/or Prior Plan Awards that have not been assumed, continued or substituted and that are held by Participants other than Current Participants, such Awards and Prior Plan Awards will terminate if
not exercised (if applicable) prior to the effective time of the Transaction in accordance with the exercise procedures determined by the Board; <I>provided</I>, <I>however</I>, that any reacquisition or repurchase rights held by the Company with
respect to such Awards and Prior Plan Awards will not terminate and may continue to be exercised notwithstanding the Transaction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(iv)</B> <B>Payment for Awards in Lieu of Exercise.</B> Notwithstanding the foregoing, in the event any outstanding Award or Prior Plan Award held by a Participant will terminate if not exercised prior
to the effective time of a Transaction, the Board may provide that the Participant may not exercise such Award or Prior Plan Award but instead will receive a payment, in such form as may be determined by the Board, equal in value to the excess, if
any, of (A)&nbsp;the value of the property the Participant would have received upon the exercise of such Award or Prior Plan Award immediately prior to the effective time of the Transaction, over (B)&nbsp;any exercise price payable by the
Participant in connection with such exercise. For clarity, such payment may be zero if the value of such property is equal to or less than the exercise price. Payments under this provision may be delayed to the same extent that payment of
consideration to the holders of the Common Stock in connection with the Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B> <B>Change in Control.</B> Unless provided otherwise in the Award Agreement for an Award or award agreement for a Prior Plan Award (as applicable), in any other written agreement or plan between
the Company or any Affiliate and the Participant, or in any director compensation policy of the Company, an Award or Prior Plan Award will not be subject to additional acceleration of vesting and exercisability upon or after a Change in Control.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e)</B> <B>Prior Plan Awards. </B>For clarity, with respect to any Prior Plan Award, the terms set forth in Sections 9(c)
and 9(d) will supersede any terms set forth in the applicable Prior Plan regarding the treatment of such Prior Plan Award in the event of a Corporate Transaction (as defined in the applicable Prior Plan) or Change in Control (as defined in the
applicable Prior Plan). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(f)</B> <B>Parachute Payments. </B>Except as otherwise provided in the applicable Award Agreement
or other written agreement between a Participant and the Company or an Affiliate, if any payment or benefit the Participant would receive pursuant to a Change in Control from the Company or otherwise (&#147;<B><I>Payment</I></B>&#148;) would
(i)&nbsp;constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Code, and (ii)&nbsp;but for this sentence, be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<B><I>Excise
Tax</I></B>&#148;), then such Payment will be equal to the Reduced Amount. The &#147;<B><I>Reduced Amount</I></B>&#148; will be either (x)&nbsp;the largest portion of the Payment that would result in no portion of the Payment being subject to the
Excise Tax or (y)&nbsp;the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes,
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-14
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Participant&#146;s receipt, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis,
of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting &#147;parachute payments&#148; is necessary so that the Payment equals
the Reduced Amount, reduction will occur in the following order: (A)&nbsp;reduction of cash payments; (B)&nbsp;cancellation of accelerated vesting of equity awards other than stock options; (C)&nbsp;cancellation of accelerated vesting of stock
options; and (D)&nbsp;reduction of other benefits paid to the Participant. Within any such category of payments and benefits (that is, (A), (B), (C) or (D)), a reduction will occur first with respect to amounts that are not &#147;deferred
compensation&#148; within the meaning of Section&nbsp;409A of the Code and then with respect to amounts that are. In the event that acceleration of compensation from a Participant&#146;s equity awards is to be reduced, such acceleration of vesting
will be canceled, subject to the immediately preceding sentence, in the reverse order of the date of grant. The accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change in Control will
perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company will appoint a nationally recognized accounting
firm to make the determinations required hereunder. The Company will bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The accounting firm engaged to make the determinations hereunder will
provide its calculations, together with detailed supporting documentation, to the Participant and the Company within 15 calendar days after the date on which the Participant&#146;s right to a Payment is triggered (if requested at that time by the
Participant or the Company) or such other time as reasonably requested by the Participant or the Company. Any good faith determinations of the accounting firm made hereunder will be final, binding and conclusive upon the Participant and the Company.
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>ERMINATION</SMALL> <SMALL>OR</SMALL> S<SMALL>USPENSION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>.</B>
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> <B>Termination or Suspension.</B> The Board may suspend or terminate the Plan at any time. No
Incentive Stock Option may be granted after<B> </B>the tenth anniversary of the earlier of (i)&nbsp;the Adoption Date or (ii)&nbsp;the date the Plan is approved by the stockholders of the Company. No Awards may be granted under the Plan while the
Plan is suspended or after it is terminated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> <B>No Impairment of Rights.</B> Suspension or termination of the Plan
will not materially impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan (including Section&nbsp;2(b)(viii)) or an Award
Agreement. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>.</B> </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Plan will become effective on the Effective Date. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>HOICE</SMALL> <SMALL>OF</SMALL> L<SMALL>AW</SMALL>.</B> </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The laws of the State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan, without
regard to that state&#146;s conflict of laws rules. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>EFINITIONS</SMALL>. </B>As used in the Plan, the following definitions will apply to the capitalized terms indicated below:
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> &#147;<B><I>Adoption Date</I></B>&#148; means April&nbsp;8, 2018, which is the date the Plan was
adopted by the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> &#147;<B><I>Affiliate</I></B>&#148; means, at the time of determination, any
&#147;parent&#148; or &#147;subsidiary&#148; of the Company as such terms are defined in Rule 405. The Board will have the authority to determine the time or times at which &#147;parent&#148; or &#147;subsidiary&#148; status is determined within the
foregoing definition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> &#147;<B><I>Appreciation Award</I></B>&#148; means (i)&nbsp;a stock option or stock
appreciation right granted under any of the Prior Plans or (ii)&nbsp;an Option or Stock Appreciation Right, in each case with respect to which the exercise or strike price is </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-15
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
at least 100% of the Fair Market Value of the Common Stock subject to the stock option or stock appreciation right, or Option or Stock Appreciation Right, as applicable, on the date of grant.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B> &#147;<B><I>Award</I></B>&#148; means an Incentive Stock Option, a Nonstatutory Stock Option, a Stock Appreciation
Right, a Restricted Stock Award, a Restricted Stock Unit Award, a Performance Stock Award or any Other Stock Award. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e)</B> &#147;<B><I>Award Agreement</I></B>&#148; means a written agreement between the Company and a Participant evidencing the terms
and conditions of an Award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(f)</B> &#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(g)</B> &#147;<B><I>Capitalization Adjustment</I></B>&#148; means any change that is made in, or other events that occur
with respect to, the Common Stock subject to the Plan or subject to any Award after the Adoption Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock
dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring
transaction, as that term is used in Statement of Financial Accounting Standards No.&nbsp;123 (revised). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(h)</B> &#147;<B><I>Cause</I></B>&#148;<B><I> </I></B>will have the meaning ascribed to such term in any written agreement
between a Participant and the Company or an Affiliate defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of one or more of the following: (i)&nbsp;the Participant&#146;s theft,
dishonesty, willful misconduct, breach of fiduciary duty for personal profit, or falsification of any Company or Affiliate documents or records; (ii)&nbsp;the Participant&#146;s material failure to abide by the code of conduct or other policies
(including, without limitation, policies relating to confidentiality and reasonable workplace conduct) of the Company or an Affiliate; (iii)&nbsp;the Participant&#146;s unauthorized use, misappropriation, destruction or diversion of any tangible or
intangible asset or corporate opportunity of the Company or an Affiliate (including, without limitation, the Participant&#146;s improper use or disclosure of confidential or proprietary information of the Company or an Affiliate); (iv) any
intentional act by the Participant which has a material detrimental effect on the reputation or business of the Company or an Affiliate; (v)&nbsp;the Participant&#146;s repeated failure or inability to perform any reasonable assigned duties after
written notice from the Company or an Affiliate, and a reasonable opportunity to cure, such failure or inability; (vi)&nbsp;any material breach by the Participant of any employment or service agreement between the Participant and the Company or an
Affiliate, which breach is not cured pursuant to the terms of such agreement; or (vii)&nbsp;the Participant&#146;s conviction (including any plea of guilty or nolo contendere)&nbsp;of any criminal act involving fraud, dishonesty, misappropriation or
moral turpitude, or which impairs the Participant&#146;s ability to perform his or her duties. The determination that a termination of a Participant&#146;s Continuous Service is either for Cause or without Cause will be made by the Company, in its
sole discretion. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by the Participant will have no effect upon any determination of the
rights or obligations of the Company or the Participant for any other purpose. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> &#147;<B><I>Change in
Control</I></B>&#148; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50%&nbsp;of the combined voting power of the Company&#146;s then
outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control will not be deemed to occur (A)&nbsp;on account of the acquisition of securities of the Company
directly from the Company, (B)&nbsp;on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#146;s securities in a transaction or series of related
transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-16
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
(C)&nbsp;solely because the level of Ownership held by any Exchange Act Person (the &#147;<B><I>Subject Person</I></B>&#148;)&nbsp;exceeds the designated percentage threshold of the outstanding
voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence)&nbsp;as a
result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases
the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control will be deemed to occur; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> there is consummated a merger, consolidation or similar transaction involving (directly or indirectly)&nbsp;the Company and,
immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A)&nbsp;outstanding voting securities representing more
than 50%&nbsp;of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B)&nbsp;more than 50%&nbsp;of the combined outstanding voting power of the parent of the surviving Entity in such
merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated
assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50%&nbsp;of the combined voting
power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other
disposition; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv)</B> over a period of 12 months or less, individuals who, on the Adoption Date, are members of the
Board (the &#147;<B><I>Incumbent Board</I></B>&#148;)&nbsp;cease for any reason to constitute at least a majority of the members of the Board; <I>provided, however</I>, that if the appointment or election (or nomination for election)&nbsp;of any new
Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member will, for purposes of this Plan, be considered as a member of the Incumbent Board. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the foregoing or any other provision of this Plan, (A)&nbsp;the term Change in Control will not include a sale of assets,
merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, and (B)&nbsp;the definition of Change in Control (or any analogous term) in an individual written agreement between a Participant and the
Company or an Affiliate will supersede the foregoing definition with respect to Awards and/or Prior Plan Awards (as applicable) subject to such agreement; <I>provided, however</I>, that (1)&nbsp;if no definition of Change in Control (or any
analogous term) is set forth in such an individual written agreement, the foregoing definition will apply; and (2)&nbsp;no Change in Control (or any analogous term) will be deemed to occur with respect to Awards and/or Prior Plan Awards (as
applicable) subject to such an individual written agreement without a requirement that the Change in Control (or any analogous term) actually occur. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If required for compliance with Section&nbsp;409A of the Code, in no event will an event be deemed a Change in Control if such event is not also a &#147;change in the ownership of&#148; the Company, a
&#147;change in the effective control of&#148; the Company or a &#147;change in the ownership of a substantial portion of the assets of&#148; the Company, each as determined under Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)</FONT> (without regard to any alternative definition thereunder). The Board may, in its sole discretion and without a Participant&#146;s consent, amend the definition of &#147;Change in
Control&#148; to conform to the definition of a &#147;change in control event&#148; under Section&nbsp;409A of the Code and the regulations thereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(j)</B> &#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-17
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(k)</B> &#147;<B><I>Committee</I></B>&#148; means a committee of one or more
Directors to whom authority has been delegated by the Board in accordance with Section&nbsp;2(c). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(l)</B>
&#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(m)</B> &#147;<B><I>Company</I></B>&#148;
means Dynavax Technologies Corporation, a Delaware corporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(n)</B> &#147;<B><I>Continuous Service</I></B>&#148; means
that the Participant&#146;s service with the Company or an Affiliate, whether as an Employee or Director, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an
Employee or Director or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#146;s service with the Company or an Affiliate, will not terminate a
Participant&#146;s Continuous Service; <I>provided, however,</I> that<I> </I>if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant&#146;s
Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the Company to a Director will not constitute an interruption of Continuous
Service. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#146;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i)&nbsp;any leave of
absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii)&nbsp;transfers between the Company, an Affiliate or their successors. Notwithstanding the foregoing, a leave of
absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in the Company&#146;s or Affiliate&#146;s leave of absence policy, in the written terms of any leave of absence agreement or
policy applicable to the Participant, or as otherwise required by law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(o)</B> &#147;<B><I>Corporate
Transaction</I></B>&#148; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> the consummation of a sale<B> </B>or other disposition of all or substantially all, as determined by the Board, in its sole discretion, of the consolidated assets of the Company and its
Subsidiaries; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> the consummation of a sale or other disposition of at least 90%&nbsp;of the outstanding securities
of the Company; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> the consummation of a merger, consolidation or similar transaction following which the Company
is not the surviving corporation; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv)</B> the consummation of a merger, consolidation or similar transaction following
which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction
into other property, whether in the form of securities, cash or otherwise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If required for compliance with Section&nbsp;409A
of the Code, in no event will an event be deemed a Corporate Transaction if such event is not also a &#147;change in the ownership of&#148; the Company, a &#147;change in the effective control of&#148; the Company or a &#147;change in the ownership
of a substantial portion of the assets of&#148; the Company, each as determined under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)</FONT> (without regard to any alternative definition thereunder). The Board may,
in its sole discretion and without a Participant&#146;s consent, amend the definition of &#147;Corporate Transaction&#148; to conform to the definition of a &#147;change in control event&#148; under Section&nbsp;409A of the Code and the regulations
thereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(p)</B> &#147;<B><I>Director</I></B>&#148; means a member of the Board. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(q)</B> &#147;<B><I>Disability</I></B>&#148; means, with respect to a Participant, the inability of such Participant to engage in any
substantial gainful activity by reason of any medically determinable physical or mental impairment that can be </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-18
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code,
and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(r)</B> &#147;<B><I>Effective Date</I></B>&#148; means the effective date of this Plan, which is the date of the Annual Meeting of
Stockholders of the Company held in 2018, provided that this Plan is approved by the Company&#146;s stockholders at such meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(s)</B> &#147;<B><I>Employee</I></B>&#148; means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a
Director to be considered an &#147;Employee&#148; for purposes of the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(t)</B> &#147;<B><I>Entity</I></B>&#148; means
a corporation, partnership, limited liability company or other entity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(u)</B> &#147;<B><I>Exchange Act</I></B>&#148;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(v)</B>
&#147;<B><I>Exchange Act Person</I></B>&#148;<B><I> </I></B>means any natural person, Entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act), except that &#147;Exchange Act Person&#148; will not include
(i)&nbsp;the Company or any Subsidiary of the Company, (ii)&nbsp;any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any
Subsidiary of the Company, (iii)&nbsp;an underwriter temporarily holding securities pursuant to a registered public offering of such securities, (iv)&nbsp;an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially
the same proportions as their Ownership of stock of the Company, or (v)&nbsp;any natural person, Entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner,
directly or indirectly, of securities of the Company representing more than fifty percent 50% of the combined voting power of the Company&#146;s then outstanding securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(w)</B> &#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of the Common Stock determined as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> Unless otherwise provided by the Board, if the Common Stock is listed on any established stock exchange or traded on any established market, then the Fair Market Value of a share of Common
Stock will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems
reliable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the
date of determination, then the Fair Market Value of a share of Common Stock will be the closing sales price for such stock on the last preceding date for which such quotation exists. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> In the absence of such markets for the Common Stock, the Fair Market Value of a share of Common Stock will be determined by
the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(x)</B> &#147;<B><I>Full
Value Award</I></B>&#148; means (i)&nbsp;a stock award granted under any of the Prior Plans or (ii)&nbsp;an Award, in each case that is not an Appreciation Award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(y)</B> &#147;<B><I>Incentive Stock Option</I></B>&#148; means an option granted pursuant to Section&nbsp;5 that is intended to be, and that qualifies as, an &#147;incentive stock option&#148; within
the meaning of Section&nbsp;422 of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(z)</B> &#147;<B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director</I></B>&#148;<B> </B>means a Director who either (i)&nbsp;is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-19
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> promulgated pursuant to the Securities Act (&#147;<B><I>Regulation <FONT STYLE="white-space:nowrap">S-K</FONT></I></B>&#148;)), does not possess an interest in any other transaction for which disclosure would be
required under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> and is not engaged in a business relationship for which disclosure would be required pursuant to Item&nbsp;404(b) of Regulation
<FONT STYLE="white-space:nowrap">S-K,</FONT> or (ii)&nbsp;is otherwise considered a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; for purposes of Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(aa)</B> &#147;<B><I>Nonstatutory Stock Option</I></B>&#148; means an option granted pursuant to Section&nbsp;5 that does not qualify
as an Incentive Stock Option. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(bb)</B> &#147;<B><I>Officer</I></B>&#148; means a person who is an officer of the Company
within the meaning of Section&nbsp;16 of the Exchange Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(cc)</B> &#147;<B><I>Option</I></B>&#148; means an Incentive
Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(dd)</B>
&#147;<B><I>Option Agreement</I></B>&#148; means a written agreement between the Company and a holder of an Option evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ee)</B> &#147;<B><I>Other Stock Award</I></B>&#148; means an award based in whole or in part by reference to the Common
Stock which is granted pursuant to the terms and conditions of Section&nbsp;6(d). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ff)</B> &#147;<B><I>Other Stock Award
Agreement</I></B>&#148;<B><I> </I></B>means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement will be subject to the terms
and conditions of the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(gg)</B> &#147;<B><I>Own,</I></B>&#148;<B><I> </I></B>&#147;<B><I>Owned,</I></B>&#148;<B><I>
</I></B>&#147;<B><I>Owner,</I></B>&#148;<B><I> </I></B>&#147;<B><I>Ownership</I></B>&#148;<B> </B>A person or Entity will be deemed to &#147;Own,&#148; to have &#147;Owned,&#148; to be the &#147;Owner&#148; of, or to have acquired
&#147;Ownership&#148; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting,
with respect to such securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(hh)</B> &#147;<B><I>Participant</I></B>&#148; means (i)&nbsp;with respect to any Award,
a person to whom such Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award, and (ii)&nbsp;with respect to any Prior Plan Award, a person to whom such Prior Plan Award is granted pursuant to any
Prior Plan or, if applicable, such other person who holds an outstanding Prior Plan Award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B>
&#147;<B><I>Performance Criteria</I></B>&#148; means the one or more criteria that the Board will select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that will be used to establish such
Performance Goals may be based on any one of, or combination of, the following, as determined by the Board: (i)&nbsp;earnings (including earnings per share and net earnings); (ii) earnings before interest, taxes and depreciation; (iii)&nbsp;earnings
before interest, taxes, depreciation and amortization (EBITDA); (iv) total stockholder return; (v)&nbsp;return on equity or average stockholder&#146;s equity; (vi)&nbsp;return on assets, investment, or capital employed; (vii)&nbsp;stock price or
stock price performance; (viii)&nbsp;margin (including gross margin); (ix) net income (before or after taxes); (x) operating income; (xi)&nbsp;operating income after taxes; <FONT STYLE="white-space:nowrap">(xii)&nbsp;pre-tax</FONT> profit;
(xiii)&nbsp;operating cash flow; (xiv)&nbsp;sales or revenue targets; (xv)&nbsp;increases in revenue or product revenue; (xvi)&nbsp;expenses and cost reduction goals; (xvii)&nbsp;improvement in or attainment of working capital levels;
(xviii)&nbsp;economic value added (or an equivalent metric); (xix) market share; (xx)&nbsp;cash flow; (xxi)&nbsp;cash flow per share; (xxii)&nbsp;share price performance; (xxiii)&nbsp;debt reduction; (xxiv)&nbsp;implementation or completion of
projects or processes; (xxv)&nbsp;customer satisfaction; (xxvi)&nbsp;stockholders&#146; equity; (xxvii)&nbsp;capital expenditures; (xxviii)&nbsp;debt levels; (xxix)&nbsp;operating profit or net operating profit; (xxx)&nbsp;workforce diversity;
(xxxi)&nbsp;growth of net income or operating income; (xxxii)&nbsp;billings; (xxxiii) submission to, or approval by, a regulatory body (including but not limited to the U.S. Food and Drug </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-20
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Administration) of an applicable filing for a product candidate or other product development milestones; (xxxiv)&nbsp;acquisitions, divestitures, joint ventures, strategic alliances, licenses or
collaborations; (xxxv)&nbsp;spin-offs, <FONT STYLE="white-space:nowrap">split-ups,</FONT> reorganizations, recapitalizations, restructurings, financings (debt or equity) or refinancings; (xxxvi)&nbsp;manufacturing or process development, clinical
trial, regulatory, intellectual property, compliance or research objectives; and (xxxvii)&nbsp;any other measures of performance selected by the Board. Partial achievement of the specified criteria may result in the payment or vesting corresponding
to the degree of achievement as specified in the applicable Award Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(jj)</B> &#147;<B><I>Performance
Goals</I></B>&#148; means, for a Performance Period, the one or more goals established by the Board for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more
business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. The Board is authorized to make
appropriate adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (i)&nbsp;to exclude restructuring and/or other nonrecurring charges; (ii)&nbsp;to exclude exchange rate effects, as
applicable, for <FONT STYLE="white-space:nowrap">non-U.S.</FONT> dollar denominated Performance Goals; (iii)&nbsp;to exclude the effects of changes to generally accepted accounting principles; (iv)&nbsp;to exclude the effects of any statutory
adjustments to corporate tax rates; (v)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under generally accepted accounting principles; (vi)&nbsp;to exclude the dilutive
effects of acquisitions or joint ventures; (vii)&nbsp;to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a Performance Period following such divestiture; (viii)&nbsp;to
exclude the effect of any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation,
<FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (ix)&nbsp;to exclude the effects of stock based
compensation and/or the award of an annual cash incentive under the Company&#146;s Annual Incentive Program; (x)&nbsp;to exclude the effect of any other unusual, <FONT STYLE="white-space:nowrap">non-recurring</FONT> gain or loss or other
extraordinary item; and (xi)&nbsp;to make other appropriate adjustments selected by the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(kk)</B>
&#147;<B><I>Performance Period</I></B>&#148; means the period of time selected by the Board over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#146;s right to and the payment of a
Performance Stock Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ll)</B> &#147;<B><I>Performance Stock Award</I></B>&#148; means an Award granted under the terms and conditions of Section&nbsp;6(c).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(mm)</B> &#147;<B><I>Plan</I></B>&#148; means this Dynavax Technologies Corporation 2018 Equity Incentive Plan.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(nn)</B> &#147;<B><I>Restricted Stock Award</I></B>&#148; means an award of shares of Common Stock which is granted
pursuant to the terms and conditions of Section&nbsp;6(a). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(oo)</B> &#147;<B><I>Restricted Stock Award
Agreement</I></B>&#148; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement will be subject to the terms
and conditions of the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(pp)</B> &#147;<B><I>Restricted Stock Unit Award</I></B>&#148;<B><I> </I></B>means a right to
receive shares of Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;6(b). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(qq)</B>
&#147;<B><I>Restricted Stock Unit Award Agreement</I></B>&#148;<B><I> </I></B>means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant.
Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(rr)</B>
&#147;<B><I>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></I></B>&#148; means Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act or any successor to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> as in
effect from time to time. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-21
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ss)</B> &#147;<B><I>Rule 405</I></B>&#148; means Rule 405 promulgated under the
Securities Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(tt)</B> &#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(uu)</B> &#147;<B><I>Stock Appreciation Right</I></B>&#148; or
&#147;<B><I>SAR</I></B>&#148;<B><I> </I></B>means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section&nbsp;5. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(vv)</B> &#147;<B><I>Stock Appreciation Right Agreement</I></B>&#148; or &#147;<B><I>SAR Agreement</I></B>&#148; means a written agreement between the Company and a holder of a Stock Appreciation Right
evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(ww)</B> &#147;<B><I>Subsidiary</I></B>&#148; means, with respect to the Company, (i)&nbsp;any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect
a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the
time, directly or indirectly, Owned by the Company, and (ii)&nbsp;any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital
contribution) of more than 50%. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(xx)</B> &#147;<B><I>Ten Percent Stockholder</I></B>&#148; means a person who Owns (or is
deemed to Own pursuant to Section&nbsp;424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(yy)</B> &#147;<B><I>Transaction</I></B>&#148; means a Corporate Transaction or a Change in Control. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-22
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g707175g55b88.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">DYNAVAX TECHNOLOGIES CORPORATION ATTN: STEVEN N. GERSTEN 2929 SEVENTH STREET, SUITE 100 BERKELEY, CA 94710 VOTE BY INTERNET -
www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time the day before the <FONT STYLE="white-space:nowrap">cut-off</FONT> date or meeting date. Have your
proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form. ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS If you would like to reduce the costs incurred by
our company in mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards and annual reports electronically via <FONT STYLE="white-space:nowrap">e-mail</FONT> or the Internet. To sign up for electronic delivery,
please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive or access proxy materials electronically in future years. VOTE BY PHONE - <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-690-6903</FONT></FONT></FONT> Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M. Eastern Time the day before the
<FONT STYLE="white-space:nowrap">cut-off</FONT> date or meeting date. Have your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have
provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: E73795-P20804 KEEP THIS PORTION FOR YOUR RECORDS THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND
DATED. DETACH AND RETURN THIS PORTION ONLY DYNAVAX TECHNOLOGIES CORPORATION The Board of Directors recommends a vote FOR the listed nominees: 1. Election of Directors Nominees: 01) Dennis A. Carson, M.D. 02) Eddie Gray 03) Laura Brege For All
Withhold All Except For All To withhold authority to vote for any individual nominee(s), mark &#147;For All Except&#148; and write the number(s) of the nominee(s) on the line below. The Board of Directors recommends a vote FOR proposals 2, 3 and 4.
2. To amend and restate the Dynavax Technologies Corporation 2018 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 2,300,000. 3. To approve, on an
advisory basis, the compensation of the Company&#146;s named executive officers, as disclosed in the proxy statement. 4. To ratify the selection of Ernst&nbsp;&amp; Young LLP as the independent registered public accounting firm of the Company for
its fiscal year ending December&nbsp;31, 2019. For Against Abstain NOTE: To conduct any other business properly brought before the meeting or any adjournment thereof. For address changes and/or comments, please check this box and write them on the
back where indicated. Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a
corporation or partnership, please sign in full corporate or partnership name by authorized officer. Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date </FONT></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g707175g52j05.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Important Notice Regarding the Availability of Proxy Material for the Annual Meeting: The Combined
<FONT STYLE="white-space:nowrap">10-K</FONT> with Proxy Statement is available at www.proxyvote.com. E73796-P20804 DYNAVAX TECHNOLOGIES CORPORATION THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF DYNAVAX TECHNOLOGIES CORPORATION FOR
THE 2019 ANNUAL MEETING OF STOCKHOLDERS May&nbsp;30, 2019 The undersigned stockholder of DYNAVAX TECHNOLOGIES CORPORATION, a Delaware corporation (the &#147;Company&#148;), hereby acknowledges receipt of the Notice of Annual Meeting of Stockholders
and Proxy Statement, each dated April&nbsp;22, 2019, and the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018, and hereby appoints Eddie Gray and Michael Ostrach, or either
of them, proxies, with full power to each of substitution, on behalf and in the name of the undersigned, to represent the undersigned at the 2019 Annual Meeting of Stockholders of the Company to be held on May&nbsp;30, 2019 at 9:00 a.m., Pacific
Time, at the Company&#146;s offices at 2929 Seventh Street, Suite 100, Berkeley, California, and at any postponement or adjournment thereof, and to vote all shares of common stock of the Company which the undersigned would be entitled to vote if
then and there personally present, on the matters set on the reverse side. THE PROXY WILL BE VOTED AS DIRECTED OR, IF NO CONTRARY DIRECTION IS INDICATED, WILL BE VOTED IN FAVOR OF THE COMPANY&#146;S PROPOSALS AS LISTED ON THE REVERSE SIDE, AND AS
SAID PROXIES DEEM ADVISABLE ON SUCH MATTERS AS MAY PROPERLY COME BEFORE THE MEETING. Address Changes/Comments: (If you noted any Address Changes/Comments above, please mark corresponding box on the reverse side.) Continued and to be signed on
reverse side </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g707175g52j05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g707175g52j05.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M$GOS)?BM/ZW-+6J.*VY;_@]?P^1NR>.UTR'4QJ^GM:RV$$4Z@3A_-60[5R<
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M>V:B.MF]$W9??;\RVFFXK=*_ZE;0[[5M1^(^LK=*5LK.*-842\8HH8$@^7M
M8MUR?N]!FG35H-O>]ONMI_P>I,VFX\NUK_G_ %;YF-XB\4:_:^,-:L=.U"X,
MEK' UG8QV F29F'S!W"Y4>Y85-*[UW]ZWRTZFDTE;IHW\[LW&\?26\>KSW6C
M.EKI<OD22I.#OE^7:JK@=2W7H..O9KWDFNKLOOM_P?O(U6DNBN_)6O\ \ LM
MXNU"&6]LIM# U6VMA=K;)=!EEBW$':^W[PQT(].>]#:2<NB=GY>?F-)MI=[V
M_P GV_$KP^/Q<:5#K,.F,=(FODM$N&EVML8[?-*[> 'XQGWJE%\T8OK?_@?>
M2W[LFNEO^#]QO:'K1UH7\B6_EV]O=/;Q2;\^=LX9L8X&[([]*E? I=_Z7W[C
M>DG'M_7X' :/XZUBWL_$#ZK<K<2!)9--_=JN2LK1;. ,_-LZ\_-2BG*E%+XG
MR_\ DRW^6I32C5=_A5_PU_)FMX>\3ZQ;>#IKO5[BTN[V"^EMGENITM(P%..6
M"X[>E5)KEBUU7ZD13YI)]+?DAL7CK5-5U+PVVE6%O]AU!IEE#W'):/(8 A2,
M#&01][VIQ7O.^W+?\O\ AK!)V@VMT[?G^?<M:?\ $G3]0UJ"R1+?R;F9X(66
M[1IMRYY>(<JIVG!R>HX&:A.\;^5_Z\RIKE=NSL5X?&=WK%CH=^VF7%A;7FH1
M0QF.[7]YG>&W#:<J"HXX)SU&.;C'WXI]4W^%_P"OZ0I^ZIVZ.W_DR7]?->9I
MGQJB>*8M#GAM5:=WCC:&]6652H)^>,#* @<<GWQ6?Q0E;=*_]>8Y+E:?FOQ(
M/"^I:DWPMM[]&-Y?B"1@UQ,06(9N2Q!/ ]NU/$/EA==E^2'32=62?\S_ #>A
MG>&/$>H6?AG0H);:2_UG5U::-9KUF5E"AF=F*G8/]D XSQ6LU:?)%;*[^_\
M$SB]'.75V7]=-B\/B!+/<V5G9:))/?7$MQ;R0F=5\J2'&X%L8((.<_3BHBN9
MJVUK_*]BFN5.^Z:7WJZ+GC/6]9T9-).E6L$OVJ]C@D,LNW[Q^Z/E/7GYNWH:
M4=:BCTU_!,-J;EU7^:,27Q5J6B>(/%5S-:2W=C9M;-(IN<"!6C&[8".3DYQQ
MFG3LXI/K)J_W6').ZMORWM\W_7R+UU\2M.M=;DLML!@AN4M9&:[19M[8&5BZ
MLH+<G(Z'@XHIKG:7>]OEW[>1,GRQOY7+OC[Q!/H.@Q+97"0:A?7"6MM(P!",
MQY;!X.!D\U&LIQ@NOY(M6493?1%:+QA/I_@235;R%;V_L9!;7*1.%WOO";@0
M,#((8?7M6CM)PY5\5OE_PS)BK<R;^&[_  NOP"\\=S:;::RUYHQ2[TPP$P)<
M!A(DK84AMHP>N1CMU[TEKRVZOE^?],?Y6;^X6Z\=36%MJ_VS2/+N]-: F%;@
M,KI*V%.[;P1SD8[=>]$5S<OG+E_K[Q/2[_NM_=<OW/BEH=2UBR6TBSIT4,GF
M37(B1_,SU)&% QUYS4W]WF\[?@G^H[:I=U?\;'.S^,7UV'1I+.3[.\>N1VEP
M+:Z\R.0;"<!UQO4Y'4=NE7!>_%]&I?@G_2)D[0FNJY?Q:_X8O?$;6=<TF'2A
MH5P(IYIGWJ8U;S%2-GV\@XSMQQ6:DE4][9*[^37Z%\MX.V]TE\[F;?\ C34;
MSQCHBZ5>*FC2- ER BMYC2HS@9(R,*HZ8^]6B7+.2ELK_P#DJNW^)FW>G%K?
M3\6E;\R]IWQ0TN^OHXV$"6TXE,3I=I)* @))DC'*9"DCD^^*B]HN3Z*_]>>N
MQ;3YN5=[?UY#++XDKJJ2PV%K:-=R6KW-LBWZOPN,B4*"8VP<[>>AYHJ7C"3Z
MK^M.]AQLYQ71NW]>HW1_%&I7:>%KC4HF2>^M9YB(+@>7(%C5@679UYX /'O5
MU+4W/RC?\?Z_R(C>27G*WX/_ "_X);TOX@-=KITU_I)LK74+22ZAD$XD.(QE
M@5P,<<@]_04IVAS7Z*_R_P QQO*UNKM\]?\ (=9>-[Z\GTN,:#L&JP2W%H3=
M#YE50RAOE^4G(]0,]30XR3E'JE?\;"NM'T;M^?\ D=;:23RV<,EU +>=D!DB
M#[PC8Y&[OCUHDDGH"OU)J0PH * "@ H * "@ H * "@ H * "@ H * "@ H
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M>6.6)HGE=AYA# @G.,9Y],5,TIJS'!N#4D9'_""Z05L5<SLEK8G3RI9<3PD
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M4XJ_W7_+3\1R3C?R:_$ZJI$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % $$UI
M!<3V\TJ;I+=B\1R1M)4J3[\$]:%H[KT_K[@>JL0OI%B\<B-!E9)UN7&YN9%*
MD-U]57CIQ33Y;6Z7_&]_S8=_/_*WY#;;1K*SNVN;=9HV9F8H+B3R\MU/E[MH
MSUZ=2326BL#U=Q][I=I?R1R3HXEC!"R12M$X!ZC<I!QP.,XXHV#R(9]!L+A(
M5D%QNA0HLBW4JR%3U!<-N8?4FC<-A6T'3&@GA^R*(I[=;61%8J#$N["C!X^\
MW3GFJYGOYW^>G^0T[6MT$O= TS4'=[JV+LXC!(D93^[)9,8/!!8G(J=OS_"W
MY"Z<O3^O\A%T#34C1/(9MDC2AGE=F+LI0DL3D_*2.2?T%#U5GM:WR8TVM5_5
MA[Z)ITD<2/:JZ16[6J*Q) C.W*]>?NKR>>*;;DVWU_0F*Y8J*V7_  PP>'[#
M[*UNWVET+*P,EW*[H1T*L6++^!%+<>Q-INE6>DQ2QV<;()9#+(6D9RSD $DL
M2<\"G?1+M_PXK:MDRV5NMY-=B/\ ?S1K&[9/*J20,=/XF_.ETY>A5]O(KV.B
MV&FRF2UB96V[%WRNX1<YVJ&)VCV&!P/2G=B:N[DLNG6D\\LTL"R/+%Y+[N0R
M9)P1T[FILK-=QW:MY?U^@Z.QMX[ 6(0M;[/+VNY;*XQ@DG)IR]]68H^Z[HJ6
MWA_2[.XLYX+0++90&W@;<Q*1G'')YZ=3SU]33YG=OO\ H*RLEV_4<-"TY?LV
MV%D-LSM$4E=2-QRP.#R">QR*FVEO*WR'M]]_G_3)+?2K*U6R$,.T641B@^8G
M8I &.3SPHZU3;<G)[L/+SO\ G_F3):01WDUVB8GF54=LGD+G QT_B/YTME;Y
M_P!?<&[N5Y-%L);9X&A(1IC/E9&5A(3DL&!RIY/0CK2M:WD.^_G_ %^@R+0-
M,B$8%MNV%R#)(SDEQABVXG<2.,G)QQ3:NK>5OD):._G<JVF@K!K\5]Y4:16E
MI]DML2,[E2026)';  Y/4\\TTW[S>[M^%_SO^ FMDME?\?\ (O7^D6FI$&Y-
MP0%*E8[F2-6'HRJP#?CFILBKM$5SH&F7<C/+;L"T2Q$)*Z JIRO"D#()R#U'
M8T_/Y_,2T22Z#1X<TL02Q>3+^]D69W^T2>877@-OW;L@ #KTHVMY?\,']?K^
M9+%HEC!=M<Q+,CLQ9D6XD$9)ZDINVY.<YQUYZTK:6Z!YCK?1["U^R^3!M^R0
M&VA^=CMC.W*]>?NKR>>*J3<KWZ[_ -?,=_SN01^'-,@,!@BF@\E$C417,J J
MGW0P##=CI\V>*.9W<A/4L)I%C''%&D&%BG:X0;CQ(Q8D]?5FXZ<TNWEI^%AM
MWO?K_P #_(?9Z=;:>)5MD9%E<R,ID9@&)R< G"Y))P,4=.476Y57P[IJFVQ%
M+LMMOEQ?:)/+!4Y4E-VTD'G)!/ ]!33MJOZTM^0/6]^O^=R6_P!&L=2E62YC
M<NJ%,I,\>Y3U5MI&X>QR*GE3OYCNU;R&KH6F)<PW M%\V&W^RHQ).(O[N,\]
M.IYZ^M.7O<U_M;DQ7*HI=-B!/#&D1HZ?9Y'#Q>2?,N)'/EY!V@EC@9 X%.[O
M?S3^:V!Q35O)KY/<DE\/:9*X<P2*P9WW1SNA)<Y8$J1D$@<'CCI4V5K="KMZ
M_P!;6_(A;PIHS;,6KH$@2V 2>1 8ESA" PW#D\'.>]4VVVWUU%?^O4L2Z!IL
MWF$P,C/*)B\<KHP<*$R&4@K\H P,<?6E=_UYZ_F'D3MIMJ^FG3Y%>2V9=I$D
MK.Q'^\3NS[YS0]?Z[ M"J/#FF""YA,,CBYV^:SSR,[%3E3O+;@0>A!]/2C_.
M_P _Z0+1W\K?+7_-D6O:+<:KIJ:=!/:K:D8E6[@DG+X(*X994(((Y))S_-WU
M4NJU!:*R*46@Z[!J4^HQZEHZW<Z+'))_9DO*KG Q]HP.O\O04EHFN^H::>6A
M5B\(:E"+,1WFCC[',\\'_$MF.QVSN/\ Q\>YX/ XQT%"TM;HK?('[U[]7?YC
MKOPGJE\U\;F^TB0W\2PW'_$MF&]5S@<7''7J,'IZ"BUE;SO\QWUOY6^3&ZKX
M9\0W^EW-H-4THB6W^S[/L$R+L]/]>0/KM)HWE=]T_N?]=KDVM&R[-?>OZ]!T
M?A35XXV3^T],?<\<A:2QN';,9W)\S7). 1G'3KQR::;6W]7T_(?_  PL_A?6
M+B\:ZEU+2S(S*[J+"<1NR]"R"YVL1@<D'H/04EIL#UT8/X=\06X$]I?:,]U&
MTCQ^983KN9_O;F\\D@^X/0<<"DUI9=K?+^OZU8]WKZ_H5[;P;JL7AZWT:2_T
MA[2%A((SILOW@V[J)QGG\_2JOJGVV^2L3NI7ZWO\RS>^%]9U"=IKG4],+.H1
MPMC.BR*.@=5N0&'^\#UI+W7=#$G\+:Q<RW$DFI:7NN-OF;;"=02N-K "YP&&
M!AA@\=:-OS'_ ,,30Z#XA@2)5UNQ812&13):7+G)!'):Y)(P>AXH$5AX1U98
MI81JFG>3)_RR^QW.Q#D$%%^TX0@C(*XQVH6BL.^MR2#POK-O)%(FIZ698Y3,
MLDEA.[E]I3)9KDD_*2,'.*:=MOZ_JPOZ^XGM?#VK03VADO\ 3&AM[EK@*EA*
MK;G+;R"9S@D.W4$#/3BB]ONM\OZ0V[WOU.AMX([6!(8MVQ.!N<L?S))-(1+0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MX!ZT %YJU[:W3PP^'M1NT7&)H9+<(W';?*K>W('2@"#^W=1_Z%/5O^_MI_\
M'J +US?W,%A#<1Z3=W$LF-UO$T0DCR,G)9PO'0X8\],CF@"C_;NH_P#0IZM_
MW]M/_CU %ZVO[F>PFN)-)N[:6/.VWE:(R28&1@JY7GH,L.>N!S0!1_MW4?\
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MC:(V<S326Y1>.^R5F]N >M !>:M>VMT\,/A[4;M%QB:&2W"-QVWRJWMR!TH
M@_MW4?\ H4]6_P"_MI_\>H TK^[FLX%D@TZXOF+;3';M&& P>?G91C\<\]*
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M.LW\L\<;^&-3A1F"F1Y+8J@)ZG$Q.![ GVH GO\ 4KNSG6.#0[Z^0KN,EN\
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M/4 7M1O[FR\O[/I-W?[\Y^SM$-F,=?,=>N>V>E %'^W=1_Z%/5O^_MI_\>H
MO?;[G^ROMG]DW?G_ //GNB\W[V.N_9TY^]T]^* */]NZC_T*>K?]_;3_ ./4
M 7M.O[F]\S[1I-WI^S&/M#1'?G/3RW;ICOCK0!5FUF_BGDC3PQJ<R(Q42));
M!7 /49F!P?< ^U !#K-_+/'&_AC4X49@ID>2V*H">IQ,3@>P)]J )[_4KNSG
M6.#0[Z^0KN,EN\ 4')X^>13G\,<]: *G]NZC_P!"GJW_ ']M/_CU &S#(TL$
M<CPO"S*&,;D%D)'0X)&1[$CWH ?0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M<G:)1(-A.<8STZ\?6BVM@W+% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M: #_ (6K<?\ 0C^(?_ 4T '_  M6X_Z$?Q#_ . IH /^%JW'_0C^(?\ P%-
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MM6X_Z$?Q#_X"F@ _X6K<?]"/XA_\!30 ?\+5N/\ H1_$/_@*: #_ (6K<?\
M0C^(?_ 4T '_  M6X_Z$?Q#_ . IH /^%JW'_0C^(?\ P%- !_PM6X_Z$?Q#
M_P" IH /^%JW'_0C^(?_  %- !_PM6X_Z$?Q#_X"F@ _X6K<?]"/XA_\!30
M?\+5N/\ H1_$/_@*: #_ (6K<?\ 0C^(?_ 4T '_  M6X_Z$?Q#_ . IH /^
M%JW'_0C^(?\ P%- !_PM6X_Z$?Q#_P" IH /^%JW'_0C^(?_  %- !_PM6X_
MZ$?Q#_X"F@ _X6K<?]"/XA_\!30 ?\+5N/\ H1_$/_@*: #_ (6K<?\ 0C^(
M?_ 4T '_  M6X_Z$?Q#_ . IH /^%JW'_0C^(?\ P%- !_PM6X_Z$?Q#_P"
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0!YY\:;2&;X>3W;+^_LYHI(7'!0E@IP?H: 1WEC(TVGVTKG
M+O$K$^Y% 'GWQ/\ ^1C\"?\ 88C_ /0TH ](H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * .#^,G_ "3'4_\ ?A_]&+0".RTW_D%6?_7%/_010!P/Q/\ ^1C\
M"?\ 88C_ /0TH ](H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MZ:/!.G/I<C20R)OD=_OM*3\Y;_:W9S71523LMNGIT,87=W+>^OJ8NLZ;8?\
M"U_#D?V*WV26ERSKY2X8\<D8YK.E\51?W5^955Z0_P 3_(H75GJ$OQ5U:/2M
M/TJXV:? "E^654&3C;M4TJ5VIM_S+\BIV3@O)_F7;RVM=1^+%GI^M1Q/;6^F
M"6RMG&8FEW88@'@D <>U53LW4EUNON_X<F=U&"Z.]_7M]PGQ#M/L/_",)I%K
M:Q3G68V1"/+C+[6Y;:/UQ2IM^V5NT@FE[*5^Z((&UIOBQ:?VW%8QR_V3-L%G
M([KC>.NY1S4:<E7T7ZERO^[_ ,3_ ".$TEV\.?#>>=W/]G:]97,39/$=TA<+
M]-RC'U45I6^'V?E%K\+K]?O*M^]E-=&T_P!']^GS.RT6VMM2\9:#:ZO&DUO!
MH$,ME#, 4,AP'8 \%@,5K)?O:SZW_#_ASEBVJ5)=-?O_ .&+,4%OIWCSQ/8Z
M3&D5@VD^=<Q1#")/R!P. 2M<DM<-471/3[M3J7\:F^KW^_0LZ--=VWP+BFL"
MPNDTMFC*]0=IY'O6N+_R_0SPN_S?YLS[[1?#,7P9^VPP6RLED)XKM0!+Y^W(
M;?UW;N/TJL1>$_<TLU;[_P#(,-[Z]_K>_P"HD*'6_'.CVWB2)9FAT6.XMK6?
M[DEP?OG!X+#].M4TE.JXK5/3T_X?J1%MTZ:>SO=^?3\-2AXFUC[7X-\9Z9)X
M>MM'NK$6QF%O*L@D+L""2%7H![U$5?V<D_MV_(Z*:Y:EGUB_R9?U"VU&Y^*I
M73;+3;J0:+$674"P0#S#R,*W-.-_WG^)?D<^G+3]&:GBCP]J@U33O$-G8Z?J
M!L+1HI=.G.V,9Y+1$C /&.1TJ')0E*3U3^_0UBG.$8;-/Y'3^&M5M=:\,6.H
MZ?;?9[>:+,<. -F.-O''&*JJG&_5V_0SIM2^\Y'X;Z9I>KZ!=:AJ5I;WFL7%
MU*M\UP@=U8,0$.>@ QQ32480Y-K)_/\ X<N;_>S\G^!+I%E9:I\2_$W]KP17
M%S:K"EI'.H8)"4Y*@^IZFIII>R;ZMN_Z"G=3C'I;3]3C==2.U\/>.+#344Z1
M;ZC:_9XU/R+(64R(O8#...U.FVU2>[YG;TZ#J))SZ>[KZFYI433>,/$=Q=:;
M!HMY;Z3Y1LH&#K,K9/F[@ #TQTXK.IIAZEO^&T_4J'\6DOG?O_PQ3\%Z'J.J
MV?A"^AT2'3X=.0R/?F5/,N5*D;0J\X)/.ZMYWC)S_NVMWT_IF"]Z'+_>O?Y_
MTC7\"Z1HNK>#;Z]UNUMKB^GGG_M&2X4,Z,&/!)Y7 QCTK*HHQHQY=K7^?7YW
M-[OV\K=_P.7M)K^>Q^'S"R74Y5EO%@AN9 @EC PN6(/\(].PK37VEVM>17_
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MB@#@?B?_ ,C'X$_[#$?_ *&E 'I% !0 4 % !0 4 % !0 4 % !0 4 % !0
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M_DF.I_[\/_HQ: 1V6F_\@JS_ .N*?^@B@#@?B?\ \C'X$_[#$?\ Z&E 'I%
M!0 4 % !0 4 % !0 4 % !0 4 % &/XDTI=3TUR;Z^M# K.K6=RT))QW*]1[
M5E4;C%R71,TIZR47U9YY81WMM\&KGQ$-;U:749[!F+2WTCA#NZJ"?E/'45KB
M/<22_N_I_F98?WW=].;]2QJ_C&XNX?"=O:P:U922:C;+-+-;R0I,I&"I8\-G
MKCO6J2>(\O>T^7;R)CIAW?>RU)I=0\1RV?CM=(GN)[VWO42W3=O,:;5W",'@
M'&2!ZUSQ_A1;VYG?O:YMI[5K^ZK=KV9O^!=0TN\MKE;'5M3NYXRHN(-2=C-
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MJ7_N\'UY?\Q/^-->?Z'*:-X@UJX\%>&]/@U*5;_5[Z:![V4^8\<:NQ."V><
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MQ: 1V6F_\@JS_P"N*?\ H(H X'XG_P#(Q^!/^PQ'_P"AI0!Z10 4 % !0 4
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M'6O#MC;:8WB.&YTR!'3R?L 1CG/\>\]SGI53_>1:EVM^@H^X[KO<V?"N@_\
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M\>7L4CKGG.?04H^[#E\[E3?,XOLK?C<W*0@H * "@ H * "@ H * "@ H *
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M&/P)_P!AB/\ ]#2@#TB@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M+PC<^'=?U:'1=/5=$U*Q/RJZCR;@ @  G.&!^F:SG>5&=/[OGT*C93A/[_\
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M!"@;> O.<GGVJX6C+G\FE\R97<.1=;7,E?!FL'0]=>.$0:LFL3:AIS%U(<'
M .#P&&1@XZ\UFTU2@ENDT_1WO_F:MIU97V=OO7_!.H\ :5>Z)X'TS3M1A\B[
M@1A)'N#;26)Z@D=#6U22;5NR_(YX)J]^[_,Z6LS0* "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * .#^,G_ "3'4_\ ?A_]&+0"
M.RTW_D%6?_7%/_010!P/Q/\ ^1C\"?\ 88C_ /0TH ](H * "@ H * "@ H
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M"K/_ *XI_P"@B@#@?B?_ ,C'X$_[#$?_ *&E 'I% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % 'F_AG1Y+_QKXJNEU?4+18-24F"WD58
MY<(I^8%23Z<$44=*2?G+\PJ:U&O*/Y"^'=;LO!4^N:;KWF6L\FH2W,,IA9A<
MH_(VD Y;MCK2C+]U&/6*M8<HOVDI='KZ>7R.;OM.OH_!VGRR++I\FI>)UNK=
M'0;X%=CM)4\9[X-7"+C.E"^J3_5C;35::6C7W[:_,ZSP8DUCXW\16&L7#7>L
M;8I$NW 0S6^/E 4<#:<@X'>E"SI.W1Z_H_N(GI-7VMI^J+'Q'^]X5_[#EO\
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M_P#H:4 >D4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MXFA>(_DP!_&BP7)Z0PH * "@ H I:AJUEI?D"\G\KSWV1_*3D^G H6KY5O\
M\,OU!Z*[_K1O\DR6.\C>^FL\,LL2J^".&4YY'X@C_(H6JN#TM_7]?\$L4 %
M'!_&3_DF.I_[\/\ Z,6@$=EIO_(*L_\ KBG_ *"* .!^)_\ R,?@3_L,1_\
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MG&<<#."<9I;2N^JM^*?Z?TAVNK+NOU_SO\A=7D;6;6Q^Q"\B*7T>YS;-&Z
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MG;\$_P!0OK;RO^:_0M4#*<NJV4&JV^F2W 2\N$:2*,@_.JXS@]._3K0M;VZ
M]+-]2:WNX+KS?)?=Y4AC?@C##J.:%JK_ -=@V=OZ[B27<$5U%:N^)Y49T3!R
M0N,G_P >'YT=_(=M+CX)A/;QS*KJKJ&"NA5AGU!Y!]C3:L[")*0!0!2M]22Y
MU*ZLHX93]EP))3MV!B VWKG."#TQ[T+57!JS2^?]?<+)JME%JL.EO.!>S1F1
M(\'E1U.>GX>Q]#0M;VZ ]$F^I<H * "@"KJ%_%IMNDTRNRM+'" @!.7<*/PR
MPII7:C_6U_T';1OL,N=6L;+4+.PN+@1W-[N$"$'Y]HR>>@X/>DM79>HGHN;I
ML.EU2RAU2WTQYP+RX1I(XL$DJN,G/0=>]"U;2Z ]$F^I;H AGNH+:2!)I C3
MOY<8Q]YL$X_)3^5"U=@Z7'03+/&7574!F7#H5/!(Z'MQP>XYH#9V)* "@"EJ
M.I)IRVX:&6:2XE$4<<6W+-@G^(@=%)Z]J%J[#MHWV_X8=>ZG:Z?Y8N&DWRD[
M$BB:5VQU(503@>N*5];"MI<=#?V\\_D1NWG")9BC(RL%;(!((XZ'@\\55K7\
M@Z)]RS2 JR7\4>JP:<5?SIHGF4@#: I4'/O\X_6FE>_E;\;_ .0VK*X0WT4V
MH7-DJN)+=49B0,'=G&/R-):J_G;\$_U)O9\OE?\ -?H6J!E73[^+4K9IX5=4
M662(AP <HY0].V5-#T2?=7^\;5FUV%T^^BU*QCNX598Y,X#C!X)']*.B?=)_
M?J+JUV;7W:%F@ H 9+%'/&8Y8UD0XRK#(XYZ4 /H SDUNS.B_P!K2&2*UP2<
MH68<XZ+DGGTI7T3[V_';\P[^5_PW_(FLM2MM0$GV=GW1-M=)(FC93C(RK ']
M*?2X=;%N@ H CGGBM;>2>>18XHU+.[' 4#J31L-*^B*<>M64D F)GBC,B1 S
M6TD668@* &49Y(IVUM_7<FZ6IH4AD-K=07D/G6\@>/<R9 (Y4E2/S!HZ)AY$
MU !0 4 4HQ8V6HO"F$NKXM.RY)WE0JD^@P-@IK5673]6-W^)^GY_\$NTA!0
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MXR?\DQU/_?A_]&+0".RTW_D%6?\ UQ3_ -!% ' _$_\ Y&/P)_V&(_\ T-*
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M?Z7]I6;4EEO=]R]PBL-@AD"A@JA0H) Z<YYSFJAH_D_OO'_+\"G\+?HOE?\
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M/Q+%;3VUW%:6$H9";27;/-CAMVW:$7/7/)]ARHZWEUU2_5_HO+U'/1<OI?\
M1?J_^'*UA#<,FBZ8;2=)["Z9YY'A94"A7&X.1M;=N' .>3GH:<.C[1M^"5OZ
M[#D[<R[O_P!NO_7F7I;!;K4?$,=W%,+2YM8HRR(26&UPVW Y(ST%2M(/OS7_
M  C^J%%M54UV7YR*%I)-#K/]LW]W.;&SM&@WR6;P;F9UQA#\S'Y1SC'(P.M6
MGO?>37Z_Y_TB6K));1N_P1V%24% '!_&3_DF.I_[\/\ Z,6@$=EIO_(*L_\
MKBG_ *"* .!^)_\ R,?@3_L,1_\ H:4 >D4 % %:\U"RTZ(2WUW!:QD[0TT@
M0$^F31?H.S([C6-,M AN=1M8=X#+YDRKN!Z$9/.<'\J+:VZBZ7Z%76_$-CHM
MG.\EQ;M=1Q&5+9IE1Y /0=>WI1'62BNZ7WNP/2/-Y/\  GU76K#18(9K^=(4
MEE6)=S <L0.Y' SD^U"UDHB^SS%"'4])U35_*N9H4O+.X:.WB-SS(=H.\)D
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M^!^U$=.7RNODUI^=O04M>;SM^#7Z+\RQ#HMV-=AN)+8>3'J,UP"64[5:':&
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MS6T$=N$F>V\EE\R,L%V88C"9&[''N:T<KSYEW3^Y_I_PQ*5HN+[/[VK>NO\
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MO&K#!"@$?A2D[MLS@FHI,DJ2C@_C)_R3'4_]^'_T8M ([+3?^059_P#7%/\
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M<J"YY*(6.LZ?J%NTMO>V\GEJ&E"3*WE<?Q8Z=^OI5R7+?L1%\R7=E2Z\3:;
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M ) ]&EZ_A;_,U: "@#@_C)_R3'4_]^'_ -&+0".RTW_D%6?_ %Q3_P!!% '
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M>?+^'+_DR"_T[7M1U6,.)XX8KMF5E:$0K'L958?\M"WS#.<#K^,\K<;=;/\
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M\MG;K#&J2VJJ"&0[D*E2<% PWXX[$G%5*5VY1Z_?U^76WS(BK)1>O]??KO\
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MS!2,G(P.I[4O\[?,7;S5_EKK^#!]?M(I TK^3!Y#3'S8I$D&&"_<*YZGZGC
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MZ;.2=1R\[HQ46H*+[6_/_,T&T&ZCT,V:V]M<3_:YYT8W+PF/>[LK*ZJ2& 8
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M^TSP+B%Q&=CL -Y&W=M7.,^O%&CBGY)_YCDN631?L-:L-2E,5K,S-MWKNB=
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MGD5QNZ'!7..O.,<8H[>;M_7W["Z/R5S;CD$L22*&"L 0&4J?Q!Y'XTVK .I
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M$;J-F]?ZOZ%==!U%/!\^A;K<F6VGC\TR.<.[';U!)&&Y).?K33UCY<OX6O\
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M4J9% 8=^0/3CM26G+;I?\6W^O];DJ_O7ZV_"W^17/A:ZBNDOH+=!,ZNLT/\
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MU5GW7W6?ZL@B\/:CYV=MM:6HN89EMH[AY44JQ+LN5&W(Q\H&.,]Z(Z6OTO\
MC%K\W\A5%S)I?\/[R?Z?.YFQ^<VIZ+HUM<6-S%874C,T,Y>55$<@!=,?)@L
M>3DTHKFB_P##;RZ+^E_D6WRW\W?\;_T_\R]/X2NKG0=*TYIXD:TL&MI&5FP7
M*H 1C!QE3Z&KJ/FJN:\OP:?Z"WBX]V_Q4E^I*OAZ\_X_!;0Q:A%)$Z;]0FN%
MD";OE+.N5'SMC /7/M2O9IKS_%6$]4XO^M4_T1I:'87]K=:K=7XMU>]N!*J0
M.6"J(U3!) R?E]*-.11]?Q8Y.[OY6_/_ #,&Y\':DY1[>[@CFM;[S;1R6^2
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M_DF.I_[\/_HQ: 1V6F_\@JS_ .N*?^@B@#@?B?\ \C'X$_[#$?\ Z&E 'I%
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M:_R_I,9!XG@N)U1;&\$3SR6R3,J!&D0L"H^;/.TX)&/>DM4GW5RFK-KM^O\
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M6B.O]?U_PP/W?E^HNI:['IMXMJ+*ZN93"TY$ 7"HI ))9AZCCK2NE=O96O\
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MC<"&(QQ]:2]W;NW]Z2_0;5V_1+[FV3:/I5QITVH3W5XMS->SB9BD7EJF$5<
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MFG]PK67*MK-?>K%W5?#IU?45EN9X1;*K)MC@(F960J4,F[E3G.-O8>E0EO\
MU_5BU)JUNG]?U\R"Z\,7>HV<EO?ZHDF+62VA9+;9MWC!=OF.XX Z;1U]>+3]
M[GZZ?@T_Q:%#W+);+_*WZD^K>&SJ=P\HND0-%'$8Y(=Z.%<MAAN&Y3G&.*BV
MK?\ 6S7ZW]1+2*CVO^G^7W,KVGA$6B(JW,2XFEFVQ6XC0&2/9A5!X Z_YS1)
M7BX^37WN_P#P!)6ES>:?W*Q#8Z&8_%5FZF4P:?9)%(SQ%$DF *HRYZD*SYQG
MJ*TY[RG/N_SW_)$J/+"$.V_RV_&[\BUJ-GJ4WBRWGL9UMU6QD1I)+<R(277
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M24R'+DIN&#D#&#QCO3>]TNEOZ^?YB6D;>=_NT7X%VQT!].DN)K:6UBDEM8X
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M_P"N*?\ H(H X'XG_P#(Q^!/^PQ'_P"AI0!Z10 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 <'\9/^28ZG_OP_P#HQ: 1V6F_\@JS_P"N*?\ H(H X'XG_P#(
MQ^!/^PQ'_P"AI0!Z10 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M <>I-%N:48+31O[OU%=1C*3Z67S?Z$WB6U\1Z-X6U#48O%ERTUI"\PS:08;
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M#G'KFJG[Z][R_ F/NNZ\_P 2QI7@VRTV^M[V6\O=0N;6,Q6[WDH;R5(P=JJ
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MHK?4-3LK.?38+I8K'3UN2K.3G<2C$#IS6RA:I.+Z2MY;&7-[L7W3_!]#T\<
M G)]:@:V. \;^+-3T[7;>PT:YB1K*W-_>HZJ3+&& \L9Z$C<>.>!2@US.4OA
M5D_G_DM2W&\5%?$[V^2_5Z!XK\6:EIVMZ'<Z7*)=*>UDO+J$(I,L0*9(.,@@
M,6X/.*J*Y:DHSV5OE=M7_(CXZ<7#=_Y7M_74H7GBG6;I)$L=6,*S>(4L8IHX
M8VVP-&#@94@\G.3S1"+;@GUYK_)NWY%.22G)=%%KYV.ET+4]4@\57WAW5+I+
MTPVR74-T(Q&Q5B5*N!QG(ZC%$?>BWU3M]ZN3+W9)=T_P*WCW7-3L18Z7H5W%
M:ZG=[Y1)*%(6.-<GAN.3M7\:SYK2;Z15WY^7]=C1)6UZNR_S^2*^I^*-2OO#
M&AZMI1F@LKOYKVXMK<3RVXV]DP<_-P3@XQ6E1*-2S?NVT?Y?@9PNX?WMO\SJ
M]$NXK[1K6Y@U :A&Z9%R%"^9[X' /M3FFGL*+NCEO#NO7\FN3V_B'4Y;*]S*
M5TV2V5(BBDX:.3&7^7!/S'Z"HBTJ?,^BU\O^ 7->_9;7T\_^"5?!7C'4-:UN
M26\NHI--U)I?[/C55#0^6V-IQR=R_-SZ&KA%\EI?%:_R?3Y:?>*HTIZ;7M^%
M[_/4I'Q)X@O4MK>+5GMI)_$,]CYJ01L5A4-M4!E(XQUZU--<WL[]8MOU05'R
MN=NCBOO2.H\.ZIJ8\0ZKH&J3QW<EDD<T5RD>PNCYX91P&!';K3C:4&^J=OU%
M)<LDNZO^ASWC#Q+K%AXQGT^QU.Y@1-.$\%O!8"X\Z;<P"MA20#@<Y%1%MJ5M
M6FK+Y&C27+?1.]W]QC77C7Q)%JNH02ZHUKJ,36R6^G?9%:%Y'12R-)M^7DG&
M6'XUK%)RM'7WFODO^ 9O17EI[M_GKT^X[!;W7/$'B/5K"RU,:5;Z7Y<9*0+*
M\LC+N.=PX49 XY/K4)7BYKNTOEW&W9J+WLF_GV,B?QIJMMX5M/$<TB;;&\>T
MU"UC48N</LW1D\@YP0 ?6DY)<LNDE]S_ *7W#46^:'6+W[K^G]Y9MM>USR?"
M=Q/?HW]LWC/+'&B%4B,;,L8.,\8'/7.>:MQY:GLWTB[^JM_2(<KP<UW27H0^
M"-=UK69YIKK4M1N'1YPL#6"):G:Q"@3!!ST_BJ%?V*DM7RI_,N:2JN.R3_ T
M?!FM7U]>26^M:G,FK>7NETR:T6$1<]8VQEU[9R>O:K27+[NNW]6)=U+73^NY
M+XCN]7D\9Z+H^G:M)I\-S;SRR,D,<A8IMQ]]3ZGI403E*7DD_P ;#D^6,?-M
M?A<YS5O&&OV^E?96O#%?6NM)I\]S9VPD::,J6RL;!OFP1P.XIQM-P??FOZK]
M"FN7G79)KYM%G7->UBQL?#B0:MJP^VW$J32-IB?:F4*2!Y/E^H[+TYH_Y>*/
MDW^0OL-^:(]=\3:[HVHZ 8=0GDLA;&YOEN;5(Y)(Q(BDLNT%" ^<#'2J@DZK
M3VT7S=U?[[$R3]G=;W?X:V+UEXGU:^^* LX[H?V$1-#'$$4[WB52S;L9^\Y'
M7'RTJ2O&3EVNOOM^C'4TY>7RO\TW_D;'CK7;C1=$ACL+A(-1O[A+6VD< A&8
M\L0>#@9/-1K*2@OZ2*5HQ<GT_/H8E_XKU0?"RZU*&[6+6;.1;:>5$5@)!(%9
M@"",$'(X[UHTI2I\NBDU_P %?)B@K.:EKRI_E=%J6\\1:9K<>@2:N+QM1LII
M+2Z:W19894 ^\ -K+R.U0[N,TMXI/UUV%%I<DGLW9_=<AT[Q9J&MQ^&H+6;R
M;J6*6?4<(I($0V,N".,R$=/2JJ6O*4?A4;KY[?=K]P13249;\UONW_"WWF5:
M^*O$$_A[0;^^U">ST^>W=[K4K>S68B0.0 R[2$7:.NW\13DDIV>FD;>=UJ"N
MT[:ZM?)/0O\ BOQAJ%OK.G:?H5_ YAM#J%T2%(N(@1A%)Z%ADC'M23M4DY?#
M'?Y_Y+4+7IQ2>LMG\OU>A/XQ\1WL.I>&TTO4KJVL]1261VL[1;F1P$5EPI5C
MW["DTXSE%]%^-QQ:E24UU:_)D.B^*-:O+WPA'<W<1%_]J%TL:+\_ECY=W7:P
M[@$<Y%6DG)_X4_G=;$RT@VOYK?+4-?US5D\?RZ3!J>I6UFMG'*J6&GI<G>S,
M"6)1B!P*BE[S=^C2\MAU'RI>C_,Z[Q)J[:!X9U#5!'YSVL)=5/&X]L^V:F;:
MVZM+[V53C=V9S=QJ'B+P\FCZC?ZM'J$%]<Q6]Q;?9U01F3@&,CG@_P![.1Z5
MJDE4]GZZ^FIFFY4W4737Y'.GQWKUKH_B(7=V!/OG?3)Q$G CEV-&1C!(&#SG
M@GTJ*?O0IWW]V_FF[?\  ^XT:2J2735>C2O_ %Z,]9B):)&/4J":;T9G!WBF
MQ](HX/XR?\DQU/\ WX?_ $8M ([+3?\ D%6?_7%/_010!P/Q/_Y&/P)_V&(_
M_0TH ](H * ,[6=$L]=M8X;KS%:&02PRQ/LDB<=&4]C2MK=;COHT]C-B\&6*
MP:@+B[O;RYO[<VTMW<2!I1&0?E7 "KUSP.O7-$DG%Q[CC)QFI=MC:TZRCTS3
M;6PA9FBMHEB0N<L0HP,X[\5<Y.<G)]3.,5%616N-$MKG7[+67>47-G%)%&H(
MV$/C.1C.>/6IC[K;756_4J7O)+L[_A8I_P#")V'V+7+7S;CR]9=WN#N7*EE"
MG;QQP.^:EQ3@H=%_G<I2:GS]=/P*<G@:W&H17MIK.J6,T=K':$V[Q@.B=,[D
M//-:<SYI2[NYFHI1C'LK'1W5I!>V4MG=1B:"5#'(C]&4C!!J))25F7%N.QBV
M/A"ULH9+1M0U"ZTYXC"+*YE#Q*A&,#Y=W3U8TY>\FI:B7NM..EB.S\%6-K=6
MDLM]?WD5DP:UM[F</' 0, @8!) Z;B<52D[\W7N)I6Y5MV(9_A]HURENDSW+
M"#4'U!?G7EV;<5/'W,XXZ\#FIA[CBU]E6'+WE)/[7^5OR+!\%Z:9TE\ZYW+J
M1U,#<N/-(QC[OW?;K[T0]SEMT37WA+WKWZV_"UOR)KSPCHVI:W)JNI6D=_*T
M*PI%=1I)'$H)/RJ1P23R:225_,;;=O(K67@?2]/^R+;2W*0VEZ][!"&79&S
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M'&.E-Z./-II=^O3Y6!?:4=;-6_7[F=YH]];W6A6]Y'J*WT)CW?:L!0X'4D#
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MO\]2?3=8\2W.OKX7GEVW-C+YUWJ C3$UO_RS 7& S=#QQM.*(6DN9]-&O/\
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M2-K6 +@3JF[A.N,_G2IV?LK_ &K7_$<M/:)?9O\ D:$GC#6+'Q7X@MKN<'3
MQM[-MBCR)Q") "<<ALGKGD8[UDV_8R?VO>M\G_3^\T27M(]O=O\ /K]^GS0^
MU\3:SJT.FV<>H_8MFD1ZA?7BVPEE8L,81,8[$GY3Z 5M4BE.?11:7WF<7I%=
M7?[D=;X7U*'5-%6:'4Y-2"2-&T\EOY#%@>04P,$?04GLGW$MVC9J2@H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@#@_C)_R3'4_]^'_T8M ([+3?^059_P#7%/\
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MV)]+\+0:0MLMMJ%]MBFDGD#2C%P[]3( O//(QCFDG:RZ)6%W[MW-VD,* "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H X/XR?\DQU/_?A_]&+0".RTW_D%6?\ UQ3_
M -!% ' _$_\ Y&/P)_V&(_\ T-* /2* "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@#@_C)_R3'4_]^'_T8M ([+3?^059_P#7%/\ T$4 <#\3_P#D8_ G_88C
M_P#0TH ](H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MRZ3_ .!L?_Q5 !_PF?A7_H9=)_\  V/_ .*H /\ A,_"O_0RZ3_X&Q__ !5
M!_PF?A7_ *&72?\ P-C_ /BJ #_A,_"O_0RZ3_X&Q_\ Q5 !_P )GX5_Z&72
M?_ V/_XJ@ _X3/PK_P!#+I/_ (&Q_P#Q5 !_PF?A7_H9=)_\#8__ (J@ _X3
M/PK_ -#+I/\ X&Q__%4 '_"9^%?^AETG_P #8_\ XJ@ _P"$S\*_]#+I/_@;
M'_\ %4 '_"9^%?\ H9=)_P# V/\ ^*H /^$S\*_]#+I/_@;'_P#%4 '_  F?
MA7_H9=)_\#8__BJ #_A,_"O_ $,ND_\ @;'_ /%4 '_"9^%?^AETG_P-C_\
MBJ #_A,_"O\ T,ND_P#@;'_\50 ?\)GX5_Z&72?_  -C_P#BJ #_ (3/PK_T
M,ND_^!L?_P 50 ?\)GX5_P"AETG_ ,#8_P#XJ@ _X3/PK_T,ND_^!L?_ ,50
M ?\ "9^%?^AETG_P-C_^*H /^$S\*_\ 0RZ3_P"!L?\ \50 ?\)GX5_Z&72?
M_ V/_P"*H /^$S\*_P#0RZ3_ .!L?_Q5 !_PF?A7_H9=)_\  V/_ .*H /\
MA,_"O_0RZ3_X&Q__ !5 !_PF?A7_ *&72?\ P-C_ /BJ #_A,_"O_0RZ3_X&
MQ_\ Q5 !_P )GX5_Z&72?_ V/_XJ@ _X3/PK_P!#+I/_ (&Q_P#Q5 !_PF?A
M7_H9=)_\#8__ (J@ _X3/PK_ -#+I/\ X&Q__%4 '_"9^%?^AETG_P #8_\
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M+I/_ (&Q_P#Q5 !_PF?A7_H9=)_\#8__ (J@ _X3/PK_ -#+I/\ X&Q__%4
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M -@Z\_\ 1EM0!N4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % &'X3_Y ]Q_V$;[_ -*Y: -R@ H * "@ H * .#^,G_),=3_
M -^'_P!&+0".RTW_ )!5G_UQ3_T$4 <#\3_^1C\"?]AB/_T-* /2* "@ H *
M "@ H * ,.Z_Y'K2?^P=>?\ HRVH W* "@ H * "@ H * "@ H * "@ H *
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M$ER_V>/_ $&=IT0Q8"^C-PV6&,YK513GRIZ723[W3O\ H2W:+;6MI:=K;/\
MK<NQ>(_$-K=2K+K#W"+-?VRAX(A_J4W(_P JCYL]>V.U8N7[IRZ\M_FI6-$E
M[11Z<T5]\;D-OXE\20R12RZR\ZJ=.=HS;Q /]H.'7(7( QD8Y]2:W<4IN/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@##\)_\@>X_P"PC??^E<M
M&Y0 4 % !0 4 % '!_&3_DF.I_[\/_HQ: 1V6F_\@JS_ .N*?^@B@#@?B?\
M\C'X$_[#$?\ Z&E 'I% !0 4 % !0 4 % &'=?\ (]:3_P!@Z\_]&6U &Y0
M4 % !0 4 % !0 4 5=0T^WU.V^SW!F";@V89WA8'_>0@_K2:3&G873]/M=*L
M8K*RA$-O$,*@)/N>3R3GG)JFV]R4K%FD,* "@ H * "@ H * ,J[\.V5[=/<
M2SZBKOU$6I7$2CZ*K@#\!22L.Y!_PB>G?\_.K?\ @XN__CE,0?\ ")Z=_P _
M.K?^#B[_ /CE !_PB>G?\_.K?^#B[_\ CE !_P (GIW_ #\ZM_X.+O\ ^.4
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M.K?^#B[_ /CE !_PB>G?\_.K?^#B[_\ CE !_P (GIW_ #\ZM_X.+O\ ^.4
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M.K?^#B[_ /CE !_PB>G?\_.K?^#B[_\ CE !_P (GIW_ #\ZM_X.+O\ ^.4
M'_")Z=_S\ZM_X.+O_P".4 '_  B>G?\ /SJW_@XN_P#XY0 ?\(GIW_/SJW_@
MXN__ (Y0 ?\ ")Z=_P _.K?^#B[_ /CE !_PB>G?\_.K?^#B[_\ CE !_P (
MGIW_ #\ZM_X.+O\ ^.4 '_")Z=_S\ZM_X.+O_P".4 '_  B>G?\ /SJW_@XN
M_P#XY0 ?\(GIW_/SJW_@XN__ (Y0 ?\ ")Z=_P _.K?^#B[_ /CE !_PB>G?
M\_.K?^#B[_\ CE !_P (GIW_ #\ZM_X.+O\ ^.4 '_")Z=_S\ZM_X.+O_P".
M4 '_  B>G?\ /SJW_@XN_P#XY0 ?\(GIW_/SJW_@XN__ (Y0 ?\ ")Z=_P _
M.K?^#B[_ /CE &I9646GVPMX7G9 2<SSO,W_ 'TY)_6G>XK6+%(9A^$_^0/<
M?]A&^_\ 2N6@#<H * "@ H * "@#@_C)_P DQU/_ 'X?_1BT CLM-_Y!5G_U
MQ3_T$4 <#\3_ /D8_ G_ &&(_P#T-* /2* "@ H * "@ H * ,.Z_P"1ZTG_
M +!UY_Z,MJ -R@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H P_"?_('N/^PC??\ I7+0!N4 % !0 4 % !0!P?QD_P"28ZG_
M +\/_HQ: 1V6F_\ (*L_^N*?^@B@#@?B?_R,?@3_ +#$?_H:4 >D4 % !0 4
M % !0 4 8=U_R/6D_P#8.O/_ $9;4 ;E !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!A^$_^0/<?]A&^_P#2N6@#<H * "@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH P_"?\ R![C_L(WW_I7+0!N4 % !0 4 % !0!P?QD_Y)CJ?^_#_ .C%H!'9
M:;_R"K/_ *XI_P"@B@#@?B?_ ,C'X$_[#$?_ *&E 'I% !0 4 % !0 4 % &
M'=?\CUI/_8.O/_1EM0!N4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M6H_]#9JW_?JT_P#C- !_86H_]#9JW_?JT_\ C- !_86H_P#0V:M_WZM/_C-
M!_86H_\ 0V:M_P!^K3_XS0 ?V%J/_0V:M_WZM/\ XS0 ?V%J/_0V:M_WZM/_
M (S0 ?V%J/\ T-FK?]^K3_XS0 ?V%J/_ $-FK?\ ?JT_^,T ']A:C_T-FK?]
M^K3_ .,T ']A:C_T-FK?]^K3_P",T ']A:C_ -#9JW_?JT_^,T ']A:C_P!#
M9JW_ 'ZM/_C- !_86H_]#9JW_?JT_P#C- !_86H_]#9JW_?JT_\ C- !_86H
M_P#0V:M_WZM/_C- !_86H_\ 0V:M_P!^K3_XS0 ?V%J/_0V:M_WZM/\ XS0
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M_P!^K3_XS0 ?V%J/_0V:M_WZM/\ XS0 ?V%J/_0V:M_WZM/_ (S0 ?V%J/\
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MM4A#1)^]A9VR^[)R&']T<8J%K][7W*XY.WW+\78R)O&%XICBB^S&X: L59,
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M_P!#2@#TB@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H X/XR?\DQU/_?A_P#1
MBT CLM-_Y!5G_P!<4_\ 010!P/Q/_P"1C\"?]AB/_P!#2@#TB@ H * "@ H
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MM@2O08QGJ<&G!<R5^JO_ ,#_ ((JGNMI='8[VD 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <'\9/^28ZG_OP_\
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M\XS1'W59 _>U9JT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % '!_&3_DF.I_[\/_ *,6@$=EIO\ R"K/_KBG_H(H
M XSXIZ-J5]I.FZMI$!N+W1KM;M81R74<G [G(!Q]<4 5;?XV^$GA!NFN[2<<
M/#) 25/<9% 6)?\ A=7@K_G]N/\ P&:@+!_PNKP5_P _MQ_X#-0%@_X75X*_
MY_;C_P !FH"P?\+J\%?\_MQ_X#-0%@_X75X*_P"?VX_\!FH"P?\ "ZO!7_/[
M<?\ @,U 6#_A=7@K_G]N/_ 9J L'_"ZO!7_/[<?^ S4!8/\ A=7@K_G]N/\
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M@_X75X*_Y_;C_P !FH"P?\+J\%?\_MQ_X#-0%@_X75X*_P"?VX_\!FH"P?\
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MP?\ "ZO!7_/[<?\ @,U 6#_A=7@K_G]N/_ 9J L'_"ZO!7_/[<?^ S4!8/\
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..5%0;44*/0#% "T ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g707175g55b88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g707175g55b88.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M^ TKM6ZV_%1_5B)XRL)&9([>X>4$ 1CR]Q.]4(QNXPS@'.!UQFKY6W9?UO\
MY"6U_*_X7-'3M:M]3FDAACE62)<R*X'R'>R[3@GG*-2M=7]/RO\ AU!Z.S_K
M_A^AHT@"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * *6J+IYME;49DAB1PRR-,8MK=L,""#U'7H32ZC5S(CM]!N7N
MK>)'E2QCRV+HE1N!.1\_#8.=YP>>O6GT<OE]UONV0DKM+OK]]U\]V37E_H4&
MDW$,UZLJ6_[QXQ>;I5(8,/F+9!SC'/I1?5-=[?I_7S!/2_E^%ATL?A]U*3SP
M1/"K3,INMKQ!F$C,2&XYVG.>.W%/;Y67Z+_(-UZA<W?AN:!;.ZU.T=8@?EDO
M,L-R$')+9/RN>OK0KWTW_K]4"=AE^?#A,SW-Q"6\T)*%N""&?$>& /&=H'/]
MW/:DE=JW]=0Z?U_77\25%T5U^S2SKYDT;Q>7-=EY&0D[ADL3CY3WXP>G-%[:
M^C_5?G_2!*S3]?T7Z+_AQT<.AWIDU*WNHW"DO)/!=D ?*N<E6QC"KP>.,T]5
M_7G_ )L-]!;@Z'9VKV-S>0PQ22$E)+K:=W#G!+9'4' Z9%+>R73;Y?U8-KOO
M^I+!8Z7I]TTR%8Y<'[\Q(4.W. 3A=S#MC)H3MI_7E_P \_Z]?^#_ )E":3PS
M''.6NX&4NT,@6Y+;6E<!A][Y<L/;&#TYHCK9+RM\M4-];_UT)+&TTEA=Q0V\
MQVX>0M,TI;YV88(8DG(/\O:E]B_];7_46\K?UKI^A7A71S9V\_V*\(OV: F1
MG9QNPIWDL<?<4=<\<=ZI-W27K]WO?U_D)NZ;?I^-OZ_S+%S%IDM^($M);F6?
M<[O!, $*.F<G>""&"].>*4=-NEO_ &[_ ((WH[]?^ OTL0JMEKFMP7%Q;OLB
MM91"LL:XE1B%9@0QXP ,$#[WY):1E+R7W;K\OD-OE:BNC?WK3]?F9TMQX?.D
M//<V%^D1\K<6G8R%)1M!+"0G9C.03Q@G%7R^\EU;:^>^OX"OR7MTU_%K3\3?
MM;C3_P"T+O1(87S'&)9<C*'>3QDGKW(]"*BW/%WVV^_4%[C5NOZ614AT_2(;
MG[,EA+'#IZ(IE,V(@%&]=P+Y;&<Y8'GO5<U[R?\ 6G^7];!RVM%=?U;_ *_X
M<57\-6*I=K=VX\M2\;?:MW"[P=H+<@;W&/?V%2](V\OZ_(:O)^K*HL]'34K6
M[CU2U@M[2,3B$3$':(]H9LOMP 1\Q7/3FKNU)M_U<5^9*W7_ #O_ %\_EH^7
MH5[>SQ+/;RW-Q&PD1)\LRNJYX!XRJKS_ (TE=:+I^C_S8[VL_P"NO_!*BQ:?
M_:$X?3[Q)(94W32W0P2WRJ 3)G&&/R^_3/%2DG&WJOP5_P D+:7X_G_P1Z)X
M8OKFW$5[:S2*%6...\R&V@[<J&PV 3U!IOWFV_/\5K^ 6Y4H[6_1Z?B$D/AV
M/3&NS<B6SME9#(+QW"@[<KG<?1>/I3N[I][?GI^(FM''[_N_R$L_^$<>:>2.
M6)9+9V++)<Y\H*V20"V%7.#Q@'CVI1T2:_K=6_.PY*[L_P"MG_PY;CBT6R1-
M46YC2'G9*]T3$-QYQEMHR?2CX=/+\ ^+[_Q_IE.Q_P"$<:2*^BG1)9%$Z++=
MDE5))R%+$ 98]..:$K:+R_*R7XV"36M_/\[M_A?Y"W</A[3Y[.:=UB"S"-&^
MTE8U=%8C<-V"0,CD$]*(V3T[/_)_UZA)7W_KK^>I+JUQH,4<]Q>7$0E2,7&$
MN-DFU0<%<,"."1D8SG%+;3S_ #LO\AQUMY_\/_P22RN-#LH'2*XMK?\ ="26
M-YU)50HY;D]B,GWSGFG);I[?TA1Z-?UN_P#,CAT_0;C%G#.LS(F5C%XSM&OR
MD%?FRHX4@C&.,4]=^W]?H&VG?_@_YLK1W?AR:[CC%WEY5DA#/=MB3:^TH<M\
MYRQQG/!XI)<R:\E^/_#:OT!OD:_KL_Z^9=BL-%N$E@AE#M!('D,=TWF1L%V<
ML&W#Y1CKV-#=US/;7_-@E;W1D5IX=N+)HX9+9[88)$<_RC*>4.AX^7C_ .O3
MNT[_ -;W_- G;^NVI-I_]D/8W%Y:RJ;.0OYA:8F,8)W<$[5YR3C%2TN5)[-?
M@$?BTW1AWEQX5TLHPG>1I$:021:@V["#;@,9 >^, XR/;-4KW_KK;_+\ LDN
M;^M+O]?Q-#58O#T%BSZBD86Y ?RGF^:0A]P ^;GYCV]<=*$K326]U^?_  6)
MOW')[6?Y?Y)$DC^'X)'8W<?S7*AHUNB564OD?)NPIW+GH.A]Z(]$OE]S_1_E
MY#EI=O\ KH3Z-;V4-QJ4MM=07$]Q<&2<PD?(V H4@$XX7\\TEI!);?YZ@_B;
M?D:U !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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ML>_I@>W-*WN./>WX;?F#UDGZ_C_PQ#%X;@ATN'3E\A;=!&9-D&TRLO!+8/<
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MD#E(=JY;RP,#<>@C'<Y)/3I5)VLET:?W-O\ 43U37?\ RL3:OHTVHR,T-W'
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M=V"1@'&/>G%.32V;U02]V[[;^1*WC2VDOI[;3])U/4DMY/*EN+2%6B1^XRS
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M.WMWJ7AS3KZ^2..ZN($ED6,$*I89P 23W]:VJ14).*Z&4)<RN:=9EA0 4 %
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M8FG+WKWZDQ7+:W0K'0=/,"PM',Z*,+ON)&*].A+9'W01CH1FG?6X]E;^NO\
MF/.C61?<5F+;#&Q-Q(=Z\\-\WS?>.,YQGBD]4T"=K-##H6GF/9Y<H^;=N$\@
M?.T+]X-G[H Z]J'KO_74%HK(<^AZ:\#0FU B)SM5B!_J_+['CY./_KT^9WO_
M %O?\P6FB)[6PM[)Y6@5T\QBS*9&*@DY.%)P.3V I;*P%F@ H * "@ H * "
M@ H * "@ H * (+V*>>QGBM;@6\[H5CE*;]A(X.,C./K4R7,K(J+2=V<?9?#
M/3=,FT>YL;J>.[L)_.EEDD>07&5(?Y2VU2Q.<@5HFHRO%:6:M_78AIRBTWK=
M._S-C2/#;Z3I.J6B7N^XOYYKAI_*QM:3IQGG''?G':LY1YJ2I]E8M2M5=1]U
M^'0J6O@J.VMO#5J;S?;Z*K93RL>>Q0KNZ_+U)QSUK2;4I2EW5O3;]%8B*Y8<
MJ[W_ #97\)>![CPBIBM=9\V"2Y:696MAETV!4C!W'&W'7O[4*7NJ+Z+\>_\
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MMLSC'EBH]B2D4% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M;^[I_P .>CUF4% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M/N(V;AAN,X/'K0M&VNN@/56^92B\*:'#J<^HIIZ?:9MQ<L[,N6&&(0G:">Y
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M4=*E6ZFO'OK:8PW*W:QAXW !*_NP%(Y!!'K5RM92CL_\R5=-J6_];'0U!04
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M24ZB[Z>NWX:MG2^(O#>E0:SX'TJWM@&M[C]V<GB*)2YXZ<MMR:J,FZ[GY/\
MR7YDN/+0Y?-+[]7^1D:*G]I>(+"W52VKIK5Q?:@V/F@C3<B*Q[ @J .XJ:.T
M9+91=_5_K_D56WDN[5O16?\ 7J>NT@"@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * ,CQ"=&^Q1#6[*"ZMBY(6>)752$9
MLX;@<*1^-2[+7M_P"HIO1%5-)\*S0Q7LND:5&9;?(,L$.[R@H!&1D;0I ZXQ
M6DDTVG\_Z]2(OF2M\B1--\*3VATQ++2)+:*3)MEBB*(Y./NXP"2,5.]G_7<?
MPW\_Z_R+DEMHK1OYL%B4N%$;;E3$@3) /J%P>.V#1>VOS_+7\M?0$NB]/^!^
M>A5NXO"\]JRWJ:5);W#B8B81E9&(X?G@D@<'T%%K-+M_7Z_B">ET27L.AQ6<
M[S6=G+'Y)A>,1HQ>-3]S'< GIT&:-W;NU]][7"_*K]K_ )7_ !1#Y'AK4+B?
M2A9:?=<>=-$(HW4,N%^8?WN,<CM[4F[IR[?K=_\ #A\+2[_I;_/0@8^&]6AL
M1>Z59O"D>8/M,,3+"NU#@==G#*,<=/3&;::GKO\ \&P6Y8VZ?\/_ )%QK'PY
M>WKW;6FF7%W:#:TICC9X0,\$]5QS^M0VDG+HPMJHE?2X/"=N+.;3;72K9[@>
M9;^5%'&[9&,@ 9SCC]*IIIN/]?UI^ M-_P"M/^'_ !)+NS\+)9MIUY;:2+:W
M82FVE2/9&6/#;3P"<GGOFIT?RT_X!5W=^?XC7D\,V-U;6RPZ<DK.)%5%C!CV
M1DJY] $& >P([5:NY/NK_C9/YNY.EO6WYZ?CJ:"SZ5IQ,22VEJ9)3E RIND/
M)X[L<@^O-2NB0W_,_P"OZL4A;^&4AU'4([;365E9;R6..,EQC)#D=>.QI:1C
MY%*[GYDD.HZ)JJS:9NM94C"@V[E"&7:K@A>ZX([=JIW^)]/PLR%:R2V?]6'3
M0Z!J:QZI/'IUVMMDI=.J.(L<G#G[OYTOA=]A[KE%:ZT%Y9F:?3S)<Q?O263,
ML8!^]ZJ!NZ\=:36C73_AO^!^ TW=-?(IV[^$[,1VMNNE01PXN(PBQJB$DKN&
M. <Y&1SS3WWZ?J+]?T'RZ?X8L;FVNY-.TN!HH]T-TT<2>6 1C:QY'+\8XY]Q
MEKW6^C_I?D@MS+O_ %>_ZEF2;0=DWF2Z?MOD+2;F3%PH&"3_ 'A@8YSP*5K^
M[_6HTVGS+T&75OX</FVEW#IG[_ DBE6/]YL4$9!Z[5(^@(I.SW]?\V"35K>G
M^2&PGPR$"PG2PB6Q4!/+PL!Y(XZ)^E.6M[_/]+BCI;E^0R+4=#@M'U.".W6"
MU(M//C" *FY1@,#@("1],&G=[O[7_!7_  WJ)):I?9_RN6 -!NYOM(&GS2EX
MW\SY&)8$JASZYW ?B!22MM_6FOX?@#:>_P#6O^?XC$MO#EJ+JQ2#3(0T?^D0
M!8UR@'\:^@![^M"U5D5JG?K_ ,/_ ,'\22:'0WG>UFCL&FN$^SM$ZH6D11G8
M0>H ;..V[WH^+\_^"):)-%7[#X4L5EM!:Z1;B.-DDB\N)-J.1D$=@3MSZ\47
MT_KY!:S_ !'1S>%K&Y,T4FDV]Q.@)=3&C2(W?/4@X_'%#V:?S_KY_B&UG_7;
M]/P(%T[P9+=(J6>B/<"+"@1Q%A&5Z#C.W;GVQ0]+W^?_  1W>GX?UZERQNO#
MVG6T-MI]QIMK!(Q\J*!XT5CD [0."<D=/6F[O1DZ+4O?;K9H7DBGCE"Q^;A)
M%Y7G!ZXP<'GIQ2>BN4DV["0:C97,[00W<$DZ#YXDD5F7Z@'CJ*=NQ-R$ZWI(
MG,!U2S$P?RRGGKN#9QMQGKGM26NPWIN,N=<L+:&:19XY_)W>8L4B%E*JS$$9
MZ_*>.OX D"5[6_K;_,=M;$HU:Q$RPR7<$4S,52-Y5W-@XX&?6A:[?U_5A;?U
M_7<DM]1L;N26.VO8)I(O]8L<JL4Y(Y /'0_E1TYN@;.Q%'K6E2QK)%J=H\;.
M(PRSJ06/1<YZ\'B@!4U?3)(S(FHVK(,Y83*0,#)[^G- /3?^OZL6(KJWG($4
M\<A(W *X/&<9_/B@"6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@"*2UMYIX9I8(WE@),3L@+(2,'![9'I0M-4'2Q+0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M (/](;MSI+:_X:CKFZ\1P;8HY9W!!;SGM_XMB$*0D;?+DOV!XQNJU;GMTO\
M?K_7;\"%\";WLOEO?].Y)=?VVT,F^YO-CO*V(X%S&$G4*%PN3E,GG).*E65O
M^W?^"4]GZ/\ +_/\S0T;4I6NI;2\EN'E=BT#2P&,.HY. 44C&0#G/;G)Q36L
M?/\ X;^OO[$O1^7_  _^1F"_UBXFNDMKJ\8_:)8S_HJ[(E$H52C;,,<9ZD]_
M2ICJE?R_/_+]"IZ-V_KW;_G8?=7FNQF=;=[M[D-(JH;4>6,,!$0VWG=QNYX#
M,?EQP:M:?T[[>EK_ '+OJ.R?]=OSO_74DT6_UB?6([*[>0HL N96DB5",C9Y
M> /[ZNV?3')%6K:VV7XWU3];:-$NZMY_I>_YJWS([_4=5ALKAHSJ!N_-<;$M
MODC4;MNTB)MV0!Z\GJ*SN[*W;\>WW^FBW[VDN;7^EW^[\7MV@U2;6WL[SS9K
M](I8Y B068<AO+3:N-A."2_)[@#(JY);>O\ Z4_TM]]Q47JG+3;\KO\ '_*Q
MLZ#->M)=0W9G=8R/+=XC&N"3\H!4'(Q@G+ \'/.*;U5_Z_K^M3.*LDO+^OZ_
M!&W4EA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M9>H&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 4=572C:9U=;0VP/_+T%V9P?[W&<9J6TM1J_0HG4-"GTT2-%;.K
MP"X-L50OL91R5^A K1Q?-R^=OO?^>I.B5_ZT3_30D5?#[Z:;9X=/2T21@8'$
M>Q6P2>!P#C)]<9J7JDV4KW=OZUM^:'K<:!LAA6;3MLO^J0,F&_@^4=_[O'TI
MZM^?]/\ X/XDV27E_2_+0GELM*O8_/EMK2=%8MO9%8!@>3GURO/T]JG2.O\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_6UOZ_,3VLOZO;_(T-3T@ZA*)5G$3J@"Y3< P=7!(SR,J./U%)>Z[KR_"_\
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M2.@YZ =JINXGNWWU^;;-&D 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 U(TCW;$5=QW' QD^M #J &+#$DSS+$@E< ,X498#ID]Z-@'T
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M 4!L0C1=*602#3+02 %0P@7(!ZC.*%IL)I/3^OZU8Y-,MDU%+U5Q)'&T2*
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MJGD =D'Y=^21+W$_ZV3_ %&]'_7D;-(04 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MA6-@.N1T('Z4OA5Q[NW49G2[N]BU'[;#-Y49B3$BE%WD9_$[<=>QHM:]^O\
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M\37G_E</A3Z6_P"&(]/TW0OMLES8Q6;S0D1_NE0^1@$;1@?+U/'UH6BNNO\
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MA_%V [_@7TL#UDW_ %J:]( H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@#$\37NH:?903Z?\ ,[2B$IM!R7!5#^#E
M2?;-"5Y*/?\ #K?[DQZ*+EVU]?(SA>ZW%*,M=RE'_?J;0;442J!L(7YLIN)P
M6_ \4XM:-_T[/3TO^FHK65NNOW6W]=OO>G:_I%QJ-Y>^=</<1VP60K') $W?
MO7"YRN1A0O''7)I+1:]E^6H2W5O/]/\ @F797NLWJQB*\O2KR 2R-:*HC_?8
MPA*88%<Y/., \9HAJHM]E_Z2V_QL*=TW;N__ $I+\KB7-_XB6%_L?VJ2[VG,
M<EH!&DF\84-@94KNR<GHO/."E\*OY?D[_=T\]-2K:OY_I;[^OSVL7]#O=3N=
M5N+:XDE:WMHPP>6)4:7S &7( &TKA@1QU%4_A;6][?U\FOQ(N[I>5_T_--_<
M4;K4]9ATV%X?[0DO3DRK]EPD;#^ 8B.X9/!ST&=WJ1MS)=-/T^[3^GTJ>BDU
MYV_&W]?D,U)M8DMKB*>>_*RO)Y<<5H&!Q,0%.$)"[ #DD9R3FE'XHW_N_P#!
M^X*GPRMV?Y:?>[FQJ2W[:Q$EJ\L$;B-7FCA5B!ER1DJ?0?3/O25[_P!=F-_"
MOZZQ_2_](BGAU"]LM#+RSPW*S;II$B7<O[IQD@@@9) Z=Z;>[7;_ "T!65UY
M_K_D9AU/Q#,=BQW<,AM,DFWR%DV*<@&/'4G@L>_ Q563DUTO^',E^5WU[W)E
M[JTUW^>C_6W;T':L^K&*ZLY9K]XP2L31V@<S?,O#D)@#!QD;>_I4PUE%ONO_
M $I_HDPGI&279_\ I*_5LG\3W_B"PNE.E02W$.V.8K'!O^5'_>(#C[S*RX_W
M3BB/Q:[7_/3\'JRFO=NM[/[UJOOV^X8R:]9O=W<+S2W#L/W!B7RV/DD]<9X;
M:N<]O>E\*M_6RU&K.2;\O_2GI\DQB7'B&2W9UN;C]W#-(@%M\TC 1[%;=$O<
MOPH&?7(K1)7^[\W?\/\ ,E:JS_K3_ANY<UV^UFWU2*UTT;S<0-(@VJ0AC!+#
MGKN+(OMSTK-;M/IK^GX;^8TE:+?>WZ_DG^ Q-2U* >83?W%J&QO>S(E)\LG&
MP(#C=CG'4XHE=)VWUM^%OU%'62OY7_&_Z%R6YOE_LSS7NHD>#=*8+?>S2?+\
MK?*=H^]V'U%7.RG*W3;\?^ 3"[A&_P _Z^\P7DU;4[5_M%M=ML=M@DA(8 Q=
M/]6F>?8\\9-*"M)-_P!>]#_@]M%L%35-+^M)_P# [FSKM_J=OJ=K#8Q7!0[=
MY2/<ARV#T0XP 3DLO;K4.^MNS_)_K;OZ=[TT]?U7Z%3S]:@MHH[BZOF1E1I)
MX[16D4F-B5"A,8W =B1FJJI>\EYV\]K?F^VQ$&W9OROY;W_0;/;WJ^&]%C N
MT9;0QRQ)%G+&$@!A@D<\=J=;6<[=G^:+IOX6_P"9?J)=3:_96ZV\,UPZJV!.
M8,M_J@0,)&W&[/\ #VQFAN\_O_-?\'L3!6BO1?+>_P"G?<TM)?5OMJF]EE>.
M7SR5:(*L>V0! "%!Y4GKG.,T[*WW?K<?9_UM_F94:ZKIL,RP->!WDGDCVVJM
MYTGFG:'(7A2-O/'!// PH[Q3_N_\'Y_UJ.?5_P!;*WZ_\ ;;C4;.:0[;RVA?
M.^2"V\Q\@R%0 5;CGKCT]:A74$EV_'E@O\_\R;>\W_5N:7_ ^3(QJ'BX,(W@
ME#+B)F6!2"THRKCCI$>#]><UHK<UNE[?<[W^:V\P;LKKU_"UOOU?9&GXAM[R
M:]1(9KL(\(4>5$&56$B'<?E(!QD\\<5,=WZQ_-W&]%\I?EH12W6O1WEO KRF
M,2,/,:$_O )0!NVQD ;>_P O7.>*(:O7^M[_ *!)63M_6B?YWZ?B6=074VUA
MDM))K>(@%I8H%);"/QEE/?;_ )-3=J,GVO\ ^VV_7^D'VDO3_P!N_P"!_3*"
MW.K7"_Z1)?#9-!(3';%0 6^9-ICR<=R"WKQTK2R4].[_ "=OZ_'M%VX>=E^E
M_P!?Q5BPM]K%K;PB8W<TLZ1D$6N=C&3# [5^4!2/O>]0KZ+T_P"":2TNU_>_
M^U*\SZE-:6TTDVH/.!()H#:#8',;87&SYESQG)'3GFA];=G^@].=?XE]VO\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MAU(84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@#!\46=Q=Q:<UHC-/;W/GI
MMS@,L;D GL"<#\:$^67-V7^5_P +E)7BX]_\_P!-S&CDU. :AJ:VM[%/J'E2
M ",EHE&_ (V/@A0N0%/S-VSFDTX0Y5O=O\%^NG38E>]+F?9+\?Z?S+-T=>N=
M.\]5D:X#VS1P/$%4'"LYZ9SDGJ<#':JE:-33:[^ZS_I>9*NX*_9??S=?U\CH
MM/O8;J,HCRM)$J^9YL91@2,\C &<=A0^Z&M-'_7]6.?GN=8-Q.L4<UQ)#,[0
MN]MA /+EV@90$8(49R0<CGYB*4?AN^W^7_!TM]]BU;FMTT_/^O\ )#+:ZU2\
MFFAM]1OS'%.5,DEHB.!Y 8 @H,#<>N/:E*Z3:[/\U;]25O%/K:__ )-?\D;E
MU=7<?AX7"Q2F[:),K&N&5CC/&UL8SS\IZ=#55+*5EM<5.[BG+>WZ&-976O3K
M%<227*JHA'E-;@"3,SJQ;*!LA IXVXZXYHM9+^OLW_/_ "'NOO\ ST)_#SWL
MVK3S7C7;.;6(/YUOY:))N?<J':-P''KVY.:%9)V\OR'/=6\_S5BO>W&H#6/,
M(OY# 9RL4=M^[5=F$*OL.2<],GDGCC%1&^OI_P"W+]->H2W7:Z_])?ZZ=/U&
M1W6MR6\-T1=M<1K<JD;0D*[<;-V8U..#@X7]>6_T_7\[=/P"-F[/:Z_+7\3:
MT"6^FL93>R.[;\1L\91]NT=043OGH/ZU4EIH3%]S#M-2UJX@+W,US%%%*]LT
MEM;+([/&""^T*<!FSV_A'3-2VVE)+=7M]VGYO]2FK2:[6^[5W^[E_'0L-J>N
M!%AD@N%NF.X[+8LBK]FSC=@C_6]LY[=*J=O>Y?/\]/P"%KQYO+\]?0TM3FN[
M'PM+*MS,;J.('SO+5GSQDA0,$^V*)VYDEM=?F1"_)=[V;^=C/6XUQRS6\MR\
M<<=PT7G6ZH9F 3RPX*C')?&-N0*.EW_6KU];6+C9NS[K[K:_B5[B^UQ(E^Q2
M7TT?FKNDEL@K^7M_>';M'(XV\<DD8..!?$K[7_#2WXW7IJ3KROO;\=?TU];*
MYIZ%>:C=:AJ,5XQ,5G)Y"G:!YC9+;N/]AHQ]<T+X$W_5M&_F[C>DK+U^_I\O
MQ*]S?:C'#>'=?&X$Y58X[?Y$3=PRL(F+97&<;N2>F.(=^56_K?\ K[NY6G-_
M7E_7^9#;76MR6"7-S+>1;A '5+8%D!0%V"["2=QP>#CG@8JY64FO-_EI^)/I
MV_\ ;G^G_#&CH[3VWA5)'CN'F5)'VM'LE<[F(^4C@GTQWI2TBEY+\EZ[?,(*
M\GZO\V8T-YXBGMI'$EW&88YV4?9P3*RB/8IW1J2,EQPJDX]JI):-^7_I3_2P
M1UNOZV_S+MF]]-XHB:Y-V1&MP"C6^V%!N79M?;R2HSU/?IC%*.S?E^H2V7JO
MR?ZDVK2ZO%->R6DDWEJL*HBQ @98^8P^5B2![''I4KS[_A96_'^D#WT[?C=_
MDBHDNKQ,+F26ZDD-LGRI 2IQ(=QP4!W;,<8&>PZ4]G_X#_P?ZW#=?^!?\#^M
MATEWK-S#=3V[W4*I!<F)#:@%F#8CR&7/3D#O[T16FOE^+=_PMZ#TYTNG_ C^
MMS9TO[6GVN&ZEDF\J4+')(@4NNQ3V !Y+#@=J;^'[_S9*,_0UNTU#-QYZ(UE
M%B,Q;8U8,^[&% !Z<9[_ )$?A_KLBI;_ #?YD5[_ &M]MO1:/-;H&D=6B@4^
M81#'M!)4Y^;/OQC/%3=I)^3_ #_R_P RK)M+S7Z_\ OZT+F32(GB>>.030N_
MD)N;;O7=Q@GIGMVJ]%-=M?R9G"[CKO8Q2=;T^VN#:FX=99+A]C0C]T/M P5P
MI))1F8 ALXX':DMDG_=_7_@+R+=FV_ZV_P S5%U?P^$KJZFD/VN.&5E?80>-
MVTD,J\X _A _"IGHM/(*24II/:YG)>ZH85)N=2^R[O\ CX^PCSL^6#C9LZ9S
MSMZ\9IRNF[>=OPM?\>W^<0=TGZ7_ !O;\.^[^44EQK4T3)<O>HZM;RMY%OA8
M_G3>@&PENYX9LC/3O:LI>5W^MOT_!W!7V\O\OZ_#H2_VEK$EY?*J7L5NK)M;
M[/N9%\PABO[L _+SCY^,&LX[*_\ 6C_6RV[Z]1RTV_K;_@M?ET*]EJ>NW,EH
M8I99("[ /+ 5\S$[*0^V,[2$"_W.3DYP<4NE^R_+_,':VG=_I_P2Y>:AJRZR
ML!:6*00Q.+>VC\Z)B9"#ND* K\H_V>_I2CO]W_!"6D;^OZ6_$B@OM7NKNZ5[
M:<Q)-"T2S0YVY=L@$QJ. %Y!;']ZDK\J:WU_])_S].PY)7M_6Z_X/YZ%GPXU
MW+J5Y/=-=NS6T 9KBW\H!QO+*ORC(&??KU-::*+2[O[K(F[NKG25 PH * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#
M,UC57TN. 16K7$T[E$0;L<*6YVJQ[>G>E?6WE?\ +_,9G3^)[F'S9/[+/DHV
MT9E(D+>3YI!3;Q@9'7J*II)ZO_AD[7_423DE;=K^E^01>*FN;J..VT^26)R#
MYB;F^0R%%<84C'REN2./6I:=GTT_2_\ E]X:6NOZM:_^7R&6?B:X_LZ&:6V6
M552))9/-"NTC1!^$ QCD=_7CBJJM0N_6WR_X9_@5RZV_K5V"3Q-.;>.*;2T>
MXG5"L,<K2H59&;DA"?X2,;2.1S1*-FUVO?Y6_P UV(A*Z3VO;\;_ .0:IKUO
MX8TM)K?1]J2P/.D$8$1,@VDH1C[VTD_\!-$FHRY6]OROJ_EOYW'"+DDUU_.V
MB_3R)5\4F:6W^RV#SPS8=70LV8RP4, JG_:/) P.O-%K2Y7_ %>]OR_$GFO'
MF7]62O\ G8FN]5N[/79(?)22R$=N&)?:R-)(R9 QSVSDCIQ1'7?N_P KEM62
M:\_T*3^,EA$KO9YB0X5T9L/E7*8W(N=Q3 (R.1@G-))NW=Z?/33\?P$[)M/9
M;^FJO^']6-#3-;EU#4);<V$D42;U$OS%=R,%()*@=<XP3D ]*:6EP=U9/^M+
ME1?$UT85;^SHM\I A47.0P\X1G<=OR_>!XSW%**YDOD_O3?Z!I=K_%^ Z?Q+
M+;H\SV*&W#RJ&$^6_=G#DKMX& Q')S@=,\"L[)]?RNE^J_'L-IK^NMKK_(AM
M->8@16%A$JR']Q&THCCV8D8-D)QD*#CGK]:4F^1OLONTCI^/YBTYK?U>[_R?
MX$-IXNG^PQ/)8R3[+=&FF7('F&(2<X7:%Y SGJ>E:2C[[2[V7WI?UZ!LKOU^
M6O\ D7XM3G^PZU-J5O$PLYB!"CAUP(T8#<0.YSR.,^U3;2-MV_QYK(.KOM;]
M-26#6;J74DL'LHEF#LLI6X+*H"JV1\N2?G'! I+7\?S!W23[V_&_^1'>>()[
M6XN(EL!)LN5MHB)&)=C'YA)"H2 !QQG\*72_K^!5OR_6PRPU:5+U8O[/CMK>
M?RBJ<HZ,ZLS;EVCG*XJMKKLVODDF0]V_)?G80>)+F2$RP:?&Z;("NZXQEI7V
MX^Z>!US^E$5?[_T3_4;TDX]K_@VOT+C:I(^D)=>48Y?M*P,BN",^=Y9Y*\C\
M,X]#2[6ZJ_X7'WN0C4]0_P"$8@O_ "8/M;E,KO.S!<#KCT/I1UCYV#^;RO\
MA<EM-9DN+Y86MD2&226*-Q+EBT9P<KC@9!QR>W3-"U^Z_P#7WK\12]W^O*YF
MC7;J&2:&63S)--\Z2ZP%!=1_J@>,#(8'/^R:(ZI/T7S;M^C^302]U_C\K7_5
M+SLR6;Q%=V]W(D]I$D=K'*]P(YBY.U%<;?E&>&Z''^)Z?T[V*46[+NU^-_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MY;OY?Y _=^5_P=K??;[T:,IT^PN;*P6Q %P0D?EPC8FP%ER>@QC@4U=M_?\
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M00O PHP !V  Z"@7G_7]:EB@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M<$9 "XSV0!<^V<=J2T27;^OS_#0;U;?]?U_F7Z "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,!
M]1U1+BY@\RT9A<I;PGR6 7<BMN;Y^< G@8SQR*%K9=[_ (7'+35=E^+L22:G
M?0:?J3.L,MQ8."Q1"%D3"N<+DD-M)'4\@'OBBZLF^]G_ )_K^ 6=[+>VGXV_
M%$:ZQ>WNIM:6+6Z1,7\N:1"X94"AN PS\SX]MIH2=K_UV7Y-_<+3=>7XIO\
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MC)+'<./O# .#]!,G:',BHI.IR]/T(8-2U.]=H;>6W62*!9G::UD0-N+ *%+
MC[IYYZBJG[J<NB_KY$0]Y1\_^!]^XMMKTUUIS7:1(H^T6\:J<G"R"(G//7]X
M?R%6XVDEZ_A?_(:V^0^YU2^C:]N(OLXM+.98VC9"7<84L0V[ ^]P,'I[\0M4
MO-V_&WY@VE>W17_"_P"1F-XMNH9%$L$)2.&59MH(/VA2^U5YZ'RGZ\\K0DY+
M3K:WKI=?BOQ&[)Z[7=_*/1_,U[&_OC=2V]\J><N-L,414E<@;PS-AAW('(SC
MGC+T>W];_G_7E&NE^W^5_P 38I%!0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MX2:& 6R/DY$8((7KST[T7>OGN-ZVO_5R)?#^FI&R+%* 2IS]HDRNTY4 [LJ
M>PP*2TM;I_E;\@>N_P#6M_S'_P!B6!G\XQ2%L@D&9RI(7;N*YP6QW(S2:35O
M7\=_3_A^X;:_UH2Q:9:16#6(1WMF784DD9^,8QEB3BJDW+5B24=$1PZ-8P,'
M6-W?<&WRS/(V0"!RQ)Q@GCIR:3UT_K4?]?J#Z-8O96]GY<B0VW^J$<SH4^4K
MPP(/0D=:'J[L:=K_ ->9$WAW2F!5K8F,LC&(ROY9*@!<IG;P%7MVIWUO_6O_
M  XNEA1X>TM)&>&U\AV;>3!(T1S@ _=(QD 9'? ]*7D!/_95F)EF\H^:KB0/
MO;=N"A>N<]  1W[T[ZW#I8232+&66>22W#M.K))DDA@P4,,=.0B_E4M7CR]/
M^'_S&I---#(M$TZ%(4CM]H@V>60[978,+@YSTX]QUS5.3<G+K_F2DDK?UW$N
M-!TNZDGDGLHY)9V#/(V=^0 !ANJXP.F*2TV&]='Z$D6E6D23H$D?[0NR0R2N
M[,N",98D@<GIZFCIRC3:?,@NM)L[PJ94D!5/+S',\9*^AVD9'L:'JVV):))=
M"-]"T^0R9CD42,K,J3NBY7;M( ( QM7IZ4[L%HK+T Z'8&82F.0ME6(,[E7*
M]"RYPQ&!R<]!Z"DM >JL-D\/:5+YV^S4^=<I=O\ ,W,JXVMU_P!D<=/S-"]V
MUNE[?/?\P>M[]5;Y$XTNU%TUS^^,Q/WC.YQ\P; YX!(&0.#C!XH6FW]?U<'J
M7* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@"JVIV"22QM?6Z
MO#_K%,J@ITZC/'4?G1TN'D,CUC2Y6C6/4K5VD)"!9E)8@X('//((_"@'IO\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MVBYS#-';A&XQSLB5O?@CI0 7FDWMS=/-#XAU&T1L8AACMRB\8XWQ,WOR3UH
M@_L+4?\ H;-6_P"_5I_\9H TK^TFO(%C@U&XL6#;C);K&6(P>/G5AC\,\=:
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M*6TFDTT6J:C<13!57[4BQ^82,9."I3)QS\N.3@#B@#-_L+4?^ALU;_OU:?\
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M%=HCN$@"@Y'/R1J<_CCGI0!!-HM_+/)(GB?4X49BPC2.V*H">@S"3@>Y)]Z
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MD;5SK6L:-\.KG6[XK+J)3SEC90$AWL-JG&,A01D]3@\T3CRRC33UNE?SZO\
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MV7]?B#UDWW-&D 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!E7/AO2;P:F)[3?_ &FJK=_O&'F!1@=#QQZ8H6B271W^
M>G^0[N]_*WRU_P QE[X7T;49II;JS\QYHXXG/F.,K&VY!P>S<_SIIV=UWO\
M,FRMR]+-?)[CK+PUI6GZI)J4%N_VR0,#))/))M#')"AB0H)[+BE'W5RH;]YW
M9-#HFG007\,5OMCOY&DN1O8[V888]>. .F*32<.1[?TQJ34N?KI^&Q5'A'0A
M$T7]GJ8WM4M&5G8@Q)]T$$]1V;K[U4FY-M]7?Y]Q+2UNE_QW(X_!F@1VLEO]
MB9TED220RSR.SE#E0S,Q) /\)./:A-IIKIK\Q6W7=6^19D\-Z3)!J<#6G[K4
MSF[02,!(<8)P#\IP.HQ4VT4>B=_U_,J[OS=;6+TMG;3V364T*26S)Y;1N,@K
MC&#FG+WMQ1]RW+T,BT\&:#93P316DK-;MNB$MU+*J'!7A68@<$CIQ33:U_K^
MM!66Q*OA/1([_P"VK8@3^:\V?,;;O=-C';G'*\=*FVG+TLU\F[O\2KN]_3\-
MBDWP_P##+^2&T]RL4*P*GVJ7:8U)(5EW88 D\'-5=WO_ %IH+_@_CN;%[H]A
MJ"VBW-N&6TD$L #%0C $ \$=B>.E)ZN[WU_'<%HN5;:?AJB#2?#FEZ')-+86
M[K+, KR2S/*Y Z#<Y)P,].E.[M85M;D-QX1T*ZNM1N9K &;4HUCNF$C@R*,8
M'!XZ#IC/>DO=5EWO\RFVVGV5ODPU+PCH6KG-YIZL?*\@^7(T>4W!L?*1W4'\
M*.M_3\-A+1)+I?\ %6?X$)\$: \4L<MI-*)8&MW,MW,[&-B&*Y9B>H%'2WI^
M&WY@M-O/\5;\B]I'A[2]#\XZ?;%'FQYDDDKRNV.@+.2<#TS3N[6%97N5V\(Z
M$^J?VBUB/M'F^<1YK^69/[YCSL+>^,TH^YM_7^0Y>]N*WA/0V-J6L 3:737<
M)\QLI*Q+,V<]R>G3VH7NM-=%;Y!+WDT^KN5T\#>'X[>[MUM)OL]T&$L1NYBA
MRVXX4OA3GG(Q1'W4DNEK?+8;;;<NKO\ B;EU:07ME-9W$8DMYD,;H?XE(P1^
M5*24E9A%\EG'H95GX0T'3[K3[FUT]8YM/A,%LWF,?+0YR.3SU/)R>:J[NWW5
MON)LK*/1._S9+%X9T>&&TBCL\)9W#7,(\Q_DD;=ENO/WFX/'-+MY*WR&];WZ
MN_S*EKX'\/V5N;>&TF$!=7\IKN9D#*X<$*6('S#/%--QM;I_PP2]YMOK>_S-
M&QT33M-OKZ\L[40W%^X>X8,?G8# .,X'X8I;1Y.G^8/67,]S.7P1X>6*>,V+
MR"?8',MS*[85MR@,S$@ C. 0*:?+:W1W^82]Z]^MU]^Y))X-T&74_P"T&LF%
MQYPG.R>14,@Y#E VTGW(I1]W;^KA+WM&._X1'0LV)^P#-C))+;GS'RC.26YS
MSDD\'BE;\K?*UAW;^^_S*T7@3P]#I<FF):3_ &*39F)KV<A=IW+MR_RX/IBJ
M;;MY"VN:%AX>TO3+&XL[2V,<5SDS,979Y"1@DN26)QWS2DN:/*]@C[LN9;D9
M\*Z(8+&$6"*EBI2WV,RE 5VD9!R>#CG-$O>;;ZJWR81]U67>_P R-O!V@,T3
M'3QNALS8H1(X(@(QLZ\\=SS[T2]YR;^UN.+Y>6W1W1)H_A?1]!D:73K0QRL@
MC\R29Y6"#HH+DD#V'%/F>Q-EIY$1\&Z"=6?4VL2]T\WGMNGD9#)C ?86VYX'
M.*4?=5EY_CN.7O;_ -6)!X5T1;&*S%BHABG%PGSMN$F[=NW9W$Y.>M-.S373
M;[K ]>:_7<2X\)Z)=65Q9RV;>1<77VR0+-(I,V<[@P8$<CL0*FUE%=MOQ_S8
M[W;???Y?\,5KCP)X>NFB:XM9Y6CB\D%[V<EDW%MK?/\ ,,D\-FGUOZ?@%W:W
M]:FQ;Z99VETUQ;P^6[1+#A6.T(N=H"YP.O84[O7SU)LE;R+=(84 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y8-:\7^
M/M<U&#PUJ$6C:)I\Q@:Y,8>29QUQ[=^W!'6@9=_X0KQW_P!%$D_\ E_QH$'_
M  A7CO\ Z*))_P" 2_XT '_"%>._^BB2?^ 2_P"- !_PA7CO_HHDG_@$O^-
M!_PA7CO_ **))_X!+_C0 ?\ "%>._P#HHDG_ (!+_C0 ?\(5X[_Z*))_X!+_
M (T '_"%>._^BB2?^ 2_XT '_"%>._\ HHDG_@$O^- !_P (5X[_ .BB2?\
M@$O^- !_PA7CO_HHDG_@$O\ C0 ?\(5X[_Z*))_X!+_C0 ?\(5X[_P"BB2?^
M 2_XT '_  A7CO\ Z*))_P" 2_XT '_"%>._^BB2?^ 2_P"- !_PA7CO_HHD
MG_@$O^- !_PA7CO_ **))_X!+_C0 ?\ "%>._P#HHDG_ (!+_C0 ?\(5X[_Z
M*))_X!+_ (T '_"%>._^BB2?^ 2_XT '_"%>._\ HHDG_@$O^- !_P (5X[_
M .BB2?\ @$O^- !_PA7CO_HHDG_@$O\ C0 ?\(5X[_Z*))_X!+_C0 ?\(5X[
M_P"BB2?^ 2_XT '_  A7CO\ Z*))_P" 2_XT '_"%>._^BB2?^ 2_P"- !_P
MA7CO_HHDG_@$O^- !_PA7CO_ **))_X!+_C0 ?\ "%>._P#HHDG_ (!+_C0
M?\(5X[_Z*))_X!+_ (T '_"%>._^BB2?^ 2_XT '_"%>._\ HHDG_@$O^- !
M_P (5X[_ .BB2?\ @$O^- !_PA7CO_HHDG_@$O\ C0 ?\(5X[_Z*))_X!+_C
M0 ?\(5X[_P"BB2?^ 2_XT '_  A7CO\ Z*))_P" 2_XT '_"%>._^BB2?^ 2
M_P"- !_PA7CO_HHDG_@$O^- !_PA7CO_ **))_X!+_C0 ?\ "%>._P#HHDG_
M (!+_C0 ?\(5X[_Z*))_X!+_ (T '_"%>._^BB2?^ 2_XT '_"%>._\ HHDG
M_@$O^- !_P (5X[_ .BB2?\ @$O^- !_PA7CO_HHDG_@$O\ C0 ?\(5X[_Z*
M))_X!+_C0 ?\(5X[_P"BB2?^ 2_XT '_  A7CO\ Z*))_P" 2_XT '_"%>._
M^BB2?^ 2_P"- !_PA7CO_HHDG_@$O^- !_PA7CO_ **))_X!+_C0 ?\ "%>.
M_P#HHDG_ (!+_C0 ?\(5X[_Z*))_X!+_ (T '_"%>._^BB2?^ 2_XT '_"%>
M._\ HHDG_@$O^- !_P (5X[_ .BB2?\ @$O^- !_PA7CO_HHDG_@$O\ C0 ?
M\(5X[_Z*))_X!+_C0 ?\(5X[_P"BB2?^ 2_XT '_  A7CO\ Z*))_P" 2_XT
M '_"%>._^BB2?^ 2_P"- !_PA7CO_HHDG_@$O^- !_PA7CO_ **))_X!+_C0
M ?\ "%>._P#HHDG_ (!+_C0 ?\(5X[_Z*))_X!+_ (T '_"%>._^BB2?^ 2_
MXT '_"%>._\ HHDG_@$O^- !_P (5X[_ .BB2?\ @$O^- !_PA7CO_HHDG_@
M$O\ C0 ?\(5X[_Z*))_X!+_C0 ?\(5X[_P"BB2?^ 2_XT '_  A7CO\ Z*))
M_P" 2_XT '_"%>._^BB2?^ 2_P"- !_PA7CO_HHDG_@$O^- !_PA7CO_ **)
M)_X!+_C0 ?\ "%>._P#HHDG_ (!+_C0 ?\(5X[_Z*))_X!+_ (T '_"%>._^
MBB2?^ 2_XT '_"%>._\ HHDG_@$O^- !_P (5X[_ .BB2?\ @$O^- !_PA7C
MO_HHDG_@$O\ C0 ?\(5X[_Z*))_X!+_C0 ?\(5X[_P"BB2?^ 2_XT '_  A7
MCO\ Z*))_P" 2_XT '_"%>._^BB2?^ 2_P"- !_PA7CO_HHDG_@$O^- !_PA
M7CO_ **))_X!+_C0 ?\ "%>._P#HHDG_ (!+_C0 ?\(5X[_Z*))_X!+_ (T
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MY9J/7GM^'](F/V+].7\W^*TOY$NB^%+_ $W1M&N=1TYCI<K0M>Z9!"\APL+
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MECGA26&19(G4,KH<A@>A![BJ::=F2FFKH?2&("& (((/0B@!: "@ H * "@
MH * (KBY@LX&GN9HX(4^])(P51]2:/("6@ H * $)"C)( '<T +0!3DU?3(=
M133I-1M4OI!E+9IE$C#U"YR>A_*A:WMT!Z;D<>O:--'<R1:M9.EKS.RW"$1?
M[W/R_C1?3FZ#MK;J3V6H66IVPN;"[@NX"2!)!('4D>XXIM-;DW'F[MEN4MC<
M1"=P66/>-S 8R0.IQD9^M):[#V)J "@ H X7XC^+;GPY%806%[!:W4I>=S,5
MP\<:Y*#=W8X4=_2E&2]IKLM7]Z7^;^17+>&F[T7EY_UW*Q\77]UXJMHK.\SI
MUQ=6@10BG,<D$CD9QGDJI_"M(1:DXRZ.7X)6_,S<KPYEVB_OE9_AH>AU!04
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M'J,8[TMQ[$T,$-M$L4$211KT1%"@?@* M8DH * "@ H * "@ H * "@ H *
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MM_U-G3[^WU/3[>^M'WV]Q&)(VQC*D9'%7*+B[,E.ZN6:D84 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M9&&"#CN*Z*WQLPAM?S?YF_6184 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_P!^K3_XS0 ?V%J/_0V:M_WZM/\ XS0 ?V%J/_0V:M_WZM/_ (S0 ?V%J/\
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MM7-\SDNZ:\K$V7*D_/\ &_\ F3W?PW>^:]GN-77[3>17"2LEMA TH095=YP
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MF[?UO=_H%OZ^5Q!XG@^TK&8)@'*IM*HNQ]SJ0S%\=4P /PSG@2O9=_\ )/\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M#))/YGK3;OJ2E96'4AA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MLU)04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % 'C9_Y*=XQ_P!^V_\ 19H&;GP7_P"1<UO_ +#$W_H$= CTB@ H * "@ H
M*   #H,4 % !0 4 % !0!!]BM/M8N_LL/VD#'G;!OQTZ]:%IL#UW)Z "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /&S
M_P E.\8_[]M_Z+- S<^"_P#R+FM_]AB;_P! CH$>D4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % 'C9_Y*=XQ_P!^V_\ 19H&;GP7_P"1<UO_ +#$W_H$= CT
MB@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M3F1XU590P(9&*@X8'D'!!Y]:*BM)VVNS.F_=2>]D:-06% !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 <WXXU&^TS0(YM.EEBN)+N"',*H7*M(%(7>-N2#QGBDM9Q
MCWO^38]H2?9&:OC::SF^S3Z=,\4$Z6<LMQ,@N#,T>\92-=A&,9*MZX&!1*5E
MS>MO^W=_0.6SMZ?B[+^OU.A\-ZM/KN@6FJ3VBVGVJ,2I&LOF84C(R<#FM)QY
M'RD1ES'(:+X]:^\>ZI927T#:<KO;VUN-OF*\:@LV/O$-\_M\H]:S@_W3F_7Y
M;?Y/[S2:M-17DOF_\MON)8OB3)*$']EP))/;Q7%NING8R*Y;"D)$Q#84D@ @
M>N.:<DXWONM_NO\ UL)*[TVU_!I?FRO;?$:ZN=21+/3C.+N**2**:Y$:Q9A:
M1N1&3_#CG/X4/W5+RN_DN7_/_@BW:7HOG>2_3_@"WGQ(O9-'NKFQTN*WE%I%
M=6_VN5LRHVS+* FTA2^/O9SU JG!J?+_ 'DOO?Z_/]!7TOY-_-=/ZM^IZ"LK
M):B6X"1L$W2!6RJ\<X.!D>^!4S:C=]$$+R2[GDEO\2=1NM+UR6+4K=Y_W=U8
MJFPF&(S^68VX/.-IYY^>G"+:@NMTG\]?PU14K*4K;6E;UBGK\]T=1'X]NVU/
M^SI-'BAE6=[9YFN6,'FA0RHKB,Y+ _Q!>AZGBI;O'F79O[KW^ZW_   T3L_+
M[G;_ #_X)4TSXBW3V.D-?V5NTMZ(_--O+(3'YCE4.#'M'3H7!ZXS526Z7;\>
M7F_+U$]+OLW]R=OZ_I)/#WQ$NKV.RCGTXO$TL%O)<O<CS-\J[E.Q8P#CH>E4
ME=I=[_@KA/W+^7Y<SC^AZ)4 >-G_ )*=XQ_W[;_T6:!FY\%_^1<UO_L,3?\
MH$= CTB@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * *LVG6EQJ%K?2Q;KFU#B%]Q&T, &XS@YP.M"T;:ZZ ]5;Y_FOU+5
M %5-.M(]3FU)(L7<T2Q/)N/*J20,9QU8_G0M$TNH/6U^A:H * "@".2WAF>)
MY84=HFWQEE!*-@C(]#@D?C1L'2Q)0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MIE$RE03T&<XS3>@+78%U?3&D6-=1M2[.8PHF7)8<;>O7D<4;AMJ+_:^F<_\
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M:>3TQFG!W<HOHK_BD*6D5+SM^#?Z'74@"@#QL_\ )3O&/^_;?^BS0,W/@O\
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M^7X6_P ANG^&K\_8)[R_V&(,[VX1L!F5P0,/M'W\]">,9Q0XKE<?*WX)?IY
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M?\(K>"$Q8M"^U0MP7;S(P(]OECY?ND^X^\>/66N96?G?SNNO]=$7=*2:VO\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M4XK./P)>O_I7Y6U_4'\;?I_Z3_GH0B_UR>R<2I=2F2"=1$;0X!!DV%MT0#9
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MGK]^MO\ @_+:X725UY?\'\+->>FNRLZ=?ZO>^';NZFD:&X$GE1[8=Y!0A'(
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M * "@ H * "@ H * "@ H * "@ H * "@ H * &R1I+&T<B*Z,,,K#((]Q0
MZ@!" 001D'J#0&PV**.")8H8UCC4854& !["@!] !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'C9_Y*=XQ_P!^V_\
M19H&;GP7_P"1<UO_ +#$W_H$= CTB@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M1HU89!)/))_6J:LOO_,B][/NC#TK6I#XRGMIYV*W#ND$0F+;0N<EU)PA&S@
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M1!D4$IG ^;/X@C\*<ERS4?-?F4E[UO,H+KMU;:PUK->VC1M=^5Y>W]Z@(3:
MN\'')Y /4'&,XF&J2]?S?Z(AZ7?I^2_7^F6?$DUU!+')%-MBCMKB5HP77>RJ
M,<JP]?\ /91^/[OS1=KI>J_)E;_A)+@7,MN]W8P[+CRS,R[HXU^<C)#\L=N,
M';@YX/&2.J7]=M%]]_1;(G;\/Z_KONR./Q%+?:H]I',ACBGBPT8"MCS"I! =
MC@X[A>G2B&K3_KX9/]/^&)F[+3^M8_YO_@FGJVKW=AJMG9PP+(+OB,[2<%3E
MP2#_ ',X]QWI7W\E?\_ULOF6]$G\ORM^K?H8,GC2\AT9[R3[*KXW*!L(^X24
M/[W@@X]SGA>#5I+F4?/_ "U_'S[BCJ^W]/\ *WD=3I=U<W:7,LYBV+,R1JBD
M$*IQR23D_E4/2-^NOYB3N_N_%)_J8%CXCU;43 D2V<332JN64.8\I(Q4JLF=
MPV 9.WJ>.*;TC?R?Z?YEM)2:[?YV_(JW?B6[G6U/VBVMRVUOLP+"20&W+[@0
MP^7/'3^'KFG)6;MTO^'?^NPXK9/R_P#2K%^?7M2MA+)_HOD!S$@,;93"*V]C
MNY R<C X'6CK;U_]*Y3&+T^[_P!)YO\ @&MH6HOJ5M<2//;W BG:)9;=2$8#
M'J3ZXZ]J/LI]_P#-HJ_O-=K?DF:E(9S7Q")'@#6L''^CD?J*%\</\4?S1<.O
MH_R9#XY4)X8M"H V7UIMQ_#^^3IZ54?X\/5_DS&/\"7^'_(ZNI+"@ H Y?P@
M,ZCXH8\L=58$]\"*/%./\&'_ &]_Z4PG_%?I'\@\!<:#=*.%74;L*.P'G-Q0
MOX</\*"7\2?K^B.HI % '+^+.=9\**>5.IY(/3B&3%.G_%_[=E^@3_A/U7YA
MK/R_$'PP1P3%=@GU&U#BE3^.?^']4$_@C_B7_I,CJ* "@#QL_P#)3O&/^_;?
M^BS0,W/@O_R+FM_]AB;_ - CH$>D4 % !0 4 ,F<QP2.,9521GZ5$WRQ;70J
M*O)(P(_$$UC;I+JK0NLL$<L9@3R\%B%VG<Q'4CG('7TS6LDE)Q71_P"?^3,X
MN\5+NO\ +_,D3Q99264EXD$[6T1"O)F/:KG "9W<G) R/EYZ]:GMY[?U_6Q2
MUV\_PO\ Y#5\6VTH4V]C=S@[06C\LA6:1HPN=_)W*>1D>].S_KTO^0/17_KI
M_F0'7[:YN_-N[&X6UMF1EE. L3G(PX#<D$8X! R/K4II+F]?NY4_R?Z ]7RK
M^GS-?FBWIWBBTU2[BMK:WG+N&8G,9" !3DD,?[XX&3UXJN5Z^0KZ7_KK_D2R
M7]Y'K9LD:&0/$[HC1/'C &/GR0W)YP,C\.96J?E_7]?\$IZ6_K^OZ[%O2;F:
M\TFUN;@()I(PSA 0N>^,]JIVZ"V;79O\&9MSJE_!?S6B/;2G=&JN(6 B+O@!
MOF.X[>>,=!TS2CKI_6S;_)??Y!+W=?ZW27XM_<.M]5OWEM%:*!E=YXI"N06>
M,L!M'8';W)Z_C2;T;7\M_GI_F-JS2\[?)JX:%K,VHW$UO<-$TD<,4Q,4;)L+
M[@4()/(V^W7H*MI)77>WKL3KI?\ X8W*D84 % !0 4 % !0 4 % ".H=&0Y
M(P<$@_F.E#5P6A!:6,%DL@@5_P!XV]V>1G9C@#DL2>@%'D!8H * "@ H * "
M@ H ;)&LL31N,HP*D>H-)I-68TVG=!&BQ1K&@PJ@ #T JFVW=DI**LAU(84
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#QL_P#)3O&/^_;?^BS0,W/@O_R+FM_]AB;_ - CH$>D4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M\;/_ "4[QC_OVW_HLT#-SX+_ /(N:W_V&)O_ $".@1Z10 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 >-G_DIWC'_ '[;_P!%F@9N?!?_ )%S6_\ L,3?^@1T
M"/2* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@#QL_P#)3O&/^_;?^BS0,W/@
MO_R+FM_]AB;_ - CH$>D4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'C9_Y*
M=XQ_W[;_ -%F@9N?!?\ Y%S6_P#L,3?^@1T"/2* "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@#QL_\E.\8_[]M_Z+- S<^"__ "+FM_\ 88F_] CH$>D4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % 'C9_P"2G>,?]^V_]%F@9N?!?_D7-;_[
M#$W_ *!'0(](H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /&S_R4[QC_ +]M
M_P"BS0,W/@O_ ,BYK?\ V&)O_0(Z!'I% !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0!XV?^2G>,?]^V_]%F@9N?!?_D7-;_[#$W_H$= CTB@ H SH=;M'M$NK
MEA90R'$;7,B+O^GS'TH6MO,'HWY%I+RUDDFCCN8F>#_6JK@F/C/S>G'/-&RO
MT#K8IW7B#2K33VO7O[=H0&*[)5.\CJ%YY/M[T[:J/?\ X8%J$GB#2HKPVKWT
M"NB%Y"95 CPRKAN>"2P _&DM=5_6_P#D']?J3-K&F1LZOJ5JK(0K S*"I.<
M\^Q_*A:[ 30WEK<"0P7,4HB)#['!VD=CCITHZ7Z!UL5(_$&E2WB6R7]NSNH9
M")5(?)Q@<\GI^8H6NG]=?\@>FO\ 73_,D;6=+CC:1]2M%17\LL9U #?W>O7@
M\>U%QV=[#CJNG+<"W.H6PF*[A&9EW$8SG&>F.?I1M?R%O;S%BU33IVB2&_MI
M&ESY82527QUQSS3MT#S%EU.P@DEBEO;>.2)"\BM*H**,9)&>!R.?>D.Q7N=?
MTJUM!<M?V[HV?+"2J3(0<$+SR<D"G;51[V_$ENR<NPZ+6K"29HFN$B<2M"@D
M=5,K# .T9R<$X^HI+5*W];_Y?<-Z/7^OZN6$O[.2U>Z2[@:WCSOE$@*KCKD]
M!BCI<.MB,:MIK.J+J%J692X F7)49YZ].#^1HV!:[$<>NZ1+GRM5LWVJ7.VX
M4X4#)/7ICG-&P+71"QZYI,N[RM4LWVJ7;;.IPHZD\]/>@!PU?3#)'&-1M2\J
M[HU\Y<N.>0,\C@_E0 EEK&G:@(_LM[!(TB[U19!N(YYQU['\J+!L[$MSJ-E9
M21QW5Y! \O\ JUED"E_H#UZC\Z%J[(-E<CAU:RF=8S<1Q2N[HD<C@.Q1BI(&
M>1\IHZ7\K@]!8M7TR9HUBU&U<R$A LRG<1CISSU'YB@-B2"^M+F!Y[>ZAEB3
M(9TD#*N.>2*'HKL.MNI5AU_2Y[X6<5] TC(KH1*I$F2PPO/)&TY^HII7!Z*_
M]?UJ2MJ^F*CLVHVH5'\MB9EPK?W3SP>#Q[4EK:W4-A]GJ%O>QEHG&5SN0D;E
MP2,D>G!HZ7_K:X=;?UIH5+?Q'I-S<)#'>Q;I!F,F10'.XK@<\G(_44+7;R?W
M@]-_-?<6[74;2[;RXKB(S!=S1"1691[@$^H_.CI<'H[,@MM>TNZMGG2^@58S
MB0-*H,9SCYN>.1BB^BET8=6NU_P+$6H64S(L5Y!(SXVA9 =V1D8]> 3]!3M_
M7]>J"_\ 7]>A9I % !0 4 % !0 4 % !0 4 % '+VOB+6-3M)K_3-'LY+%'D
M1&GOVCD?8Q4G:(F Y4X^;\J3?+!3EM:_RW_(JUY."W3M\S;T?4X=9T>SU.W5
MEBNHEE57Z@$9P:N<>65C.+NB[4E!0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MI">:Y;_5YQF Q8Z^^?T]ZOFM*_\ 6Z?Z$Q]U)=DE]SN)J/A@7ZR8NO*9KD7
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H \;/_ "4[QC_OVW_HLT#-SX+_ /(N:W_V&)O_ $".@1Z10 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 >-G_DIWC'_ '[;_P!%F@9N?!?_ )%S
M6_\ L,3?^@1T"/2* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#QL_P#)3O&/
M^_;?^BS0,W/@O_R+FM_]AB;_ - CH$>D4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % 'C9_Y*=XQ_W[;_ -%F@9N?!?\ Y%S6_P#L,3?^@1T"/2* "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M;_"P7TM_6I0MO"T\=S)/<ZD;AV7:"R,3]UUSEG/]\G P.P J6KP<>]_QY?\
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M=(QNR$ZYC)Q@=>M7%VLGY?A)O\F)::K^M"S)X?O-C"*&Q$PFDD\]B2TP99
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MOT2_-7+32DGY_P#MU_RT_ T],T-M-U266"WMH;5H0A"'+%@% Q\H*C@Y&2.
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M$P?O..!VZ$BJC9M7Z_\ VW_ (2M V++4I7TRYCEED-[#&\@,D6QMFYQ&S#
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M13ZVO_Y-?\D7M0?5)!IKVZR0S20J)9$@#-&6DAW#Y@<?+OX]L]JMI*;2VO\
M_)?\ (-NFG+?_@#KFVO+[2+:*Y:9G2^ ?]TN7192 6!7&, '( ]:E:2B_+\>
M5_J$OADEY?FC-O9]2U&!;=[:Z9HHOWFZV909-LH.#CG^'IQR/6H:NK^7Z:FJ
M:4K>?X<T;?A<UKB:_BNHXHS<(@ME,*QP[DDDYRKMM.T?=[KU//'%3;]YK?\
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M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!XV?\
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MFBE=?E=HAA=PX(QDXY[9H=NA"O;4FI#"@ H ;)&DL;1R(KHPPRL,@CW% #J
M"@ H * &O&D@ D17 (8!AG!!R#^= "LJNI5@"I&""."*&KZ,$[; JJBA5 50
M, #@"C<$K:(6@ H 0@,"" 0>"#0U?1AL0VMG:V49CM+:*W0G)6) H)Z9X^E.
MX6)Z0!0 4 % ",JNI5@"I&""."*&KZ,$[; JJBA5 50, #@"C<$K:(6@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /&S_R4[QC_ +]M
M_P"BS0,W/@O_ ,BYK?\ V&)O_0(Z!'I% !0 4 1K;Q)<27"KB6155FSU SC^
M9HV5OZ_K0"2@ H * "@".*WBA>5HUP97WOSU. ,_D!1TM_7</,DH * "@".X
M@CNK>2"4$QN-K!6*DCZCFDTGN--K5#D18T5$4*JC  ["J;N[LE))60ZD,* "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#QL_
M\E.\8_[]M_Z+- S<^"__ "+FM_\ 88F_] CH$>D4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % 'C9_P"2G>,?]^V_]%F@9N?!?_D7-;_[#$W_ *!'0(](H Q_
M%LTMMX,UV>"5XIHK"=TD1BK*PC8@@CH0: (_^$3T[_GYU;_P<7?_ ,<H /\
MA$]._P"?G5O_  <7?_QR@ _X1/3O^?G5O_!Q=_\ QR@ _P"$3T[_ )^=6_\
M!Q=__'* #_A$]._Y^=6_\'%W_P#'* #_ (1/3O\ GYU;_P '%W_\<H /^$3T
M[_GYU;_P<7?_ ,<H /\ A$]._P"?G5O_  <7?_QR@ _X1/3O^?G5O_!Q=_\
MQR@ _P"$3T[_ )^=6_\ !Q=__'* #_A$]._Y^=6_\'%W_P#'* #_ (1/3O\
MGYU;_P '%W_\<H /^$3T[_GYU;_P<7?_ ,<H /\ A$]._P"?G5O_  <7?_QR
M@ _X1/3O^?G5O_!Q=_\ QR@ _P"$3T[_ )^=6_\ !Q=__'* #_A$]._Y^=6_
M\'%W_P#'* #_ (1/3O\ GYU;_P '%W_\<H /^$3T[_GYU;_P<7?_ ,<H /\
MA$]._P"?G5O_  <7?_QR@ _X1/3O^?G5O_!Q=_\ QR@ _P"$3T[_ )^=6_\
M!Q=__'* #_A$]._Y^=6_\'%W_P#'* ,KQ#X?M;'389;:\U9':]M(B?[7NC\K
MW$:,.9.ZL1^- &K_ ,(GIW_/SJW_ (.+O_XY0 ?\(GIW_/SJW_@XN_\ XY0
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M_P _.K?^#B[_ /CE !_PB>G?\_.K?^#B[_\ CE !_P (GIW_ #\ZM_X.+O\
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MFFE\J]NXE::5I'VK<R*H+,23@ #D]J -R@ H * "@ H * "@ H * "@ H *
M"@ H \;/_)3O&/\ OVW_ *+- S<^"_\ R+FM_P#88F_] CH$>D4 8?C/_D1?
M$/\ V#KC_P!%M0!N4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % &'XL_Y ]O\ ]A&Q_P#2N*@#<H * "@ H * ,/7?^0QX8_["+_\
MI)<4 ;E !0 4 % !0 4 % !0 4 % !0 4 % !0 4 8=U_P CUI/_ &#KS_T9
M;4 ;E !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!AV
MO_(]:M_V#K/_ -&7- &Y0 4 % !0 4 8?A/_ ) ]Q_V$;[_TKEH W* "@ H
M* "@ H * "@ H * "@ H * "@#QL_P#)3O&/^_;?^BS0,W/@O_R+FM_]AB;_
M - CH$>D4 8?C/\ Y$7Q#_V#KC_T6U &Y0 4 % !0 4 % !0 4 % !0 4 %
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M9N3C(R5'?;GV%-NREYW_ *^=M?EY@_>V77\WM\KZ?/R-_0 1X>TX$8_T=/\
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MK[N9[_*W](B5^1M]G]_*MOG<MRZ?K,$#>2+J9I=QD#73$J?-RNT>8N/EXP&
MQUSC%1KRI>2^^SO^-BOM7]?S5OPN)966KVCP74MM=2SF*W,X%PIWE58.N"^,
MY(/H?4FKE9-V[O\ )?J*UW\O_;K_ )#/[-UY[))':Z69GB$L8N23L"<@8D4
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MD>-HUEN,HI[855)^A8-]>O>C2R2\_P W_P .+K\E_7Z?(TZ0PH * "@ H *
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M_P#B: #[5\4O^?WP]_WQ)_\ $T 'VKXI?\_OA[_OB3_XF@ ^U?%+_G]\/?\
M?$G_ ,30 ?:OBE_S^^'O^^)/_B: #[5\4O\ G]\/?]\2?_$T 'VKXI?\_OA[
M_OB3_P")H /M7Q2_Y_?#W_?$G_Q- !]J^*7_ #^^'O\ OB3_ .)H /M7Q2_Y
M_?#W_?$G_P 30 ?:OBE_S^^'O^^)/_B: #[5\4O^?WP]_P!\2?\ Q- !]J^*
M7_/[X>_[XD_^)H /M7Q2_P"?WP]_WQ)_\30 ?:OBE_S^^'O^^)/_ (F@ ^U?
M%+_G]\/?]\2?_$T 'VKXI?\ /[X>_P"^)/\ XF@ ^U?%+_G]\/?]\2?_ !-
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ME_S^^'O^^)/_ (F@ ^U?%+_G]\/?]\2?_$T 'VKXI?\ /[X>_P"^)/\ XF@
M^U?%+_G]\/?]\2?_ !- !]J^*7_/[X>_[XD_^)H /M7Q2_Y_?#W_ 'Q)_P#$
MT 'VKXI?\_OA[_OB3_XF@ ^U?%+_ )_?#W_?$G_Q- !]J^*7_/[X>_[XD_\
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MI?\ /[X>_P"^)/\ XF@ ^U?%+_G]\/?]\2?_ !- !]J^*7_/[X>_[XD_^)H
M/M7Q2_Y_?#W_ 'Q)_P#$T 'VKXI?\_OA[_OB3_XF@ ^U?%+_ )_?#W_?$G_Q
M- !]J^*7_/[X>_[XD_\ B: #[5\4O^?WP]_WQ)_\30 ?:OBE_P _OA[_ +XD
M_P#B: #[5\4O^?WP]_WQ)_\ $T 'VKXI?\_OA[_OB3_XF@ ^U?%+_G]\/?\
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%F: /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g707175g74w49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g707175g74w49.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X6B_:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM
M<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I
M/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR
M,#$Y+3 T+3$X5#$V.C0Q.C R*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @
M(" @(" @/'AM<#I-971A9&%T841A=&4^,C Q.2TP-"TQ.%0Q-CHT,3HP,BLP
M-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$
M871E/C(P,3DM,#0M,3A4,38Z-#$Z,#(K,#4Z,S \+WAM<#I-;V1I9GE$871E
M/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH
M96EG:'0^,3<V/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
M03-!1&-!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!
M04)!03-!04%!045!)B-X03M!441C04%!04%104(O*S1!1&M&:V(R2FQ!1U1!
M04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#
M=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(
M>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&8O.$%!15%G07-!14%!=T52)B-X03M!04E205%-4D%F
M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%
M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#
M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT
M+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ
M8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
M341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C13
M3D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG
M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7
M5G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A9
M84AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+
M;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E,-F)P=6Y(5')5;3%H2DU-
M9%0V)B-X03MA+WEJ,GA612]O>E1F*U=32"]K5W8Y359D*VI.3B\U6DEF.$%K
M5W8Y359D*VI.3B\U6DEF*U)A+S!X5C,V33 S+VQK:"]W0U)A+S!X)B-X03M6
M3')R579*9'!C=F$S5C%P='9D4FM"-$I:245K57-9,55&5TE)<5HT=U X05A8
M*UE9<6],-6<O3#$V.&13,&AQ2TA.2C=9+T-Z1E90)B-X03LR=6A:4T(W:D96
M<BM:4'DU4C)2.54P9%A65F1L33EQ0T5K45-)>$A,;WE-1T(W9S%X5DPO041&
M9C9.9&%81$YO1W(V4F)G6$9,:35-)B-X03LQ<7%T1VI#1U-/3U8T<G%.6$4X
M,%-M<V)B:TQS5T)X5FA$>&5F=G(K;$903U!L;C9T95A-4RMH+V]O939I6F)A
M57)B2#9S,WAU:VA:)B-X03M".%9%;%1D:E)Y5E%4-FPU-75964Q85%!/9FLR
M-&US-'):.5)U4F-7,W%U.&%Y0S4U>')A>6]I4$Q-:4)H5&%.5#A*9&Q!5D4V
M5F0K)B-X03MA<$=T-#5F4%!L839K*T)*5FEK<VU,4V5L14=50F)C5C500F-L
M96A&461W:%%L561E+S1N9E)R5G)(>F@U9$TY=%DK;G%..#5S,6IA)B-X03LY
M;%<U4TM9,'0U1D-.2W%C9&PO=35"4C8O0W%M56PP,FUV<D5/;RMA3D1-3%%W
M,C%N4%!,6E<P.6Q.0D-9<GEE4F9Q-U)U-75P679G)B-X03MC8U%#0E%D1U93
M:E12-2MT<FTR=4PW>D@U6G9D3W4W;$E35VYT-'AZ:G0R4S=T-V)H67)Y9$QH
M;6M8:S=-06EQ,U9Y5E91>2M:3&)Y)B-X03LW83)/<"MB=DQL=C5K=&]B*S-V
M-V]3,F%+,3=)-T-W6FMK=&%5:3E'5EI)=VE%;&$Q4$9L=TLS95=(-6AJ5D=J
M:3AZ95AO<F52959V)B-X03MA=CA!5FA/2'1P24)E07-B4F<V271T9$1:055:
M=FER>$A%<3%,8RMB-W)4-VAR4'I"-5EJ<S1B9E5N1W)X,U9V231:<$9N<W!:
M06)))B-X03MW2VQV1DQ"2$PO37-N3W9)<&=63&18;3AY4C9->C)F-6IE6$QE
M*VI,<6MT,"MM1TIU8R]Q,FYQ4T,P5VAK<UAB;GA49&M1<CA,3FEQ)B-X03MB
M=&-A;DIQ=')C>&5C9DPV-E1Q33A,,F-(<3)$;5,S9U=&8G=7-V96:#9P.5),
M;&9T9#!.531S<D950TY9,35,5%)$8F5B9DMD-$Q7)B-X03M#2S0X=UA%.3=:
M;V)H=G)C87DK:UER36]K2$-.;U5B:4<U4T=V>$E+:%58<G1L-3185FYV1C@P
M849P;FQZ56)I,6XP;T8W3DIF<5)I)B-X03LT5&E+4V5X;5-1=E!.0U50>&)%
M0W9X1$-Q6$Y(-3=B5%DR<V902&QY-'4T<G4Q9W5:2EAS4%--,S%5+U=,5&Q(
M6F9#-UA%8E!'2V,K)B-X03M',GA8-&Q78F55=%8P2T126EID9CAW84IQ531N
M95%8:T5T;W-35SAZ33%T1U-I>$PO9'%D>5!I;U1G5DYM.'DO;'=S8V-J87)O
M-&IM)B-X03M74U-&>F-7;U8P:4A+4FQ03&-)3C))-F0X5F)0;4PX=7=/4C%0
M4T%V<&UA<&YT<65K23!M3"]A*WHV57%06'!X64AO4FEQ>B]!0E8K)B-X03M7
M9D%Y9G!J4F9457AH;BMS,G1!6E9,>&=N;"LR9S5,-&IC67%N=C9-,#,O;&MH
M+S5&<B]41EAF;WI49BM74T@O04I&<B]41EAF;WI4)B-X03MF*U=32"]K5W8Y
M359D*VI.3B\U6DEF.$%K5W8Y3591,G!A8G!W,#8V271945)$2E$K;78X<#ES
M5E)/;68X8S(P+W=#34UF.$%X15EQ)B-X03MI8U9D:7)S5F1I<D1R=CA!2T@X
M=F)V5T@Q:38P='!T4V4V*W8O5UAU<G1I='E'5B]544=8:6TV2TM+04]+:&9S
M9T1&5C!F-5-F;#-')B-X03MQ<6UJ;W))<V%*2TI:+U9665-H:4-Y*W V9S1E
M:DAX;S)W5E%.9TU65C,O3$AY4$I,2DQ*<'AD-59G4BM6>&-K571V<7AI;T1*
M4E0O)B-X03M!3&HW9FM2=3-!8W$W,5956"]+6#AV,VTY5G1,2E!P6$5"5#9Z
M9&5M579#>'5+>"MR=TIK6BM266ET47!R5E9O<7%1+VQF-4MG,6HY)B-X03M,
M=S)C.&0Y.6%&*T=7.7921TQH4GA$:45496M+2BLW<'AP=RM#;D0T8U95-5!Y
M;CAH4V%O9%9B5&XO4T),15A!=7)S34,Y,F(T;&%3)B-X03MG02]7;4UO239.
M,'A64D@U3F9L<C9T-TQ*;W%Z=G%59VYV:F-4,TTO<7EH,FLU<TI:2$A,;DEX
M<C<T<7%Y9FQ.-4)K16]K,#92>$UR)B-X03M*34=U-W-H=S=4335A<S(W36)U
M64TS56E2=U12:4U68G9F>6XX:%AT>%!C6$=N3UIR;'!(;%I,<3=J*TM7-5,X
M8W%%;%5*5S1J5U0T)B-X03MA8C1Q<C)V-6$K5#=:9E17>F0W9&(S.4IW,CAS
M.#!K8U8S54U:63%:>GA*8V-V;5-E*TMP96XU3&9L<W%U4#!823-Q1FUK6C<R
M*V1M)B-X03LU<DMJ9W,P-4I$<F-Y.&@P8FUX3S5X5E9S9GEJ.&M71C=$9#)6
M=%!#,%144$EJ6$TX=VQA94M72FI),#=Y>5956$UP57%W;WIS97)()B-X03M&
M54YA+VMD*U=&;TI6=&1)94-/84]A1U=+3SAV5FI-9'I'27!L-$-F:BLX4E%'
M,C=!.5%-5E8W6#AN9GDY=$QQ0S9T9%!N9VYT;F=K)B-X03MG6DPK+U5+.7!$
M.5AG8FE**TY5:2M!16IP.#A64G-N-6%E4TI9=$MI;3!W4W@V2D-,8E-K:VUN
M8U%X0FMC04)N3E-':5-J3E5I9S-X)B-X03M63%EF>5(O3$M";F5(4UAJ95<Q
M1FI+-C-L-D=E,490,TQN,7%U;D9&5VIF<VIJ.6YB1E5:9"]L6#5,=FUT;3%+
M,G5.4F$P:&4Q9TXS)B-X03ME6&-W*W)Y4T=1>$]R4VQ:1G%W*S)#9FA7<%!%
M55984F9L6C5%:35C3DY)3%AA86A8-GAC,49X1DI*3$=Y;C%F:$-Y6$5J0D(X
M24Q%)B-X03LP,WA65S O.'502T=N86)A-EI9,FLQ=EI736YR5TU36&0R4%%K
M2U-)>E).-G9*3V%Z>4(K2BM,:V568U91378U3R]L>$Q(1$<K:U93)B-X03LS
M:6UG:$@Q;39(1T\U9U<R;%=O;')V0D=S63A&04%O0FEQ26LO2WIY2DMK:50V
M85HO5E-33C-L=4QM4BM-=&]T:3E(959M571B4G)')B-X03M31%=G.&0X5E%S
M6#5-+VQZ1$ID4U$V8DY$2F5Y4E188G@S,3AJ4WEW171(23578T5U<FYN>38X
M+VHK,79I<DYC5F1I<G-69&EQ1S%0)B-X03LO:FTS9B]'1U0O:4IX5C)M9CAC
M,C O-'=X+SA!15)I<4IX5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R)B-X03M+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+;V)5+RM/8F0O.%E:4"M);D9885HO>'IB5"]J1$@O=T%21TMS3S%(.'8O
M3DXS)B-X03MQ.3-D=RMC8C(P<W)M-$TX9&Q%<FXP;#57>G%I3UIT9T1B3TMC
M94I%:$9/=DI63G1),#-6<E)B3%)P.6%U8F@W1%1R6DIR=W)%6DHU)B-X03MK
M<D<X>FU62FUQ+T1K87-F;6-65%@Y1UAV+U8R=78X06=B6"]!2V]9<3<Y1UAV
M.$$Q9')R+V=B6"]Q:&ER=C!:92\X058R=78K0G1F)B-X03LK<4=+=2]2;#<O
M,61R<B]G8E@O<6AI<G8P6F4O.5AA-B]W0T)T9CA!<6AI<G8P6F4O=T16,G5V
M*T)T9BMQ1TMU+U)L-R]W0EAA-B\T)B-X03M',2\V;UEQ-SE'6'8O5C)U=BM"
M=&8K<4=+=2]2;#<O,61R<B]!24<Q+W=#<4=+=2]2;#<O04Y8838O-$<Q+S9O
M67$W.4=8=B]!1F1R)B-X03MR+V=B6"]Q:&ER=C!:92\Y6&$V+S1',2\V;UEQ
M-SE'6'8O5C)U=CA!9V)8+T%+;UEQ-SE'6'8X03%D<G(O9V)8+W%H:7)V,%IE
M+SA!)B-X03M6,G5V*T)T9BMQ1TMU+U)L-R\Q9')R+V=B6"]Q:&ER=C!:92\Y
M6&$V+W=#0G1F.$%Q:&ER=C!:92]W1%8R=78K0G1F*W%'2W4O4FPW)B-X03LO
M=T)8838O-$<Q+S9O67$W.4=8=B]6,G5V*T)T9BMQ1TMU+U)L-R\Q9')R+T%)
M1S$O=T-Q1TMU+U)L-R]!3EAA-B\T1S$O-F]9<3<Y)B-X03M'6'8O049D<G(O
M9V)8+W%H:7)V,%IE+SE8838O-$<Q+S9O67$W.4=8=B]6,G5V.$%G8E@O04MO
M67$W.4=8=CA!,61R<B]G8E@O<6AI)B-X03MR=C!:92\X058R=78K0G1F*W%'
M2W4P<#=J,4PV0V5D<FHV=&-#3T]344E'-&U#2U-H.4Y56#=4;G1I<71Q9CA!
M>'IB=B]J1$HO=T%2)B-X03M/2W4P>B]J;3)N+T='4#A!-&E-5EE4<D=K9FY.
M3'$X-S94<FUN,BML3F0K<$)(4$5(;%<R-5=X.4TP9R]L5S1(,G$W<CA89%95
M-C!.)B-X03M036-&>&%W-F\P1C5Q,&5L,FEA:F1)-6I34S15=4I84E)%0GA:
M-FMF0U!K3VU+<#4V;7!F-S1H+S5(3B\Q4WA6,W%A;"]V:4@O:V,S)B-X03LO
M5DQ&6&5P<5@K*TEF*U)Z9CE5<U9D-FUP9C<T:"\U2$XO,5-X5C-Q86PO=FE(
M+VMC,R]63$9897!Q6"LK268K4GIF.55S5F0V;7!F)B-X03LW-&@O-4A.+S%3
M>%8S<6%L+W9I2"]K8S,O5DQ&6&5P<5@K*TEF*U)Z9CE5<U9D-FUP9C<T:"\U
M2$XO,5-X5C-Q86PO=FE(+VMC,R]6)B-X03M,1EAE<'%8*RM)9BM2>F8Y57-6
M9#9M<&8W-&@O-4A.+S%3>%8S<6%L+W9I2"]K8S,O5DQ&6&5P<5@K*TEF*U)Z
M9CE5<U9D-FUP9C<T)B-X03MH+S5(3B\Q4WA6,W%A;"]V:4@O:V,S+U9,1EAE
M<'%8*RM)9BM2>F8Y57-69#9M<&8W-&@O-4A.+S%3>%8S<6%L+W9I2"]K8S,O
M5DQ&)B-X03M897!Q6"LK268K4GIF.55S5F0V;7!F-S1H+S5(3B\Q4WA6,W%A
M;"]V:4@O:V,S+U9,1EAE<'%8*RM)9BM2>F8Y57-69#9M<&8W-&@O)B-X03LU
M2$XO,5-X5C-Q86PO=FE(+VMC,R]63$9897!Q6"LK268K4GIF.55S5E$R:T=5
M,U=Q;5965B]R83%65TQ$+V571'51=C9S5E)/<"\X)B-X03MC,C<O04]-36XO
M151I<G1-+W=#3V)A9CA962\K26I&5TDV:#4Y.'DR,G!8=&YB*U5R>3=J=&)G
M=U)816)30EIK1%=W.5)3665/-EA-)B-X03MJ1#1Q9G5Y2SEW<6U7:#8S3&4S
M1G)F,W1J4' Y,65A6&%4>C)$>'EU.$1Y;#-A2GE%2'A)5'A.440T9V1-5E1Z
M.4E19GE49CAI2G8K)B-X03MA359D*VM)4#5*=BM213,O0412:7)V,&A"+TI.
M+W=!:4IV.$%M:D989G!#1"M38B]!2D549C@P67$W.4E19GE49CAI2G8K84U6
M9"MK)B-X03M)4#5*=BM213,O3D=+=2]314@X:S,O26EB+VUJ1EAF<$-$*U-B
M+VM23B]Z4FER=C!H0B]*3B]Y26TO-6]X5C,V46<O:VTO-4549CA!)B-X03M.
M1TMU+U-%2#AK,R]!0TEM+W=#84U69"MK25 U2G8X06M23B]Z4FER=C!H0B]*
M3B]Y26TO-6]X5C,V46<O:VTO-4549C@P67$W.4E1)B-X03MF>51F.&E*=BMA
M359D*VM)4#5*=BM213,O3D=+=2]314@X:S,O26EB+VUJ1EAF<$-$*U-B+VM2
M3B]W03!9<3<Y25%F>51F.$%):6(O)B-X03M!2F]X5C,V46<O:VTO=T-213,O
M3D=+=2]314@X:S,O26EB+VUJ1EAF<$-$*U-B+VM23B]Z4FER=C!H0B]*3B]Y
M26TO-6]X5C,V46<O)B-X03MK;2\U151F.#!9<3<Y25%F>51F.&E*=BMA359D
M*VM)4#5*=BM213,O0412:7)V,&A"+TI.+W=!:4IV.$%M:D953G!%<7E85W%U
M;UE!)B-X03LS83=-<DEF.3593WI!2$955'%F+T%">F)V+VI$2B]X131Q-U10
M*T]B868X04='4"]!26E-5EDO<5@U;BM29$UV2F)/+S%28F$T:&Y.)B-X03MR
M26IX5&=#64=&4V]B:'A.4')5931.2T=V44=I<4DP>E@Y1G8Y4FDQ1S%V23-S
M-S-4<F$T=%I74' X;W!79#!B:2]&:%94,$ER:7%C)B-X03MF<%!49BM7=4@O
M:UEV.6-69"MK.4XO-6$T9CA!:UEV.6-69"MK.4XO-6$T9BM2:2\Q>%8S-E0P
M,R]L<F@O=T-2:2\Q>%8S-E0P,R]L)B-X03MR:"\U1TPO6$989G!05&8K5W5(
M+T%*1TPO6$989G!05&8K5W5(+VM9=CEC5F0K:SE.+S5A-&8X06M9=CEC5F0K
M:SE.+S5A-&8K4FDO)B-X03LQ>%8S-E0P,R]L<F@O=T-2:2\Q>%8S-E0P,R]L
M<F@O-4=,+UA&6&9P4%1F*U=U2"]!2D=,+UA&6&9P4%1F*U=U2"]K678Y8U9D
M*VLY)B-X03M.+S5A-&8X06M9=CEC5F0K:SE.+S5A-&8K4FDO,7A6,S94,#,O
M;')H+W=#4FDO,7A6,S94,#,O;')H+S5'3"]81EAF<%!49BM7=4@O)B-X03M!
M2D=,+UA&6&9P4%1F*U=U2"]K678Y8U9D*VLY3B\U831F.$%K678Y8U9D*VLY
M3B\U831F*U)I+S%X5C,V5# S+VQR:"]W0U)I+S%X)B-X03M6,S94,#,O;')H
M+S5'3"]81EAF<%!49BM7=4@O04I'3"]81EAF<%!49BM7=4@O:UEV.6-69"MK
M.4XO-6$T9CA!:UEV.6-69"MK.4XO)B-X03LU831F*U)I+S%X5D1A4DQ&3&1A
M<3A4<DEH=3%O>6M%8E=S2&-9<6ED5"\T-70S+WAH:R\T:6-69'!N+TA.=% K
M34UF+T%"15EQ:%IF)B-X03M++VQQ8653-&TP;7IL;FUK13!S<C(X5$\P;TM%
M3WI&86QG65EZ6"]*6'='2W),2S%T<E175&$R<U-7.7)B,D5%545%4VA),&I2
M-496)B-X03M%5F%"5E5#9T%X5DYS5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I)B-X03MR
M<U911VUF-S(V="]Z1DPO04Y1<T=+<3)P+SA!2$YU+RM-36XO151I<G1-+S0U
M=' O=T%962\X06E)>%9H=6]F:S<U8W8Y879T56YV)B-X03M,,$YF>F972F)E
M3F]%:E=4;F)Y5E)X1#9W*T]Z:E X065E4&9&53(P4'DU63948U=U:U<X:S=7
M,FTV6&%7:T1V331C<$%8:E5V=TM,)B-X03MY;W4Y04(W67%N;C909R]N;2\U
M2'IF.$%.94MU+U(X2#@X,R]!0U!M+W=#83A69"MJ-% U-78X06MF3B]Z6&ER
M=C!F0B]03B]Y4&TO)B-X03LU<GA6,S909R]N;2\U2'IF.#$T<3<Y2'=F>GIF
M.&HU=BMA.%9D*VHT4#4U=BM2.#,O3F5+=2]2.$@X.#,O22MB+VUV1EAF;RM$
M*V5B)B-X03LO:V9.+W=!,31Q-SE(=V9Z>F8X04DK8B]!2G)X5C,V4&<O;FTO
M=T-2.#,O3F5+=2]2.$@X.#,O22MB+VUV1EAF;RM$*V5B+VMF3B]Z)B-X03M8
M:7)V,&9"+U!.+WE0;2\U<GA6,S909R]N;2\U2'IF.#$T<3<Y2'=F>GIF.&HU
M=BMA.%9D*VHT4#4U=BM2.#,O0418:7)V,&9"+U!.)B-X03LO=T%J-78X06UV
M1EAF;RM$*V5B+T%*2'IF.#$T<3<Y2'=F>GIF.&HU=BMA.%9D*VHT4#4U=BM2
M.#,O3F5+=2]2.$@X.#,O22MB+VUV)B-X03M&6&9O*T0K96(O:V9.+WI8:7)V
M,&9"+U!.+WE0;2\U<GA6,S909R]N;2\U2'IF.$%.94MU+U(X2#@X,R]!0U!M
M+W=#83A69"MJ-% U)B-X03LU=CA!:V9.+WI8:7%',&E*63=R5E55<U%,=&0R
M6FY0*SAS2&1I5&EQ2C%0+T%)-70S+WAH:R\T:6-69'!N+TA.=% X06I$2"]!
M35)')B-X03M+<TDQ9CAU=DXQ.7)6,64R,VY3.'-,3V4U5S1I=$E6;4IJ45!B
M<S!)6G)J,"M"*W)S0E-)9F)05F%Q5E4W,%!43E8P-C1T9%!L,4@V)B-X03LY
M8U=E;#)K13DY8U)S,',W>$8P858O,VQA=5)Y3E-4-VYR:7%E96YQ6"LO-&8K
M4DQF.59C5F0V97!F-R]!268K4DQF.59C5F0V97!F)B-X03LW+V@O-45T+S%6
M>%8S<#9L+W8X06@O-45T+S%6>%8S<#9L+W8K2"]K4S,O5EA&6&5N<5@K+W=#
M2"]K4S,O5EA&6&5N<5@K+S1F*U),)B-X03MF.59C5F0V97!F-R]!268K4DQF
M.59C5F0V97!F-R]H+S5%="\Q5GA6,W V;"]V.$%H+S5%="\Q5GA6,W V;"]V
M*T@O:U,S+U981EAE)B-X03MN<5@K+W=#2"]K4S,O5EA&6&5N<5@K+S1F*U),
M9CE68U9D-F5P9C<O04EF*U),9CE68U9D-F5P9C<O:"\U170O,59X5C-P-FPO
M=CA!)B-X03MH+S5%="\Q5GA6,W V;"]V*T@O:U,S+U981EAE;G%8*R]W0T@O
M:U,S+U981EAE;G%8*R\T9BM23&8Y5F-69#9E<&8W+T%)9BM23&8Y)B-X03M6
M8U9D-F5P9C<O:"\U170O,59X5C-P-FPO=CA!:"\U170O,59X5C-P-FPO=BM(
M+VM3,R]66$9896YQ6"LO=T-(+VM3,R]66$9896YQ)B-X03M8*R\T9BM23&8Y
M5F-69#9E<&8W+T%)9BM23&8Y5F-69#9E<&8W+V@O-45T+S%6>%9$85%*4F1A
M<4I75FXK=')6;%5Q4#DU64]X3&9R)B-X03MX5D4V;B]X>F)V.$$T=WEF.%)/
M2W4P>B]!235T<"]X:&HO-&E-5EEN9C9R*V%I,S$O2%DV4%IY,G-D,$8P*V%6
M9V]K='56=5-Z,&XU)B-X03MC:7)Z:C=!;U9(=VYO5E5W,$\Y,7@W:3%L,65W
M.4Q6-4Y,=$@Q1T,S84UX4C-$1GI+:49P1'-R,4$K22]-.6-65'HV,U O>7A4
M9F9$)B-X03LO=T)6359D.6)N+S59<'9V:"\V<5EQ-S8S4#A!.'-5,S-W+SE6
M359D.6)N+T%/5TMB-S1F*W%M2W4K='HO=T1,1DXY.% O5E1&6&97)B-X03LU
M+SA!;&EM*RM(+W%P:7)V<F,O+T%#>%1F9D0O04Y6359D.6)N+S59<'9V:"]W
M0W%M2W4K='HO.'-5,S-W+SA!5E1&6&97-2\K5TMB)B-X03LW-&8K<6U+=$<Y
M;4)#;7IM-4AO3U5.5%0O;G!I<F8Q=68O;&EM*RM(+W%P:7)V<F,O=T1Y>%1F
M9D0O,55X5C,Q=68X0359<'9V:"\V)B-X03MQ67$W-C-0+T%-<U4S,W<O.59-
M5F0Y8FXO=T-72V(W-&8K<6U+=2MT>B\X04Q&3CDX4#A!,55X5EI.<5)G:DUK
M,71*1D=/<G4X0VHW)B-X03MZ2FEQ1V)Z2%I"=5!&;6%O57%J=T]14TMJ:T9K
M3D)1.51I<FAR-%DP5%0W,3EY=%)%2V9#4T1U5T$V:D97,3%I.6M1;4Q2-W5T
M1%0Q)B-X03M$8GAJ;#)"<DQY-SE1<"LO8D973F5C3F(O339+9E(Q.',V1D<X
M8W0S1VUR3F-34DYX=#)0>&QE36<T,"]M;V9L:7)*9G(K=3%0*S1K)B-X03M5
M,C0O-E-M+S@Q9F@R<#(X9F)&5W9R,G9S2V9O,5EZ6&,K<VMN=S V,"]D-S$W
M5GA6<UAE=3AH5WE!6&UA,%I#46QD<69V0E9Q8F9J)B-X03LW67$W-CEQ-49$
M67I!:TAC3&(Q0D$O-6E4,4E.4&U-5F(K=&%H5W8Q3SDV5G!7>38Q3S,Y-3$S
M+T%!*V165TLO;&AQ97(S=7%E8VPQ)B-X03M!6'%I1%=:170Q=F]K:F]I>')'
M0D55*T9K-'AR46IB=4]U2W,P,5 O04DU=#,O>&AK+S1I8U9D<&XO2$YT4#A!
M:D1(+T%-4D=+<U Q)B-X03MB.#1F3$]L,S$S6EA.=&9.3EHS<39F2C954U-!
M>7,P0VAG1FM,8V8Y3%1Q065O04IO0W%G9$XO3C=Y9F5E83=E,D)U;W W+U(W
M5R]H)B-X03MJ83-D>7-C=TUY<7=H.5@T=45Q,7!592M+<VMB.'<O2UDR1C13
M,4=*47A34G-/3F1I2D91,7%T2V9W=S!R569N-U%:;4M7-U!-=RMY)B-X03M&
M-$%T=4%A07-',D<K-$@S-#!Q3518-35)*V-6:$Q)=3-&:T1L5W%.-DAH,D]X
M=TMV3W S<E,P4TYL44Y2;6MT<&A686YD94IE=3%+)B-X03M607A63'1F=B]-
M;BM(.5%B5$EY*W-,87HO55DT-#555G!X1BLU,VUI2R]&24\W2T(S4&9&548U
M175F3G-F;$13;R]-9VY86$DW8W!F)B-X03M",4QT-FE--F]794]'5E=,2GA,
M34<V+U165DU*=DYM;5%3=$1,9F]S-$$O8T9J>C5K:C1E4&]C=7@W5CEV07$P
M+VU)3D=41%DS.3-+)B-X03M106]71SAH-59"0E!*-%E9:%-U,40W-'$P=7,V
M>$MX34]J5%%G3E5F6$HU,'%/5F5K160P4&\K:D96<&9Z1DE2.&-6<V@U2WE#
M3%5*)B-X03LR5F%!06E1;45&=FUN=C-X5FAN;4QY>#4U=79Z1#AS-C59,S W
M,D]M>#-1=F9713-"6&Y5:FES56-50F%.:49Q2S$Y.6AI<DU&,6I5)B-X03M,
M8FMU<7=44E)+;3$W8E$S:S!.44%/5&EQ>7!S<'(X2D$V;"MU2W!J0F916%5#
M,T9R8W1.1$E!67!9-&)P,$\U-45&6&]256UN:# W)B-X03M91E94-D939EAV
M9T]824PV8S%!3G9H+W4V,"M(-2]E8U9A0S(T<"]P1CA256MG<$YU0TM5+W4K
M,69N.7=X5G=I,#1!0W0X84%I<&$K)B-X03LO838Q,R\R=3)+<V0X:F9L+W=#
M52]*,FET;SEH.69V3%)P6&U)=FML;#-K0V=J9VM58U90:$@W1F9F1E=3>')O
M,&-H:VIS=45J57$V)B-X03LR:V=*<# S165+;VXY25%F>51F.&E*=BMA359D
M*VM)4#5*=BM213,O0412:7)V,&A"+TI.+W=!:4IV.$%M:D951'%F;3-Y.7!C
M;')()B-X03MQ5C),3C<V55<Y;7,V4U)M5U9U:4IY559/2V\W.4E19GE49CAI
M2G8K84U69"MK25 U2G8K4D4S+T%$4FER=C!H0B]*3B]W06E*=CA!)B-X03MM
M:D989G!#1"M38B]!2D549C@P67$W.4E19GE49CAI2G8K84U643)K4W)*9&%Q
M-FAG1&1R<WES:"]W0C593WI!2$955'%F.$%X>F)V)B-X03LO:D1*+W=!4D]+
M=3!Z+VIM,FXO1T=0.$$T:4U657(W6&1#,#8T:G0W+U5B5WIU2F=$1D903DA%
M-VAN5TU&5F-G;7)S<2]-9UEQ:$Q*)B-X03MT4'5T9D]O,G!I;E,T,"M"-$QY
M3&DT:VEE4C)6:VM7=DI71D-#1%$T<6Y/2W)*65E::S13;W-I9&5,9TU0=4]+
M;THO3'9L*U)Y.&UM)B-X03M7:G5457,P15I.9FU6>%9B+VAN>3E4-&1.=&]Z
M,41X>$I'=RM424999F9I<6YC*U8Y3&UT-6)C4&114GEQ>4@P3'4U:30X:%-Q
M:%I!)B-X03MO4#!9<6@Y2CAJ*UA.3S R,C X,C5V-#=335)24S9G>'4U94MI
M;C)P=59.=7EG1$95-F=T-V4S:456=D5K35,O6FIJ54MO*U%&0FEQ)B-X03MP
M:7)S5F1I<G-69&EQ5S-/9U=5:S=85G5Z,D8V-7$Y,6%K4G,U-E9K46AO-61U
M;G%),4\R2W%8,7I83$-V,3(S1V]7-"]W0U!Q>EAJ)B-X03M+0B]L,C=%:S X
M63)9;G-G>%9(5T]P,D8K:E!A5'),-EHT>6].;FIB*U=21%)K8B]!0U=!3TMO
M;D9867$W1E5.9F%N<#%G<4YE,U56)B-X03MS2D1X:CE6,51K,V=O2BM)*W=X
M5D(O<&DW=4YT3S V855';$HW<71P1C=G:5)44#DP4DAV:7)V,&1R5GEA,W5P
M96I'9BM097AJ15=X)B-X03LO6F5747EY2"]75&AI<G8X2RM80U9E8E1O3&U6
M1T1R4&1)3&EB:W1A35I:=6-H27)S95=+=&YY>F]Q,"MR=T=Y<#)S<$I,44@O
M5T5$)B-X03M2:'9P>%8S-DTQ84EH<F)6<$=P+W5Q-VEI;6I!+W=#95ET-4LK
M-6,T<3<Q+TUC2#DU85<Q-&DY6DE*5VAK668U34UI<V=0>FUX5C,V)B-X03MF
M:FI(*VU75C5A2'=A0G!X5'A,,G9R;V\O=T)::&EQ2G,Y63!M.6-P6C-S1GA)
M3C)J:FM6;4AZ54=O*VY&5E!44#DW9%<O-6EL+S9H)B-X03M93596=%0O-#5T
M,R]!35E:4"M);D9885HO=T%C,C O-'=X+SA21TMP8G)V:W)Y>'(Q-41E879:
M0S=N=#1Z1$5795%+16%22E-#:7-&)B-X03M0>'A+9'@W9$-C5E5D33!$4F)$
M55ET3W1B3TY,3WDP-C)T-U=*:#9N1TM*;E)&-5!Y63!59%-A-'%N2#9-,#,O
M04I:268K4F$O=T)-)B-X03M69"MJ3DXO-5I)9BM282\P>%8S-DTP,R]!2EI)
M9BM282]W0DU69"MJ3DXO-5I)9BM282\P>%8S-DTP,R]!2EI)9BM282]W0DU6
M9"MJ)B-X03M.3B\U6DEF*U)A+S!X5C,V33 S+T%*6DEF*U)A+W="359D*VI.
M3B\U6DEF*U)A+S!X5C,V33 S+T%*6DEF*U)A+W="359D*VI.3B\U)B-X03M:
M268K4F$O,'A6,S9-,#,O04I:268K4F$O=T)-5F0K:DY.+S5:268K4F$O,'A6
M,S9-,#,O04I:268K4F$O=T)-5F0K:DY.+S5:268K)B-X03M282\P>%9#6#-L
M9E%,,&AP<D=*6FQ&175):#95>6IR4EI)*TQG94ER43DX5E%F-DMV<D0W3G1B
M-G9B1',P8U5&,D(W14)92D0X+U0K)B-X03M:>%9"84IR8T]V-F5,>E-V3%5S
M0TTX:UE/<7A2,E%R1351+T-"3DYU4G0K-W W9S=9<6IX-5IK=5%0,&A.17%'
M;DLS<UE6=#%)-FM.)B-X03M),W%49C=*1U0U67%J3%!Y>C5F<S9M1%0T1FM)
M;SAZ27)Y="]R>5!Y9'8X05I(1E54*VI.3B\U6DEF.$%K5W8Y359D*VI.3B\U
M6DEF)B-X03LK4F$O,'A6,S9-,#,O;&MH+W=#4F$O,'A6,S9-,#,O;&MH+S5&
M<B]41EAF;WI49BM74T@O04I&<B]41EAF;WI49BM74T@O:U=V.4U6)B-X03MD
M*VI.3B\U6DEF.$%K5W8Y35958FY13D)U;$-85VTR<S9G,4-Y=WAU069K>6Y&
M57(X;RM79$8P3S@Q.&%88B]6;'4W.%1424=9<GIA)B-X03LR:$HT<7A)5599
M-TQT:7%D86XO>'IB=B]!27=Y9CA23TMU,'HO:FTR;B]'1U O:4EX5DEF>D5H
M;F9167!).5EM,%-/0SAT6&YU<E=')B-X03ME-&YD5$UQ3$-I5S=++S=X,U94
M5EA7;C)L27A62SE%,51124Y$<TQP9DYS;7!3,C%J6E=6>F110T]E-&QC>4,R
M5U=A07!C>G$P:S<P)B-X03MB;'5R5C5(631Q>5!4:T]P869B86A:83%D4S)D
M-45K.71,-F1S=D]/5E$V3E)R8TU+<6$W:D955"MJ3#,O<3=86"]!,G8O5D1&
M6&9O)B-X03MY.2\V=3$Q+W=.<B]!3E5-5F0K:DPS+W$W6%@O04%.<B]W0E5-
M5E-7.3$O4G)(5B\P5&9E6DQI,'9326EV,6E+0TM%;6-S26M79#=:)B-X03M9
M5V1Y:F-51#AJ5'!I<F-'=#962G%D<'!#*UIP<&13=DE6;G19,%,R26UI35IK
M.5=*:&)L1U%Q<%!)3E1&534O4FPW+T%.6&$V+S1')B-X03LQ+S9O67$W.4=8
M=B]!1F1R<B]G8E@O<6AI<G8P6F4O.5AA-B\T1S$O-F]9<6@Y46IF5#=#-78W
M=E=,=$Q7>FEE931D67)D>7-C4VPS)B-X03M)4DQD;6%I:F]O2D]+<%!$-7 X
M=GI7,7AD>&5A<%-L;DAC4UAD;UDW8UAA0S%!95AL86TS1G=#:3<X9E1Q45%2
M,49653 P<5).5W,O)B-X03MR;6XV,V14,GAK;&A%;G R-B](0DLP36=O,75P
M,F1#2SE$,492:7%-+U)L-R]W0EAA-B\T1S$O-F]9<3<Y1UAV+U8R=78K0G1F
M*W%')B-X03M+=2]2;#<O,61R<B]!24<Q+W=#<4=+<%!R5W5A5&]L,41B870U
M:75B2G T,FU785=+1EE&:E)L4FUK=5!Q,V]X1&Q);RM.>'52:7%Y)B-X03MB
M6'1(=#=Q>7,U=DTX>C-'<%-V1EE#3DQ:,6QD6D1',&%-;'5Y;&\R1DA&9'%%
M;6U+<#,K:DPS+T%+=3$Q+W=.<B\Q47A6,S9-=F8K)B-X03MR=&1F.$1A+SE5
M359D*VI,,R]Q-UA8+T$R=CA!,5%X5C,V379F*W)T9&8X04$R=B]!1E%X5FIM
M;2MB9DQM<'%R5V9M<5E0.$%#9G%S)B-X03LX545&>39Y4D=34&AB>E<P8WIC
M,2M*4T502VAP,$]+<&YO,35"<E5%<RMN83-E>7A1=7-B<S!%35<W>$I/<%@Q
M8EI/4W1(36I";#(S)B-X03LV-'%M2#9-=F8K<G1D9CA!03)V+T%&47A6,S9-
M=F8X07$W6%@O03)V+U9$1EAF;WDY+S9U,3$O=TYR+S%1>%9+.6,Q2WHP3F)D
M.54Q)B-X03MY.&=3-F1O-'!"0D9);TM)6D=,=$AB3TDQ5D5,1FYO;T$V-'%H
M=CA!1VYK=E)B6C=U-3$Q3'%#.6-4+UA506YJ,T9R079+4S%1>$Q8)B-X03LV
M>D%25VQ68FPP<6-66DAQ9B](3G4O.$%J1$HO>$4T<3=44"M/8F%F.%E9+RM)
M:D97-R]4=% Q1S!E>C%#,6EV3%-1<5I,93126EDR)B-X03M+34A5;$A"53A7
M54U08UEQ9U4X;RM622M(<#9,64IW24MC8F%%8U-R37EK55AA:D]X2'54-#1Q
M;61V8G=7,$5D=F)X<$1"0V]32T=.)B-X03M1<4EQ:6=65D9!04(P07A69FER
M<U9D:7%86%AL>GDY9#-J6#$Q<&1P4&5S159R<5=#2C5326TU4F=U>6QV9V)D
M9#EJ:7$R,#AS95=R)B-X03M/94,T=$Y*<W)E-'115G1P;W)E2DAJ5F=1=U)L
M549143=6<#1N1E5Z>%8R2W5X5E1U<E<R=3=A5S%U;VMU3%<T4F]P-$I61'AV
M1S0T)B-X03MS:G$Q47ES1%%G-'%L82M49DM#;UDQ,%!4,5$Q<6=T65%0:30Q
M,C0Y+U18-V@T67%M;'1A,C%R0TEB84I)25%765)X<4551C),36%,)B-X03M1
M9D5X2E!V:7%P:7)S5F1I<4$Q1'DO;T]P5$I0<4]M,G0W3D=J4E)Y,T5%8W),
M2$HY=$%Z<7A#=#-(9D962F9+;FQ:6F\U;#!E>$4P)B-X03M5>'59<$)B46AK
M;DI$1U94>'%(<4%E43-X5DY-5F1I<G-69&EQ4WAE4U!*8U-):U=G86)':V)2
M>5)Q='!!07)X16U.;$%467!5.%0R)B-X03LW67%M;'):5V1N1C96<$)(8GAB
M9G4T:U9&*T919S)506)+;TAY1TMQ,DMU>%8R2V]454Y(,&I5:D-D4G-B93E.
M<R]Q5S5U26ML.4YY)B-X03M+8VLU9SA443!Q35914CAM*U5#<G%D1# X<DEQ
M>'5V,5=#:DEG54MP*T1C3'=79SEH:7%0,4E!85ID06)!47EF.%%/2W4P>B]!
M235T)B-X03MP+WAH:B\T:4U64D]+=7A6,DMO0V%'>F4O;F4V4TYK:FAI4$M5
M2U%T6&MR=3-41E5)*V\K5$DW-DMW930P.6(R6D=L:71I,$EK6D5))B-X03M$
M348V:T-U2V],5V9-,VM84C(T,WAI1$=0,6@V3G)*8U94;'<R.4-/4W)C=C)E
M=G1I<4=(;G(X=$=T=G)#6%9S.%%2<$MP8G5X-$MY)B-X03MO5S1R1U=P>FM6
M83 K,&%D8TMR;3@V9FPV1V1526XY3E!66G)E>'5*,31E<V)A;V%+1C%0-S53
M;7@V9RM'2V]-9FU4*U9X=&)E.$5W)B-X03LK<5A69E%U4#!F9&5M>%AJ>4A,
M,$M";$1!<T1U;W%4<T112VIO=D]0-65Z45!01$I&3$=I<3E5=$I73$LU54M9
M=TEI6DLK;U!S5B]!)B-X03LT5E5,;GHY*U=T=$\X13!Q3$EN3W1,1S1:9C-C
M6FQA:G)#5E W<V-H43=J<&EQ=G%0;2]Y0G!Z4VDX2U)#1&M:;D9L339,=TA*
M<7-S)B-X03M43'11.2MO239G-'$Q6BMC+W=!=3=Y-71,83)L:&5E*VQA0S)4
M-G)+=DM24%4U2U,P44-K96<Y9590>$965D=0>C<K5SAQ3$I#-&UI)B-X03MD
M43AC<U9H8W9'>7-O8TUJ<D%666-453!/,V9&53@P5S4X<V$S66DK,'1)3'$P
M3'1'2FQI-'%743!A;DI6<G8S-EE&5619,6)Y6&\P)B-X03MC36UP>3)D<6LY
M=W1P15A64&EN8T5R2'-$.%(T;D954')(;5AY1F\P<5(V;%!A,C=02$I-<$U8
M2E-K2VQP1'E25U@T1E5K:7941E9")B-X03M03T@U9',W2UHW9$%J2VAL:W0S
M:FE,3D],6E%S:GAQ:D5Z2&IS9F9P=FA6='9.,S5F<$%S-U!'23)I96-(-G!,
M55)X1F<U2RML554Y)B-X03M.=&E+:V)J66I&52]G<W1*;FAJ;6ET651(2V]D
M0UEG<$MS2VI99T5F5&=646YF>7IB<6I80G-O5FMD630R:TU3:&YF-TMI=$ML
M<6)$)B-X03M&54IQ,G)E5'1)3G5.4DYT0CEA:SE#02ML>D132%E*5D9A:%!A
M=4MP6D@U-B],4U-)>DIC,C5T>$4X-75F<3!N;VE.259U1UEY*VXV)B-X03MF
M.3 T3D]7+U1R=&EQ=DPU=2],>4M70T]7-'1O>F,S4G-91V5";%)P=T%E26-P
M>&]E431V6&DS66Y#<4EI.'AF;#--6D)$<65K4T=*)B-X03ME8W9#93)B:71!
M95158EE564@V8T-U1W8O;"M:,6=7+S!X<%=D;V=Q>5%.4C0R0TUH24I!64]W
M56<Y>E1R:7%.,#984S=I-'1R=E16)B-X03M4-G9.1%!34TY/2$QH2D=P,F]P
M,DE/2W!R:7)S5F1I<4<Q4"]!235T,R]X:&LO-&EC5F1P;B](3G10.$%J1$@O
M04U21TMO;D9867$W)B-X03M&54),4%IX,S@V6%5K84I*0D5/37!50FAY:W)S
M,UA&54DK;F542DPV2R]E,S Y<C)&1VEI=5-S2FM62$E,2T<V9T=M2W%J,C-L
M3U-5)B-X03M44U)71'EQ;G!I4FQH3$)/469J53<X96%H<65)<FEQ:DAP6&ME
M2UI:-#=05$5N4E)':W%X,C1D554Q5E%W1E%!96=X5C%V<%!K93)!)B-X03M&
M=%HV6D-!<%%#3T\S4VE&9S58641B;6ET5'A!3TMQ0RM84'DV47%6,'931DLP
M-&M15W=P46=I;G<Y:6]/2W%S*VIE4DHR3%0R3VQY)B-X03MS4GA*94LS66M5
M554S2%-I3#EW.$U65WEA1"M8.'-Z5'EA9'!,>D]83'ET1&)&:5I"4GE727%E
M438K3TMQ='AP;FMM-6U-.7AA86).)B-X03M-4U-:6DDT1UEK<490>$5%-W%O
M2'E'2W)2<$AK54I#9W-T3$-7-G)(06]I=#92<$A527%#;G=H95)O0C!X5EE.
M0R],.%%R04Y/,&M1)B-X03MQ>&M73#!B8FE(63%,0F%5<50S>%9-<E=F47)3
M3#!B5U,Q=#114W=J:6%.1G%456UI,$<K2V]B5C=8>7!R34U-3W%R6C-S5G9-
M='I!)B-X03MK-6IC2DUG25=2451S>6AJ431Q=G99+TLY.&$S>3).,%%P4W,T
M:&M013E6*TMU,W1I<4%(;'8X04QK5R\Q66%8;S1T+U0Y2#!F471E)B-X03M(
M<#%,8T]01VY(:WA.3596671).&M2,G=T5G1T4$YU<7E2<D4T:616:FUK.5=3
M34)Q,%)N*TQI3G-65$M+.3!I1TI9;V)I,VII4553)B-X03M.2%)604A904=G
M>%9"-G9A959D6E,R5%90<70R;&YC2F0R;VMD5'=N:7)W:U=H-G)5-'%R,V)E
M6&(P24QW,FQY27E39VU-56Y%;G)4)B-X03ML5VU+<&1&-64O3'E*94U7;6%2
M1W188FES1G-"5U=N<4A:9C(K235E3TMT,BMG*U%R93)A,6AS=$Y3,$PK;TQ9
M2D0V4W121G%K6BM")B-X03M0-W!0<V=D0FEQ>4QY,2M814MS<U=L85!'<D1I
M>7!B,G%G<G1S84PP,GA69"]H,SAU>$]B9V%:<$AR;&UC>2MH8F,K8G-'6G58
M1W17)B-X03M:45-F15EQ:G)&3DMH=6)7,3!X64ER5T-#6E5G=&=I>&]#.%IO
M1E1:92M+<'!I<G-69&EQ1S%0+T%)-70S+WAH:R\T:6-69'!N+TA.)B-X03MT
M4#A!:D1(+T%-4D=+;VY&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&)B-X03M867$W1EA9<3=&
M6%EQ:'14+W=#3V)D+SA96E K26Y&6&%:+WAZ8E0O04EW>"]W1$52:7%*>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+)B-X03MP3')F;E!Y>F]D=TQB53<P45A"
M:CEB,%%K:VHK;E-2=69'3EA.2U%V=C=F3$95<"\U5S4K6'=)5G146DI4-E(Y
M0G)7-U=7:WAP1WAJ)B-X03M-46-+5RM(;%-G8C14=G1I<4QI+TUJ>5A)=U9D
M4D-L;S1:5C5X5$I63&QI:U(K3D(Y;VHV3W R>'!53$XK8F8U9E%3<D1,<6A3
M5G=R)B-X03M2;V)E-G$T:U%3255(<&9%1T1!1&HK,3A0,G1S5E=T*V(S:T%2
M=DHY96Y-8V%X35I&<TPU;%!R<7)20E=%0D1--&-55F0X5E)P+TUB)B-X03MY
M67,Q<D%D47!,96A48DM96C9S6%5S12MX.$PX5DI+2#1H5&-9,'%&9C@R4$EI
M8RM6.4U"1D0Y6FU)<W(P:4]+=DAL25)$4DYX*S%4)B-X03M&5DTO;D0K6%@Q
M5T,V6%9J3$1D4FEA,V%+,G5P4S9%;W5Y<$5Z5C53<79';&%M;$LT<6US2&YJ
M>7AC44=E1S=A4TU7+S%Z84-F:UE$)B-X03M%<R].5C1C;2]D=4110W9B<FEQ
M<'!F;D1Y-W%L,FQN65AF<EA%:5-3;VYP>7)625A%8V@U37%R<S5P,7A63V-6
M9&ER<U9D:7)S5F1I)B-X03MR<U9D:7)S5F1I<4<Q4#A!-#5T,R]W05E:4#A!
M:4IX5C)M9CAC,C O-'=X+SA21TMO;D9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<6QE)B-X03MP95<O2SDW8T<O,5!3<D<U=45J6D=U-VU#1U(Q:4DK2E1)-FMH
M86125VU+<TDX-#)N;&)5<D=%959N.'%N55=K-71092]61TAP4V\W)B-X03M"
M;S926$AX;#(Y445R43!0:6-+<V)U=DQM=&%:4#E::#$S>71A5%!)-%54<%E2
M56AH3$)5:F1B3D=$5S1#34=B:T$Q459)07A66&<P)B-X03MZ5C=,5#5(=G9-
M6&QM0FM+:E5,:%192D=),F=#4F,K5FUO,VMI2E5.,E5B;FIX>%%G<&1';&Q9
M-F1$-6LX<'I,3456;T-U;41M,$UI)B-X03ML,45!<S50-W5,-$9*63 R*T5D
M8U5Q,&1N<6M-<4IC96)02W9R3G P:6%:25)P-G-'-&])2&AJ*W)!<F)X34AO
M=DHK,BM+;TLS.'98)B-X03M&>F1433-M5'ED1W)/<TU%2WAA6F1#3EIM6F],
M6F8X05),6F=(-# K2FU,54I50VU+='(U479R,714:71F35!L63(Y=DDX3FI:
M47@V)B-X03M43$1!2#5Y2DA-:# X<V@T>&EQ.&I8:7@K4W)09DQU;2M7=$\P
M5#9P-7-U3D5M,4]"<&MV;54R:4IX.4U)-E1"67)21W!#-CAG66Q&)B-X03M/
M3E)S0U9765=E:#9&83-!=3=05#=70S0T1D9U25E9,&8P,F)M5D1Q065*8F5N
M:F=62%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E5.)B-X03MQ9CA!>'IB=B]J
M1$HO=T%23TMQ1FIE4GA75G9&2DA-2%-*1EEE:$UA14M!96DT<7(O<$-$*U-B
M+T%*151F.#!9<3<Y25%F>51F.&E*)B-X03MV*V%-5F0K:TE0-4IV*U)%,R].
M1TMU+U-%2#AK,R]):6(O;6I&6&9P0T0K4V(O:U).+WI2:7)V,&A"+TI.+WE)
M;2\U;WA6,S919R]K)B-X03MM+S5%5&8X04Y'2W4O4T5(.&LS+T%#26TO=T-A
M359D*VM)4#5*=CA!:U).+WI2:7)V,&A"+TI.+WE);2\U;WA66DYD,FLP5'A3
M4GI')B-X03M/4E-J:C!:>%5-2TAC3%A&5TUP-4(X9U)P2DA(<&QX2$A,0TQ7
M4TY$9G%H:$-'4# K2W-&-#A73S,P.6-+<C(X:BM2;G-7<TI.4'5P)B-X03M,
M4FQD4%1K8E5(;W-G5EA#;&U,3'E%67)1+WAX5D-W+VQN*UA%1F<Q:$1P9#!L
M<2]P;&M%;7!6<D-3,%HU."M12TUZ16(Y4V9(07%O)B-X03MN-60O;#!K;'4V
M-E).4S%:5W0T5#EE34M&1D-P>&A*.5 T44YV:#)W<79N.&=E47 U<F5A6%0W
M=&YT13E/1#DU<4E64E%I<%5/1EIQ)B-X03M-9FE)-6(Y8U918R\U5F9L:F-8
M,#$O4'!&>DQE6$A!>GI.2G%26B]48FMV2W(W,&)F07%-=%!)4&M+,#E8-G9P
M,3!G;68Q2E%8,4)G)B-X03MZ56-B:&U),CE:>4(R2DHV-%98,TAK:GE69%!.
M3&4R5C-D>C-#3DAC5'I.9DTX:79'<U0Q;U%">5)".6M$9F-B-'%Y5F(V,E91
M;U-A)B-X03MG1D(K-&U05"]9649B+U-%2#AK,R]):6(O;6I&6&9P0T0K4V(O
M:U).+W=!,%EQ-SE)469Y5&8X04EI8B]!2F]X5C,V46<O:VTO=T-2)B-X03M%
M,R].1TMU+U-%2#AK,R]):6(O;6I&6&9P0T0K4V(O:U).+WI2:7)V,&A"+TI.
M+WE);2\U;WA6,S919R]K;2\U151F.#!9<3<Y25%F)B-X03MY5&8X:4IV*V%-
M5F0K:TE0-4IV*U)%,R]!1%)I<6AF6&MC=&QC4E)X>D8S:6162&]40W!+:T1Q
M=4MV.$$O.6L]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4
M:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @
M(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @(" @(" @('AM;&YS.G-T
M1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1F]N=",B
M"B @(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]G+R(^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%10
M9SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R
M96YC>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @
M(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#Y4<G5E/"]X;7!4
M4&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @(" @(" @/'AM<%109SI-87A0
M86=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(#QS=$1I;3IW/C@N-3 P,# P/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$
M:6TZ:#XQ,2XP,# P,# \+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I;3IU
M;FET/DEN8VAE<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X;7!44&<Z36%X
M4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z1F]N=',^"B @(" @(" @(" @
M(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.
M86UE/E1I;65S3F5W4F]M86Y04RU";VQD/"]S=$9N=#IF;VYT3F%M93X*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^5&EM97,@3F5W(%)O
M;6%N(%!3/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14
M>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SXP
M,#$N,# Q/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^351"7U]?7RY0
M1D([(%1)34533D574D]-04Y04RU"3TQ$+E!&33PO<W1&;G0Z9F]N=$9I;&5.
M86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT3F%M93Y4:6UE<TYE=U)O;6%N4%,\+W-T1FYT
M.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL
M>3Y4:6UE<R!.97<@4F]M86X@4%,\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y2;VUA;CPO<W1&;G0Z9F]N
M=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E
M(#$\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M=F5R<VEO;E-T<FEN9SXP,#$N,# Q/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N
M=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL
M94YA;64^35127U]?7RY01D([($U44E]?7U\N4$9-/"]S=$9N=#IF;VYT1FEL
M94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @(" @(" \
M>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @
M(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @
M(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z
M4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E
M9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @
M(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q
M/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C
M+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z9F]R;6%T/F%P<&QI8V%T
M:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA=#X*(" @(" @(" @/&1C.G1I=&QE
M/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL
M:2!X;6PZ;&%N9STB>"UD969A=6QT(CYG.#-B,C$\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @
M(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @
M(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E<&%I<B(^9S@S8C(Q
M+F%I)B-X03M4:'4@07!R(#$X(#(P,3D@,38Z,S Z,#$@1TU4*S U,S F(WA!
M.U-C<FEP="!V,BXT+C(L($EL;'5S=')A=&]R('8Q-BXP+C F(WA!.T=R87!H
M:6,@='EP93H@3&EN92!#:&%R="8C>$$[)B-X03LJ*BI4:&4@9&]C=6UE;G0@
M:&%S('!A<W-E9"!P<F5F;&EG:'0N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I
M;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B!;5&5X=$9O
M;G0@5&EM97-.97=2;VUA;E!372PL6U1E>'1&;VYT(%1I;65S3F5W4F]M86Y0
M4RU";VQD72PL6U1E>'1&;VYT(%1I;65S3F5W4F]M86Y04UTF(WA!.R8C>$$[
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.V<W-'<T.2YA:28C>$$[5&AU($%P
M<B Q." R,#$Y(#$V.C0P.C0X($=-5"LP-3,P)B-X03M38W)I<'0@=C(N-"XR
M+"!);&QU<W1R871O<B!V,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z($QI;F4@
M0VAA<G0F(WA!.R8C>$$[*BHJ5&AE(&1O8W5M96YT(&AA<R!P87-S960@<')E
M9FQI9VAT+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P
M<F5S96YT(&EN('1H92!D;V-U;65N=#H@6U1E>'1&;VYT(%1I;65S3F5W4F]M
M86Y04UTL+%M497AT1F]N="!4:6UE<TYE=U)O;6%N4%,M0F]L9%TL+%M497AT
M1F]N="!4:6UE<TYE=U)O;6%N4%-=)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@
M(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @
M(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.E)E;F1I
M=&EO;D-L87-S/G!R;V]F.G!D9CPO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @
M(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z0T5!,44Y-D9!1#8Q
M13DQ,3DW0D1#-$)&1#)!0CDV,T4\+WAM<$U-.D1O8W5M96YT240^"B @(" @
M(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z0T5!,44Y-D9!1#8Q13DQ
M,3DW0D1#-$)&1#)!0CDV,T4\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @
M(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#I".41#,T4Y,T(V
M131%-#$Q.34T0T(R-#!#035!1D)",3PO>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YU
M=6ED.CDR.&4T-#!F+68V.3@M-#4Q9"UB-F(W+30P,&,Q-# R93EF,SPO<W12
M968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^
M>&UP+F1I9#I#0T$Q13DV1D%$-C%%.3$Q.3="1$,T0D9$,D%".38S13PO<W12
M968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C
M=6UE;G1)1#YX;7 N9&ED.D(Y1$,S13DS0C9%-$4T,3$Y-31#0C(T,$-!-4%&
M0D(Q/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS
M=%)E9CIR96YD:71I;VY#;&%S<SYP<F]O9CIP9&8\+W-T4F5F.G)E;F1I=&EO
M;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @
M(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z0CE$0S-%.3-"-D4T130Q,3DU-$-",C0P0T$U049"0C$\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,34M,#0M,3=4,38Z-3$Z,C0K,#@Z,# \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A
M=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D-%03%%.39&
M040V,44Y,3$Y-T)$0S1"1D0R04(Y-C-%/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3 T+3$X5#$V.C0Q
M.C R*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O
M=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \
M+WAM<$U-.DAI<W1O<GD^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @
M(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P
M9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D
M9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_
M>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!#
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &> F # 1$  A$! Q$!_\0 '@ !
M  (#  ,! 0            <(! 4& 0,) @K_Q !>$   !0,!  P*!@8&!P4%
M"0 #! 4&!P ! @@)$Q46%U97E9:7UM<1$A08-U58=[;5&2$Q5-/4(B,U.'6T
M)$%Q>+&U"B4F)T=182@R,T5V-D)$4F(T1E-D:(&$AJ7_Q  8 0$! 0$!
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MJZG- L(O:1&%*28U&FL1(A18Z9+/CP.X5)K,EL32Z3K*C5R.!VHK#4FZ10G
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M6#JRB/@NWS0@!++--Q/6&+;>6DVY4WQ%]U[N9-E?2-$<:L"57A&!P9O2>*E
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M_!I9!6C-+/BNM52'2B$I$[-:6Q%M]L3-/ERFR8NNSA]H*,E H% H% H% H%
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M,%A^+1$UPA(H"^GB1^T\R*X"V\ PVZ"L%,DBX"F$@A@A8(H9T,?!+P"#Q(V
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ML>0\_;1K[1T7=( _PZ4G+6/(>?MHU]HZ+ND ?X=*3EK'D//VT:^T=%W2 /\
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MWCU^&U*@PX1]#$1>[!@_"B302?0<R]3CE3F<[5!F$4=4>!%LKQQJ)CA4!$E
M47*52S0Z$17%0$,89-1S:I@5+J:@$"*(3)"#F, \\@[8W#YC%=D.-$&%&5W$
M=:B3*KBG>)HUD9GO-GN!AJ<=I3ODV)V.[6P>1L'<Z2*Q(19,D;)U-1>:[L78
MY6V5=,?2<IK2(?;X;M-?&_A,UC??I=OMRPXXILC$LJ"0TMJ93&3E1ZZ2F;K(
M+JJHG.$-MMALO>%IYDTI#"UE@Y<1S[\0E2($P%5=@!I-)FVLLJBF"RB!E/+[
M:*6TOMF-)BVZR+?;EH]<S[3S&@Z;UTXE.<G=Y0 ZE JG%FLY%TTE"*;2N?\
M)%[) 25(%$R*6-8ES!E6S(E+#!C8V&\(>=L=;/Y1[N8G[CO&*SMI=:G@M_JF
M3_LM_P $9G_Y?^@:RKSPNM3U3)_4C,_8&@<+K4]4R?U(S/V!H'"ZU/5,G]2,
MS]@:!PNM3U3)_4C,_8&@<+K4]4R?U(S/V!H'"ZU/5,G]2,S]@:!PNM3U3)_4
MC,_8&@<+K4]4R?U(S/V!H'"ZU/5,G]2,S]@:!PNM3U3)_4C,_8&@<+K4]4R?
MU(S/V!H'"ZU/5,G]2,S]@:!PNM3U3)_4C,_8&@<+K4]4R?U(S/V!H'"ZU/5,
MG]2,S]@:!PNM3U3)_4C,_8&@<+K4]4R?U(S/V!H'"ZU/5,G]2,S]@:!PNM3U
M3)_4C,_8&@<+K4]4R?U(S/V!H'"ZU/5,G]2,S]@:!PNM3U3)_4C,_8&@<+K4
M]4R?U(S/V!H'"ZU/5,G]2,S]@:!PNM3U3)_4C,_8&@<+K4]4R?U(S/V!H'"Z
MU/5,G]2,S]@:!PNM3U3)_4C,_8&@<+K4]4R?U(S/V!H'"ZU/5,G]2,S]@:!P
MNM3U3)_4C,_8&@<+K4]4R?U(S/V!H'"ZU/5,G]2,S]@:!PNM3U3)_4C,_8&@
M<+K4]4R?U(S/V!H'"ZU/5,G]2,S]@:!PNM3U3)_4C,_8&@<+K4]4R?U(S/V!
MH'"ZU/5,G]2,S]@:!PNM3U3)_4C,_8&@<+K4]4R?U(S/V!H'"ZU/5,G]2,S]
M@:!PNM3U3)_4C,_8&@<+K4]4R?U(S/V!H'"ZU/5,G]2,S]@:!PNM3U3)_4C,
M_8&@<+K4]4R?U(S/V!H'"ZU/5,G]2,S]@:!PNM3U3)_4C,_8&@<+K4]4R?U(
MS/V!H'"ZU/5,G]2,S]@:!PNM3U3)_4C,_8&@<+K4]4R?U(S/V!H'"ZU/5,G]
M2,S]@:!PNM3U3)_4C,_8&@<+K4]4R?U(S/V!H'"ZU/5,G]2,S]@:!PNM3U3)
M_4C,_8&@<+K4]4R?U(S/V!H'"ZU/5,G]2,S]@:!PNM3U3)_4C,_8&@<+K4]4
MR?U(S/V!H'"ZU/5,G]2,S]@:!PNM3U3)_4C,_8&@K%K6E)LGM(&IXD F2-@,
M;@>5"P69R'I;3BF @S,6 \,C*@H,@J0)%\<LK7%-'#(!4OAXPHXP86.6=K%\
M<82?N.\+MH_[)2_X<2_E@JBMC0*"/)=]$\G^[QZ_#:E08<(^AB(O=@P?A1)H
M)/H,%33$U;35!&64\BKHZN1-IBJE*90 ^FJ::?+B%3R>H$308I4Z1.E112QL
MH9"$ , "" C!YAYY8W#CT>+(V0&^"U4AB-,FW %Y*=8:/9"3AB.^E"4TQ:0W
M,("8 &L.XD581$5425L:XBFFGT=)-DC0 Z:2S #!%A>(!TXZD#Q='XR6I+ S
MA4$X5H( A(ZN&4PXB&50T5R(7!'.FD124D0T.+AEF915)12!KB)QXV6&"%=>
MO[EVJ#W)O_\ R$W6MC\HY]I2;N<=X6UM]EO[+?X5E7F@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4%6=<7[FNJC^[_+/P0M58OCC'=)NYQWA95'_9*7_#B7
M\L%45L:!01Y+OHGD_P!WCU^&U*@PX1]#$1>[!@_"B302?0*!0*"I.O7]R[5!
M[DW_ /Y";K6Q^4<^TI-W..\+:V^RW]EO\*RKS0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*"K.N+]S751_=_EGX(6JL7QQCNDW<X[PLJC_LE+_AQ+^6"J*V
M- H(\EWT3R?[O'K\-J5!APCZ&(B]V#!^%$F@D^@XR1CJLFQZ_%%!<+>:2X09
MCH.HKK=P5QVFV58JB'ATYPN<'$P5R&;R*<#!4EH*QHM<1-+&<+& ;WVS$/FN
MQ]1,JKD=14JG7R^R4G(6I>-XLEZ.]I@=S!J"*['/%S?=!X@?+MMLGY&BXFFO
MY(<" ^8VLP'JU"KJ%.R"VC2ZQ%Z*+EI3.)BR?<[,,[I<B]-3>HAHE'[D9?*2
M,2Q59Q>B!)S248\DZ);MIN:?G_*L2QTS5!/BMEJ1-6-&4+=%]-AX&GR[\$IJ
M@&T"0S*6^T\1.+2/-:UBVDSGANX+.:YG,X<]!TWJ)QB+XJJX( =1E>2TLVV\
M-Z!TXTKF3Q=4S<"^@CF 2)H88G?<H!2.99%L\LB>/AP\?6S^4>[F)X[XMYQS
M6=L_G7X+?[D9/^RW_FT,?\O>[65>=_SKY$9/YVACO=H&_P"=?(C)_.T,=[M
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M.\+MH_[)2_X<2_E@JBMC0*"/)=]$\G^[QZ_#:E08<(^AB(O=@P?A1)H)/H%
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M6YTEGI:&GB!&R9S!:.";A9$S(8N*GD)@,$&*9Q'&OAZWJ\]2@B6MF(0;TN2
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MK]1@H(\EWT3R?[O'K\-J5!APCZ&(B]V#!^%$F@D^@4"@4%2=>O[EVJ#W)O\
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MXGDDL&_$*"XV(18.\CUQLRI:Q:Y@Z3"''M_M.;T\+S7N7C\T&B2B(%)1OR-
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MT!\H *EO+[AFA31,>^V^X,C=.8?*) QWDQK<HGE?'BP7A1=%C#N.[09R\GD
MOP07"CDKY3B3"\L;AJ4AK #F3'D-Q"H18X/9]KX8]U::[%F!E9@1;D<43NUR
MF#>7W9B69R?Y26Q\J8!G@/S%DH[Y)D<'\@<12* /*0"Q7=+:C0IPF+/8_;W[
MJS#Y1(..\6-/(TTI?.*Q^%AT>4/(]M!G+R>02O OM49E/*<"8-SK<.2R-8 <
MR9\@VPH$5.CV?:^'$.F676QRT>YO0#3ZT#BL-823@'3J%4F^6:21Y8 #=0CT
MVJPX5%DP:Q:R@+8JX"44E;G"@!+=*P9D<X1'#DYY^:CTV+1G'E)KMTNQTGJZ
M0.IP*:?6IP!I#RM<L6L(/FX2J_%Y %F)()@VC!#*K+.S%<(LIV-9$;"8E2A\
MM*W5G&R[WDQG-J+56FT(7>BFEQ2>1I(S!,N-0:DE26^DPDB&,4\Z K1,:9.G
MEP&Y:Q,HIH=1*XK2;%9 UG@1+@JF8)\0\1'O]VV/>J:@76E,US2+G&1E29YV
M]B<-XMQ$U'NA]/)6N MY8AR?&#=TNJ;[AE#N;2,0-\V"-(2;B <+FLK6S.HA
M99%/W=YMZ,<.=9@/1JQ)#0=/*DO#J2Q9.D=C[NOAG/=L$]U")')283?E"'&$
MI/P/ H.=4;XO(K#Q?(,F'@$=$#,YF2HY^\J^WLQ"E_4&LM>67,9TFKS?--:]
MPHA8ZY+T9X/N71K%01;&%8),-J;&C!+R-&<"MAU5_.%6M@253&2'C8)*"6B<
M^_A^&_*&J)>0$\^;TJH;-7[^/9:;[RU"-JX1;*X.68%T)98K*?@"R%MV.T&L
ME0JV!0+YX"%P3V&V;66S'I^_/T_A^E396ME)2-FIRTV)4[JR*S<]>D?1<7@C
M%>23D9X-Y9EAL(N<?&W[C%&#NWG*) _FE*3F+M,5:*I)LRH$T<V8!!+C'HC8
MV/\ IUI;\9FN^Z;;]']PK-3M:(RNUE*07?I?3D$7*^;U9K-CB5EE7(8X'B&=
MB[6DM;E-!)*V1E-Q5"USJM$R+8D>&('?(#X!8P0-GGLSUCM3[8[6AO463<SV
M67GK#=;A0E@F>),9H-J&87:*<RLCP)L(-44E12;3S7G>L).8I0RD9"*2$B;>
M4RQ6T%=+&<BX8K%EG>WJP4O203)/1@2"HZBM6CA<S'6E5=4 %&>'"09$B&53
M.V6)%^Q0VRJ%%)I#2@\S)=(0VXRFTFEPS.W& #9TDE&R K?9%N5W";^KR-H5
MTH'G[($HK4/I+HD.2E<FNN!X/%==SR7$A5(9F,R9N.#;H<"ME$&8&9G+*UHG
MLRL!,P"(@V(HB<0R+"L^_>/-+X4%0O@.QCHT5L%24XRRVR/%Q;:J,ON)E&+A
M$ <SC:<:V44%U(/BA)26&.H$U (Z/BFD+##B>2%]K)6<;[\TAD$5'2ACYE+2
M4Q-,*IK,\J#D"!4F,I'<\L\LS9\4N$'F<-9Y"9Y9F#&0@N66>=[YWOE?PALZ
M!0*!0*!0*!0*!0*!0*!0*!0*!0*"K.N+]S751_=_EGX(6JL7QQCNDW<X[PLJ
MC_LE+_AQ+^6"J*V- H(\EWT3R?[O'K\-J5!APCZ&(B]V#!^%$F@D^@TCE<B$
MSFXX'<Z%0HAMEJHBJY'$M'Q-J(HZ$AD!U-75#HO@OM91/3RI@V9$\%_$!!SR
M\%_!X*".$2>HR7\6'Y(JKA063'@HL)EEEIDO=!,JSK2V"X90-I@@2PW25TP.
M[$:J^OE%16N12% -.$3R!\RK"@$!13WG1R(NKK3J"D;NB241W,R*8*I<;!$=
M(HI]MBM5T/@L]4HD$AYGE>/CK19+N<"?(286-LA13FZK#$5\Q<H)C8M)]]]O
MN5?V5C5# &GS1S*I&9I2;3 -3''#^9\8!+.9W/?FY;MO,Q9)1\R!,X'F8R -
M%Q<<A\P0,L!<<K"WMX?!K9LVH]W)\9VK(B9FL39QA=&"9[A[4S&2#,<#/Y$D
MV,7*.KE4)Y-ZYNZ2IF&^KG4!9"+W/%29GQD]833R>/XY?"VWEA/$OGAXN5\D
MQ,63%)PFQ(I]RMU*Q5,U1?14W!#2S"XMY'U4B3Q1T4H%D.;6%3(P.'9/2RH&
M&0QA0-W!* A8Y""#8X6O>P1?EJ/@'R)BJ1:9HU5$^3UD9O1R=0GBAN L^5HJ
M:,$CB>U!D,ZH8+HZ>;)G %+<ZYC!-$)F['LR_DH]PRTG"Z]QQC6/IL+R6[H;
MSE%)O*C+QO@H,?).7BRPM*GDF)S!LL44ZE%DN1G@)CGB7LT&&H.)R!G[Y)XZ
M8$="% #)3>YI<UN0NBKK):%S(QI^NYS);:58U-.V(FA)T<[MF2@*4L2#'<B2
M:S7BG)Z@3/$EDBG(2,XG4>1CA,Z2;ACRPJ$,6GMMO"8L;-]ZHB[">KY8BK'C
MPW40F\ I,D^1;4B/-)?:L?)9BIY$SP0QS**TT4>Y_&Q%05U%$/*A(/ P=+ME
M1PQ+!'"/3(,[2)']HX3G P12KI5QL5.0TV/(VU.ZA6PD-W!6%*>2-%^QM J>
MD&W(<(EAA?)'L398J8.,6&S3%),S /'"^WQ#8O=_R^UQE@V21W$^4-]MTP-&
M"5&\%C@O"-%+<TIXAV45I_S@DM]PCY'5$,V2;]FK'9@/$B>35 ?,4L*8N3WC
MT8+B.S.GL6'%TL3U).QSDU !6?+8C9-T?MI:7B^8@*EDWY0(R\Y;-U)1L0P[
MH ^,,OPNX\;#F1@W#<3R95+%C?=QFO2GW#,4$Q^&F>Z'F284T*;FE,,1!5X=
M=4X-UCG(X1,@E9-%/-ETQHYUM':"@. &74 5=BO!3=1814)&BRN144T0(@3W
MVK$ C9T'XR9AH[#;959+B]>#4HZ:DG:DI-=R>6%P6$XW9P.*8U)COYW*B\5"
M $/IV[;2>(I<X1(IP*L2*F,SI(N^^SA]5;9J1VY@D6572I0#IF84PR)>Q98&
M:B\H/9%D@F 3P!*"RJ]!X0BYT*]PLC2F4LF&F^X@@B?B9!*/A.F"Q83-ULV7
M5W<+9?-79AHEU227L2^L*+45BH+_ '\XDJ%R$;QEIH9#^67(<*$)YC=3=9$!
M%P%4U1=#!0"9@\( B(*>$31R*T84 ARE\LBTG[CNUL3$;>S-T1?6F%OZW\WS
M4_T533'JKTWMK6J1U 0M*T$ISI5H3,M)&F.)WTPSSB54\A)H*DL-TPZKH1=1
M3DD R0*N D023!D08^B9BK*?@"$6.W?I]M_YMK9VIV:36R7]13"1-02<M9CR
MA)T-O!NW(& \$MA04]HW6L53(8OD5.9KSAU%2J1S( @8F@S";9MAF#(PQ<<-
M5*8%A"YLY6;JZ_J'X;*'J'*NT,Z\91AA>8EC"GD*VVS SX:;MS*"@&\48$-Z
MJFH]Z(P1@@9S(BJ9K)@"AJP!<V7*E$40X"9("S.O']?8"AZA\7Q=0,2C# L:
M[MCCV:8,#/@!\6;F0@MRJ5>0L]1YA NM@@W!P'<'!C8@9$#%%#;17$; $ 68
M3K^A90]0X[UN?;THPPEQUNFEBV:JS SX7GK9'!P)V6B%W\1U'MQ"NIJ F"AF
MEJW!K8JD8&B89M%7,B(XJB+,Z\?U]N:F%8E9IFQG*GS[ISB*/ @"V.?##$;C
M7S8!D+&^2@,,] -3,3H=@![>#(L7NV@Q".-K[>:/>'QK"S":\?JGVI/..RAZ
M6V\YBR-&6R%:/@30!':5)E(<:/?5^_1U@,T-<44FG:=9Q0U0D#Y-F4+60QFF
MHJ.!L,8Q=0SP-!$BQ8V9I6=F:8W1UARKWV1F8'R3;H6DG3?JSD4U8D*$L.-Q
M;'U(C49+M41 R.)-2;*QJ*U+Z/P6LA6'P4!#&!TR]Q[@&RF&)L,1-,9J0^.,
MQ_Y1/_K&UV>Y9F#9KI$;K338BTB:2H%<P-B]WH^-64RJCH2UC&Q;#$S=O1)I
MH6Y",M488SMAD !1FQYX%@;X$!3)C.V2C<4V8OF9_P"V/N8CMY2(1A[9<GTF
M@X2'K7TDP><L7O@8"TYZ/78]CF8^=K_K@G'/D]+R:%M.5[>+CG'XN V./Z88
M=[WO0KL?[9GCM>(^_+BU/8T=03U:*J!+.RBZQI#D(^?L(74T94)0#%9=*N;*
MY#)AF,]+JE"+M."#)V!TGF:"F$B7\H,ES=T[( J,0/#Y1NV8[S7&VNE*#%V'
M#2N@-]:-R!%$ 3?+68P@K4D>:XTE><D]&\8 M;$1P-?41J0FI8<YKRL,T9$'
M)OIL!9X#@ !E@;E,AC(^4[IF.$T[1"VC)T^.J*XCEIHMS"!4]57&*N),?E(0
MT[E8*2T58&0%LJ6LJ)1.3W0 O!CJ1A(S*!%U!JXD<29G#,V)<Z&93S-:WVOX
MX=AGV%76>S]9ZTL;(=I&R4=/+UBN22#TREAQQ5)K?6WRJ!$KMI54D0B]'6I&
M706,CJII'<UT^ZBCG!S!LLJ$C ]Q<ST?Y-O9G9CX3;7=$Q92:[HQN?TQ,C0;
MK T@H1</1?K8=$DMY-,FC-M-FN(M>2HD%3Q+^ JV8XE=ID$^;(534H"^8*("
M(?E=M$_ !B8:)D$+P7.7RB?RV:9[-DZ39/3BT$=ZU"4/R2E$-D%6-3VD=['E
M0XGHO#BLQ6X]%CN4%G R6)I[)U*1#&+180@10,V$.C),QFXT>X0P1*Y]$.'0
MQ<A23%?QI/"M=)FOO!]*D>&(\4G43EE*>,N+AI34+NQ*R*ZDIS/QL;#4_&.%
M_((\)27>+#S:$",8YIZ3=KFD&Q:X'DY6X6 5[&:^TAFK&GV*' ][2(N(*NK.
MK!33%DN.H/E^FD<BI(V)2R:936J,Y\FHE^3Y$2PUP4Y$+%QS6(ALP$*:,&!A
M0/33?IXDAR7>,B0-#+^=UP29??2]8P9+J<5@$ZW@3P,5I=0SZEB"1_\ A L3
M-L"]_K!QPO1:SC.KNEF/V&XU<LON%DM%>7B93 @46UEMHRHKE2 0XYD,D64C
MQ(<X 4#,F3)C L$-B#@.8'%QPL(*)ED1UF&& 6& 8>&(88>.. 8>&-L,,,,+
M6QQPPQQM;''''&UL<<<;6M:UK6M:UK4'ZH% H% H/3Y,7VS;O)P=NO>V5Q=J
M#VR^5K6M:_C^+XWAM:UK6OX?#:UK6M]5J#W4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4%6=<7[FNJC^[_+/P0M58OCC'=)NYQWA95'_9*7_#B7\L%45L
M:!01Y+OHGD_W>/7X;4J##A'T,1%[L&#\*)-!)]!IG&G&5AO+R22$2@CBHC*B
M<4%74C? B!&3I$<L (L(-CR9NVE8"BX9*"1NDG[I%+#$_+BFW;>&%+8FT@+4
M9(T'HA1])P+?A>?7',3>9!=,6E)L-1IK\"R'"V$0QV955_=%NM-*4Y%6'^B!
M&,#J.V[CC,%JME"9I9OED$OO[T\H?*[&J F)S>NDRI<JX67IN:VD!H*HS5R-
M$BD%LR+9=C5O&%1,R7\,3\C@&Y>//!372XY!&5!4 FV041*)*9I5+"O>9X5F
M)^E-]GPV-$SK'T=,#>K*1.-$G1RD/)_8$E=LG7:8>*.GLA/1BB$&; 7D2R8=
M# 1L,LU0R I6$R%R\!;#]/Q[$5FC6QM_].:TK6*7TOF.+T:5O]'F@:'M/<8Q
M9+TX:AWW($<KSB<9)Z19.<S1 RBBHHN]6<J&I-6)P7\XF<TEA&+GB81A52"0
M)I36"HZ^8RLH'!1*B[7^29F9ILVTOB)FS.E9KGNL=HU/]'OTLQH]U>38;U-:
M^(8DA?(")2U($>:@&V6>JNE"X% Q$M7=3BBQQ+RPF9AD"(8A!44#A40,D4P$
M#RL7!\0D[<S9,;-,*6;]T665;!M;"<KQDXLW=#FR)ZLV4Z,S2B>R<BPS=+SG
M<8QQ6Q,8*ALTXR4&-9?&-*89LV&I&L5,(R>P-&,3 N=AQ;9#Y5_T[/+Y>9Y8
M4BB1BVQX:XT,R8.-S90W 8-FA1!S!IZ:=154P;'$ROD(,?'8,_Q<*9&%O>]Q
M1+9@Y"7O>_AQO>B5V=^SI-.\3[HV/FM[*4@_HI>L;2_(&./U>%ZP_K0: XMK
M?UY",[9 %  '._U>'+$H+A;Z[V#^RU#^.&U_Y1V^/V\\$^RQ)W_Q.A]X^+_^
MH'9"XVVWP?\ ]HE;R?QO_P"3XO\ ]=#^/_+I[[>\;3LH"!]2OI%T]/[Q?^]F
MP]E1U;MC(3P?UA O?3MEC:]_ZL!3&-OZKB8_;0IL?[MKGLQ_^O<CA%UVI_[8
MV,J4E+Q?^]O!V4E/7/&\'@\.T;^7%&'C^'Z_%V[R?P^#]+Q?#0I'^[I[[!YQ
MDWHO_MML6VR4D;8_^)FQ-4L)25A;P7\'C!V2M<R:,+C_ %_4#82]OL#O?ZJ'
MQC_?L_\ VC_^:=3SRVT3_P#:+0GLO[<\'_B?[&2T\]K_ .?HNU!OW;?!_P#E
MMO\ #_[GC>&U"=G_ );,\)\T//\ =)2;];VCW9.8UQQ_\3-[Z9-DT+!!6^R^
M68Z&TUX'+"W_ ,X0@F%[?7;*]O!>A\9QV?\ RV?)])-L8@/[8U'3,TO_ )M_
MP&O"/-J_Y[?OY1&_M'@\'U[=XG@_K\%#XSAI,3F]PVR7[$: BK*Z+L@#!P+(
M26H*QT@)JPE,%Q#%TTH*<,%DMK#R $XUI7%#!S"(H:0EG5A2-Y!$4\B9.#!
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MB:GK:3^NZ9^WU X(FIZVD_KNF?M]0.")J>MI/Z[IG[?4#@B:GK:3^NZ9^WU
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M"(']? 0YU<V+]=UHZ)^F7^,_\9UV>ML:[6EUA-/FOC31J/<1R.FN\%)ASBC
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MORF@<"<,\D<8] FK\IH' G#/)'&/0)J_*:!P)PSR1QCT":ORF@<"<,\D<8]
MFK\IH' G#/)'&/0)J_*:!P)PSR1QCT":ORF@<"<,\D<8] FK\IH' G#/)'&/
M0)J_*:!P)PSR1QCT":ORF@<"<,\D<8] FK\IH' G#/)'&/0)J_*:!P)PSR1Q
MCT":ORF@<"<,\D<8] FK\IH' G#/)'&/0)J_*:!P)PSR1QCT":ORF@AR:=">
MCG4*UQ6A+VFV(G6E9>#,F<#9R6WG2@FL/&VM1:CV:X**\FBK ^.)M*LV%Y)4
M0K""8X&L<!!,<BQM3%TS"BGF*:D]*M_*]+K@B;5U%!#PB6TXZU4!! DU.3P_
MUHB;&&L!NM%1<@QF^./DB2GSPR)'PMAM81Q]IX?C&\"UV9K6*3CLXYQ/U,<W
M>1IJ_P!%:P\DF']1$")>BF?E87R),BG4]&+$9R:\U .^((V,0S(G!JT*S$3%
M-^."G8L=]GW"9QQQR-MM-&RN6P)\9OBV,K=8OCG$/HE:$X9O]=HDC&]K_7:]
MF$U?K_\ \JB' G#/)'&/0)J_*:!P)PSR1QCT":ORF@Y)\-'2]&3;4'E)+8@2
M/F@DA[:JNI[HL>M1MI@?@RRVQ07%XL03">'BXY7\8P:#Q\&.5_#X+7H/GF:U
MOZ/7\9,(NCC22[==:_@,*0P6-/\  C73X0)J6.>0882UJ7E8O'T%AD\L\<LA
M3+9>;M.!A8"9A)AC+#(.QKXXS&SQOLFDV16=:/1YMFO&?OTW.D:+] +'.?K+
M(,310V]5^H? KG^KR)GI'D=JLJ#6DHW#OF+D(DQ/*!<L+M>)=4'\&0F(_C&Z
M9XV1I%O6.MDD1EL.^AQE. !\R,P%K5+)8(P)JS]U4+]Y=R ,EO'R*BHD<&R2
M7";0\B%&,#D+,R,&]<D*/GF7RPO;"^ ^4[II&5G[7P*01!Q L 2(PU%)(F6#
MQ!+%"D=M L6+A86\& 0  */@$$'C;ZL< \,<<;?5:UJ,LC@3AGDCC'H$U?E-
M X$X9Y(XQZ!-7Y30.!.&>2.,>@35^4T#@3AGDCC'H$U?E- X$X9Y(XQZ!-7Y
M30.!.&>2.,>@35^4T#@3AGDCC'H$U?E- X$X9Y(XQZ!-7Y30.!.&>2.,>@35
M^4T#@3AGDCC'H$U?E- X$X9Y(XQZ!-7Y30.!.&>2.,>@35^4T#@3AGDCC'H$
MU?E- X$X9Y(XQZ!-7Y30.!.&>2.,>@35^4T#@3AGDCC'H$U?E- X$X9Y(XQZ
M!-7Y30.!.&>2.,>@35^4T'(.[2CI<?Y(9-?>FV WHG&2V1,P1=D/1ZXB@Q3/
M*^>184NKMTV%F!EG>^=PLL+X>/?Q_%\;ZZ%9Q]]F7PDV5W8)]&+UT@32\M/+
M0#TP21'+469+(Y1VK.LG%[K),PD=<9YD.J)L'!O$+I*O<#,=/66ZWTM;;R\
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M5!YFTC#2@G-<VR4^1AI%AL1^$68=40E<ZTR;NS6;N LV32L" IF4(%0P2QE
M,,X*5R,8XB4'9^=[I-]J#3OUUQKVFH'G>Z3?:@T[]=<:]IJ!YWNDWVH-._77
M&O::@>=[I-]J#3OUUQKVFH'G>Z3?:@T[]=<:]IJ!YWNDWVH-._77&O::@>=[
MI-]J#3OUUQKVFH'G>Z3?:@T[]=<:]IJ!YWNDWVH-._77&O::@>=[I-]J#3OU
MUQKVFH'G>Z3?:@T[]=<:]IJ!YWNDWVH-._77&O::@>=[I-]J#3OUUQKVFH'G
M>Z3?:@T[]=<:]IJ!YWNDWVH-._77&O::@>=[I-]J#3OUUQKVFH'G>Z3?:@T[
M]=<:]IJ!YWNDWVH-._77&O::@>=[I-]J#3OUUQKVFH'G>Z3?:@T[]=<:]IJ!
MYWNDWVH-._77&O::@>=[I-]J#3OUUQKVFH'G>Z3?:@T[]=<:]IJ!YWNDWVH-
M._77&O::@>=[I-]J#3OUUQKVFH*UZRM4FF1PZ2M2R$@:BX)7%Q8@R4$U(1D>
M78_4U5543K.5RY-/3DXDX1S9XZ;'$P +%2P(HXXV> 80>>>5L;V+XXPD_<=X
M?0M'_9*7_#B7\L%45L:!01Y+OHGD_P!WCU^&U*@PX1]#$1>[!@_"B302?0*!
M04T'T,PTIV<)UPGGLX74Z2RND+SZ.+"8GN]5:ZX@2&UE1KGU%!0D@L>*'F_*
M+P(G%PV1&>(XAA$/W<N)]H,XP@%K[_=5H7 RVZY&4L1^?3P0VLM-H\TC"<4!
M+A ET0\F").94D"( *6 L7)";64QN7$!!O@'^JRQPMC1'HX.X_XBL[HRB?D:
MM9QG60X.X_XBL[HRB?D:5G&=9#@[C_B*SNC*)^1I6<9UD.#N/^(K.Z,HGY&E
M9QG60X.X_P"(K.Z,HGY&E9QG60X.X_XBL[HRB?D:5G&=9#@[C_B*SNC*)^1I
M6<9UD.#N/^(K.Z,HGY&E9QG60X.X_P"(K.Z,HGY&E9QG60X.X_XBL[HRB?D:
M5G&=9#@[C_B*SNC*)^1I6<9UD.#N/^(K.Z,HGY&E9QG60X.X_P"(K.Z,HGY&
ME9QG61IV_$$:-M&3T,@R6N*330/)P!#C>0QS.6'CY9^$86R<';//PYW_ $K8
M8_5X+>#ZJ5G&=1N.#N/^(K.Z,HGY&E9QG60X.X_XBL[HRB?D:5G&=9#@[C_B
M*SNC*)^1I6<9UD.#N/\ B*SNC*)^1I6<9UD.#N/^(K.Z,HGY&E9QG60X.X_X
MBL[HRB?D:5G&=9#@[C_B*SNC*)^1I6<9UD.#N/\ B*SNC*)^1I6<9UD.#N/^
M(K.Z,HGY&E9QG60X.X_XBL[HRB?D:5G&=9#@[C_B*SNC*)^1I6<9UD.#N/\
MB*SNC*)^1I6<9UD:=,B"-$HZXCY9DM?,9S+ "V?Q';R(($$;+M]";> 9+"R?
MCY.6N0;Y(7,*^0E\C@AL?Q[6&L'@K.,ZR-QP=Q_Q%9W1E$_(TK.,ZR'!W'_$
M5G=&43\C2LXSK(<'<?\ $5G=&43\C2LXSK(<'<?\16=T91/R-*SC.LAP=Q_Q
M%9W1E$_(TK.,ZR'!W'_$5G=&43\C2LXSK(<'<?\ $5G=&43\C2LXSK(<'<?\
M16=T91/R-*SC.LAP=Q_Q%9W1E$_(TK.,ZR'!W'_$5G=&43\C2LXSK(<'<?\
M$5G=&43\C2LXSK(<'<?\16=T91/R-*SC.LC3CQ!&AAP)CDS9+7L?2D==1"P6
M#>1,2>91P'6Z?.B#@;GWN(9#&;)#$H+83&P(0IW"^&?E%L@U9QG61N.#N/\
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MEB32LTNW<$L4$+O5L3RJ./(ZPI>C]GM>X)3'% <$+*;U5<1P\? =&NXRLNM
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M-=LN:AUNQ39/%#2&[FQLWF2SI$1E-E?O7FE"-6)(S&\H3%F,7"LCL?4EJAG
MDM)JDPS!1XLZ1E.9U^/&VT!5-X)Y\)SB)\CM5I )CH+-=$13314 SRVFH!5L
M**R)GM$<*4\=7B'V-+<>3])JX?9BVXHR>2N^#R4X5X-@E)):ZPZ9<#.;FB.%
M"?EB<F0Z*B&3;P9&#G;"-)D,M).*1Z$,]\U?!#:8W9]/U-EM]<E[J(]8V(N0
M(N( F 0^0>>((H@=QL A;XWL&)F#80*XN&&?@RR#L*'?.UKXV$P\/C6"'KMF
M==Y9!+M+;!L_ 5^QQ2=]X:4KM\\W/$,6NAEF7PM6-$%.XF97/=_-WG@K8@"X
M;B7N8QS +9G3C^OI\%]F%?>S"HNK72QGH+AA_P CP9#RLW)M>N3,+)",E/YS
MB&G$TEJ)'LK&'X7-N1LBLS)5'.)@S?1BI(T\4U2+BJ"L@I*FGF]CX4VOE-)F
ML19,TLOLC%]V4M&GI2C9NX#R2ST613)XDL+*RIPV8R( H9HH(,*TQF61F(V&
M07R0PY< TO%GVLI^W$C.)=.,!&0QPCG9[/Z:+47%KEE>/5MGEE=? R5GS$2D
MU%F/1DYI/V,+MU_-967'RDNI:7K$#RDAE2*BM@%;)=PCZ>&9:I]NO!/53J4H
MEB:354QWQMK/6XN7$PFC(*-+C9?BO.)=?93F3V\R9E?T1[Q0XQ:@A 5P@*S<
M;,^G6XHN!]-ER!FT=F 'KML\\EVY.RRJEL^IYUK/*Z[.CC9JA342[E74.MLV
M,' M$9DB%\%BS<?!Z)B#\8S\.%(H)MMOL"1T23\49<9:_9K&#Y]IO\GF/'CI
M;ZVIM"2<&LN(+<6Q%(F,M\<=]E?U2*.\<L%ZB'87U L=A!+\%1_++K1EV.!<
M70WLS$/J+%CI+R$=*"FM)X*0+;L_ID*M1?)L%MW46FI);,?RN^L$%6DXXGJ8
MK%F^G6W.,++NSA7H0U!+)=;6Y'8SACR:IW<6FLW"#B"4$IQM?2ZH-ULL0[*+
M <[W:RPLH+:)I;\;THN(8]NCN!/"5(+:BPLI.15.B-,@,JV16N=<N4<+\VYU
M8Z4Y8FA_:GW2V$]P)I873.@(\3XM]7:"2=E>4^#/5PQU=A&E8^\R0B"U1!97
MC)2<&+L145)<"VV68< <00+,R&+")I$1G;PK'C-DOI:V2$CBY4=BM=Y*PY(I
M-Q9LN=0&TL7#6]O(:J#D(J!DJ*LHP)!83U=)TR)BE8RGET8^BN4Q=<2B"HGO
M%3P)%-^6.5>E><6.N4".O9'D8'!%67^ZX\3'T1!L,N Z52P[B8Z5(FE$J*;4
M-S$QMJ@ [ECQ=U8*2KBG (B@ <9K7P1BR >,(*>[193/^_$<IG?=S[/=&R,'
MPCI9QL%Q(QH=/45%E'U0UIR,DBSE"C6&UDHUYBNWW$(9S9!A_GY<:Y1PQ@EA
MNCQT3(ZH%2R6.US"D+//6[E2]BJYW9$%!)44Y$3I!"L\&J2%0U->3-+S;=$=
M+AI,U"EW$F.>S??3K01SB8JJ<!#-A8;9APE#A! ,F#P !P1T%5@L?'?]VVQ^
M]71M[/6D@N9;+W8#UP;"PI8+B:O)HFF')W+2JAPUIC+%RDL#CN  ,\4<#F2Y
MP9@3F1;G762,(:)@9- ,PNRC1PEF.M<9RX3Y=;IL0]2ZE*Q-_3XSEM('+QE(
MS0R7E<_%FWF0C<O)SE8"4>3HY<!H P?),L48KFJ@H"84$%3C>9W FHG[!&Q.
M5UGO*U;!'],4@>[N*/B&7Z(DZ@4"@4"@4"@4"@CR7?1/)_N\>OPVI4&'"/H8
MB+W8,'X42:"3Z!0*!0*!0*!0*",%STO1U_Z(E+_-8PH)/H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M,#4%%$ G!TF07@MJ!Y4E9K0NZR*^214V(A3YDHD$I>S+&D\KB.=-&FWX0+8
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MDFPL#)DL"7,9E7;'SS0C 8 N8P1E!&,Y![FGD@\H"GND_<)&H% H% H% H%
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-RMCX;VQRO]5Q%MC_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
